

Market Survey cum Detailed Techno Economic Feasibility Report

on

Active Pharma Ingredients

- Metformin
- Amoxicillin
- Ibuprofen
- Paracetamol

OP: AECACD RP: OS-1

Prepared By:

NIIR PROJECT CONSULTANCY SERVICES

AN ISO 9001: 2015 CERTIFIED COMPANY 106 E, Kamla Nagar, Delhi–110 007 (India).

Tel: 91-11-23843955, 23845886, 23845654,

Mobile: +919097075054 +918800733955

Fax: 91-11-23845886

E-mail: npcs.india@gmail.com; info@niir.org
Website: www.niir.org

vessite. www.mm.org

www.entrepreneurindia.co



AN ISO 9001: 2015 CERTIFIED COMPANY

[NPCS/5515/24212] Page No. **2**



TABLE OF CONTENTS

1.	PROJECT LOCATION	14
	1.1. DISTRICT PROFILE & GEOTECHNICAL SITE CHARACTERIZATION	14
	1.1.1.General	14
	1.1.2.Location & Geographical Area	14
	1.1.3.Physical Characteristics	15
	1.1.4.Climate	15
	1.1.5.Administration	16
	1.1.6.MAP	17
	1.1.7.Demographics	18
	1.1.8.Economy	18
	1.1.9.Culture and Attitudes	
	1.1.10. Transport	22
2.	INTRODUCTION	
3.	METFORMIN	25
	3.1. Introduction	
	3.2. MEDICAL USES	
	3.3. CHEMICAL & PHYSICAL PROPERTIES	
	3.4. Product Detail	
	3.5. RAW MATERIAL-DESCRIPTION	
	3.6. MANUFACTURING PROCESS OF METFORMIN	
	3.7. Process Flow Diagram	34

	3.8. HANDLING AND STORAGE	35
	3.8.1.Precautions for Safe Handling	35
	3.8.2.Hygiene Measures	35



	3.8.3.Storage Conditions	35
	3.8.4.Storage Stability	35
	3.9. PERSONAL PROTECTIVE EQUIPMENT	36
	3.9.1.Eye/face Protection	36
	3.9.2.Skin Protection	36
	3.9.3.Full Contact	36
	3.9.4.Splash Contact	36
	3.9.5.Body Protection	37
	3.9.6.Respiratory protection	37
	3.9.7.Control of Environmental Exposure	
4.	AMOXICILLIN	
	4.1. Introduction	
	4.2. MEDICAL USES	38
	4.3. RAW MATERIAL	42
	4.4. Manufacturing Process	
	4.5. Process Flow Diagram	44
5.	IBUPROFEN	47
	5.1. Introduction	47
	5.2. Properties	47
	5.3. RAW MATERIAL	48
	5.4. Brief Description of Manufacturing Process of Ibuprofen	49
	5.5. DESCRIPTION	49
	5.6. PROCESS FLOW DIAGRAM	51
6.	PARACETAMOL	53
	6.1. Introduction	53
	6.2. Medical Uses	54



	6.3. RAW MATERIAL	57
	6.4. BRIEF DESCRIPTION OF MANUFACTURING PROCESS OF PARACETAMOL	61
	6.5. PROCESS FLOW DIAGRAM	62
7.	TABLET MAKING PROCESS	64
8.	PROCESS FLOW DIAGRAM	67
9.	SWOT ANALYSIS	68
	9.1. Strengths.	68
	9.2. WEAKNESSES	68
	9.3. Opportunities	69
	9.4. THREATS	69
10	RISK ASSESSMENTS	71
	10.1. CHEMICAL AND BIOLOGICAL EXPOSURE	72
	10.1.1. Nature of the Risk	72
	10.1.2. Potential Outcomes	72
	10.1.3. Contributing Factors	72
	10.1.4. Mitigation Strategies	73
	10.1.5. Regular Review and Audits	74
	10.2. Environmental Contamination.	74
	10.2.1. Nature of the Risk	74
	10.2.2. Potential Outcomes	75
	10.2.3. Contributing Factors	75
	10.2.4. Mitigation Strategies	75
	10.2.5. Regular Review and Audits	76
	10.3. QUALITY CONTROL FAILURE	77
	10.3.1. Nature of the Risk	77
	10.3.2. Potential Outcomes	77



	10.3.3.	Contributing Factors	78
	10.3.4.	Mitigation Strategies	78
	10.3.5.	Preparedness for Failures	79
10.	4. SUPPLY	Y CHAIN DISRUPTIONS	80
	10.4.1.	Nature of the Risk	80
	10.4.2.	Potential Outcomes	81
	10.4.3.	Contributing Factors	81
	10.4.4.	Mitigation Strategies	81
	10.4.5.	Regular Review	82
10.		ATORY NON-COMPLIANCE	
	10.5.1.	Nature of the Risk	83
	10.5.2.	Potential Outcomes	84
	10.5.3.	Contributing Factors	84
	10.5.4.	Mitigation Strategies	84
	10.5.5.	Preparedness for Non-compliance Issues	85
10.	6. INTELL	ECTUAL PROPERTY BREACHES	86
		Nature of the Risk	
		Potential Outcomes	
	10.6.3.	Contributing Factors	87
	1111	Mitigation Strategies	
		Preparedness for IP Breaches	
10.		MENT FAILURE	89
	10.7.1.	Nature of the Risk	89
	10.7.2.	Potential Outcomes	89
	10.7.3.	Contributing Factors	90
	10.7.4.	Mitigation Strategies	A 00
	40.7.7.	The second secon	



	10).7.5.	Response Plan for Equipment Failures	91
	10.8.	ACCIDE	ENTS AND FIRES	92
	10).8.1.	Nature of the Risk	92
	10).8.2.	Potential Outcomes	93
	10).8.3.	Contributing Factors	93
	10).8.4.	Mitigation Strategies	94
	10).8.5.	Response Plan for Accidents and Fires	94
	10.9.	Marki	ET DYNAMICS RISKS	95
			Nature of the Risk	
			Potential Outcomes	
			Contributing Factors	
).9.4.		
			Preparedness for Market Dynamics Shifts	
11.			CT AND JUSTIFICATION FOR API MANUFACTURING UNIT	
	11.1.	SOCIAL	- IMPACT	99
	11.2.	JUSTIFI	ICATION FOR AN API MANUFACTURING UNIT	100
12.	ECONO	OMIC II	MPACT AND JUSTIFICATION FOR API MANUFACTURING UNIT	103
	12.1.	Econo	OMIC IMPACT	103
	12.2.	JUSTIFI	ICATION FOR AN API MANUFACTURING UNIT	104
	12.3.	FUTUR	e Challenges for API Manufacturing Unit	107
13.	MARKI	ET SUR	VEY	110
	13.1.	REPOR	T OVERVIEW	110
	13.2.	TYPE O	OF MANUFACTURER INSIGHTS	113
1	13.3.	Type In	NSIGHTS	114
	13.4.		CATION INSIGHTS.	115
	XX.			113
	13.5.	TYPEO	PF SYNTHESIS INSIGHTS	10



13.6.	REGIONAL INSIGHTS	117
13.7.	KEY COMPANIES & MARKET SHARE INSIGHTS	118
13.8.	ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SCOPE	119
13.9.	GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION	120
13	3.9.1. Type of Synthesis Outlook	120
13	3.9.2. Type of Manufacturer Outlook	121
13	3.9.3. Application Outlook	122
13	3.9.4. Regional Outlook	122
13.10.	. API IN INDIA	123
13.11.	. API Manufacturers in India	127
13.12.	. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET	141
13	3.12.1. Industry Insights	146
13	3.12.2. Application Insights	149
13	3.12.3. Regional Insights	150
13	3.12.4. Market Share Insights	151
13.13.	. KEY PLAYERS IN THE GLOBAL APIS MARKET	157
13.14.	. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT	166
13	3.14.1. Market Dynamics	166
13	3.14.2. Market Regional Analysis	167
13	3.14.3. Market Drivers and Key Restraints	168
13	3.14.4. Market Trends	169
13	3.14.5. Market Segmentation	169
13	3.14.6. Market Regional Outlook	171
13.15.	. ACTIVE PHARMACEUTICAL INGREDIENTS	173
13	3.15.1. Market Dynamics	173
13	3.15.2. Market Segmentations	174



13.15.3. Market Regional Analysis	175
13.15.4. Market Key Players	176
14. MAJOR FIVE ACTIVE PHARMACEUTICAL INGREDIENTS COMPANIES	177
15. EXPORT & IMPORT: ALL COUNTRIES	180
15.1. EXPORT: ALL COUNTRIES	180
15.1.1. Ampicilline and Its Salts	180
15.1.2. Cephalexin and Its Salts	183
15.1.3. Ibuprofen with or without Paracetamol or other Compounds	185
15.1.4. Other Cyclic Amides and Thr Drvtvs And Salts	191
15.2. IMPORT: ALL COUNTRIES	196
15.2.1. Ampicilline and Its Salts	196
15.2.2. Cephalexin and Its Salts	197
15.2.3. Ibuprofen with or without Paracetamol or other Compounds	198
15.2.4. Other Cyclic Amides and Thru Drvtvs and Salts	199
16. FINANCIALS & COMPARISON OF MAJOR INDIAN PLAYERS/COMPANIES	201
16.1. ABOUT FINANCIAL STATEMENTS OF CMIE DATABASE	202
16.2. Profits & Appropriations	203
16.3. Total Liabilities	205
16.4. Total Assets	207
16.5. NET CASH FLOW FROM OPERATING ACTIVITIES	208
16.6. Section –I	210
16.6.1. Name of Company with Contact Details	211
16.6.2. Name of Director(S)	213
16.6.3. Plant Capacity	217
16.6.4. Location of Plant	222
16.6.5. Credit Ratings	224



	16.6.6.	Name of Raw Material(S) Consumed with Quantity &Cost	228
	16.7. SECTIO	DN-II	230
	16.7.1.	Assets	231
	16.7.2.	Cash Flow	233
	16.7.3.	Cost as % Ge of Sales	234
	16.7.4.	Forex Transaction	236
	16.7.5.	Growth in Assets & Liabilities	237
	16.7.6.	Growth in Income & Expenditure	239
		Income & Expenditure	
		Liabilities	
		Liquidity Ratios	
		Profitability Ratio	
		. Profits	
		. Return Ratios	
	16.7.13.	. Structure of Assets & Liabilities(%)	247
		. Working Capital & Turnover Ratios	
17.		F PLANT & MACHINERY	
		F RAW MATERIAL	
		HS/IMAGES FOR REFERENCE	
		INERY PHOTOGRAPHS	
		X/////////////////////////////////////	
		Material Photographs	
	NNNN	JCT PHOTOGRAPHS	311
X	AAAA	UT	313
21.	CONCLUSION		315

Continued on Next Page



PROJECT FINANCIALS

•	Proj	ect	at a	Glance

		Annexu
•	Assumptions for Profitability workings	1
•	Plant Economics	2
•	Production Schedule	3
•	Land & Building	4
	Factory Land & BuildingSite Development Expenses	
•	Plant & Machinery	5
	Indigenous MachineriesOther Machineries (Miscellaneous, Laboratory etc.)	
•	Other Fixed Assets	6
	 Furniture & Fixtures Pre-operative and Preliminary Expenses Technical Knowhow Provision of Contingencies 	
•	Working Capital Requirement Per Month	7
	 Raw Material Packing Material Lab & ETP Chemical Cost Consumable Store 	
•	Overheads Required Per Month and Per Annum	8
	 Utilities & Overheads (Power, Water and Fuel Expenses etc.) Royalty and Other Charges Selling and Distribution Expenses 	
	Salary and Wages	9
•	Turnover Per Annum	10
	Share Capital	11
	Equity Capital Preference Share Capital	

Continued on Next Page



Annexure 1 :: Cost of Project and Means of Finance

Annexure 2 :: Profitability and Net Cash Accruals

- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items
- Gross Profit
- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals
- Annexure 3 :: Assessment of Working Capital requirements
 - Current Assets
 - Gross Working Capital
 - Current Liabilities
 - Net Working Capital
 - Working Note for Calculation of Work-in-process
- Annexure 4 :: Sources and Disposition of Funds
- Annexure 5 :: Projected Balance Sheets
 - ROI (Average of Fixed Assets)
 - RONW (Average of Share Capital)
 - ROI (Average of Total Assets)
- Annexure 6 :: Profitability Ratios
 - D.S.C.R
 - Earnings Per Share (EPS)
 - Debt Equity Ratio
- Annexure 7 :: Break-Even Analysis
 - Variable Cost & Expenses
 - Semi-Variable/Semi-Fixed Expenses
 - Profit Volume Ratio (PVR)
 - Fixed Expenses / Cost
 - B.E.P
- Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume
 - Resultant N.P.B.T
 - Resultant D.S.C.R
 - Resultant PV Ratio
 - Resultant DER
 - Resultant ROI
 - Resultant BEP

Continued on Next Page



Annexure 12 :: Shareholding Pattern and Stake Status

- Equity Capital
- Preference Share Capital

Annexure 13 :: Quantitative Details-Output/Sales/Stocks

- Determined Capacity P.A of Products/Services
- Achievable Efficiency/Yield % of Products/Services/Items
- Net Usable Load/Capacity of Products/Services/Items
- Expected Sales/ Revenue/ Income of Products/ Services/ Items

Annexure 14 :: Product wise Domestic Sales Realisation

Annexure 15 :: Total Raw Material Cost

Annexure 16 :: Raw Material Cost per unit

Annexure 17 :: Total Lab & ETP Chemical Cost

Annexure 18 :: Consumables, Store etc.

Annexure 19 :: Packing Material Cost

Annexure 20 :: Packing Material Cost Per Unit

Annexure 21 :: Employees Expenses

• Annexure 22 :: Fuel Expenses

• Annexure 23 :: Power/Electricity Expenses

Annexure 24 :: Royalty & Other Charges

• Annexure 25 :: Repairs & Maintenance Expenses

• Annexure 26 :: Other Manufacturing Expenses

• Annexure 27 :: Administration Expenses

Annexure 28 :: Selling Expenses

Annexure 29 :: Depreciation Charges – as per Books (Total)

• Annexure 30 :: Depreciation Charges – as per Books (P & M)

Annexure 31 :: Depreciation Charges - as per IT Act WDV (Total)

Annexure 32 :: Depreciation Charges - as per IT Act WDV (P & M)

Annexure 33 :: Interest and Repayment - Term Loans

Annexure 34 :: Tax on Profits

Annexure 35 :: Projected Pay-Back Period and IRR



Project Location

District Profile & Geotechnical Site Characterization

General

†Rs³/₈⁵/₈^E_R¹/₃²/₃¹/₃³/₈ 3/8€^LF^NL^CR€1/8^NL ₩1/3^LF ⁷/₈¹^C_RN⁰⁵/₈³/₈ 1/₃7/₈N_L5/₈C_R ■10/₀₀€1/₈5/₈ "1/₈N_L€1 – 2/₃R_S Nº5/8^CR®€-® "NL^CR1/37/8¥1/3¥-1/30/003/81/3 (€LFN_CR€1/8N_1/3-3/8 -1/3@01/3N_ (€LFN_CR€1/8N_Pt -1/3@01/3N_ ₩1/3LF HTCR5/8€1/1VTLF0/6Rs 1/3 ff¹/3¹/₃ \(\frac{1}{3}\) \(\frac{1}3\) \(\frac{1}3\) \(\frac{1}3\) \(\frac{1}3\) \(\frac{1}3\) \(\frac{1} L_E5% H_T1/₃C_R1/₃N_L5% 3% €L_EN_LC_R€1/₈N_L €- ⁹\(\tilde{\pi}\)1/₄⁹\(\pi\)1/₄¢ V_T-3%5% C_R N_L®5% L_EV_T2/₃5/₈3/₈1/₃C_R 17/₈ (€LFNLER€1/8NLPt [□]V_T[□]R¹/₃%₀ †Rs³/₈⁵/₈^E_R¹/₃²/₃¹/₃³/₈ †**R**s³/₈⁵/₈^ER¹/₃²/₃¹/₃³/₈ ₩¹/₃^L_F 0/₀₀¹/₃^N_L5/₈^E_R ^E_R5/₈-1/₃N⁰5/₈3/₈ 1/₃^L_F □¹/₃-@¹/₃ 3/8€LFNLER€1/8NL (€LFNLER€1/8NLP++Rs3/85/8ER2/31/33/8 ffiER2/31/3- 3/8€LFNLER€1/8NL €LF -1₩ %-1₩- 1/3LF †Rs³/₈⁵/₈^C_R1/₃²/₃1/₃³/₈ 3/₈€^L_FN_LC_R€1/₈N_LPt †Rs³/₈⁵/₈C_R1/₃²/₃1/₃³/₈ nPt[©] N[©]€‰0‰€1— "1/₈1/₈1/_CR³/₈€—® $^{N}L^{1}$ $^{1}/_{2}^{\underline{a}\underline{o}\underline{o}}$ $^{1}/_{8}^{5}/_{8}$ $^{L}F^{V}_{T}^{L}FP_{t}$ t t $^{0}/_{8}$ t $^{1}/_{3}^{L}R^{5}/_{8}^{1}/_{3}$ $^{n2\underline{a}}$ c u u u

Location & Geographical Area



Physical Characteristics

□¹/₃€-7/₈1/₃‰%₀

Climate

@1/3LF †Rs3/85/8^CR1/32/31/33/8 1/3 NL^CR1H_T€1/81/3/60 ₩5/8NL 1/3-3/8 ²/₃1[□]R³/₈5/₈[□]R€-® 1- 1/₃ 1/8%0€Nº1/3NL5/8 iSMÖHTHT5/8- "₩; ®1NL LF5/8Nº€¥1/3CR€3/8 $1/_8\%_0 \stackrel{\textstyle \leftarrow}{\in} N^{\underline{0}1/_3} \stackrel{N}{\downarrow}_{\underline{5}\%} P_t \quad \text{ff} \stackrel{\textstyle \leftarrow}{=} 1/_3 - V_T 1/_3\%_0 \quad N^{\underline{0}5/_8} 1/_3 - V_L 5/_8 N^{\underline{0}H}_T 5/_8 \stackrel{\textstyle \leftarrow}{\vdash}_{R} 1/_3 N_L V_T \stackrel{\textstyle \leftarrow}{\vdash}_{R} 5/_8 \quad \stackrel{\textstyle \leftarrow}{\in} \stackrel{\textstyle \leftarrow}{\vdash}_{F} \quad 1/_2 n P_t n^{\underline{0}} - V_T 1/_3 N_L N^{\underline{0}5/_3} \stackrel{\textstyle \leftarrow}{\vdash}_{R} 1/_3 N^{$ i®¤Pt¤°○;3 Nº1-N_®%nRs Nº5%1/3- N_5%NºHT5%ER1/3N_VTER5%EF 1/3ER5% 1/2º-1/41/4°- i®º-¤°°° O¿Pt - VTN°N°5% CRLF ; ● 1/3 CR1/8° — TM VT — 5/8; 1/3 CR5/8 ®1NL 1/3 — 3/8 ® VTN° €3%£ ₩€NL® N_5%NºH_5%ER1/3N_V_TER5%EF 17/8N_5%= 5%N 1/85%5%3% ¢ª °— ;ºª¢° ○; 2/35%N_₩5%5%- "HTER€%0" 1/3-3/8 TM V_T-5/8PtF¢®€ ff®5/8 1/8110%05/8LFNL NL5/8NºHT5/8ER1/3NLVTER5/8LF √5/8¹/8⁵/8N⁰²/3⁵/8^ER 1/3−3/8 ^{™1}/3−^VT1/3^ERRS£ ₩^{®5}/8− N_L®5/8 %0¹₩⁵/8^LFN_L N_L^{5/8}N^{0H}T5/8^ER1/3^NL V_T^ER5/8 11/81/81/3^LF€1-1/3/00/00Rs 3/8€HT^LF NL1 020 j220 O; Pt ●1/3Rs €LF NL®5/8 ®1NLNL5/8^LFNL Nº¹-N₋®£ ₩®%- 3%1%€%0Rs NL5%NºH-5%ER1%NLYTER5%EF ER1%-®5% 7%ER1Nº 1½n NL1 1¼\$°-:®¤—ººº1½°○¿³ <5%1%5%Nºº2/35%[□]R£ NL®5% 1/810/03%5%□FNL£ ®1/3^LF NL5%NºHT5%□R1/3^NLVT□R5%□F **⊕**1/3^C_RRs€-@ 7/8^C_R1Nº º¢Pt² N_L1 1/2©°- i²®-©1/2°○;Pt



Administration

 $\text{``1/8}^{1/8}^{1/8}^{1/8} = \text{``0} \quad \text{``1} \quad \text{``1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8} = \text{`1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/8}^{1/8}^{1/8}^{1/8}^{1/8}^{1/8}^{1/8} = \text{``1/8}^{1/$ 1/2^{ao}¢ H_T1/3^CR^NL 1/2 -5/81/8^NL€1- 23/40; II- 1/3-3/8 7/8^CR¹Nº N_L®5/8 1/3 H_TH_T1€-N_L5/83/8 3/81/3 Rs£ +Rs³/₈⁵/₈^E_R1/₃²/₃1/₃³/₈ €- N_L®5/₈ 5/₈+F®£ -N_L€-® -N_L1/₃N_L5/₈ 17/₈ "-3/₈®^E_R1/₃ ■ E_R1/₃3/₈5/₈+F®£ 17/8 N_@5/8 _N_1/3 N_5/8 N_L®5/8 1/81N^QN^{Q1} 1/81/3 H_T€N_L1/30/00 L_F®1/30/000/00 2/35/8 17/8 ff5/80/001/3-@1/3-1/3 1/3-3/8 N_@5/8 -N_1/3 N_5/8 17/8 "-3/8 ® □ R1/3 ■ □ R1/3 3/85/8 □ F® 7/8 1 □ R □ F \ T1/8 ® H_T5% C_R€13% -1NL 5% N 1/85/85/83/8€-® NL5%- RS5% 1/3 C_RL_FPt j1/2; "7% NL5% C_R 5% N + T € C_RRs 17% N_@5/8 H_T5/8 F_R€13/8 F_R5/87/85/8 F_RF_R5/83/8 N_1 €- F_V_T2/3 ¥ F_5/81/8 N_L€1- 12;£ +Rs3/85/8 F_R1/32/31/33/8 N_@5/8 C_R5/8 L_F@1/3 %00 %0 2/35/8 1/3 -5/8 + 1/8 1/3 H_T € N_1/3 %0 7/8 1 C_R N_0 6/8 - N_1/3 N_5/8 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_0 6/8 - N_1/3 N_5/8 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_0 6/8 - N_1/3 N_5/8 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_0 6/8 - N_1/3 N_5/8 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_0 6/8 - N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 H_T € N_1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/2 % 17/8 "-3/8 6/C_R1/3 %0 7/8 1 C_R N_1/3 N_1/ ■CR1/33/85/8LF®PtOff®5/8 LF1/3N°5/8 LF5/81/8NL€1-LF 1/30/00LF1 3/85/87/8€-5/8 NL®1/3NL NL®5/8 $1/8^{1}N^{Q}N^{Q}1 - 1/8^{1}N^{2}N^{Q}1 - 1/8^{1}N^{2}N^{Q}1 - 1/8^{1}N^{2}N^{Q}1 - 1/8^{1}N^{2}N^{Q}1 - 1/8^{1}N^{Q}1 - 1/8$ $3/85/8^{L}_{F} = 0.00 - 1/3^{N}_{L} 5/83/8 \qquad 1/3^{L}_{F} \qquad N_{L} 0.05/8 \qquad \square^{C}_{R} 5/81/3^{N}_{L} 5/8^{C}_{R} \qquad + R_{S} 3/85/8^{C}_{R} 1/32/31/33/8 \qquad 0.07 - 0.05/8 + 1.07$ $-1^{\Box_{R}H_{T}}^{\Box_{R}}^{\Box_{N}}^{\Box_{N}}^{\Box_{L}} = V_{T} - \frac{3}{8}^{5} \frac{1}{8}^{\Box_{R}}$ N_{L®5/8} +Rs³/₈⁵/₈^ER¹/₃²/₃¹/₃³/₈ ● V_T-€1/8€H_T1/3‰ -1^LR^HT1^LR1/3^NL€1- "1/8^NL£ ^QZ²²Pt "^LF ^LF^NL€^HT^VT%01/3^NL5/8³/8 €- ^LF5/81/8^NL€1-^LF 1/4 1/3-3/8 ^{2©}i²; 17/8 N_L[©]5/8 □5/81^CR[©]1/3—€ L_F1/3N_L€1— "1/8N_L£ 1/8€N_LRs ● R"L_F 1/3^CR5/8 N^Q5/8N^Q2/35/8^CRL_F 17/8 $ff^{5/8}\%0^{1/3}-\%1/3-1/3$ $L_{F}N_{L}^{1/3}N_{L}^{5/8}$ $1/3^{L}_{F}L_{F}^{5/8}N^{2/3}\%0RsPt$



AN ISO 9001 : 2015 CERTIFIED COMPANY

MAP

[NPCS/5515/24212] Page No. **17**



Demographics

11/81/8 V_TH_T€5/83/8 2/3**Rs** N_L@5/8 N°V_T-€1/8€H_T1/3/00€N_LRs €-1/8^CR5/81/3^LF5/83/8 2®2 %\Nº1/2 in© LFFF Nº€; NL1 n22 %\Nº1/2 i1/222 LFFF Nº€; Pt[41]—1—LF58FFVT58—NL900Rs£ $^{N}_{L} @ 5/8 \\ ^{H}_{T} {}^{1}_{T} {}^{V}_{T} \%_{0} {}^{1}/_{3} {}^{N}_{L} \\ \in ^{1}_{A} \\ \stackrel{}{\vdash}_{R} 5/_{8} {}^{1}/_{3} \\ ^{}{\vdash}_{F} 5/_{8} 3/_{8} \\ ^{2}/_{3} R_{S} \\ ^{\otimes 0}_{\star} \\ \pounds \\ ^{7}/_{8} \\ \stackrel{}{\vdash}_{R} ^{1} N^{\circ}_{2} \\ ^{1}/_{4} \\ \stackrel{}{\vdash}_{L} ^{\circ}_{1} {}^{1}/_{4} \\ \stackrel{}{\vdash}_{L} \\ \stackrel{}{\vdash}_{L} \\ \stackrel{}{\downarrow}_{R} \\ \stackrel{}{$ $\frac{1}{2^{220}} \frac{1}{8^5} - \frac{1}{F} \frac{1}{7} - \frac{1}{F} \frac{1}{10} \frac{1$ $N^{9} \in \mathbb{R}^{1/3} - \mathbb{N}_{-} \vdash 7/8^{-} = 7/8^{-} + 1 \times \mathbb{R}^{1} \times \mathbb{R}^{1}$ N_®5/8 -1/3 N_€1-\$-F fourth most populous cityPt "LF 17/8 1/2 aoo € N_®5/8 H11H1 V1001/3 N_€1-"@@0001N²⁵/8^ER¹/3^NL€1— ®1/3³/8 1/8⁵/8-L_FV_TL_F£ N_L[®]5/8 +Rs³/8⁵/8^LR¹/3²/3¹/3³/8 ffi^LR²/3¹/3-H_T1H_TV_T‰1/3N_L€1- 17/8 ®£®¢¤£1/41/4¢£ Nº1/3°V₁€-® €N_L N_L®5/8sixth most populous urban agglomeration \in – $^{N_L@5/8}$ $^{1/8}^{1}$ V_T – N_L E_R RsPt ff $^{@5/8}$ H_T 1 H_T V_T W_1 V_1 E_1 − 17/8 5/8^LF^NL€Nº1/3^NL5/83/8 2/3Rs 5/8%05/81/8NL1^CR1/3%0 17/87/8€1/8€1/3%0^LF NL1 $N^{\circ} \in \%0\%0\%0 \in 1-1\%^{-17/8} \times 5\%1\%^{-17/8} \times 10^{-17/8} \times 10^{-17/$ $^{\underline{02}} \quad N^{\underline{0}} \in \% \\ 0\% \\ 0\% \\ 0 = 1 - 2\% \\ Rs \quad ^{N} \\ 0 = 5/8 \quad ^{1} \\ 3/8 \quad ^{N} \\ 0 = 5/8 \quad ^{1} \\ N \\ 0 = 1/2 \quad ^{1} \\ N \\$ $N^{21/3}\%_{0}^{5/8} \quad {}^{1/3} - {}^{3/8} \quad {}^{1/4} \pounds^{1/4} {}^{2} \mathfrak{Q} \pounds^{2n} {}^{0} \quad {}^{7/8} {}^{5/8} N^{21/3} \%_{0}^{5/8} \quad {}^{1/8} \pounds^{N} \mathcal{L} \in \mathbb{N} \\ \mathbb{L} = \mathbb{N} \\ \mathbb{L} \times \mathbb{N} \\ \mathbb{L} = \mathbb{N} \\ \mathbb{L} \times \mathbb$ $7/85/8 N^{9} 1/3 \%_{0} 5/8^{L}_{F} \qquad {}^{1} 1/3 \%_{0} 5/8^{L}_{F} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} + {}^{1} 1/3 \%_{0} +$ $\frac{1}{3} \odot \frac{5}{8} = \frac{1}{3} \odot \frac{5}{8} = \frac{17}{8} \times \frac{$ $\frac{1}{4} \cdot \frac{1}{4} \cdot \frac{1}$ $H_{T5\%}E_{R} = \frac{0.0242}{1.00}P_{t} \times \frac{1}{2} \times \frac{1}{2$ $@x P_t @x _* \text{?£} @ \neq @05 \%^{\square}_{R} & \text{$^{N_t} @_{1/3} - $^{N_t} @_{5/8} = 1/3 N_t = 1 - 1/3 \%_{0}} & \text{$^{N_t} @_{5/8} = 1/3 M_{0} =$ L_F11/8€1¥5/81/81—1N⁰€1/8 L_FN_LL_R1/3 N_L1/3 1/81—L_F€L_FN_L 17/8 1/2 upper class£ 22 middle class 1/3-3/8 1/4^a working classPt

Economy





■5% CR®13 HT LF 17% Nº1 CR5% €NºHT 1 CRNL 1/3 — 1/85% £ ®1₩5% **3**5% CR£ €LF †Rs³/₈⁵/₈^C_R1/₃²/₃1/₃³/₈' ^L_F 5/₈N⁰5/₈^C_R®€−® 7/₈^V_TN_L V_TC_R5/₈ 1/₃^L_F 1−5/₈ 17/₈ ‡−3/₈€1/₃' ^L_F 1/85/8-NL^CR1/3/3/0 ‡-7/81^CRN^Q1/3/NL€1- ff5/81/8[®]-1/3/1[®]Rs 1/3-3/8 #ff 5/8-1/32/3\\005/83/8 L_F5/8^CR**⊕**€1/85/8 ®^VT²/₃^LFPt ff¹ ³/₈¹/₃^NL⁵/₈£ N²1/₃-Rs ^LF¹7/₈^NL₩ 1/₃^LR⁵/₈£ ²/₃^VT^LF€-5/₈^LF^LF HTCR11/85%-FCF 1VTNLLF1VTCR1/8€-® ;-■■;£ 1/3LF ₩5/800000 1/3LF 1/81/300000 1/85%-NL5%CR 7/8€CRNºLF @1/3 **@**5/8 NL1/3 %15/8 — VTHT 17/87/8€1/85/8 €— †Rs3/85/8^CR1/32/31/33/8Pt ff@5/8 1/8€NLRs ®1/3^LF 2/3⁵/8¹/8¹N²⁵/8 ®1N²⁵/8 ^NL¹ "N²⁵/8^LR€1/8¹/3− ‡ff ®€1/3−^NL^LF ^LF^VT1/8® 1/3^LF ‡−●£ <5/8/00%£ ■ FR1/31/80/05/8£ 1/3-3/8 □ 5/8-5/8 FR1/30/0 ,0/05/81/8 NL FR€1/8 Pt + Rs3/85/8 FR1/32/31/33/8 ®1/3 F 1/30/0 F1 $^{N}_{L}$ $^{05}/_{8}$ $^{7}/_{8}$ $^{1}_{R}$ $^{5}/_{8}$ $^{N}_{L}$ $^{1}_{F}$ $^{N}_{L}$ $^{1}_{L}$ 1 1 1 1 1 7/81[□]R ●€1/8^CR1^LF17/8^NL —€^LRs£ 1/3 ^L¹₩+--L=®€++ ++-L®5%+++++5%3% ₩€^L® L=^L1/3^L5% 17% ^L®5<u>% 1/3</u>L2^L N_{_}5%1/8®—10001®€5%LF 1/3—3/8 7/81/31/8€000€N_{_}€5%LF£ 1/3000LF1 ®5%000H_T5%3/8 H_TCR1NºH_T1



_@1^CRNL%0Rs£ 1/3^CR5%1/3^LF 17% ‡—3%^VT^LFNL^CR€1/3%0 □^CR1₩NL® €— †Rs3%5%^CR1/32/31/3%

- •#ff #-3%VTLFNLERRs
- •-H_T€1/85/8LF
- •■1^VT%0^NL^CRRs ○1/3^CRNº€-®
- •-^V7%0% (^CR^V7®^LF 1/3-3/8 ■®1/3^CRNº1/31/85/8 V_TN_L€1/81/3%0^LF
- $\bullet ff^{1} {}^{V_{T}} {}^{C}_{R} { \in }^{L}_{F} N^{\circ} \ {}^{1}\!\!/_{3} + {}^{3}\!\!/_{8} \ {}^{1}\!\!/_{2} + {}^{8} {}^{C}_{R} {}^{N}_{L} {}^{1}\!\!/_{3} { \in } N^{\circ} {}^{5}\!\!/_{8} {}^{N}_{L} \ {}^{+} {}^{3}\!\!/_{8} {}^{V_{T}} {}^{L}_{F} {}^{N}_{L} {}^{C}_{R} Rs$
- •○113% ¶ "®□R1 HT□R111/85%□F□F€-® 5%Ħ1/85%HTNL NL□R1/33%€NL€1-1/300 €-3%VT□FNL□R€5%□F
- •■5/8N CR10005/8 VTNº£ ■5/8N CR1¥1/8®5/8Nº€1/81/3000 LF
- --@5/8Nº€1/81/3%0LF ¶ O5/8CRNL€600€MD5/8CRLF
- • € 5% CR1/3 000 2/31/3 CF5/83/8 € 3% VT CR € 5% CF
- •-€1N_L5/81/8®-10/001®Rs
- •>-58^LR®Rs -1/3 € = 0 (5/8 € 1/85/8 LF£ "HTHT 00 € 1/3 1/85/8 LF£ 5/8 NL 1/8 Pt



Culture and Attitudes

Transport



H_T1/3^LF^LF⁵/8-@⁵/8^LR^LF 3/81/3€%0RsPt —1NºHT%05/8Nº5/8—NL€—® N @5/8L=5/8 1H_T5/8^LR¹/3^NL⁵/8 7/8^CR¹Nº †Rs³/8⁵/8^CR¹/3²/3¹/3³/8³ N_L[®]5/8 N²1/3 € -£ 1/3 -3/8 % 1/3^CR[®]5/8 C_FN_L£ C_FN_L1/3 N_L€ 1 -€^L_F -5/81/8 V_T -3/85/8 ^ER1/32/31/33/8 □ 1/3 € 0/0 ₩ 1/3 Rs - N_L 1/3 N_L € 1 - £ ₩ ® € 1/8 ® L_F5/8 R 35/8 F MD1_5/8 ®5/81/33/8 FF VT1/3 FRN_5/8 FR F 1/3-3/8 1/3 ® VT2/3 7/81 FR 2/31 N_0 2/3 VT F5/8 FF 1/3-3/8 ● ● ff-†Rs³/8⁵/8^CR¹/3²/3¹/3³/8 1/3^CR⁵/8 †Rs³/8⁵/8^CR¹/3²/3¹/3³/8 (5/8¹/8¹/8¹/3 — N_L¹/3 N_L€1—£ SM¹/3¹/8[®]€[®] V_T³/8¹/3 -5/8¹ TN¹ T⁵/8 L □1/3€‰₩1/3**R**s -N_L1/₃N_L€1-£ □1/3€‰₩1/3**R**s _N_1/3N_L€1_ R € -@1/3 NºH_T1/3 %0 %0 Rs □1/3 € %0 ₩1/3 Rs -NL1/3 NL € 1 - Pt ff®5/8 †Rs3/85/8 ER1/32/31/33/8 ●5/8 NL ER1 £ 1/3 -5%₩ ^CR¹/₃^HT€³/₈ ^N ^CR¹/₃-^LF€^N ^L FRs^LF^N ^L5/₈N⁹£ €^LF N ^L1 2/₃5/₈ 1/₃3/₈3/₈5/₈3/₈ N ^L1 N [©]5/₈ L_F1/₈®5/₈3/₈V_T0/₀₀5/₈3/₈ N_L1 1H_T5/₈E_R1/₃N_L5/₈ N_L®E_R5/₈5/₈ 0/₀₀€ −5/₈L_F 2/₃Rs 1/₂⁸⁰2Pt



Introduction

The Active Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways.

Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place.

The similar terms active pharmaceutical ingredient and bulk active are also used in medicine, and the term active substance may be used for natural products. $-^1N^{25}$ % N^{25} % 8^{1} % 1^{1} %

1/81-LFNL€NLVT5/8-NL ff^{®5}/8 N 5/8^CRNºLF 1/31/8NL€**®**5/8 1E_R 1/31/8^NL€**3**5/8 H_TC_R€-1/8€H_T005/8 1/3C_R5/8 17/8N_L5/8- 1/8®1L_F5/8- ₩®5/8- C_R5/87/85/8C_RC_R€-® N_L1 N_L®5/8 1/31/8N_L€®5% LFVT2/3LFN_1/3-1/85/8 17/8 €-N_5% LFN_L €- 1/3 HT001/3-N_L ;LFVT1/8® 1/3LF L_F1/₃%0€1/8R_S%0€1/8 1/₃1/₈€3/8 €- ₩€%0%01₩ 2/₃1/₃L_R% 1L_R 1/₃L_R5/₈1/₈1/60€-5/8 €-1/3[□]R5/81/81/3 - V_TN_L L_{F/,£} 2/35/81/81/3 V_TL_F5/8 N_L®5/8 ₩1[□]R3/8 €-®□R5/83/8€5/8-N_L €- N□1/3-Rs Nº€-3%^LF 1/8¹--1^N-5/8^LF 1/3 ^LF5/8-^LF5/8 17/8 ® V_TNº1/3- 1/3®5/8-1/8Rs i^NL®1/3^NL L_F1N⁰⁵/₈N₁ ®€ _0 ₩€N® N @1/3 N 1/3 H_T5/8^CR^LF¹-1/81Nº2/3€-5/8LF L=V_T2/3 L=N_L1/3 − 1/8 5/8 L=7,£ ₩®5/8 L=5/8 1/3 L= N_L®5/8 − 1/3 N_L V_T L=1/3 % N₀ H_T L= H_T L=5/8 L=5/8 − N_L €- H_T1/3-N_L-F ₩5/8^ER5/8 -1N_L 1/33/83/85/83/8 2/3Rs 1/3-Rs ® V_TN^Q1/3- 1/3®5/8-1/8Rs 2/3 V_TN_L F_R¹/₃N_L⁰⁵/₈F_R 11/₈1/₈V_TF_RF_R5/₈3/₈ −1/₃N_LV_TF_R1/₃%₀%₀Rs ¡○1/₃ H_T%₀1/₃−N_L 3/₈15/₈F_F−§N_L ®1/₃⊕5/₈ E-@^CR⁵/8³/8€⁵/8-NL^LFO;



Metformin

Introduction

Metformin, sold under the brand name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. It is not associated with weight gain and is taken by mouth. It is sometimes used as an off-label augment to attenuate the risk of weight gain in people who take antipsychotics as well as phenelzine.

●5%NL7%1 ¬RNº€- €-F ®5%-5% ¬R1/3 % 0 % NL1 % 5% ¬R1/3 NL5% 3% Pt -1 Nº Nº1-3/8€1/3^CR^CR®5/81/3£ 1/33/8**@**5/8^LR^LF⁵/8 5/87/87/85/81/8^NL^LF €-1/80%0 V_T3/85/8 $-\frac{1}{3}V_{T}^{L} = \frac{5}{8}\frac{1}{3}$ 1/3/3/3/8/1Nº€-1/3/00 HT/3/€-Pt ‡NL ®1/3/F 1/3 %01₩ TR€F% 17/8 1/8/1/4F€-® %01₩ 2/3/6/11/3/8 Nº5/8³/8€1/81/3NL€1- €LF VTLF5/8³/8 €- 1\\$5%ER\00R\$ \001/3ER\05/8 3%1LF5/8LF 1ER HTER5/8LF1/8ER\€2/35/83/8 €- H_T5%1H_T5%5% ₩€NL® L_F5%**®**5%E_R5% %€3%-5%Rs H_TE_R12/3%5%NºL_FPt ‡NL €L_F -1NL ●5%NL7%1^LRNº€- €LF 1/3 2/3€®V_T1/3-€3%5% 1/3-NL€®RsH_T5%E_R®90%Rs1/85%Nº€1/8 1/3®5%-NLPt ±NL ₩¹┗R%┗F 23Rs 3858186┗R\$ 385818 FR\$ 818 FR\$ 888 N_058 €-1%^LR5%1%^LF€-® N_0% €-^LFV70%€- LF5%-LF€N_L€**®**€N_LRs 17% 2%13%Rs N_L€LFLFV75%^LF£ 1/3-3% $2\% \text{Rs} \hspace{0.2cm} \text{$=$^{1}\%^{\square}_{R}$} \hspace{0.2cm} \text{$=$^{1}\%^{\square}_{$ 1/81/3%01[□]R€1/8 €-NL1/3%15/8Pt

●5% N_7% 1 CRNº ← ₩1/3 LF %8 € LF1/81 **6**5% CR5/8 %8 € - $^{\circ}$ \mathbb{\mathba\mathbb{\mathbb{\mathbb{\mathba\mathba{\mathba{\mathba{\mathba{\mathb



Medical Uses

Metformin is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes. With this type of diabetes, insulin produced by the pancreas is not able to get sugar into the cells of the body where it can work properly.

Using metformin alone, with a type of oral antidiabetic medicine called a sulfonylurea, or with insulin, will help to lower blood sugar when it is too high and help restore the way you use food to make energy.

Metformin is used to lower the blood sugar in those with type 2 diabetes. It is also used as a second-line agent for infertility in those with polycystic ovary syndrome.

Type 2 Diabetes

Efficacy

The U K Prospective Diabetes Study, a large clinical trial performed in 1980–90s, provided evidence that metformin reduced the rate of adverse cardiovascular outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents. Accumulated evidence from other and more recent trials, though, reduced confidence in the efficacy of metformin for cardiovascular disease prevention. Outcomes are improved even in those with some degree of kidney disease, heart failure, or chronic liver disease.





Polycystic Ovarian Syndrome

‡- N_@1LF58 ₩€N_@ HT136Rs18RsLFN_€18 1@13CR€13- LFRs-38CR1N258 ; ----;£ N_L5%-N_L1/3N_L€**6**5% L_F®1₩L_F N_{L®1/3}N_L N²⁵/₈N_L⁷/₈1^E_RN²€− 5/8**3**€3/85/8−1/85/8 €-1/8^CR⁵/8¹/3^LF⁵/8^LF N_L®5/8 CR1/3 N_L5/8 17/8 000€ 5/8 2/3€ CRN_L®LFPt ff®€ LF €-1/8 000 YT3/85/8 LF €- $^{N}_{L} @_{1}^{L} = 5\% \qquad \qquad \\ ^{M} @_{1} \qquad @_{1}^{3} \textcircled{\textcircled{\textcircled{0}}} 5\% \qquad \qquad \\ -^{1}N_{L} \qquad 2\% 5\% 5\% \qquad \qquad \\ ^{1}/_{2} 2\% 5\% 5\% 5\% \qquad \qquad \\ ^{1}/_{2} 2\% 5\% 5\% \qquad \\ ^{1}/_{2} 2\% 5\% 5\% \qquad \\ ^{1}/_{2} 2\% 5\% 9\% \qquad \qquad \\ ^{1}/_{2} 2\% 5\% 9\%$ 1/80/00¹Nº€HT®5/8−5/8Pt ●5/8NL7/81□RNº€- 3/815/8□F -1NL 1/3HTHT5/81/3□R NL1 1/8®1/3-®5/8 NL®5/8 ^L_R€^L_F% 17/8 N°9€^L_F1/81/3 ^L_R^L_R€1/3 ®5/8 1/3 - V_TN°2/35/8 ^L_R 17/8 1N_L®5/8 ^L_R 2/35/8 - 5/87/8€N_LL_F ®1/3 **®**5/8 7/81 V_T −3/8 2/31 N_L® 3/8 V_T □_R € −® H_T □_R5/8® −1/3 −1/8 Rs 1/3 −3/8 € − 2/35/85/8--1-H_TC_R5/8®-1/3-N_L ₩1N²⁵/8- ₩€N_L® ■-■-Pt ‡- 1/3- V_TH_T3/81/3N_L5/83/8 -11/8®C_R1/3-5/8 ^CR⁵/8**⊕**€5/8₩ **1**42 Nº5/8^NL⁷/8¹[□]RNº€-⊕5/8^CR^LFVTLF $H_{T}\%01/31/85/82/31f - 1$ $1/2^{\frac{a}{2}}/2^{\frac{a}{2}}$; N_ CR5/81/3 N_N°5/8 - N_ 2/35/87/81 CR5/8 1 CR 3/8 YT CR€ - ® \$\ff| O f \$\dagger + \dagger + \d -1 1/81-1/80% \rangle ₩¹/₃¹F 7/81VT-3%Pt ‡- 1001-100 □-□+¥1/3001-€¹FNL HTER1NL11/81000¹F NL005/8ER5/8 ₩1/3¹F V_T-1/85/8^ER^NL1/3€-NLRs €- NL®5/8 5/8 **⊕**€3/85/8-1/85/8 17/8 €N^{QH}T^ER1 **⊕**5/83/8 0/0€ **⊕**5/8 2/3€ ^ERNL® Nº5/8^NL⁷/8¹^E_RNº€− Nº1/₃Rs V_T-1/85/8^LR^NL1/3€-NLRs 1- €NLLF 5/87/85/81/8NL 1- 1/80/0€-€1/81/30/0 H_T^LR5/8®-1/3-1/8Rs $^{\Gamma_{R}1/_{3}N_{L}5/_{8}P_{t}} \quad \bullet ^{5/_{8}N_{L}7/_{8}1} \\ ^{\Gamma_{R}N_{2} \in -} \quad N^{21/_{3}}Rs \quad ^{\Gamma_{R}5/_{8}L_{F}V_{T}} \\ ^{N_{L}} \stackrel{\leftarrow}{=} \quad 1/_{3} \quad ^{\Gamma_{R}5/_{8}3/_{8}V_{T}1/_{8}N_{L}} \\ \stackrel{\leftarrow}{=} \quad 1/_{7} \quad \bullet ^{17/_{8}N_{L}} \\ \stackrel{\leftarrow}{=} \quad 1/_{7} \quad ^{17/_{8}N_{L}} \\ \stackrel{$ 2/3 V_TN_L 1/8 1 V_T0/0 3/8 1/8 1 N²5/8 ₩ € N_L 0 1/3 Θ^CR 5/8 1/3 N_L 5/8 C_R 7/8 C_R 5/8 F_F V_T 5/8 − 1/8 R_S 17/8 C_F € 3/8 5/8 5/87/87/85/81/8N_L=Pt ff@5/8-R5/8 ₩1/3-E V_T-1/85/8-RN_1/3-E-N_Rs 1/3-E N_1 Nº5/8N_7/81-RNº€-Ş-E €NºHT1/31/8NL 1- Nº€LF1/81/3CRCR€1/3®5/8Pt ff®5/8 5/8�€3/85/8-1/85/8 3/815/8LF -1NL LFYTHTHT1CRNL ®5/8−5/8^CR¹/3⁹/₀ V_T^LF⁵/8 3/8 V_T^CR€−® H_T^CR⁵/8®−1/3−1/8Rs 7/8¹^CR €N²H_T^CR¹**3** €−® N²1/3 N_L5/8^CR−1/3 % $1/3 - 3/8 \in -7/81/3 - N_L 1 V_T N_L 1/81 N_L 9/8 - F \in -12/35/8 - F_5/8 + 1 N_L 9/8 - P_t$



women with glucose intolerance. The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of $3\%5\%65\%\%1^HT=0$ 0 NLRs $^HT5\%8$ 1/2 $3\%65\%3^HL5\%8^HT$ 1 N $^{9}5\%9\%9\%9\%1^HT^{1}=0$ 0 NLRs $^HT5\%8$ 1/2 $3\%65\%3^HL5\%8^{H}=0$ 1 N $^{9}5\%9\%9\%9\%1^{H}=0$ 1 N $^{9}5\%9\%9\%9\%1^{H}=0$ 1 N $^{9}5\%9\%9\%1^{H}=0$ 1 N $^{9}5\%9\%1^{H}=0$ 1 N $^{9}5\%9\%1^{H}$

Chemistry

;°£°¥3%€N°5%°L°Rs%°2/3€°°VT1/3−€3%5/8 ●5/8^NL7/8¹C_RN¹€- ®Rs3/8^CR11/8®0/00¹C_R€3/85/8 ®Rs3/8^LR11/8®0/001^LR€3/85/8; L_F10/00 V_T2/30/005/8 €F ⁷/₈^E_R⁵/₈⁵/₈% Rs €-₩1/3^NL5/8^ER£ L_F‰€®®N_L‰Rs L_F10‰V_T2/3‱5/8 €- 5/8N_L®1/3-10‰£ 2/3 V_TN_L 1/3 6/3 N^Q1 L_FN_L €-L_F10‰V_T2/3 0/05/8 €- 1/31/85/8^NL1-5/8£ 5/8^NL®5/8^CR£ 1^CR 1/8®%01^CR17/81^CRN^QPt ff®5/8 ^HT^{SM1}/3 17/8 N^{Q5}/8^NL7/81^CRN^Q€-€L_E º1/₂P_t¢P_t $ff^{\odot}5/8$ V_TL_FV_T1/3%00 LFRs-NL®5/8LF€LF 17/8 N²⁵/₈N_L7/₈1^C_RN²€-£ ${}^{1} \stackrel{\Gamma}{\Gamma}_{R} \in \emptyset \in -\frac{1}{3} \% \% \stackrel{\Gamma}{N} = \frac{3}{8} \stackrel{\Gamma}{N} = \frac{2}{3} \frac{5}{8} \frac{3}{8} = \frac{9}{4} \frac{1}{2} \frac{1}{2} \stackrel{\Gamma}{\Sigma} = \frac{1}{3} \frac{1}{3$ ^L_R5/81/31/8^N_L€1 - 17/8 3/8€N^Q5/8 N_L®Rs⁰0/13N^Q€ -5/8 ®Rs³8^LR¹¹/8[®]0/01^LR€3/85/8 1/3 -3/8 1/8Rs 1/3-1@ V_T1/3-€3/8€-5/8 1 **3** 5/8 □_R ®5/8 1/3 N_L Pt



Chemical & Physical Properties

 6 8-LES 9 Pt 1 4± 2 Pt 9 9 f 1 8N 9 1/4

●1%05%1/8 V T%01/3 L R ○1 L RN 2 VT%01/3 — $_{\phi}$ † $_{22}$ 02

●10%05/81/8V_T0%01/3^LR fi5/8€@®N_L 21/2¤Pt^{on}¢


0%01/3^LF® ■1€-N_L 2©Ptº±1/21/2Ptn °-

,₩1/31/8^NL •1/3^LF^LF •1/2^QPt⁰⁸⁰¢¢⁸

-†>•‡-"R ∘"•> -€®V_T1/₃-€3/₈5/₈£ °£°¥3/₈€N°5/₈N_L®Rs%∘¥

—"- □¬□‡-ff□... offi •->□ n2®¥1/2¢¥¤

Chemical Structure:



 ${}^{\underline{\circ}} \underline{\mathsf{Y}} {}^{3} \! / \! \underline{\mathsf{N}} {}^{\underline{\circ}} \! / \! \underline{\mathsf{N}} {}^{\underline{\circ}} \! / \! \underline{\mathsf{R}} {}^{\underline{\circ}} \! / \! \underline{\mathsf{N}} {}^{\underline{\bullet}} \! / \! \underline{\mathsf{N}} \! / \! \underline{\mathsf{N}} {}^{\underline{\bullet}} \! / \! \underline{\mathsf{N}} {}^{\underline{\bullet}} \! / \! \underline{\mathsf{N}} \! / \! \underline{\mathsf{N}} {}^{\underline{\bullet}} \! / \! \underline{\mathsf{N}} \! / \! \underline{\mathsf$

°£°°¥3/8€N°5/8°NL®Rs%°°2/3€®VT1/3−€3/85/8°®Rs3/8°ER11/8®%°°1°ER€3/85/8



Product Detail

Specification:

Name ●5%NL7%1^LRNº€- †—R

Cas No

MF $-_{\phi} +_{\frac{91}{2}} - \frac{9}{00} +_{\frac{9}{2}}$

Mol. mass $^{\underline{\circ}n2}P_{t}^{n1}/_{2}\mathcal{C}^{n}$

Grade ●5/83/8€1/8€-5/8 ®□R1/33/85/8

Assay ¤¤Ptn*

Melting point $\frac{1}{2}\frac{1}{2}\frac{1}{4}\frac{1}{2}\frac{1}{2}^{n^{o}}$

Boiling point $\frac{1}{2}\frac{1}{2}\mathbb{C}\mathbb{R}^{9^{\circ}} - \frac{1}{3}\mathbb{N}_{1} \otimes \mathbb{N}^{2}\mathbb{N}^{9}$

Usage †Rs^HT¹®‰Rs¹½⁵½N°€¹½



Raw Material-Description

The main raw materials that are required.

«€1/8Rs1/3-3/8€1/3Nº€3/85/8

■C_R13/8V_T1/8N_L -1/3N^{Q5}/8

³/₄ (€1/₈Rs1/₃−3/₈€1/₃Nº€3/₈5/₈

3/₄ ¢nº¥2©¥2

●1%05/81/8VT%01/3^LR 7/81^LRNºVT%01/3 3/4 —1/2†¢°¢

●1005/81/8V_T001/3^ER ₩5/8€®®N_L 3/4 ©¢Pt²©

"H_TH_T5/81/3^ER1/3-1/85/8

3/4 — FRRs FNL1/30/00 ■1₩3/85/8 FR

«€Nº5/8NL®Rs%01/3N°Nº1-€VTN° -®%015R€3/65/8

 $N^{\circ H}T$

onao_

2/3 V_T%0°/_u 3/85/8−L_F€N_LRs

 $2^{22} C_{W} f N^{21/4}$

L_FN_L1^C_R1/₃®5/₈ N_L5/₈N^{9H}_TP_t

1/2¥1/4ª0—




Manufacturing Process of Metformin

The manufacturing method of metformin is start with reaction with the charging dicyanodiamide, dimethylammonium $1/8^{\circ}\%^{1}$ R=3/8 1/3 A=3/8 1/3 A=3/8 1/3 A=3/8 1/3 A=3/8 1/3 A=3/8 1/3 A=3/8 A=

- $\circ \text{ "3/8}^3 \text{ $858N^9$} = -58^{\Box}_{R}^{1/3}\%_{0} \text{ $$ $^{MD5/8}$}^{3/8} \text{ $$ $$ $$ $$ $$ $^{L}_1$ $^{N}_L \circ 5/8$ $^{L}_R$ $^{N}_L \circ 5/8$ $^{L}_R \circ 5/8 \circ 1/3 \circ 1/8 $^{L}_L \circ 1/3 3/8$ $^{N}_L \circ 5/8$ $^{L}_R \circ 5/8 \circ 1/4 9/4 $^{L}_R \circ 5/8$ $^{L}_R \circ 1/3 3/8$ $^{L}_R \circ 1/3$
- $\circ \quad \text{ff}^{1/3}\%_{1}\%_{8} \ ^{\text{L}}_{\text{F}}^{1/3}N_{2}^{\text{QH}}_{\text{T}}\%_{0}\%_{8} \ ^{1/3}_{3}-3/8 \ ^{\text{L}}_{\text{F}}^{5/8}-^{\text{N}}_{\text{L}} \ ^{\text{N}}_{\text{L}}^{1} \ ^{\text{F}}_{\text{F}}^{\text{V}}_{\text{T}}^{1/3}\%_{0} \\ \overset{\text{C}}{\in}^{\text{N}}_{\text{L}} \text{Rs} \ ^{1/8}_{1}-^{\text{N}}_{\text{L}}^{\text{E}}_{\text{R}}^{1/9}\%_{\text{Pt}} \\ \overset{\text{C}}{\mapsto}^{\text{N}}_{\text{L}}^{1/3}\%_{0} \\ \overset{\text{C}}{\in}^{\text{N}}_{\text{L}} \text{Rs} \ ^{1/8}_{1}-^{\text{N}}_{\text{L}}^{\text{E}}_{\text{R}}^{1/9}\%_{\text{Pt}} \\ \overset{\text{C}}{\mapsto}^{\text{N}}_{\text{L}}^{1/3}_{\text{L}}^{1/9} \\ \overset{\text{C}}{\mapsto}^{\text{N}}_{\text{L}}^{1/9}_{\text{L}}^{1/9}_{\text{L}}^{1/9}_{\text{L}}^{1/9}_{\text{L}}^{1/9}_{\text{L}}^{1/9}_{\text{L}} \\ \overset{\text{C}}{\mapsto}^{\text{N}}_{\text{L}}^{1/9}_{\text$
- $\circ \quad \text{``7'8}^N L^{5/8}^C R \quad \text{'1'3}^H T^H T^C R^1 \textcircled{3}^1 \text{'3}\% 0 \quad \text{'17'8} \quad \text{$^{L}_{F}}^1 \text{'3} N^{9}^H T\% 0^5 \text{'8} Pt$
- $\circ \quad \mathsf{ff}^{@5}\!/\!\!\! 8 \ \mathsf{N}^{@1}\!/\!\!\! _3 ^\mathsf{N}\!\!\! _\mathsf{L}^{5}\!/\!\!\! _8^\mathsf{E}_\mathsf{R} {\in} ^1\!/\!\!\! _3 ^\mathsf{N}\!\!\! _0 \ \in ^\mathsf{L}_\mathsf{F} \ ^\mathsf{H}_\mathsf{T}^1\!/\!\!\! _3^1\!/\!\!\! _8 ^\mathsf{N}\!\!\! _0^{5}\!/\!\!\! _8^{3}\!/\!\!\! _8 \ \in \ ^2\!/\!\!\! _3^1 \mathbf{N}^5\!/\!\!\! _5^\mathsf{L}_\mathsf{F}$







Handling and Storage

Precautions for Safe Handling

- "3/8 € 1/85/8 1- LF1/37/85/8 @1/3-3/80/0€-@
- "**@**¹€¾ ½¹-½½½½½ ₩€½© └ç¼€- ½-¾ 5%Rs½ └çPt "**@**¹€¾ 7½¹[∠]RNº½½½€¹17% ¾ └√ç½ ½36 ¼5% └çPt
- ■FR1@€3/85% 1/3 HT HT FR€1/3 N_5% 5%#O1/3 YT FN @5%-N_€%01/3 N_€1- 1/3 N_ HT %01/3 1/8 5% FF ## @5% FR5% 3/8 YT FN €FF 7/8 1 FRN €563/8 Pt

Hygiene Measures

- f % % % = %

Storage Conditions

- \$\sin_6^5/8^H_T \quad \gamma^1-\sum_1\gamma\gamma\in -5/8^F_R \quad \text{\infty} \end{aligned \text{\infty} \in \gamma\gamma\infty \frac{\text{\infty} \text{\infty} \

Storage Stability

- □5/81/81NºNº5/8-3/85/83/8 LFNL1CR1/3/®5/8 NL5/8NºHT5/8CR1/3 NLVTCR5/8 1/2 ¥ ©°—



Personal Protective Equipment

>Rs 5/8 f 7/8 1/3 1/8 5/8 ■ CR 1 NL 5/8 1/8 NL €1-

- -1/37/8⁵/8^NLRs ®%01/3^LF^LF⁵/8^LF ₩€^NL® ^LF€³/8⁵/8¥^LF®€⁵/8%03/8^LF 1/81-7/8¹^LRN^Q€ -® NL 1 >0^{Qnn} ffi^LF⁵/8 ⁵/8^FF^VT€^HTN^{Q5}/8-NL 7/8¹^LR ⁵/8Rs⁵/8 ^HT^LR¹NL⁵/8¹/8^NL€¹- NL⁵/8^LF^NL⁵/8³/8 1/3-3/8 1/3^HT^HT^LR¹ ⊕⁵/8³/8 V_T-3/8⁵/8^LR 1/3^HT^HT^LR¹H_T^LR€¹/3^NL⁵/8 ®¹ ⊕⁵/8^LR-N^{Q5}/8-NL ^LF^NL¹/3-3/8¹/3^LR³/8^LF ^LF^VT¹/8[®] 1/3^LF

- °‡■-† ¡fffi-¿ ¹□R › ° ºnn; › ffi¿Pt

Skin Protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. $\langle \in \vdash_{\mathsf{F}} \vdash_{\mathsf{T}} \vdash_{\mathsf{F}} \vdash_{\mathsf{S}} \rangle$ 17/8 $18/1 - \mathsf{N}_{\mathsf{L}} \cdot \mathsf{1}/3 \mathsf{N}^{2} \in -1/3 \mathsf{N}_{\mathsf{L}} \cdot \mathsf{5}/8 \cdot \mathsf{3}/8$ $9\%0^{1} \cdot \mathsf{9} \cdot \mathsf{5}/8 \cdot \mathsf{L}_{\mathsf{F}}$ $1/3 \cdot \mathsf{7}/8 \cdot \mathsf{N}_{\mathsf{L}} \cdot \mathsf{5}/8 \cdot \mathsf{L}_{\mathsf{F}}$ $1/3 \cdot \mathsf{7}/8 \cdot \mathsf{N}_{\mathsf{L}} \cdot \mathsf{5}/8 \cdot$

Full Contact

●1/3^NL5/8^CR€1/3‰

³/₄ ○€^NL^CR€%05/8 □^VT²/₃²/₃⁵/₈^CR

-^CR⁵/8¹/3⁶/₄ N_L®^CR¹V_T®® N_L€N²⁵/8 3/4 ¢®² N²€-

●1/3^NL5/8^CR€1/3/00 NL5/8^LFNL5/83/8 3/4 <5/8^CRN^Q1/3^NL^CR€/00®

(KCL 740/Aldrich Z677272, Size M)

-HT 1/3 1/8 NL

●1/3^N 5/8^ER€1/3%0

³/₄ ○€^NL^CR€‰⁵/₈ ^CR^VT²/₃²/₃⁵/₈^CR

 $\bullet \in - \in \mathbb{N}^{\circ} \mathbb{V}_{\mathsf{T}} \mathbb{N}^{\circ} \ \%_{0} \ ^{1} \% \mathbb{R}_{\mathsf{S}} \ ^{5} \%^{\mathsf{L}_{\mathsf{R}}} \ \ ^{\mathsf{N}_{\mathsf{L}}} \\ \bullet \in - \in \mathbb{N}^{\circ} \mathbb{V}_{\mathsf{T}} \mathbb{N}^{\circ} \ \%_{0} \ ^{1} \% \mathbb{R}_{\mathsf{S}} \ ^{5} \%^{\mathsf{L}_{\mathsf{R}}} \ \ ^{\mathsf{N}_{\mathsf{L}}} \\ \bullet \in \mathbb{N}^{\circ} \mathbb{N}^{0} \mathbb{N}^{\circ} \mathbb{N}^{\circ} \mathbb{N}^{\circ} \mathbb{N}^{0} \mathbb{N}^{0}$



 $ff^{\textcircled{\tiny 0}} \in ^{\bot}_{\textbf{R}} ^{5} 8^{1} 8^{1} N^{\textcircled{\tiny 0}} N^{\textcircled{\tiny 0}} 8^{-3} 8^{1} 3^{\textbf{N}} L \in ^{1} - \in ^{\bot}_{\textbf{F}} ^{1} 3^{3} 8 \bigoplus \in ^{\bot}_{\textbf{F}} ^{1} ^{\Box}_{\textbf{R}} Rs ^{1} - \text{$\%$} Rs ^{1} 3^{-3} 8 N^{\textcircled{\tiny 0}} ^{\textbf{Y}} L^{\textbf{F}} N_{\textbf{L}} ^{2} 2^{3} 8^{8} \\ 5^{\textcircled{\tiny 0}} 1^{3} \% 0^{\textbf{Y}} 1^{1} 3^{\textbf{N}} L^{5} 8^{3} 8 ^{2} 3^{\textbf{R}} S ^{1} 3^{-1} - \in ^{-3} 8^{\textbf{Y}} L^{\textbf{F}} N_{\textbf{L}} ^{\textbf{F}} R \in ^{1} 3^{3} \% 0 @ \textbf{Rs} @ \in ^{5} 8^{-1} L^{\textbf{F}} N_{\textbf{L}} ^{1} 3^{-3} 8 L^{\textbf{F}} 1^{3} 7^{8} 5^{8} N_{\textbf{L}} Rs \\ 1^{7} 8^{7} 8 \in ^{1} 1^{8} 5^{\textbf{N}} L^{\textbf{R}} R & 1^{3} 1^{3} N_{\textbf{L}} \in ^{-1} 1^{3} 1^{3} L^{\textbf{R}} R & 1^{3} 1^{3} N_{\textbf{L}} \in ^{-1} 1^{3} 1^{3} N_{\textbf{L}} = ^{-1} 1^{3} 1^{3} N_{\textbf{L}} = ^{-1} 1^{3} 1^{3} 1^{3} N_{\textbf{L}} = ^{-1} 1^{3} 1^{3} 1^{3} N_{\textbf{L}} = ^{-1} 1^{3} 1^{$

Body Protection

Complete suit protecting against chemicals, the type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

05% - HT € R1/3 N_1 - RRs HT - R1N 5/8 1/8 N_€1 -

 $\bigcirc^{1} \stackrel{\Gamma}{\Gamma}_{R} - \stackrel{V}{V}_{T} \stackrel{\Gamma}{=} \stackrel{1}{\vee}_{3} - \stackrel{1}{\vee}_{8} \stackrel{5}{\otimes}_{8} \stackrel{N}{H}^{+}_{T} \stackrel{1}{\downarrow}_{F} \stackrel{V}{V}_{T} \stackrel{\Gamma}{\subseteq}_{R} \stackrel{5}{\otimes}_{L}_{F} \quad \stackrel{V}{V}_{T} \stackrel{\Gamma}{=} \stackrel{5}{\otimes}_{8} \quad \stackrel{N}{\downarrow}_{R} \stackrel{N}{\downarrow}_{R} \stackrel{N}{\downarrow}_{R} \stackrel{1}{\downarrow}_{E} \stackrel{1}{\downarrow}_{E} \quad \stackrel{1}{\downarrow}_{R} \stackrel{N}{\downarrow}_{R} \stackrel{N}{\downarrow}_{E} \stackrel{1}{\downarrow}_{E} \stackrel{N}{\otimes}_{E} \stackrel{N}{\downarrow}_{E} \stackrel{N}{\downarrow}_{E}$

-1-N_CR100 17/8 >- @€CR1-Nº58-N_1/300 >N+T1-FY-CR5/8

 $\mathsf{C}_{\mathsf{F}}^{\mathsf{L}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{O}} \mathsf{I}_{\mathsf{N}}^{\mathsf{L}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{O}} \mathsf{I}_{\mathsf{N}}^{\mathsf{C}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{O}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{C}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{O}} \mathsf{I}_{\mathsf{N}}^{\mathsf{C}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{O}} = \mathsf{I}_{\mathsf{N}}^{\mathsf{C}} = \mathsf$



Amoxicillin

Introduction

Amoxicillin is an antibiotic used to treat a number of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and urinary tract infections among others. It is taken by mouth, or less commonly by injection.

Medical Uses

Amoxicillin BP

Amoxicillin is used in the treatment of a number of infections, including acute otitis media, streptococcal pharyngitis, pneumonia, skin infections, urinary tract infections, Salmonella infections, Lyme disease, and chlamydia infections.

Acute Otitis Media



Respiratory Infections

Amoxicillin and amoxicillin-clavulanate have been recommended by guidelines as the drug of choice for bacterial sinusitis and other respiratory infections. Most sinusitis infections are caused by viruses, for which amoxicillin and amoxicillin-clavulanate are ineffective. 1/3-3/8 N_L @5/8 ²/₃⁵/₈−⁵/₈⁷/₈€^NL [∞]1/₃€−5/₈3/₈ $\frac{2}{3}$ Rs €L_F L_{R5/81/81}N^oN^o5/8-3/85/83/8 "Nº1₩€1/8€‱%0€-5/87/87/85/81/8^N1 LEPt $^{H}\mathsf{T}^{\mathsf{L}}\mathsf{R}^{5}\!/\!\!8^{1}\!/\!\!8$ H_T-58 V_TNº1-€1/3 €- 1/33/8 V_T\%0 N_LL_F 2/3 Rs 1/31/8^FF \T€ \R5/83/8 N_L®5/8 01/3 N_L€1 – 1/3 %₀ [‡]-^L_F^N_L€^N_L^V_TN_L5% ⁷/₈1^C_R †5/₈1/₃% N_L® 1/₃-3/₈ —1/₃^C_R5% →N 1/₈5/₈% 0.005/₈ - 1/₈5/₈£ 5/₈€ N_L®5/₈^C_R 1/3/1001-5/8 iNº€/003/8 NL1 Nº13/85/8 FR1/3/NL5/8 F5/8 **@**5/8 FR NLRS 3/8€ F5/8/1/3 F5/8; 1 FR €- $1/_{8}^{1}N^{1} \times 1/_{3}^{2} = -1/_{3}^{1}N_{L} = 1 - \text{ W} \in N_{L}^{0} \quad 1/_{3} \quad N^{1}/_{3}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8} = 1/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1}/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1}/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{8}^{1}/_{8}^{1}/_{8}^{1}/_{8}^{1} = 1/_{8}^{1}/_{$ %0€-5% N_CR5%1/3N_N°5%8-N_ 7/81CR HT-5% N_N°1-€1/3 N_®1/3N_ €LF -1N_ OLF5% 65% CR5% OPt "Nº1₦€1%€5000€- €-F VT-F5%3% €- HT1-FN_¥5%₦HT1-FVT-R5% €-®1/3%01/3N_€1- 17% 1/3-N_®CR1/3+N_1 HTCR5/8⊕5/8-N_ 3/8€-F5/81/3-F5/8 HTCR1®CR5/8-F-F€1- 1/3-3/8 7/81-CR H_TC_R1H_T®Rs‱1/3N€L_FPt

†Pt HTRs‰1 TR€



RRSNº5/8 2/31 CR CR5/8 00€1 LF€ LF

-%€- €-7/85/81/81/€1-4F

Infections in infants in resource-limited settings

Amoxicillin is recommended by the World Health Organization for the treatment of infants with signs and symptoms of pneumonia in resource-limited situations when the parents are unable or unwil%=- $^{\odot}$ N _L 1 1 _3 1 _8 1 _8 5 _8 H _T N _L $^{\odot}$ 1 L _F H _T $^{\odot}$ N_L 1 _3 $^{\odot}$ 0 $^{\odot}$ 4 MD1 3 N 1 O 2 1 - 17 8 N 2 $^{\odot}$ 8 1 8 $^{\odot}$ 6 $^{\odot}$ 8 O 8 O 8 O 8 O 8 O 8 O 9 O 9

Prevention of bacterial endocarditis

It is also used to prevent bacterial endocarditis in high-risk people having dental work done, to prevent Streptococcus pneumoniae and other encapsulated bacterial



-1Nº2/3€-1/3NL€1- ff^ER5/81/3NLNº5/8-NL

-^H_T5%1/8^N_L^C_RV_TNº 17/8 "1/8^N_L€**⊕**€N_L**Rs**



3/85/8[©]R5/85/8^LFPt

Properties

Name : "Nº¹₦€1%€‰%€−

CAS Number : nº1/41/4n¥®ª¥®

Purity : ≥¤®_{*}

Molecular Weight : ¢°¤Pt¢²

Molecular Formula $: -\frac{1}{2} + \frac{1}{4} + \frac{1}{4} = \frac{1}{4} + \frac{1$

Appearance : ₩®€NL5% 1^ER ‰€®®NL Rs5%60001₩

1/8^CR**R**S^LF^NL1/3‱%0€−5/8 H_T1₩3/8⁵/8^CR£ NL1/3^LFNL5/8^LF

S‰€®®NL‰Rs 2/3€NLNL5%ER£ 1/3-3/8 3/8€LFLF15/6 \$5%LF €- ₩1/3NL5%ER

Raw Material

The main raw materials are:-

^⁰P_t n¥"■"

1/8[®]0/00¹ ^CR€3/85/8

 $- \ \ \, ^{\text{h}} \ \ \, ^{$

Properties

Chemical formula —⊚†2½°½■¼−

Molar mass $\frac{1}{2}^{2n}P_t\frac{1}{2}^n \otimes N^{21}\%_0-2$

Appearance 1/810/01 VT R 805/8 FF



Melting point $^{\circ}\mathbb{Z}^{\circ}$ $^{\circ}$ $^{\circ}$

Solubility in water ^aPt¢ [®]f^{oaa} N°R

■®5%-Rs% ®%Rs1%€-5% —®%01^LR€3%5% †Rs3%^LR11%hloride

39878-87-0

Physical State −1‰€3/8

Appearance R€®®NL 2/3^CR1₩−


Melting Point/Range ²⁸⁸ °—

Manufacturing Process

- 1/8®1/3 □R®5/8 ₩1/3 N_5/8 □R €-N_1 N_05/8 □R5/81/31/8 N_1 □R
- 1/₃3/₈3/₈ n¥"∎"
- 1/8110/00 NL1 0a 0__
- "3/83/8 1/81/3 NL1/3 % oRs LFNL
- 1/33/83/8 ₩1/3^NL5/8^CR
- L_FN_L€C_R 7/81C_R n ®1 V_TC_RL_F 1/3N_L 22 0_Pt
- 1/3³/8³/8 ₩1/3^NL⁵/8^ER
- 7/8€%0^NL5/8^CR
- "3/83/8 1/81/3^ER²/3¹—
- "3/8% VTLFNL HTT
- 1/8^CRRs^NL1/3%0€MD5/8
- 7/8€‰^NL5/8^CR
- (^CRRs V_T-3/85/8^CR **3**1/31/8 V_T V_TN^oPt
- □581/858€\$58
 N_058
 1/3N_01\$\delta \in 1/8 \in 8/60\$\widehta \in 1/8 \i




Process Flow Diagram






AN ISO 9001: 2015 CERTIFIED COMPANY





AN ISO 9001: 2015 CERTIFIED COMPANY





Ibuprofen

Introduction

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body.

Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug (NSAID) class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used by mouth or intravenously. It typically begins working within an hour

Ibuprofen is used to reduce fever and treat pain or inflammation caused by many conditions such as headache, toothache, back pain, arthritis, menstrual cramps, or minor injury.

Properties

Chemical and Physical Data

Formula —21/4 †20 ■1/2

Molar mass 1/2^{an}Pt1/2^{®2} ®⋅N^{Q10}/00−^Q

Chirality □1/31/85/8Nº€1/8 Nº€₩NLVTCR5/8

Pta1/4 @fNº%0 @f1/8Nº1/4

Melting point ®2 N_L1 ®© °—

Boiling point ^{92®} °— j¹/₄⁹² °○¿ ½^N_L ¢ N^oN^o†®

Solubility in water Pt²½° N^{2®}fN°R ;½° °—;

Ibuprofen is practically insoluble in water, $^23^{\text{V}}_{\text{T}}^{\text{N}}_{\text{L}}$ ⊕5% $^{\text{L}}_{\text{R}}$ Rs $^{\text{L}}_{\text{F}}^{10}$ % $^{\text{V}}_{\text{T}}^{2}$ 3% $^{\text{S}}_{\text{N}}$ ∈ $^{\text{N}}_{\text{L}}^{11}_{\text{F}}^{\text{N}}_{\text{L}}^{\text{N}}_{\text{L}}^{11}_{\text{F}}^{\text{N}}_{\text{L}}^{\text{L}}^{\text{N}}_{\text{L}}^{\text{L}}^{\text{L}}_{\text{L$



Raw Material

Properties

Chemical Formula —₂¹¹₂¢

Molar Mass

²1/4¢Pt1/21/2

²√N²10/00−²

Appearance $-1\%0^{1}$ $R\%0^{5}$ L_F L_F $M_{\odot} \in F_F$ $L_T \in M_{\odot}$

0dor "[□]_R1N⁰1/₃N_L€1/₈

Density ${}^{\underline{a}}P_{t}{}^{\underline{o}21/4} {}^{\underline{o}}f^{1/8}N^{\underline{o}1/4}\mathfrak{L} {}^{\underline{o}0} {}^{\underline{c}1/4}\mathfrak{L} {}^{\underline{o}0} {}^{\underline{c}1/4}\mathfrak{L}$

Melting Point

Boiling Point

Vapor Pressure ¢Pt½ NºNº†® ¡¼®Pt® °—¿

Refractive Index (nD)
^oPt©^{on}

Properties

Chemical formula —†_{1/4}—■—‰

Molar mass ®©Pt®¤ ®fNº1‰

Appearance $-1\%^{1}_{R}\%^{5}\%^{L}_{F}^{L}_{F}\%^{5}\%^{F}^{V}_{T} \in \%$

Density ${}^{\circ}P_{t}{}^{\circ}{}^{\circ}{}^{\circ} \otimes f N^{\circ}{}^{\circ}{}^{\circ} \cdot {}^{\circ} \otimes {}^{\circ}F^{\vee}{}_{T} \in {}^{3}\!\!/_{8}$



Melting point

_001/2 0__

Boiling point

21/2 0__

Brief Description of Manufacturing Process of Ibuprofen

†Rs¾^CR¹₦Rs‰⅓Nº€ 56 ¥†½■

Description

Step-1



-N_5/8HT¥1/2

- □5/8Nº1 **3**1/30/00 17/8 □R5/81/31/8NL€1- ₩1/3NL5/8□RPt
- ff®5% $^{\text{C}}_{\text{R}}$ 5%1/31/8 $^{\text{N}}_{\text{L}}$ €1— $^{\text{L}}_{\text{F}}$ ®1/30%0%0 2/35%8 $^{\text{C}}_{\text{R}}$ 5%8 $^{\text{N}}_{\text{P}}$ 1**®**5%3% 2/3Rs 3/8€ $^{\text{L}}_{\text{F}}$ N_L€%0%01/3 $^{\text{N}}_{\text{L}}$ €1— $^{\text{L}}_{\text{F}}$ 9%0%01/3 $^{\text{N}}_{\text{L}}$ 17/8 $^{\text{N}}_{\text{L}}$ 10%0 $^{\text{N}}_{\text{T}}$ 5%8 $^{\text{L}}_{\text{R}}$ 9%1

-N_5/8HT¥1/4

-1.5%+1.5%


_N_5/8HT¥2

05%VTN_ER1/300€MD1/3N_€1- ₩€N_@ LF13%€VTNº ®Rs3%ER1₩€3%5%Pt

_N_5/8HT¥n


- ○€‰N_5%^CR N_05% H_TC_R5%1%€H_T1/3N_5%
- CRRs VT-3/85/8 TR 1/31/8 VT VTNºPt







AN ISO 9001: 2015 CERTIFIED COMPANY





Paracetamol

Introduction

Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.

Paracetamol may also be used for other purposes not listed in this medication guide.

Paracetamol, also known as acetaminophen and APAP, is a medication used to treat pain and fever. It is typically used for mild to moderate pain relief. There is mixed evidence for its use to relieve fever in children. It is often sold in combination with other medications, such as in many cold medications. Paracetamol is also used for severe pain, such as cancer pain and pain after surgery, in combination with opioid pain medication. It is typically used either by mouth or rectally, but is also available by injection into a vein. Effects last between two and four hours.

■1/3^LR1/31/85/8^NL1/3N^Q10/00 €^LF @5/8−5/8^LR1/30/00/00**R**S ^LF1/37/85/8 1/3^NL ^LR5/81/81N^QN^Q5/8−3/85/83/8 $3/8^{1} + F/8 +$ N_1 N_1++€1/8€N_Rs£ €-1/800 V_73/8€-® 00€\$5/8 R 7/81/3€000 V_7 ER5/8Pt -5/8 ER€1 V_7 EF EF0/1€-CR1/3 LF®5/8 LF N°1/3 RS CR1/3 CR5/8 600 RS 11/81/8 VT CRPt ±NL 1/3 HT HT 5/81/3 CR LF NL1 2/35/8 LF1/37/85/8 3/8 \rangle T \cdot R \frac{1}{2} = \text{0} \rangle T \cdot R \frac{5}{8} \text{0} = 1/3 = 1/8 \rangle R \frac{1}{3} = 3/8 \rangle \frac{14}{90} \frac{5}{8} = 2/3 \rangle R \frac{5}{8} \frac{1}{3} \rangle F \rangle T \rangle 8 \frac{1}{8} \frac{5}{8} \frac ₩€^\® ‰€®⁵%^CR ³%€^LF⁵%¹½¹F⁵%£ €^L №¹%Rs └F^L€‰‰ ⅔⁵% Ү⊤└F⁵%³%£ ⅔Чт^L €— %01₩5/8^ER 1/80%01/3^LF^LF€7/8€5/83/8 3/8¹L_F5/8L_FPt ±N_L €'F 1/3^LF -1N_L 1/3-1/3000^{®5}/8^LF€1/8Pt ^{‡N}L 3/8¹⁵/8^LF @1/3**@**5/8 L_F€@-€7/8€1/81/3-N_L €-7/8%01/3NºNº1/3^NL1^ERRs 1/31/8^NL€**⊕**€^NLRsPt †¹₩ €NL ₩¹^ER%^LF 5/8-N_L€^CR5/8/00Rs 1/8/005/81/3^CRPt



Medical Uses

Fever

Paracetamol is used for reducing fever in people of all ages. The World Health Organization (WHO) recommends that paracetamol be used to treat fever in children only if their temperature is higher than 38.5 °C (101.3 °F). The efficacy of paracetamol by itself in children with fevers has been questioned and a meta-analysis showed that it is less effective than ibuprofen. Paracetamol does not have significant anti-inflammatory effects.

Pain

Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain.

■^LFN_5/811/3^LRN_@^LR€N_€^LF



R1₩5/8^LR -1/31/8%

 $-1/3^{L}F^{5/8}3/8 \quad 1-1/3 \quad LFRS^{L}F^{N}L^{5/8}N^{9}1/3^{N}L \in 1/8 \quad \Gamma_{R}^{5/8} \bigoplus \in 5/8 \biguplus \mathfrak{L} \quad L^{1/3}\Gamma_{R}^{1/3}1/8^{5/8}N^{L}1/3N^{9}10/00 \quad \biguplus 1/3^{L}F^{5/8}1/8^{1}N^{9}N^{2}N^{2}S/8 = 3/85/8^{3/8} \quad 2/3Rs \quad N^{1}_{0}0^{5/8} \quad (N^{9}5/8^{L}R) \in 1/8^{1/3} - 1/90/00/05/8^{9}5/8 \quad 17/8 \quad \blacksquare 0^{9}Rs^{L}F \in 1/8 \in 1/3 - LF + 1/3 - 1/8 \in 5/8^{N}LRs \quad 1/3^{L}F \quad 1/3 \quad 7/8 \in \Gamma_{R}^{L}F^{N}L^{1/3} + 1/9 - 1/90/00/05/8^{9}5/8 \quad 17/8 \quad \mathbb{L}^{1/3}N^{1}L^{1/3}N^{1$

+5/81/33/81/31/8[®]5/8^LF



■1^LF^NL1^HT5/8^LR1/3^NL€**@**5/8

ff5/85/8NL®

 $0-\text{``$$^{\bot}_{F}$}^{\bot}_{F}\text{'}^{\top}_{1/8}\text{'0} \text{ $1/3$}^{\bot}_{F} \in \text{$2/3$}^{\lor}_{T}\text{'}^{\top}_{R}\text{1}^{7}/85\% - \text{\^{E}} \text{ $-1/3$}^{H}_{T}\text{$\Box}_{R}\text{1}^{H}_{5}\% - \text{\^{E}} \text{ $1/3$}^{-3}/8 \text{ $3/8$} \in \text{$1/8$}\% \text{0}^{17}/85\% - \text{$1/3$}^{1/8} \text{ $1/8$}^{-1}/85\% - \text{\^{E}} \text{ $1/3$}^{-3}/8 \text{ $1/8$}^{-3}/8 \text{ $1/8$}^{-3}/8$ 1/₃□_R5/₈ Nº1□_R5/₈ 5/₈7/₈7/₈5/₈1/₈N_L € **®**5/₈ N_L®1/₃ - H_T1/₃□_R1/₃1/₈5/₈N_L1/₃Nº10/₀₀ 1/81-N_CR10000€-® 3/85/8-N_1/3/00 HT1/3€- 1CR HT1/3€- 1/3CR€CF€-® 7/8CR1Nº 3/85/8-N_1/3/00 H_TC_R11/₈5/₈3/₈V_TC_R5/₈L_F3 1/₈1N⁰2/₃€ -1/₃N_L€1 - L_F 17/₈ 0 - "‡√F 1/₃ - 3/₈ 1/₃1/₈5/₈N_L1/₃N⁰€ - 1^HT[®]5/₈ -1/3 ^C_R5/8 N^{01 C}_R5/8 5/87/87/85/81/8 N_L€**®**5/8 N_L®1/3 - 5/8 € N_L®5/8 C_R 1/3 0/01 - 5/8 Pt ■1/3 ^C_R1/3 1/85/8 N_L1/3 N⁰¹⁰00 V_TL_F5/8⁷/8 V_T%0 H_T1/₃C_RN_L€1/₈V_T‰1/₃C_R‰R_S ₩^{®5}/8-0-"±(LF 1/3^ER⁵/8 1/81-N_CR1/3€-3%€1/81/3N_5/83/8 3% N_T5/8 N_1 ®RsHT5% CRLF5%-LF5%-LF5%-LF5%-LF5% Or history of gastrointestinal ulceration or bleeding. It can also be used in combination with NSAIDs when these are ineffective in controlling dental pain alone. The Cochrane review of preoperative analgesics for additional pain relief in children and adolescents shows no evidence of benefit in taking paracetamol before dental treatment to help reduce pain after treatment for procedures under local anaesthetic, but the quality of evidence is low.

Combination Medications

The efficacy of paracetamol when used in combination with weak opioids (such as codeine) improved for about 50% of people, but with increases in the number experiencing side effects. Combination drugs of paracetamol and strong opioids such as morphine improve analysis effect.

The combination of paracetamol with caffeine is superior to paracetamol alone for the treatment of common pain conditions, including dental pain, post partum pain, and headache.

Patent Ductus Arteriosus



Raw Material

The main raw materials are followings:

^ºPt ¢¥°€NL^ER1HT®5/8-10/00

¹/₂Pt "¹/₈5/₈N_L€¹/₈ ¹/₃¹/₈€³/₈

1/4Pt • 5/8NL®1/3-10/00

¢Pt ‡^CR¹− H_T¹₩³%⁵%^CR

¢¥0±ff□■■+>0■R



 $78^{1} \stackrel{\Gamma}{\Gamma}_{R} N^{\varrho} \qquad \qquad \bigoplus \stackrel{\Gamma}{\Gamma}_{F} \qquad \qquad \qquad \stackrel{\Gamma}{R}_{5} \% \% \% \% ^{1} \biguplus \qquad \qquad \stackrel{\Gamma}{\Pi}_{F} \stackrel{\Gamma}{\Psi}_{G} \% \% ^{1}_{3} \stackrel{\Gamma}{\Gamma}_{R} \stackrel{\Gamma}{\Gamma}_{E} \qquad \qquad \qquad \stackrel{\Gamma}{\Gamma}_{F} \stackrel{\Gamma}{\Pi}_{1} \stackrel{\Gamma}{\Pi}_{2} \stackrel{\Gamma}{\Pi}_{3} \% ^{1}_{3} \% ^{1}_{3} \% ^{1}_{3} \% \% ^{1}_{3} \% \% ^{1}_{3} \% \% ^{1}_{3} \% \% ^{1}_{3} \% \% ^{1}_{3} \% \% ^{1}_{3} \% ^{1}_{4} \% \% ^{1}_{6} \qquad \qquad \qquad \stackrel{\Gamma}{\Pi}_{F} \stackrel{\Gamma$

■^CR¹^HT⁵/8^CR^NL€⁵/8^LF

—®5/8Nº€1/81/30/00 7/81 ^CRNºVT0/001/3

●10/001/3^LR Nº1/3^LF^LF

º1/4¤Pt^{ooa} ∞·Nº10/00-°

"HTHT5%1/3 R1/3-1/85/8 —10001 R005% LFLF 1 R R55/800001₩ HT€00001/3 RLF

●5/8/11€-® H_T1€-N_L

-1€‰€-® H_T1€-N_L

"1/8€3/8€NLRs ;HTSM1/3;

-10%0V_T2/3€%0€N_LRs €- ₩1/3N_L5/8E_R

991/4 N 1 99¢ °—

1/₂®¤ °_

oa ∞fR io2 o—¿

²⁰Ptn @fR i1/2ª °—¿

^{on} ∞fR i½² °—¿

®Pt² j€- ₩¹/₃^NL⁵/₈E_R¿

"→ff‡— "—‡<



■CR1HT5%CRNL€5%LF

 $-®5/8N^{2}€1/81/3\%0 7/81^{\Gamma}RN^{2}V_{T}\%01/3 - \frac{1}{12} + \frac{1}{$

□5%7%^CR1/31/6^NL€**®**5% €-3%5%**₦** ¡-'¿ºPt1/4®º ¡ffI' 'º®Ptº¤¿

●›ff+"o■R



■ G1HT5% GRNL €5% F

—®5/8N°€1/81/30/00 ○1[□]RN°V_T0/001/3 —†1/4■†

●10/00¹/₃^L_R ●1/₃^L_F^L_F 1/₄1/₂P_t²¢ ® N⁰10/₀₀ ●

"H_TH_T5/81/3 E_R1/3 - 1/85/8 —10/01 E_R0/05/8 F_FF R€F V_T€3/8

■381^CR ,N_L@1/3-10/00¥0/00€0/u5/8

 5 8-LF \in NLRs 2 Pt 8 X1/2 9 f 1 8N 2 1/4

-1€%0€-® ■1€-N_L n¢Pt®°-

 $-1\%^{V}_{T^{2}_{3}} \in \%^{E}_{L} R_{S} \in -f_{1}^{1}_{3}^{N}_{L}^{5}_{8} = N^{2}_{E}^{E}_{F^{1}_{8}} \in \%^{5}_{8}$

□5/8⁷/8^CR¹/3¹/8^NL€**3**5/8 ‡-3/8⁵/8 **†** ;-4; °Pt¹/4¹/4°¢°

ffl€^LF¹/₈¹^LF = N_LRs ^aPt²¢² N² 1/₃ 1_LF i 1/₃ N_L 1/₂² °—¿




Brief Description of Manufacturing Process of Paracetamol

- The manufacturing process of paracetamol is summarized in the following steps.
- Charge acetic acid to the reactor.
- Add p--€N_CR1HT®58-1‰ as a LFN_1/3CRN_C€-® N°1/3N_58CR€1/3‰ 1/3-3/8 €CR1-HT1₩3858CR 1/3LF 1/81/3N_L1/3‰RSLFN_LPt
- +5/81/3 NL NL1 NL5/8 NOH @2 ¥ X20 Pt
- ff®5% $^{\text{C}}_{\text{R}}$ 5% $^{\text{N}}_{\text{A}}$ 1% $^{\text{N}}_{\text{L}}$ €1 € $^{\text{L}}_{\text{F}}$ 5% $^{\text{N}}_{\text{A}}$ 1 $^{\text{N}}_{\text{L}}$ 0°5% $^{\text{C}}_{\text{R}}$ N°€1% 1/3 3/8 $^{\text{N}}_{\text{L}}$ 5% $^{\text{N}}_{\text{L}}$ 1 $^{\text{Q}}_{\text{L}}$ 4 $^{\text{Q}}_{\text{L}}$ 9 Pt
- "7/8NL5/8CR LF000€@®NL 1/811000€-@Pt
- □5/87/80/00 V_TN N_®5/8 □R5/81/31/8N_€1- 1/3N_ 200 7/81□R 1/4¥¢ ®1 V_T□R □FPt
- _110/00 N_1 nao_Pt
- "3%3% Nº5%NL®1/3-10%0 NL1 NL®5%8 ER5%1/31/8NL€1-Pt
- □5/8⁷/8⁹/₀₀ V_TN 7/8¹ □_R □ ®1 V_T □_R P_t
- <€^LF^NL€‱ Nº58 N°58 N°13-1‰ 1/3-38 ^LR581/8Rs1/8605/8Pt
- "3/83/8 ₩1/3^NL5/8^CR NL1 N_®5/8 12/3^NL1/3€—5/83/8 1/81/3°\u5/8Pt
- "-3% Nº1/3°/u5/8 1/3 LF10/00 VTNL€1-Pt
- "3/83/8 1/31/8N_L€**®**1/3N_L5/83/8 1/81/3^CR²/31−Pt
- O€‰NL5%ERPt




Process Flow Diagram





AN ISO 9001: 2015 CERTIFIED COMPANY





Tablet Making Process

Detailed description of the tablet making process along with the estimated consumption rates of raw materials:

- **fi5/8€®®€−® 1/3−3/8 ●€₦€−®**3/4 **ff**®5/8 ^CR¹/₃₩ N^Q1/₃N_L5/8^CR€1/3⁶/₃% ^CR ^ER⁵/8⁷/8 ^CR⁵/8⁸/8 N ®€LF LFNL5/8HT €-1/8%0V_T3/85/8 N_L@5/8 H_T@1/3 LRNº1/3 1/85/8 LRLE 1/81/3 0/0 €-@LR5/83/8 €5/8 - NL ; "■‡;£ 2/3 €-3/85/8 LRLE 1/4 LPV 1/8 ® 1/3 LE 3/8€LE€-N_5/8@ER1/3-N_LE ;LEVT1/8® 1^LR L_FN_L1/3^LR¹/8[®];£ Nº1/3®-5%^LF€^VTNº ^LFN_L5%1/3^LR1/3N_L5%;£ 1/3-3% 7%€%0%05%^LR^LF ;^LFV_T1/8® Nº€1/8^CR11/8^CRRS^LF^NL1/30/0000€-5/8 1/85/80/000^VT0/01^LF5/8; Pt ff®5/8 5/8^LF^NL€Nº1/3 NL5/83/8 $^{\mathsf{L}_{\mathsf{F}}\mathsf{H}_{\mathsf{T}}} 5 \% 1 \% = 7 \% = 1 \% 8$ $\frac{1}{3}\%_{0}^{L}_{F^{1}} \quad \frac{3}{8}5\%_{1}^{H}_{T}5\%_{8} - \frac{3}{8} \quad 1 - \quad \frac{N}{2}05\%_{8} \quad \frac{L}{F}H_{T}5\%_{1}\%_{8} \\ = \frac{7}{8}1\%_{8} - \frac{7}{8}1^{L}_{R}N_{2}^{V}_{T}\%_{0}1\%_{3}^{N}_{L} \\ = \frac{1}{3}-\frac{3}{8}1^{L}_{R}N_{2}^{V}_{T}\%_{1}^{N}_{2} + \frac{1}{3}\frac{1}{8}N_{2}^{N}_{1} + \frac{1}$ 3/81LF1/3@5/8 17/8 NL@5/8 NL1/32/30/005/8 NLLFPt



- $\frac{11/3}{N} \underbrace{- \textcircled{@} \quad i^{1}} + \frac{1}{N} \underbrace{- \textcircled{@} \quad i^{1}} \underbrace{- \textcircled{@} \quad i^{1}} + \frac{1}{N} \underbrace{- \textcircled{@} \quad i^{1}} \underbrace{- \textcircled{$
- **■½½½½®€−®¾**○¹ ⅓¾®**¾**€NL€¹−⅓3‰ ^CR⅓₩ №⅓NL5%^CR€⅓‰^LF ⅓^CR5%

 CR5%^FFVT€^CR5%¾ 7%¹^CR NL®€^LF LFNL5%^HTPt

Please note that the consumption rates for raw materials can vary depending on the specific formulation and dosage of the tablets, as well as the equipment used and the manufacturing process employed. The above consumption rates are only estimates and should be used as a general guideline.

TABLET STRIP PACKING PROCESS:


○5%5%3%€—®¾ ff®5% NL1/32/3%05%NL1F 1/3^CR5% 7/85%3% €—NL1 1/3 ®1HTHT5%^CR£ ₩®€1/8® 7/85%5/83%LF NL®5%Nº €—NL1 NL®5% LFNL^CR€HT HT1/31/8′N€—® Nº1/31/8®€—5%Pt



- $\bigcirc \textbf{6\%0\%0} \textbf{6-934} \qquad \text{ff} @ 5\% \qquad \begin{tabular}{lll} $ & $^{N}_{L}$ $^{1}_{3}$ $^{2}_{3}$ $^{3}_{0}$ $^{5}_{8}$ $^{N}_{L}$ $^{L}_{F}$ $^{1}_{3}$ $^{L}_{F}$ $^{1}_{3}$ $^{N}_{L}$ $^{1}_{4}$ $^{N}_{L}$ $^$



Process Flow Diagram





SWOT Analysis

API (Active Pharmaceutical Ingredient) manufacturing is a critical component of the pharmaceutical industry. A SWOT analysis provides a comprehensive view of the strengths, weaknesses, opportunities, and threats associated with the venture. Here's a SWOT analysis for an API Manufacturing Unit:

Strengths

Specialized Knowledge: Requires in-depth understanding and expertise in organic chemistry, allowing for niche market positioning.

Quality Control: Strict adherence to global standards (like Good Manufacturing Practice) ensures high product quality and minimizes recalls.

Intellectual Property: Proprietary manufacturing processes and patents can offer a competitive edge.

Supply Chain Control: Direct manufacturing can allow for better control over the supply chain, ensuring timely production and delivery.

Strategic Partnerships: Existing collaborations with pharmaceutical firms can guarantee demand and steady contracts.

Weaknesses

Capital Intensive: Significant upfront investment required in infrastructure, equipment, and R&D.

Regulatory Challenges: Stringent regulatory landscape that requires continuous compliance and can lead to potential shutdowns if not met.



Environmental Concerns: Manufacturing can lead to waste generation and environmental hazards if not managed properly.

Dependency on Raw Materials: Reliance on specific raw materials which may be sourced from specific regions, leading to supply chain vulnerabilities.

High Competition: A competitive market with established players, especially from regions with lower manufacturing costs.

Opportunities

Growing Pharmaceutical Market: With an aging global population and increased healthcare needs, demand for medicines and, consequently, APIs is on the rise.

Biosimilars & Biologics: Growing interest and demand in this segment offer new avenues for API manufacturers.

Diversification: Expanding into different types of APIs or related products can tap into new revenue streams.

Global Expansion: Exploring markets in emerging economies or regions with less API manufacturing penetration.

Sustainable and Green Manufacturing: Adopting eco-friendly processes can be a market differentiator and reduce environmental liabilities.

Threats

Regulatory Changes: Sudden policy shifts or regulatory changes in major markets can impact operations.

Price Wars: Competitive pricing from manufacturers in regions with lower production costs can erode profit margins.



Intellectual Property Violations: Risk of process imitation or patent infringements, especially in regions with lax IP enforcement.

Supply Chain Disruptions: Natural disasters, geopolitical tensions, or global crises (like pandemics) can disrupt raw material availability or transportation.

Technological Advancements: New production methods or breakthroughs can render current manufacturing processes obsolete.

While the API manufacturing industry is lucrative, it's also fraught with challenges, particularly from a regulatory and competition perspective. Strategic planning, continuous innovation, and strict adherence to quality and regulatory norms are critical for success in this field.



Risk Assessments

Risk assessment in API (Active Pharmaceutical Ingredient) manufacturing involves evaluating potential hazards and implementing measures to prevent or mitigate their impact. The complex nature of the pharmaceutical industry, combined with stringent regulatory requirements, makes risk assessment vital. Here's a comprehensive risk assessment for an API Manufacturing Unit:

- 1. Chemical and Biological Exposure:
- 2. Environmental Contamination:
- 3. Quality Control Failures:
- 4. Supply Chain Disruptions:
- 5. Regulatory Non-compliance:
- 6. Intellectual Property Breaches:
- 7. Equipment Failure:
- 8. Accidents and Fires:
- 9. Market Dynamics:



Chemical and Biological Exposure

Chemical and Biological Exposure is a major concern in API (Active Pharmaceutical Ingredient) manufacturing units due to the nature of materials and processes involved. Let's delve deeper into this specific risk:

Chemical and Biological Exposure Risk in API Manufacturing:

Nature of the Risk

Chemical Exposure: Employees in an API manufacturing unit are at risk of exposure to various chemicals, solvents, and reagents, some of which may be toxic, carcinogenic, or harmful in other ways. Prolonged or high-level exposure can lead to acute and chronic health conditions.

Biological Exposure: While chemical exposure is more common, there are instances, especially in biopharmaceuticals, where employees can be exposed to harmful microorganisms or biological toxins.

Potential Outcomes

Immediate Health Effects: Inhalation, ingestion, or skin contact with certain chemicals can cause immediate reactions such as burns, respiratory issues, or poisoning.

Long-term Health Effects: Chronic exposure can lead to diseases like cancer, organ damage, respiratory diseases, or neurological disorders.

Contamination: Accidental exposure can also lead to product contamination, impacting product quality and patient safety.

Contributing Factors

Inadequate Safety Protocols: Lack of proper guidelines or their enforcement can lead to accidents.



Lack of Training: Employees unaware of the hazards associated with specific chemicals or processes are at a higher risk.

Equipment Failure: Breakdown or malfunctioning of safety equipment can lead to exposure.

Operational Errors: Accidental spills, incorrect handling, or procedural errors can result in unwanted exposure.

Mitigation Strategies

Safety Protocols: Establish and enforce strict safety guidelines tailored to the specific chemicals and biological agents in use. This includes safe storage, handling, and disposal methods.

Training: Regularly train employees on the hazards associated with their work, safe handling procedures, and emergency response actions.

Personal Protective Equipment (PPE): Provide and mandate the use of appropriate PPE like gloves, masks, protective clothing, and eyewear.

Containment: Utilize closed systems, fume hoods, and biosafety cabinets to minimize exposure risks, especially during processes that release vapors or aerosols.

Monitoring: Install chemical and biological exposure monitors in high-risk areas to detect and alert of any accidental releases or elevated exposure levels.

Emergency Response Plans: Ensure that there are protocols in place to handle accidental exposures, including first aid measures, antidotes, and decontamination procedures.

Health Surveillance: Regularly monitor the health of employees to detect early signs of chemical or biological exposure effects.



Regular Review and Audits

Given the dynamic nature of API manufacturing and the ever-evolving list of substances and processes, it's crucial to regularly review and update safety measures. Regular audits can ensure adherence to protocols and identify areas of potential improvement.

In conclusion, while chemical and biological exposure risks are inherent to API manufacturing, a proactive and thorough approach to safety can minimize these risks, ensuring the wellbeing of the workforce and the integrity of the product.

Environmental Contamination

Environmental contamination risk in API (Active Pharmaceutical Ingredient) manufacturing pertains to the potential release of chemicals, waste products, and other substances into the environment, which can harm ecosystems, human health, and the reputation of the manufacturing entity. Here's a detailed assessment:

Environmental Contamination Risk in API Manufacturing:

Nature of the Risk

Water Contamination: Discharge of untreated or inadequately treated effluents can lead to water pollution, affecting aquatic life and entering the human water supply.

Air Pollution: Release of volatile organic compounds (VOCs), particulate matter, and other pollutants can affect air quality and contribute to global environmental issues like climate change.

Soil Contamination: Spills, improper waste disposal, and leakage can lead to soil pollution, impacting agriculture and local ecosystems.

Biodiversity Impact: The introduction of foreign chemicals into ecosystems can reduce biodiversity by harming specific species.



Potential Outcomes

Regulatory Penalties: Violation of environmental regulations can lead to hefty fines, legal actions, and even cessation of operations.

Cleanup Costs: Companies might be obligated to finance cleanup operations for contamination they've caused.

Reputation Damage: Environmental harm can tarnish a company's image, impacting its relationships with stakeholders, customers, and investors.

Ecological Damage: Long-term harm to local ecosystems which might be irreversible.

Human Health Concerns: Contaminated water or crops can lead to health issues in local communities.

Contributing Factors

Lack of Treatment Facilities: Inadequate or outdated wastewater treatment plants.

Operational Negligence: Spills or accidents due to operational errors or equipment malfunctions.

Inadequate Waste Management: Lack of proper protocols for waste storage, treatment, and disposal.

Lack of Monitoring: Absence of regular monitoring of emissions and effluents.

Mitigation Strategies

Effluent Treatment: Install advanced wastewater treatment facilities to ensure that all effluents meet regulatory standards before discharge.



Air Emission Control: Use technologies like scrubbers, filters, and catalysts to minimize airborne emissions from operations.

Waste Management: Implement stringent waste segregation, treatment, and disposal protocols. Consider waste reduction and recycling methods.

Spill Prevention: Invest in spill containment infrastructure, such as secondary containment systems and leak detection systems.

Continuous Monitoring: Regularly monitor and analyze emissions, effluents, and waste to ensure they meet regulatory and internal standards.

Employee Training: Educate employees about the importance of environmental responsibility and train them in best practices.

Community Engagement: Engage with local communities to address their concerns and ensure that the manufacturing unit's operations are not adversely affecting their environment and health.

Regular Review and Audits

Environmental standards and best practices evolve over time. It's essential to stay updated with the latest regulations and technologies and regularly audit environmental practices to identify potential areas of improvement.

Environmental contamination is a significant risk for API manufacturing units, not just due to potential regulatory penalties but also because of the ethical implications of causing harm to the environment and communities. Proactive environmental management and a commitment to sustainability can substantially reduce these risks, benefiting both the company and society at large.



Quality Control Failure

Quality control (QC) is a critical function in the production of Active Pharmaceutical Ingredients (APIs). Any failure in QC processes can result in severe consequences for both the manufacturer and the end-users (patients). Let's assess the risk associated with Quality Control failures in an API manufacturing unit:

Quality Control Failure Risk in API Manufacturing:

Nature of the Risk

Substandard Products: A lapse in QC can result in the release of APIs that don't meet the required specifications, compromising drug efficacy and safety.

Recalls: APIs failing to meet quality standards can lead to extensive product recalls, which are costly and damaging to the manufacturer's reputation.

Regulatory Sanctions: Regulatory bodies may levy fines, enforce shutdowns, or take other punitive actions if substandard APIs are discovered in the market.

Patient Harm: Perhaps the gravest risk is the potential harm to patients consuming drugs made from substandard APIs. This can range from lack of therapeutic effect to serious adverse reactions.

Potential Outcomes

Financial Impact: The cost associated with product recalls, regulatory fines, and potential lawsuits can be substantial.

Reputation Damage: Once the trust is broken, it may take years to rebuild a brand's reputation, leading to a potential loss of market share.

Operational Disruptions: QC failures might warrant a full-scale review of manufacturing processes, causing disruptions in production.



Legal Liability: If substandard APIs result in harm to patients, manufacturers might face lawsuits.

Contributing Factors

Human Error: Mistakes during testing, oversight in following protocols, or misinterpretation of results.

Equipment Malfunctions: Failure of instruments used in QC can lead to inaccurate results.

Inadequate Training: If staff aren't properly trained, they may miss critical QC steps or fail to recognize anomalies.

Sampling Errors: Not selecting representative samples or not sampling frequently enough.

External Factors: Contamination from external sources or variability in raw materials.

Mitigation Strategies

Robust QC Protocols: Establish stringent and comprehensive QC processes that are well-documented and regularly updated.

Regular Training: Ensure QC staff receive regular training to stay updated on the latest standards, tools, and best practices.

Equipment Maintenance: Schedule regular maintenance and calibration for all QC equipment.

Audit and Review: Periodically audit the QC processes and results. Third-party audits can offer unbiased insights.

Data Management: Invest in reliable data management systems to accurately track and analyze QC data, ensuring traceability.



Feedback Loop: Establish a system where issues detected post-production can be traced back to QC processes to identify and rectify gaps.

Quality Assurance Integration: Integrate QC with the wider Quality Assurance (QA) framework, ensuring that quality is embedded throughout the production process.

Preparedness for Failures

Despite best efforts, QC failures can still occur. Preparedness can help in swift response:

Rapid Response Protocols: Develop protocols to quickly address and rectify QC failures when detected.

Communication Strategy: Establish a strategy to communicate QC failures to stakeholders, regulatory bodies, and the public if necessary, emphasizing transparency and accountability.

Insurance: Consider insurance coverages that can help mitigate financial impacts of QC failures, such as product recall insurance.

Quality Control is of paramount importance in API manufacturing. A proactive, thorough, and continually improving approach to QC can substantially reduce the risk of failures, ensuring the safety and efficacy of the end pharmaceutical product. It's not just about compliance but also the ethical responsibility of manufacturers to deliver quality products to patients.



Supply chain Disruptions

Supply chain disruptions can have significant implications for the continuity and profitability of any manufacturing operation, including the production of Active Pharmaceutical Ingredients (APIs). Given the global nature of pharmaceutical supply chains and the critical importance of APIs, these disruptions can be especially consequential. Here's a breakdown of the risk associated with supply chain disruptions in an API manufacturing unit:

Supply Chain Disruptions Risk in API Manufacturing:

Nature of the Risk

Raw Material Shortages: Unavailability or delay in obtaining essential raw materials can halt production.

Transportation Delays: Disruptions in transportation can delay the arrival of raw materials or the shipment of finished APIs.

Supplier Insolvency: A key supplier going bankrupt or facing financial difficulties can interrupt the supply chain.

Geopolitical Issues: Trade wars, sanctions, or other geopolitical tensions can block or delay the import or export of essential materials.

Natural Disasters: Events such as earthquakes, floods, and hurricanes can disrupt production or the transportation of materials.

Pandemics or Epidemics: As seen with COVID-19, pandemics can significantly strain and disrupt global supply chains.



Potential Outcomes

Production Halt: Without necessary materials, API production can come to a standstill.

Financial Impact: Delays and disruptions can lead to increased costs and lost revenue.

Contractual Penalties: Failure to deliver APIs on time might result in penalties or legal actions based on contractual obligations.

Loss of Market Share: Consistent supply chain issues can lead customers to switch to more reliable competitors.

Increased Prices: Shortages in the supply chain can drive up prices of raw materials, affecting profit margins.

Contributing Factors

Over-reliance on Single Supplier: Depending heavily on one supplier for crucial materials can be risky.

Lack of Visibility: Not having clear visibility into the entire supply chain can prevent early detection of potential disruptions.

Complex Supply Chain: A multi-tiered global supply chain can have more potential points of failure.

Lack of Contingency Planning: Without a backup plan, even minor disruptions can have outsized effects.

Mitigation Strategies

Diversify Suppliers: Rely on multiple suppliers, ideally from different regions, for crucial materials.



Stockpile Essential Materials: Maintain a strategic reserve of essential raw materials to buffer against short-term disruptions.

Supply Chain Visibility: Invest in supply chain monitoring tools and systems to gain real-time insights.

Regular Risk Assessment: Continuously assess suppliers and logistics partners for potential risks.

Contingency Planning: Develop robust contingency plans for various scenarios, from supplier issues to transportation disruptions.

Supplier Relationships: Build strong relationships with key suppliers, fostering communication and collaboration.

Local Sourcing: Where feasible, source materials locally or regionally to reduce the complexity and vulnerability of the supply chain.

Regular Review

Given the dynamic nature of global supply chains, regularly review and update risk assessments and mitigation strategies. New suppliers, routes, or methods may emerge that offer lower risk or more reliability.

While the pharmaceutical industry and API manufacturers, in particular, can't predict or prevent all potential supply chain disruptions, they can significantly reduce their risk and impact through careful planning, diversification, and continuous monitoring. Given the critical nature of APIs in the healthcare sector, ensuring a robust and resilient supply chain is paramount.



Regulatory Non-compliance

Regulatory compliance is a critical element in the API (Active Pharmaceutical Ingredient) manufacturing industry. Given the potential consequences for public health and safety, regulatory agencies worldwide set strict standards and requirements. Non-compliance with these regulations can have severe repercussions for API manufacturers. Let's dive deep into the regulatory non-compliance risks for an API manufacturing unit:

Regulatory Non-compliance Risks in API Manufacturing:

Nature of the Risk

Product Seizures: Non-compliant products may be seized and destroyed by authorities, leading to a direct financial loss.

Production Halts: Regulatory agencies can order the suspension of manufacturing activities until compliance is restored.

License Revocation: In severe cases, authorities might revoke manufacturing licenses, effectively shutting down operations.

Fines and Penalties: Regulatory bodies can levy significant financial penalties for non-compliance.

Criminal Liability: In extreme cases, company executives and decision-makers can face criminal charges.

Loss of Market Access: Non-compliant products might be banned from certain markets or countries.

Audits and Inspections: Increased frequency of regulatory audits and inspections, adding to operational overhead.



Potential Outcomes

Financial Impact: Direct costs from fines and indirect costs from halted production or lost sales.

Reputation Damage: The public, clients, and stakeholders may lose trust in a company that fails to meet regulatory standards.

Operational Disruptions: Regular disruptions due to increased inspections and audits.

Reduced Competitive Edge: Losing access to key markets or facing restrictions can provide competitors an advantage.

Contributing Factors

Lack of Knowledge: Not being aware of all relevant regulations or updates to existing regulations.

Negligence: Overlooking or underestimating the importance of regulatory compliance.

Inadequate Systems: Absence of robust systems to track, monitor, and ensure compliance.

Poor Training: Employees unaware of compliance requirements or not trained adequately to meet them.

Mitigation Strategies

Stay Informed: Regularly review and stay updated with regulations in all jurisdictions where the company operates or sells.

Invest in Compliance: Allocate resources (both human and financial) specifically for regulatory compliance.

Training Programs: Regularly train staff on regulatory requirements and updates.



Internal Audits: Conduct periodic internal audits to identify areas of non-compliance and address them proactively.

Engage Experts: Consider hiring or consulting with regulatory experts or legal counsel specialized in the pharmaceutical industry.

Feedback Mechanisms: Establish mechanisms for employees to report potential compliance issues or concerns without fear of retaliation.

Collaborate with Authorities: Foster a cooperative and transparent relationship with regulatory bodies. Engage in industry forums and associations to understand best practices.

Preparedness for Non-compliance Issues

Despite best efforts, instances of non-compliance can occur. Being prepared can help address them swiftly:

Crisis Management Plan: Develop a plan detailing the steps to take in case of non-compliance issues, including communication strategies.

Insurance Coverage: Evaluate insurance options that cover regulatory fines or related liabilities.

Transparency: If non-compliance is identified, proactively communicate with regulatory bodies, showcasing efforts to rectify and ensure it doesn't recur.

Regulatory compliance is non-negotiable in the API manufacturing sector. The risks associated with non-compliance are substantial, both in terms of financial and reputational impact. Proactive measures, continuous training, and a culture that prioritizes compliance can help mitigate these risks, ensuring the company's longevity and trustworthiness in the market.



Intellectual Property Breaches

Intellectual property (IP) is a critical asset in the pharmaceutical and API (Active Pharmaceutical Ingredient) manufacturing industry. It can pertain to proprietary formulations, processes, methods, and various other facets of the production. Protecting IP ensures competitive advantage, brand reputation, and long-term profitability. Let's explore the risks associated with intellectual property breaches for an API manufacturing unit:

Intellectual Property Breaches Risk in API Manufacturing:

Nature of the Risk

Industrial Espionage: Deliberate acts by competitors or other entities to steal trade secrets, processes, or formulations.

Inadvertent Disclosure: Accidental leak or exposure of IP due to negligence or lack of proper controls.

Infringement: Other entities using or producing similar APIs without authorization, potentially infringing on patents or other IP rights.

Counterfeiting: Unauthorized production of duplicate APIs that can flood the market and impact original sales.

Reverse Engineering: Competitors developing a similar or identical product by analyzing and replicating the original API.

Potential Outcomes

Financial Losses: Loss of revenue due to unauthorized sales or competition from counterfeit products.

Decreased Competitive Advantage: If the unique processes or formulations become public or are copied, the company might lose its edge in the market.



Litigation Costs: Engaging in legal battles to protect IP rights or sue infringing parties can be expensive and time-consuming.

Reputation Damage: Counterfeit or substandard products in the market can damage the brand's reputation.

Loss of Exclusivity: If patent rights are infringed upon or trade secrets are exposed, the company may lose exclusive rights to produce certain APIs.

Contributing Factors

Weak IP Protection Mechanisms: Inadequate measures to protect and secure IP can make it vulnerable.

Lack of Employee Training: Employees unaware of the importance of IP and how to safeguard it.

Insufficient Legal Protections: Operating in jurisdictions with weak IP laws or enforcement.

Complex Supply Chains: The more complex and global the supply chain, the more points of potential IP exposure.

Poor Contractual Agreements: Contracts with suppliers, partners, or employees that don't adequately address IP protection.

Mitigation Strategies

Strong IP Portfolio: Regularly review and strengthen IP rights through patents, trademarks, copyrights, and trade secrets.

Confidentiality Agreements: Ensure that employees, contractors, and partners sign NDAs (Non-Disclosure Agreements) or other relevant confidentiality agreements.



Employee Training: Regularly train staff on the importance of IP and the methods to protect it.

Access Controls: Implement strict access controls to sensitive information. Use digital security measures for digital assets.

Regular Audits: Conduct periodic IP audits to identify vulnerabilities and address them.

Legal Vigilance: Stay updated on IP laws in all operating jurisdictions and be prepared to enforce rights when needed.

Collaboration with Stakeholders: Engage with suppliers and other partners to ensure they also prioritize IP protection.

Preparedness for IP Breaches

Response Strategy: Develop a well-defined strategy to address any potential IP breaches, including legal and PR responses.

Insurance: Consider intellectual property insurance to help mitigate potential financial losses from IP breaches.

Continuous Monitoring: Invest in tools and services that monitor the market for potential unauthorized products or IP infringements.

Intellectual property is among the most valuable assets for an API manufacturing unit. Given the significant investment in research, development, and production, safeguarding this asset is paramount. While risks can't be entirely eliminated, a proactive and comprehensive approach to IP protection can significantly mitigate potential damages and ensure the company remains competitive and profitable.



Equipment Failure

Equipment failure in an API (Active Pharmaceutical Ingredient) manufacturing unit is a significant concern, not just due to the potential financial implications but also because of the potential impact on product quality, safety, and delivery timelines. Let's delve into the risks associated with equipment failure in such a setting:

Equipment Failure Risks in API Manufacturing:

Nature of the Risk

Mechanical Breakdown: Wear and tear, or the inherent failure of mechanical parts.

Electrical Failure: Issues related to power supply, electrical circuits, or electronic components.

Software Glitches: Malfunctions in the software controlling the equipment, leading to errors or shutdowns.

Calibration Errors: Equipment not calibrated correctly can lead to deviations in production standards.

Overheating: Inadequate cooling or prolonged usage can lead to overheating and subsequent failure.

Human Error: Misuse or mishandling of equipment by operators.

Potential Outcomes

Production Delays: Manufacturing processes could be halted until equipment is repaired or replaced.

Increased Costs: Costs associated with repair, replacement, and potential wasted raw materials.



Compromised Quality: Malfunctioning equipment can lead to subpar products that don't meet quality standards.

Safety Hazards: Equipment failures can pose direct safety risks to workers, especially if it leads to explosions, leaks, or the release of toxic substances.

Regulatory Implications: Producing substandard APIs due to equipment failure can attract regulatory scrutiny, penalties, or recalls.

Contractual Penalties: Delays in production might result in breaches of delivery contracts, leading to penalties or loss of business.

Reduced Capacity: Until the equipment is fixed or replaced, the manufacturing unit may operate below its optimal capacity.

Contributing Factors

Inadequate Maintenance: Failing to perform regular maintenance checks and services.

Old Equipment: Aging machinery is more prone to breakdowns.

Lack of Spare Parts: Not having essential spare parts on hand for quick replacements.

Operator Unfamiliarity: Using equipment without proper training or not following SOPs (Standard Operating Procedures).

Environmental Factors: Exposure to extreme conditions like humidity, temperature, or corrosive materials.

Mitigation Strategies

Preventive Maintenance: Implement a rigorous preventive maintenance schedule based on the manufacturer's recommendations.



Operator Training: Ensure operators are well-trained on the equipment they handle and are aware of potential signs of malfunction.

Inventory Management: Maintain an inventory of essential spare parts for quick replacements.

Equipment Modernization: Periodically assess the age and performance of equipment and consider upgrading or replacing outdated machines.

Monitoring Systems: Implement real-time monitoring systems that can detect and alert for any anomalies in equipment performance.

Redundancy: For critical equipment, consider having backup systems in place to ensure continuous production.

Safety Protocols: Establish safety protocols to handle equipment failures, especially when there's a risk of hazardous occurrences.

Vendor Relationships: Foster good relationships with equipment vendors for faster service, repairs, or replacements.

Response Plan for Equipment Failures

Emergency Response: Have an immediate action plan for equipment failures, especially if there's a safety concern.

Root Cause Analysis: After addressing the immediate concern, conduct an analysis to understand the cause of the failure to prevent future occurrences.

Documentation: Document all equipment failures, actions taken, and changes implemented. This not only aids in continuous improvement but can also be essential for regulatory compliance.



While equipment failures in an API manufacturing unit can have substantial repercussions, with proactive planning, regular maintenance, and proper training, these risks can be significantly reduced. Investing in high-quality equipment, modern monitoring systems, and continuous staff training are vital to ensuring smooth and uninterrupted operations.

Accidents and Fires

The API (Active Pharmaceutical Ingredient) manufacturing environment, like many industrial settings, is vulnerable to accidents and fires due to the handling and storage of volatile chemicals, complex equipment, and various processes. Understanding the risks associated with accidents and fires is crucial to establishing prevention and response strategies.

Accidents and Fires Risks in API Manufacturing:

Nature of the Risk

Chemical Spills or Leaks: Accidental release of hazardous chemicals can lead to contamination and expose employees to health risks.

Equipment Malfunctions: Mechanical or electrical equipment failures might cause sparks or excessive heat, leading to fires.

Explosions: Some chemicals, under specific conditions, can be explosive, especially if stored or handled incorrectly.

Human Error: Mismanagement or mishandling of chemicals, equipment, or processes can initiate accidents or fires.

Structural Failures: Poor facility design or maintenance can lead to accidents, including collapses.



Potential Outcomes

Injury or Fatality: Workers or staff might get injured or, in extreme cases, lose their lives.

Production Delays: Manufacturing processes could be halted until the facility is restored or deemed safe.

Property Damage: Fires or explosions can cause substantial damage to the facility and equipment.

Environmental Contamination: Chemical spills or fires might release toxic substances into the environment, affecting surrounding communities or ecosystems.

Regulatory Penalties: Accidents can result in violations of safety and environmental regulations, leading to financial penalties and increased scrutiny.

Increased Insurance Premiums: Recurrent accidents or fires can lead to higher insurance premiums.

Reputation Damage: Accidents, especially those that harm the environment or community, can severely damage the company's reputation.

Contributing Factors

Inadequate Training: Lack of proper training on equipment use and emergency procedures.

Poor Maintenance: Neglecting regular maintenance of equipment and facilities.

Ineffective Safety Protocols: Absence of or not adhering to established safety protocols.

Aging Infrastructure: Old equipment or facilities that don't meet current safety standards.



Lack of Monitoring: Absence of alarms or monitoring systems that could detect and alert for potential hazards.

Mitigation Strategies

Safety Training: Regular and comprehensive training sessions for all employees, focusing on both prevention and response.

Emergency Drills: Routine fire and emergency evacuation drills to ensure preparedness.

Equipment Maintenance: Rigorous schedules for inspecting and maintaining all equipment and infrastructure.

Safety Equipment: Adequate provision of safety equipment like fire extinguishers, sprinkler systems, safety goggles, chemical-resistant suits, etc.

Safety Audits: Periodic safety audits to identify vulnerabilities and potential hazards.

Monitoring Systems: Implement real-time monitoring systems for detecting gas leaks, chemical imbalances, or other anomalies.

Proper Storage: Ensure chemicals are stored in appropriate containers, in designated areas, and under suitable conditions.

Safety Signage: Clear signage indicating potential hazards, emergency exits, and safety equipment locations.

Response Plan for Accidents and Fires

Immediate Evacuation: Prioritize human safety. Ensure all personnel know evacuation routes.

Emergency Response Team: A dedicated team trained to handle emergencies, including first aid, firefighting, and containment of chemical spills.



Communication Plan: A strategy for communicating with employees, stakeholders, authorities, and, if necessary, the media.

Incident Reporting: Document the incident, actions taken, and outcomes. This is crucial for regulatory compliance, insurance claims, and future risk assessments.

Review and Revise: After managing the incident, review the causes and the response. Adjust protocols, training, and infrastructure as needed to prevent recurrence.

While the risks associated with accidents and fires in an API manufacturing unit can be severe, proactive risk management can substantially mitigate potential damages. A combination of prevention strategies, continuous training, and a robust emergency response plan is essential to safeguard both human and material assets.

Market Dynamics Risks

Market dynamics refer to the forces and factors that influence the behavior of buyers and sellers in a market. In the context of an API (Active Pharmaceutical Ingredient) manufacturing unit, understanding market dynamics is crucial to ensuring the unit's profitability, sustainability, and growth. Let's delve into the risks associated with market dynamics for an API manufacturing unit:

Market Dynamics Risks in API Manufacturing:

Nature of the Risk

Demand Fluctuations: Sudden changes in the demand for specific APIs can impact production and sales.

Price Volatility: Prices of APIs can be volatile due to competition, regulatory changes, or market demand.

New Competitors: Entry of new players in the market can reduce market share and pricing power.



Shifts in Regulatory Landscape: Changes in regulations can influence production methods, quality control, and export-import policies.

Technological Advancements: New technologies or production methods can render existing processes obsolete.

Dependence on Few Buyers: Reliance on a small number of large buyers can be risky if they change suppliers or alter their requirements.

Global Market Influences: Global economic conditions, pandemics, or geopolitical events can affect the international demand and supply for APIs.

Potential Outcomes

Reduced Profit Margins: Intense competition or price wars can squeeze profit margins.

Inventory Surpluses or Shortages: Misreading demand can result in excessive inventory or stockouts.

Stranded Investments: Heavy investments in now obsolete technologies can result in financial losses.

Loss of Market Share: Inability to compete effectively can lead to a reduced market presence.

Regulatory Penalties: Non-compliance with new regulations can lead to fines and penalties.

Reduced Demand: Global influences can significantly reduce the demand for certain APIs.

Contributing Factors

Inadequate Market Research: Not staying updated with market trends, demands, and competitive landscapes.



Slow Adaptability: Inability to swiftly adapt to changing market or technological conditions.

Fixed Long-term Contracts: Locked-in contracts that don't allow flexibility in changing market dynamics.

Lack of Diversification: Over-reliance on a specific market segment or geography.

Mitigation Strategies

Continuous Market Research: Regularly assess and predict market trends, demands, and potential threats.

Diversification: Diversify product offerings and explore new markets to reduce dependency on a single segment.

Flexible Production Capabilities: Ensure the manufacturing unit can adapt to produce different APIs based on changing demands.

Adaptive Pricing Strategies: Implement pricing strategies that can adjust based on market conditions while ensuring profitability.

Invest in R&D: Invest in research and development to stay ahead in technological advancements and develop innovative products.

Build Strong Relationships: Foster good relationships with key buyers and suppliers to ensure stability and insights into market shifts.

Regulatory Compliance: Stay updated with global regulatory trends and ensure continuous compliance.

Risk Management Planning: Incorporate market dynamics risks in the company's broader risk management strategy.



Preparedness for Market Dynamics Shifts

Scenario Planning: Engage in "what-if" analyses to foresee potential market shifts and plan responses accordingly.

Financial Resilience: Maintain a robust financial position to withstand short-term market disruptions.

Agile Supply Chain: Ensure the supply chain can adapt swiftly to changing market dynamics, allowing for sourcing flexibility and responsive distribution.

Continuous Training: Train the workforce to be adaptive and skilled in new technologies or processes as market demands evolve.

While market dynamics present significant risks to an API manufacturing unit, they also offer opportunities for those companies agile and prepared enough to capitalize on them. Being proactive in understanding, predicting, and responding to market changes can turn these risks into competitive advantages. An adaptive, well-informed, and resilient approach is key to navigating the intricate landscape of market dynamics in the API manufacturing industry.



Social Impact and Justification for API Manufacturing Unit

Active Pharmaceutical Ingredients (API) are the core components of medicines, responsible for their therapeutic effects. Setting up an API manufacturing unit has a variety of implications for society. Here's a breakdown of the potential social impacts and justifications for starting such a venture:

Social Impact

Access to Medicines:

Producing APIs locally can lead to increased availability of essential drugs in the region, ensuring timely access to medicines for the populace.

Employment Opportunities:

An API manufacturing unit can provide direct employment to a range of professionals, from skilled workers and technicians to scientists and administrators.

Skill Development:

The pharmaceutical industry requires specialized skills. By providing training and development, such units can uplift the skill set of the local workforce.

Research and Development:

API manufacturing units often tie up with academic institutions or research centers. This promotes scientific research and innovation in the region.



Healthcare Cost Regulation:

Local production of APIs can potentially reduce the cost of importing them, leading to more affordable medicines.

Strengthening Healthcare Systems:

A reliable supply of APIs ensures that the healthcare system can respond effectively to health crises, be it chronic diseases or pandemics.

Environmental Concerns:

API manufacturing can sometimes lead to environmental pollution if not managed properly. This can affect the health and well-being of local communities.

Dependency Reduction:

By producing APIs domestically, a country can reduce its dependence on foreign suppliers, ensuring a stable supply even in geopolitical or global economic crises.

Justification for an API Manufacturing Unit

Market Demand:

With the global demand for medicines on the rise, starting an API manufacturing unit can be a lucrative venture if there's a market gap.

Strategic Advantage:

If the region has a strategic advantage, like availability of raw materials, skilled labor, or supportive infrastructure, it can be a compelling reason to start the unit.



Policy and Incentives:

Governments often provide incentives for sectors that are crucial for public health. If such incentives are available, they can justify the establishment of the unit.

Export Potential:

If the domestic production exceeds local demand, there's potential for export, opening up additional revenue streams.

Integration with Existing Pharma Business:

For those already in the pharmaceutical business, producing APIs can be a backward integration strategy, giving better control over quality and costs.

Innovation and Patenting:

Developing new or improved APIs can lead to patenting opportunities, providing a competitive edge and higher profitability.

Responding to Global Crises:

As seen during situations like the COVID-19 pandemic, having domestic API production capabilities allows for a swift response in ramping up the production of essential drugs.

Sustainability and Green Manufacturing:

With increasing demand for sustainable practices, setting up a green API manufacturing unit can cater to this niche, offering environmental benefits and potentially attracting specific markets or partnerships.



Diversification:

For investors or businesses in related sectors, API manufacturing can be a means to diversify the portfolio, spreading risks and tapping into the lucrative pharmaceutical sector.

Establishing an API manufacturing unit is a significant venture that requires rigorous planning, adherence to stringent regulatory standards, and a long-term vision. While the social impacts and justifications are compelling, potential entrepreneurs should also be aware of the challenges, including competition, regulatory hurdles, quality control, and environmental concerns. Properly managed, however, such a unit can be both economically rewarding and socially beneficial.



Economic Impact and Justification for API Manufacturing Unit

Active Pharmaceutical Ingredients (API) manufacturing plays a crucial role in the global healthcare value chain. Establishing an API manufacturing unit can offer significant economic benefits to both the local community and the broader pharmaceutical industry. Here's a breakdown of the potential economic impacts and justifications for such an endeavor:

Economic Impact

Direct Employment:

An API manufacturing unit requires a diverse workforce, from R&D scientists and quality control experts to technicians, laborers, and administrative staff, creating substantial direct employment opportunities.

Supply Chain Development:

The establishment of such a unit can spur the growth of related businesses, from raw material suppliers to packaging and logistics providers.

Export Revenues:

If the unit produces APIs at competitive prices and quality, there's potential to tap into the global market, earning valuable foreign exchange for the country.

Local Pharmaceutical Industry Boost:

A domestic API production unit can lead to a reduction in medicine prices, as the dependency on imported APIs decreases. This can bolster the growth of local generic medicine manufacturers.



Investment Attraction:

A thriving API unit can attract further investments in the region, from both local and foreign investors, leading to broader economic development.

Infrastructure Development:

To support the API unit, there might be enhancements in local infrastructure, including roads, utilities, and possibly even research institutions.

Tax Revenues:

A profitable manufacturing unit will contribute to local and national tax coffers, supporting public expenditures.

Skills and Knowledge Spillover:

The technical know-how and expertise developed within the API unit can spill over to other sectors, elevating the overall industrial competence of the region.

R&D Investments:

A portion of the profits from API manufacturing can be reinvested into research and development, leading to the discovery of new APIs or more efficient production methods.

Justification for an API Manufacturing Unit

Growing Global Demand:

With an aging global population and increasing healthcare needs, the demand for medicines, and by extension APIs, is on the rise.



Cost Competitiveness:

If the region has advantages like low labor costs, affordable raw materials, or supportive infrastructure, manufacturing APIs can be economically viable.

Policy Incentives:

Many governments provide incentives, subsidies, or favorable policies to promote the pharmaceutical sector, given its strategic importance.

Vertical Integration:

For pharmaceutical companies, producing their own APIs offers better control over quality, costs, and supply chain reliability.

Diversification:

Investors or companies in related sectors might see API manufacturing as a strategic diversification, tapping into the lucrative pharmaceutical market.

Supply Chain Resilience:

The COVID-19 pandemic underscored the risks of over-relying on a few regions for API supply. Diversifying the API production landscape can offer more resilience to global supply chains.

Geopolitical Advantage:

In a world with changing geopolitical dynamics, having domestic API capabilities can be a strategic advantage, ensuring medicine security for a nation.



Innovation Potential:

The pharmaceutical sector is driven by innovation. If there's potential to develop novel APIs or improve existing ones, it can justify the establishment of a specialized unit.

While the economic incentives for starting an API manufacturing unit are substantial, potential entrepreneurs should be mindful of challenges such as stringent regulatory requirements, international competition, technological advancements, and environmental concerns. A rigorous feasibility analysis, coupled with a clear understanding of the market dynamics, will be crucial for the venture's success.



Future Challenges for API Manufacturing Unit

The Active Pharmaceutical Ingredients (API) manufacturing sector is dynamic and influenced by a range of factors, from technological advancements to geopolitical shifts. As companies contemplate venturing into or expanding within this domain, they should be mindful of the potential future challenges:

Regulatory Compliance:

Governments and international bodies are continually updating regulations to ensure drug safety and efficacy. Staying compliant can be costly and complex, especially when operating in multiple markets with differing regulatory requirements.

Environmental Concerns:

API manufacturing can be resource-intensive and potentially polluting. Stricter environmental regulations, combined with increased societal pressure for sustainable operations, could necessitate significant investments in cleaner production processes.

Price Pressures:

With the growth of the generic drug market, there's consistent downward pressure on prices. Manufacturers will need to continually optimize processes to maintain profitability.

Intellectual Property Issues:

Patent disputes and intellectual property challenges can arise, especially when dealing with innovative drugs. Navigating this landscape requires legal expertise and can be costly.



Geopolitical Risks:

Reliance on specific regions for raw materials or key ingredients exposes manufacturers to geopolitical uncertainties, which can disrupt supply chains.

Supply Chain Disruptions:

From pandemics to natural disasters, unforeseen events can disrupt supply chains, causing delays and potential revenue losses.

Quality Control:

Ensuring consistent quality is paramount in the pharmaceutical industry. Failures can lead to product recalls, legal challenges, and significant reputational damage.

Technological Advancements:

The sector is constantly evolving, with new manufacturing techniques, digitization, and automation. Keeping up with these changes necessitates continual investment in technology and training.

Competition:

With the lucrative nature of the pharmaceutical industry, more players are entering the market, leading to increased competition and potentially reducing market share for existing manufacturers.

Antimicrobial Resistance (AMR):

As resistance to existing drugs grows, there's pressure on the pharmaceutical industry to innovate and find new solutions. For API manufacturers, this can mean shifts in demand patterns and the need for R&D investments.



Shift in Demand:

With changing global health demographics and emerging diseases, the demand for specific APIs may decrease, while others may see a surge. Adapting to these shifts in real-time is crucial.

Trade Barriers:

Tariffs, trade wars, and protectionist policies can impact the import and export of APIs, affecting profitability and market access.

Increasing Clinical Trials Complexity:

As regulatory bodies demand more comprehensive data on drug safety and efficacy, the complexity and duration of clinical trials can increase, impacting the time-to-market for new APIs.

Consumer Awareness:

An increasingly informed consumer base is demanding transparency in drug sourcing and manufacturing. Meeting these expectations while protecting proprietary information can be a delicate balance.

To thrive in the future, API manufacturers need to adopt a proactive approach, investing in research, technology, and sustainable practices. Building resilient and adaptable business models, while fostering partnerships and collaborations, can also aid in navigating these challenges.



Market Survey

Report Overview

The global active pharmaceutical ingredients market size was valued at USD 222.4 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.90% from 2023 to 2030. The growth can be attributed to the advancements in active pharmaceutical ingredient (API) manufacturing and the rising prevalence of chronic diseases, such as cardiovascular diseases and cancer. Favorable government policies for API production, along with changes in geopolitical situations, are boosting market growth. $\text{ff}^{@5/8} \quad \text{``$=$^{\downarrow} \quad N^{2}/_3 L_{R} C_{V_0} 5/_8 N_L \quad \text{\in} L_{F} \quad V_{T} - 3/_8 5/_8 L_{R} @1 \\ \text{\in} - \mathbb{N}^{ϱ} N^{ϱ} + \mathbb{N}^{ϱ} N^{ϱ} - \mathbb{N}^{{\varrho}} N^{{\varrho}} - \mathbb{N}^{{\varrho}} N$ LFVTHTHT000Rs 1/801/3€- 3/8€LFCRVTHTNL€1- 2/3Rs -■fflt/42×2Pt -1VT-NLCR€5/8-F LFVT1/80 1/3-F ±-3%€1/3 1/3 CR5% 2/35%€-® HTCR5%7%5%CRCR5%3% 1**3**5%CR -®€-1/3 7/61 CR NL®5% 5%H+T1 CRNL 17/8 C_R5/83/8 V_T1/85/8 3/85/8^HT5/8-3/85/8-1/85/8 7/81[□]R "■‡ H_TC_R13/8 V_T1/8 N_LC_FPt O^VT^CR^NL^{®5}/8^CRN^{№1}^CR⁵/8[£] ^{®1} **®** ⁵/8 ^CR − N^{№5}/8 − N[№] 1/8 N^{№1}/3 − Rs 1/8 1 V_T − N^CC_R € 5/8 ^CF 7/81 CRNº VT0001/3 N_5/83/8 HT0001/3 - LF 1/3 - 3/8 ® CR1/3 - N_5/83/8 € - 1/85/8 - N_L € € 5/8 LF N_L 1 HT CR1 Nº 1 N_5/8 N_{L®5/8} H_TC_R13/8 V_T1/8 N_L€1- 17/8 "■‡Pt

®%012/31/30%0 "■‡LF Nº1/3 TRXLPt ff®5/8 HT®1/3 TRNº1/31/85/8 YTNL€1/81/30%0 €-3/8 YTLFNL TRRS ₩¹/₃¹F ¹/₃- 5/8^HT€¹/85/8-N_5/8^LR €- N_LFR5/8¹/3N_L€-® LFRSNºHTN_1NºLF CR5/8/01/3N_5/83/8 N_1 —■ff|±⟨¥^QΩ£ €-½%%, √₇3%€-∞ ®€∞® 7%5%**®**5%^CR£ ½1, √₇∞®£ ½3-3% ½1, √₈1, √₇5% N_L1 N_@5/8 €-1/8CR5/81/3-F5/83/8 HT1HTVT001/3CR€N_RS 17/8 N_@5/8 HT®1/3CRNº1/3 €-3/8VT-FN_CRRS 3/8 \rac{1}{12} \rac{1}{12} \rightarrow \rac{1}{12} \ €▂®┖℞⁵‰¾€⁵‰▂凡┖╘╴№⅓┖℞℀ℴ℅札╴⅓‱┖╒↿╶₩€凡▁⋍%┖╒╘%३% ®┖℞↿₩┖،℗╶℁┖┰⋤€҈∠℗᠃┖℗₅% ^HT5%^CR€13%Pt ○1500001₩€—® N_05% ff1^CR503% +5%1/350N_0 ■^CR91/3—€MD1/3N_€1—\$^LF 3/85/81/80/01/3 \text{\$\lambda_{\text{R}}\lambda_{\text{\$\lamba_{\text{\$\lamba}}}\end{\text{\$\lamba_{\text{\$\lamba_{\text{\$\lamba_{\text{\$\la 3/8€**3**5/8^LR^LF5/8 ^{∞C}R¹V_TH_T ¹⁷/₈ □ R⁵/₈ - 1 ₩ - 5/₈3/₈ H_{T®1/3}C_RNº1/31/85/8V_TN_L€1/81/30/00 1/3-3/8 1/81NºHT1/3-€5/8LF£ ²/₃€1^HT®1/₃^CRNº1/₃1/₈5/₈V_TN_L€1/₈1/₃%₀ 1/3^LE ₩⁵/₈%00%00 1/3^LE **-**5/8₩ L_FN_L1/₃C_RN_LV_TH_TL_F£ L_FN_L5/₈H_TH_T5/₈3/₈ 7/₈1C_R₩ 1/₃C_R3/₈ N_L1 1/₈C_R5/₈1/₃N_L5/₈ N_L®5/₈C_R1/₃H_T€5/₈L_F N_L1 1/81Nº2/31/3NL NL®5/8 **⊕**€CRVTLFPt



-1/8€5/8-N_€-FN_L= 3/8€-F1/81 **@**5/8-FR5/83/8 1/3 0/0€-FN_ 17/8 1/81N²+T1V_T-3/8-F N_®1/3 N_C ^L1/3^CR®5/8^L —■ffl±<¥º¤Pt —^VT^CR⁵/8—NL%0Rs£ ^L®5/8^CR⁵/8 1/3 ^HT HT CR1*N € Nº1/3 ^L5/8 %0 Rs. ²²² 1/81N²H₇1V₇-3/8^LF €- 1/80%€-€1/81/30% N_LC_R€1/30% L_F 1/3-3/8 ¢² N²10%05/81/8 V₇0%05/8^LF €-HTCR5/81/80/0€—€1/81/30/0 3/85/8 \$65/80/01 HTN 25/8—NL NL1 1/81 N 2/31/3 NL —■ff| L+42 AP+ ○1 YTCR **⊕**1/31/81/8€-5/8^LF [®]1/3**№**5/8 2/35/85/8- ^CR5/8^HT V_TC_R H_T1^LF5/83/8 7/81^CR N_L C_R5/81/3 N_LN[®]5/8-N_L —■ff|‡¢¥º¤£ €-1/8%0°V_T3/8€-® _®%01ER1FFVT€-5%£ 1/3®1/3€-LFNL †Rs¾^ER¹₩Rs½[®]0%¹^ER¹^FF^VT€−5%£ R¹^HT€−½**®**€^ER ¶ □€NL¹-½**®**€^ER£ ⅓-¾ □5/8N^{Q3}/8⁵/8^LF€**3**€^CRPt ‡- ●1/3^CR¹/8[®] 1/2²1/2²£ fi†■ ^LF^NL¹/3^CR^NL⁵/8³/8 1/3 ₩1^CR⁰/0³/8 ₩€3/8⁵/8 N_CR€1/3/00 17/8 N_05/8 7/81 VTCR —■ffl‡«¥°¤ N°5/83/8€1/8€-5/8-FPt ‡-1/8-CR5/81/3-F5/83/8 €-**®**5%^LF^NLN²⁵%-^NL 1/3-3% ^LR5%^LF5%1/3^LR1/8[®] 1/3-3% 3/85%**®**5%[®]001^HTN²⁵%-^NL €-H_T@1/₃C_RNº1/₃1/₈5/₈V_TN_L€1/₈1/₃0/₀₀ H_TC_R13/₈V_T1/₈N_LL_F ₩€0/₀₀0/₀₀ H_TC_R1H_T5/₈0/₀₀ N_L@5/₈ @C_R1₩N_L® 17/₈ N_@5/8 Nº1/3^CR%5/8N_ 7/8 YT^CRN_@5/8^CRPt †1₩5/8**@**5/8^CR£ N_@5/8 1/8^{1C}R¹—1/3**@**€^CRYT^LF ${}^{1} {}^{V_{T}} {}^{V_{L}} {}^{2} {}^{J_{C}} {}^{5} {}^{8} {}^{1} {}^{3} {}^{V_{U}} = {}^{9} {}^{1} {}^{3} {}^{V_{T}} {}^{L} {}^{F} {}^{5} {}^{8} {}^{8} = {}^{9} {}^{0} {}^{0} {}^{12} {}^{3} {}^{1} {}^{3} {}^{0} {}^{0} = {}^{2} {}^{3} {}^{V_{T}} {}^{L} {}^{F} {}^{E} {}^{-5} {}^{8} {}^{L} {}^{F} {}^{L} {}^{F} = {}^{1} {}^{3} {}^{-3} {}^{8} = {}^{5} {}^{8} {}^{1} {}^{8} {}^{1} {}^{-1} {}^{N} {}^{9} {}^{E} {}^{1} {}^{8} {}^{1} {}^{8} {}^{1} {}^{-1} {}^{N} {}^{1} {}^{E} {}^{E} {}^{1} {}^$ 3/8€LFCRVTHTNL€1-Pt



H_{T®1/3}C_RNº1/31/85/8V_TN_L€1/81/30/00 H_T1N_L5/8−N_L 1/31/8N_L€**⊕**5/8 €-®^CR⁵/8³/8[€]5/8-^NL^LF; €-³/8[€]1/8¹/3^NL⁵/8 1/3 ³/8^CR¹/3^N²1/3^NL[€]1/8 ^LF®€⁷/8^NL €-17/87/85/8 C_R -5/8 ₩ Nº5/83/8 € 1/8 € -5/8 L_FPt "L_F 1/3 C_R5/8 L_FV_T0/00 N 17/8 N 05/8 1/8 01/3 - 005/8 N 1 †■"■‡┗F£ 1/3 HT€HT5%00€-5% 17% Nº1┗R5% 5%7%7%5%1%NL€\$5% 3%┗RVT®┗F ₩€NL® 001₩5%┗R 3/81^LF5/8^LF ®1/3^LF 5/8N^Q5/8^LR®5/83/8Pt †■"■‡^LF\$ 1/33/8**®**1/3−N_L1/3®5/8^LF£ €−1/8/00 Y_T3/8€−® N_L®5/8 ^C_R5%^F_F^V_T€^C_R5%N^Q5%−N_L 7%¹^C_R 1/3 0/01₩ 5%^C_R N_L®5%^C_R1/3^H_T5%^V_TN_L€1/8 3/81^L_F5%£ 1/81/3 H_T1/31/8€N_LRs 1/81/3- 2/35/8 1/3 N_ N_ C_R € 2/3 V_T N_ 5/83/8 N_ 1 N_ ® 5/8 € C_R C_R € L_F € - ® 3/85/8 N № 1/3 - 3/8 1/3 N № 1 - ® H_TC_R¹³% V_T1/8⁵% C_RL_F 1/3 − 3/8 1/8 V_TL_FN_L¹N²⁵% C_RL_FPt ff[®]5/8 "■‡ N²1/3 C_R% 5/8 N_L [®]1/3 L_F 1/3 % 0 W 1/3 R_SL_F 2/3Rs L_FNº1/3‰%0 2/35/85/8-3/81Nº€-1/3^NL5/83/8 Nº1%05/81/8VT%05/8LFPt Nº1/3-V_T7/81/31/8N_LV_TC_R5/8C_RL_F 1/3^CR5/8 1/3³81^H_TN_L€-@ †■"■‡L_F N_L1 3/8€7/87/85/8C_R5/8-N_L€1/3N_L5/8 $^{N}_{L}@5/8N^{QL}_{F}5/8\%_{0}\textcircled{3}5/8^{L}_{F} \quad ^{7}/8^{L}_{R}^{1}N^{Q} \quad ^{N}_{L}@5/8 \quad ^{1}/8^{1}N^{QH}_{T}5/8^{N}_{L} \overset{\bullet}{\in} ^{N}_{L} \overset{\bullet}{\in} ^{1}_{L} \quad ^{1}/3^{L}_{F} \quad ^{N}_{L}@5/8 \quad ^{@5}/8 - ^{5}/8^{L}_{R} \overset{\bullet}{\in} ^{1}/8 \quad ^{\bullet}_{L} \overset{\bullet}{=} ^{1}/8^{L}_{R} \quad ^{\bullet}_{L} \overset{$

In addition, APIs are used as Antibody Drug Conjugates (ADCs). ADCs are important and effective treatment modalities used in combination with biologically active drugs and monoclonal antibodies for cancer. APIs effectively target cancer cells while causing minimum exposure of drugs to healthy tissues. Thus, the development of cancer-specific APIs is expected to boost the API market growth.



Type of Manufacturer Insights

The captive API segment accounted for the largest revenue share of 51.5% in 2022. It is anticipated to grow at a significant rate in the upcoming years owing to the easy availability of raw materials and extensive investments by major players to develop highend manufacturing facilities. Furthermore, recent developments and initiatives by key players suggest that they are highly focused on in-house manufacturing over outsourcing.

 $\bigcirc^{1} \stackrel{\Gamma}{\Gamma}_{R} = \stackrel{\Gamma}{\Gamma}_{L} \stackrel{1}{1}_{3} - \frac{1}{8} \stackrel{5}{8} \stackrel{\Gamma}{\Gamma}_{E} = 0 \stackrel{1}{\bullet} \stackrel{5}{8} \stackrel{N}{N} \stackrel{22}{3} \stackrel{5}{8} \stackrel{\Gamma}{\Gamma}_{R} = 0 \stackrel{1}{\bullet} \stackrel{1}{3} \stackrel{1}{\Gamma}_{R} \stackrel{1}{N}_{L} \stackrel{1}{\subseteq} \stackrel{1}{\Gamma}_{R} = 0 \stackrel{1}{N}_{1} = 0 \stackrel{1}{N}_{1} \stackrel{1}{\Gamma}_{R} = 0 \stackrel{1}{N}_{$



Type Insights



Application Insights

7/81 CR NL®5/8 0/01/3 CR®5/8 LFNL CR5/8 \$\cdot 5/8 - \rangle T5/8 LF®1/3 CR5/8 17/8 1/2 Pt 2 + € - 1/2 1/2 1/2 Pt ff®€ LF € LF®1/3 CR5/8 17/8 1/2 Pt 2 + € - 1/2 1/2 1/2 Pt 1 + € LF®1/3 CR5/8 17/8 1/2 Pt 2 + € LF®1/3 CR5/8 1/2 Pt 2 + € LF $1/_{3}^{N} L_{1}^{N} L_{1}^{C} = 2/_{3}^{N} L_{1}^{N} L_{5/8}^{5/8} N_{1}^{1} L_{1}^{0.5/8} = -1/_{8}^{1} L_{1}^{1} L_{1}^{C} = -1/_{8}^{1} L_{1}^{1} L_{1$ 3/8€LF5/81/3LF5/8LF ₩1CR/003/8₩€3/85/8Pt ff|1/3CR€1VTLF 1CR@1/3-€MD1/3NL€1-LF LF/T1/8@ 1/3LF †5/81/3 C_RN_L ○5/83/85/8 C_R1/3 N_L€1-£ N_L®5/8 fi¹C_R%03/8 -N_LC_R1%5/8 N @5/8 fi¹C_R%₀3/8 ■CR®1/3-€MD1/3NL€1-£ 1/3-3/8 NL®5/8 -NLCR10/15/8 "LFLF11/8€1/3NL€1- 1/3CR5/8 \\ 1 CR5/8 \\ 1 CR0/15/8 \\ 1 CR0/15 NL1₩1/3^CR³/8 €-1/8^CR⁵/81/3^LF€-® 1/3^H/3^CR⁵/8-5/8^LF^LF 1/3²/31^VTNL 1/81/3^CR³/8€1**®**1/3^LF1/8^VT0/01/3^CR 3/8€LF5/81/3LF5/8LFPt □1\\ 658ER-N\\ 6-€N\\ €-€N\\ €1/3N\\ €\\ 658EF\\ 18\\ 18\\ 6058EF\\ 60 01/3^NL€1-1/3⁰/₃0 -®1⁰/₃05/8^LF^NL5/8^LR1⁰/₃0 ,3/8 V_T1/81/3 N_L€1- ■^LR1[®]LR1/3 N^Q 1/3^LR5/8 1/3 €N^Q5/83/8 1/3 N_L €NºHTCR1�€-® 1/3₩1/3CR5/8-5/8CFCF CR5/8/001/3N_5/83/8 N_1 ‰€^Hτ€% 1/8[®]10%05%^LF^NL5%^LR1%0¥^LR5%9%01/3^NL5%3/8 3%€^LF5%^LFPt +€^{®®} H_T^LR5%**®**1/30%05%−1/85% 1/3−3% €-1/8^CR⁵/8¹/3^LF€-® 1/3^H1/3^CR⁵/8-5/8^LF^LF 1/3²/3¹/_TNL 1/8¹/3^CR³/8€¹**®** 1/3^LF¹/8^VT⁰/0¹/3^CR $38^{V_{T}} - \mathbb{R} = -0 \quad \text{N_05} \\ 8^{V_{T}} - \mathbb{R} = -0 \quad \text{N_05} \\ 8^{V_{T}} - \mathbb{R} = -0 \quad \text{N_05} \\ 8^{$ "■\$\textsup 7/81\textsup 7/81\textsup 1/81/3\textsup R3/8\textsup 10001\textsup Rs 3/8\textsup R\textsup 7/8\textsup R\textsup 7/8\textsup R\textsup 7/8\textsup R\textsup 7/8\textsup R\textsup 7/8\textsup R\textsup 7/8\textsup 7/8\te

N @5/8 7/81^ER5/81/81/3^LFN $^{H}_{T}5\%^{L}_{R} \in ^{13}\%P_{t} \bigcirc ^{1}\%^{1}\%^{N}_{L}^{1}_{L}^{L}_{R}^{L}_{F} \quad ^{L}_{F}^{V}_{T}1\%^{0} \quad ^{1}\%^{L}_{F} \quad ^{1}\%^{0}1\%^{3} - ^{00} \in ^{-00} \quad ^{00} \in ^{7}\%^{5}\%^{L}_{F}^{N}_{L}^{R}_{S}^{0} + ^{00}\%^{5}_{R}^{N}_{L}^{0} + ^{1}\%^{0}_{R}^{N}_{L}^{0} + ^{1}\%^{0}_{R}^{N}_$ ®^CR¹₩€—® H_T^CR⁵%**3**1/30/00⁵/8—1/8⁵/8 17/8 1/81/3—1/8⁵/8^CR 1/3^CR⁵/8 3/8[□]R€**3**€-∞ N 05/8 Nº1/3^CR°\u58^NLPt ff®5/8 €-1/8^CR5/81/3^LF€-® 1/33/81^HT^NL€1- 17/8 1/3 ^LF5/83/85/8-N_L1/3^CRRs $\%_0 \in 7/\!85\% \ ^{L}_{F} \ ^{L}_{RS} \%_0 5/\!8 \ \in ^{L}_{F} \ ^{3}\!\%_{R} \in \ \bigoplus \in - \ ^{\Theta} \ ^{N}_{L} \otimes 5/\!8 \ ^{H}_{T} \ ^{L}_{R} 5/\!8 \ \bigoplus 1/\!3 \%_0 5/\!8 - 1/\!85/\!8 \ ^{17}\!\% \ \ \ \ \bigoplus 1/\!3 \ ^{L}_{R} \in ^{1}_{V_{T}} \ ^{L}_{F} = 1/\!3 \ ^{N}_{T} \ ^{L}_{F} + 1/\!3 \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} = 1/\!3 \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} = 1/\!3 \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} = 1/\!3 \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} = 1/\!3 \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} = 1/\!3 \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} \ ^{N}_{T} = 1/\!3 \ ^{N}_{T} \ ^{$ ®^CR¹₩€→® 1/8¹−1/8⁵%^CR→ €→ №¹^LF^NL 1/8¹V_T→N_L^CR€5/8^LFPtff®5/8^LF5/8³%€^LF¹^CR³%⁵%^CR^LF N_L®Rs^CR¹€3/8 1/3-3/8 ^L_F5/8N ®1^C_RN°1−5/8 €N°2/31/30/01/3−1/85/8Pt R5%**®**1^NL[©]Rs^CR¹₩€−5% €^LF 1/3 ^HT¹HT VT 1/00 1/3 ^CR "■‡ V_TL_F5/₈3/₈ N_L1 NL E_{R5/81/3}NL ®RsH_T1NL®RsE_R1€3%€L_FNºPt +1E_RNº1−1/3000 NL®5%E_R1/3H_TRs €L_F 17/8 **3**1/3 ^LR€1 ^VTL_F N_Rs^HT⁵/₈^LF³/₄ ⁷/₈¹^LR H_T¹^LF^N_LN²5/₈−¹H_T¹/₃ V_T^LF¹/₃% ₩¹N²5/₈−£ ⁷/₈¹^LR N²5/₈− ¹− ¹/₈¹/₃−¹/₈⁵/₈^LR N_CR5%1/3N_N°5%-N_£ 1/3-3% 7/81CR 1/8®€\%03%CR5%- N_1 5%-1/32/3\%05% HTCR1HT5%CR ®CR1₩N_®Pt $\text{``} \quad ^{\sqsubseteq}_{R} \in ^{\sqsubseteq}_{F}5\% \quad \text{\in-$} \quad \text{$\otimes1}^{\sqsubseteq}_{R}N^{\varrho 1} - 5\% \text{$^{3}\%}5\% \text{1}^{\lnot}_{T}\% - 3\% 5\% - N_{\bot} \quad 1\% \otimes \in ^{\bot}_{\Theta} \quad ^{1}_{T}{}^{\sqsubseteq}_{R}12\% \% 5\% N^{\varrho L}_{F} \quad \text{\in^{1}\%}3\% \text{$^{1}\%}^{\bot}_{F}12\% + 1\% 3\% \text{$^{1}\%}_{F}12\% + 1\% 3\% \text{$^{1}\%}_{F}12\% + 1\% 3\% \text{$^{1}\%}_{F}12\% + 1\% 3\% \text{$$ 5%**N**^H_T5%1/8N_L5%3/8 N_L1 3/8^ER€**3**5% N_L®5% N^Q1/3^ER^C√5%N_LPt



Type of Synthesis Insights

ff®5% 2/3€1N_5%1%® LF5%®Nº5%-N_ €LF 1/3-N_€1/8€HT1/3N_5%3% N_1 ₩€N_-5%LFLF H_T5% C_R€13% Pt ff®€L_F L_F5%®N°5% - N_L €L_F 3% C_R€®5% - 2% Rs 7%1/31/8 N_L1 C_RL_F L_F V_T1/8® 1/3 L_F €-1/8^LR⁵/8¹/3^LF€-@ 3/8⁵/8^N²¹/3-3/8 7/8¹^LR 2/3€1^HT[®]1/3^LR^N²1/3¹/8⁵/8 N^L¹/3 N_L€1/8¹/3 N_L[®]5/8 N_L[®]5/8 ®€®®5%^ER 5%7%7%€1%€5%−1%Rs 17% N_®5%^EF5% N^{Q1}005%1%^VT0005%1%^VT0005%^EFPt ○ VT^ERN_®5%^ERN^{Q1}ER5%£ ®€®® €-**®**5%^LF^NLN²⁵%-N_LL_F €-N_{L®5/8} 2/3€1N 5/81/8®—10/001®Rs ²/₃€1^H_T®1/₃^L_RN^Q1/₃1/₈5/₈V_TN₁€1/₈1/₃%₀ L_E5/81/8N₁ 1C_RL_EPt ff®€└ϝ 1/3%00%01₩^LF N @5/8 €--1**3**1/₃N_L€1- 17/₈ -5/₈₩ N^Q10/₀5/₈1/₈V_T0/₀5/₈L_F N_L®1/₃N_L 1/3€3/8 €-N @5/8 N_CR5%1/3N_Nº5%-N_ 17/8 3%€-F5/81/3-F5/8-F£ -FVT1/8® 1/3-F 1/81/3-1/85%-RPt ff®5/8 ®€®® C_R5/8 **3**5/8 − V_T5/8 17/8 2/3 € 1 N_C 5/8 1/8 ® ¥C_R5/8 % 0 1/3 N_C 5/8 8 "■‡ N^Q1/3 C_U5/8 L_F N_C ® 5/8 N^Q1/3 C_RC/U 5/8 N_C ®€®®%Rs HTER17%€NL1/32/3%05%£ 1/3NLNLER1/31%NL€-® Nº1/3%1ER HT%01/3Rs5%ERLFPt ○1ER €-L_FN_L1/3-1/85%£ ■C_R10/05/8 V_TC/u€- i1/30/03/85%L_F0/05% V_TC/u€-i 2/3 Rs -0/0€-€@5%-£ ±-1/8 Pt €LF 1/3 2/3€10/01®€1/81/30/0 NL®5/8ER1/3HTRS 7/81ER Nº5/8NL1/3LFNL1/3NL€1/8 ER5/8—1/30/0 1/85/80/00/0 1/81/3[□]R1/8€-1N⁰1/3Pt



□5/81/81Nº2/3€-1/3-NL HTCR1NL5/8€-LF 1/3CR5/8 5/8tNL5/8-LF€®5/8/0/Rs VTLF5/8/3/8 €-L_F5%^F_FV_T5%-1%€-®£ 5%^L_FH_T5%1%€1/30000Rs N_L1 1/8^CR⁵/81/3 N_L5/8 1/3 - N_L€2/3 13/8 Rs @5/8-5/8 H_TC_R12%5%L_F ₩€N_L®€- 1/85%0000L_FPt ff®V_TL_F£ C_R5%1%1Nº2%€-1/3-N_L H_TC_R1N_L5/8€-L_F ff@5/8^L=5/8 H_T^C_R¹N_L⁵/₈€−^L_F H_T‰¹/₃Rs 1/₃ 1/8^CR^VT¹/8€1/3‰ ^CR¹0/0⁵/8 N_L @5/8 3/85/8 **⊕** 5/8 %01 H_T N⁰25/8 − N_L 17/8 −1 **⊕** 5/8 %0 N_L C_R5/8 1/3 N_L N⁰25/8 − N_L L_F£ L_F V_T 1/8 ® 1/3 L_F 1/8 5/8 %00 %0 H_TCR1NL5%€-N_L@5/8^CR1/3^HTRsPt ■‰1/3Rs5/8^CR^LF 1/3^CR5/8 €-**6**5%^LF^NL€-® €-Nº1/3-V₇7/81/31/8N_LV₇C_R€-® H₇0/01/3-N_LL_FP_t O1C_R €-L_FN_L1/3-1/85/8£ €- 01 65/8 Nº2/35/8C_R 1/2 aº X£ - \in 1\ff5\gamma1\gamma0-5\gamma\quad \\1/3-1\gamma-V_TH_T@^CR¹/₃3/₈5/₈ €NLLF H_TC_R1N_L5/8€- Nº1/3-V_T7/81/31/8N_LV_TC_R€-® Nº€‰‰€1– 7/81/31/8€0/00€NLRs 1/3-3/8 Nº5/85/8NL 1/85/80/00/00 NL®5/8 RR1/3 HTRS 3/85/8Nº1/3-3/8 LFPt +1₩5/8**@**5/8 RR£ N_@5/8 CR5/8 1/3 CR5/8 1/3 0/00€N°2€N_5/83/8 - V_TN°2/35/8 CR 17/8 H_T0/01/3 Rs5/8 CR E €- N_@5/8 7/8€5/8003/8£ 0005/81/33/8€-® NL1 €-LFVT7/87/8€1/8€5/8-NL LFVTHTHT00/Rs 7/81^CR 1/8 VTCRCR5/8-NL 1/3-3/8 7/8 V_TN_L V_TC_R5/8 3/85/8 N^Q1/3-3/8 C_FPt

Regional Insights

North America accounted for the largest revenue share of 38.80% in 2022 and is expected to maintain its lead over the forecast period. It is due to the rising incidence of cancer and other lifestyle-induced diseases, which stimulates R&D, thereby boosting the market.

Asia Pacific is anticipated to exhibit the fastest CAGR of 7.1% during the forecast period. The presence of economies such as China and India that the world relies on for the production of APIs at a lower cost is an advantage for the region. Increasing healthcare expenditure in the region is anticipated to fuel the market growth.

Europe is expected to witness significant growth during the forecast period. An increase in research funding and the local presence of key market players in this region is expected to drive the market. The number of biopharmaceutical companies is growing in Europe owing to increasing investments. For instance, in 2018, USD 20 billion was raised as an investment by the biopharma industry, which increased by 28% to USD 27.5 billion in 2019. Many key global players conduct their biopharmaceutical R&D in Europe.



Key Companies & Market Share Insights

The market for active pharmaceutical ingredients operates with high complexity. A blockbuster drug patent expiration, increasing outsourcing activities due to high manufacturing costs, and stringent regulations on the production of APIs are expected to maintain the competitive rivalry at a high level during the forecast period.

Many key players are focusing on launching new products to maintain their position in the market. $\bigcirc^{1}^{\Box}R$ \in $-^{\bot}F^{N}_{\bot}^{1}/_{3}-1/_{8}^{5}/_{8}^{2}$ \in - " $^{V}T^{\odot}V^{T}_{\bot}F^{N}_{\bot}$ $^{1}/_{2}^{a}1/_{2}^{a}2^{a}$ $ff^{5}/_{8}$ \bullet 1/3 \bullet 1/4 \bullet 1/3 \bullet 1/3 \bullet 1/4 \bullet 1/4

H_TC_R5/8L_F5/8-1/85/8 H_TCR1Nº€-5%-NL H_T1001/3Rs5%CRLF ff^{®5}/8 17/8 €-\ N ®€LF L_F€@_€7/8€1/81/3-NL‰Rs L_FH_T1/₃1/₈5/₈ Nº1/3^ER°/u⁵/8^NI 3%€Nº€-€LE®5%LE N @5/8 1^HT^HT¹^LR^NL ^VT — € N € 5% ^LF 7% ¹^LR 1% - 5% ₩ 5% - N ^LRRs € - N ^L1 N [®]5% N ^Q1% ^LR % 5% N ^L£ 1% ^LF € N ^L 3/8€7/87/8€1/8V_T‰NL €F Nº1/3^NL1/8® N @5/8 e€@e 1/81/3^HT€N 1/3‰ CR5%FFVT€CR5%N°5%-N_LFPt -1N°5% HTCR1N°€-5%-N_ HT001/3Rs5%CRLF €- N_05% 00012/31/300 1/31/8^N1 €**®**5/8 H_{T®1/3}C_RNº1/3¹/8⁵/8 V_TN_L€1/8¹/3³/00 €-@^CR⁵/8³/8€⁵/8-NL^LF Nº1/3^ER°/_U5/8^NI €-1/8\%0 V_T3/85/83/4

- 5/8 R1/8 Wu ¶ 1 Pt£ ‡—1/8 Pt
- "2/32/3ffl€5/8£ ‡-1/8Pt
- -^CR€^LF^NL¹0‰¥•Rs⁵%^CR^LF -^FF^VT€²/₃²/₃ -¹N²H_T¹/₃-Rs
- -15/8[®]C_R€-^{®5}/8^CR±-^{®5}/8[®]/₀^{®5}/8€N[®] ±-^N_L5/8^CR-¹/3^N_L€1-¹/3⁹/₀ □N²/3+
- —€HT1001/3£ ±-1/8Pt
- ff5%⊕1/3 ■®1/3^LRNº1/3¹/85% V_TN_L€1/81/3/6 ‡—3% V_TL_FN_L^LR€5% L_F R_NL3%Pt



- "%₀²/₃⁵/₅Nº¹/₃^ĽR%₀⁵/₅ —¹^ĽR^HT¹^ĽR¹/₃^NL€¹—
- ffl€1/3NL^CR€LF ‡-1/8Pt
- "V_TC_R12/3€_3/81■®1/3^C_RNº1/3
- -V_T- ■®1/3^LRNº1/31/8⁵/8 V_TN_L€1/81/3%0 ‡-3/8 V_TL_FN_L^LR€5/8^LF RNL3/8Pt
- ⟨^L_RP_t □5/83/83/8Rs'^L_F R1/32/31^L_R1/3N_L1^L_R€5/8^L_F RN_L3/8Pt

Active Pharmaceutical Ingredients Market Scope

Report Attribute	Details
Market size value in 2023	ffi–‹ ½¹¼®Pŧ¢® billion
^{□5} / ₈ ⊕ ⁵ / ₈ − ^V _T ⁵ / ₈ 7/ ₈ 1 ^L _R 5/ ₈ 1/ ₈ 1/ ₃ ^L _F ^N _L €− 1/ ₂ ² 1/ ₄ ²	ffi–₁ 1/421/2Pt¤® 2/3€‱€1–
□ ^E R ¹ ₩ ^N L [®] □ ¹ / ₃ ^N L ⁵ / ₈	—"□□ 17/8 2Pt¤ ^a * 7/8 [□] R ¹ Nº 1/2 ^a 1/2 ¹ /4 NL1 1/2 ^a 1/4 ^a
-1/3 ^L F ⁵ /8 Rs ⁵ /8 ¹ /3 ^L R ⁷ /8 ^{1L} R ⁵ /8 ^L F ^N L€N ² 1/3 ^N L€1-	1/281/21/2
†€ ^L F ^N L ^{1E} R€ ¹ / ₈ 1/ ₃ % ₀ ³ / ₈ 1/ ₃ ^N L ¹ / ₃	1/2 ⁸⁰ X ¥ 1/2 ⁸ 1/2 ⁰
01 ^L R5/81/81/3 ^L F ^N L H _T 5/8 ^L R€13/8	1/2 ^a 1/2 ¹ /4 ¥ 1/2 ^a 1/4 ^a
□ ^V _T 1/ ₃ -N _L €N _L 1/ ₃ N _L € ® 5/ ₈ V _T -€N _L L _F	□ $^{5/8}$ 6 $^{5/8}$ - V - $^{5/8}$ €- ffi- $^{6/8}$ - $^$
□5/8 ^H T ^{1□} R ^N L 1/81 ⊕ 5/8□R1/3®5/8	□5/8�5/8-VT5/8 7/8 ¹ CR5/81/81/3 ^L FNL£ 1/8 ¹ N ² HT1/3-RS ^C R1/3-%+€-®£ 1/8 ¹ N ² HT5/8 ^N L€NL€�5/8 %01/3-3/8 ^L F1/81/3 ^L HT5/8£ ® ^C R ¹ ₩NL® 7/81/31/8 ^N L ¹ CR ^L F£ 1/3-3/8 N _L CR5/8-3/8 ^L F
-5/8 [®] N ²⁵ /8- ^N L ^L F 1/81 ⊕ 5/8 ^E R ⁵ /8 ³ /8	ffRs ^H T ⁵ / ₈ ¹⁷ / ₈ ^L FRs−N _L © ⁵ / ₈ ^L F€ ^L F£ N _L Rs ^H T ⁵ / ₈ ¹⁷ / ₈ N ^Q 1/ ₃ −V _T ⁷ / ₈ 1/ ₃ 1/ ₈ N _L V _T ^C _R 5/ ₈ ^L RS N _L Rs H _T 5/ ₈ £ 1/ ₃ H _T H _T 0/ ₉ 0€1/ ₈ 1/ ₃ N _L €1−£ C _R 5/ ₈ ©€1−
□5/8®€1-1/3/00 L _F 1/81H _T 5/8	01 ^L RNL® "Nº5/8 ^L R€1/81/3 ³ , V _T ^L R1 ^H T5/8 ³ "L _F €1/3 ■1/31/8€7/8€1/8 ³ R1/3 ^N L€— "Nº5/8 ^L R€1/81/3 ³ ●>"
—1 ^V T— ^N L ^E RRs ^L F ¹ / ₈ 1 ^H T ⁵ / ₈	$\begin{array}{llllllllllllllllllllllllllllllllllll$
SM5/8Rs 1/81NºHT1/3-€5/8LF HTCR17/8€%05/83/8	●5% ^L R1/8% ¶ —1Pt£ ‡—1/8Pt³ "2/32/3ffl€5%£ ‡—1/8Pt³ — ^L R€ ^L F ^N L10‰¥●Rs5% ^L R ^L F — ^F F ^V T€2/32/3 —1N ^{2H} T1/3—Rs³ —15% [©] LR€— [®] 5% ^L R‡— [®] 5%0° [®] 5%€N° ‡— ^N L5% ^L R—1/3NL€1—1/3%



	□N°2/3†3 ff5/8 1/3 ■©1/3 ^L RN°1/31/85/8 V _T N _L €1/81/3%0 \$\pmu_{-3/8}\text{V}_{-1}\text{L}_{-1}\text{E}_{-5/8}\text{L}_{-1}\text{R}_{-5/8}\text{L}_{-1}\text{R}_{-5/8}\text{L}_{-1}\text{R}_{-5/8}\text{L}_{-1}\text{R}_{-1}\te
— ^V T ^L F ^N L ¹ Nº€ ^{MD1} / ₃ ^N L€ ¹ — LF ¹ / ₈ 1 ^H T ⁵ / ₈	○□R5/85/8 □R5/8HT1□RNL 1/8VT□FNL1Nº€MD1/3NL€1— i5/8FFVT€ 3 1/3005/8—NL NL1 VTHT NL1 © 1/3—1/3000RS□FNL□F\$ ₩1□R\(\)\(\)\(\)\(\)=0 3/81/3RS□F; \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
■ ^C R€1/8€-® 1/3-3/8 H _T V _T C _R 1/8®1/3 ^L F ⁵ /8 1H _T N _L €1-L _F	"♠¹/₃€%0 ¹7/8 ¹/8 ^V T ^L F ^N L¹Nº€MD5/8³/8 HTVT ^C R¹/8®¹/3 ^L F ⁵ /8 ¹HTNL€¹—LF NL¹ Nº5/858NL Rs¹VT ^C R 5/8†*1/3¹/8 ^N L CR5/8 ^L F5/8¹/3 ^L R¹/8® -5/85/8³/8 ^L FPt →†HT7/00¹ ^C R5/8 HTVT ^C R¹/8®¹/3 ^L F5/8 ¹HTNL€¹—LF

Global Active Pharmaceutical Ingredients Market Segmentation

Type of Synthesis Outlook

- _€1N_L5/₈1/₈®
- o -€1^NL⁵/₈1/₈® "■‡^LF ●1/₃^LR%₁5/₈N_L£ -Rs ffRs^HT⁵/₈
 - o □5%-5%^ER€1/8 "■‡^LF
 - o ‡--1**3**1/3^NL€**3**5/8 "■‡^LF
- o -€1^NL⁵/₈1/₈® "■‡^LF ●1/₃^ER⁶/₄5/₈N_L£ -Rs ■^ER¹³/₈V_T1/₈N_L
 - $\circ \quad \bullet^{1}-^{11}\!/\!8\%0^{1}-^{1}\!/\!3\%0 \quad \text{``-N_L} \stackrel{?}{=} ^{2}\!/\!3^{13}\!/\!8 \stackrel{?}{=} ^{5}\!/\!8^{L_{\text{F}}}$



- o †1^LRNº1-5/8^LF
- o -RsNL10/u€-5/8LF
- O □5/81/81Nº2/3€-1/3-NL ■CR1NL5/8€-LF
- o ff®5/8^CR1/3^HT5/8 VTNL€1/8 >-MDRsNº5/8^LF
- o ffl1/31/81/8€-5/8LF
- O −00113/8 O1/31/8NL1ERLF
- -Rs-NL®5/8NL€1/8
 - o -Rs-N_L®5%N_L€1% "■‡L_F ●1/3^LR°u5%N_L£ -Rs ffRsH_T5%
 - o □5/8-5/8^CR€1/8 "■‡^LF
 - o ‡--1**3**1/3^NL€**3**5/8 "■‡L_F

Type of Manufacturer Outlook

- —1/3^HT^NL€**3**5/8 "■‡^LF
- ●5/8^CR¹/8[®]1/3-NL "■‡^LF
 - o ●58^LR1/8[®]1/3-NL "■‡^LF ●1/3^LR%15/8 NL£ -Rs ffRs H_T5/8
 - o □5/8-5/8^ER€1/8 "■‡ F
 - o ‡--1**3**1/₃N_L€**3**5/₈ "■‡L_F
 - 0 ●58^CR1/8[®]1/3-NL "•‡^LF ●1/3^CR%1/5[®]NL£ -Rs ffRs^HT58 178 -Rs-NL[®]58^LF€^LF
 - 0 -€1N_5/81/8®
 - o -Rs-NL®5/8NL€1/8
 - ffRs H_T5/8 V_TN_L‰¹¹%_u
- □5/8-5/8^CR€1/8 "■±^LF
- ‡--1**3**1/3^NL€**3**5/8 "■‡^LF ffRsH_T5% 17% (ERV_{T®}
- \blacksquare $^{\square}R^{5/8}L_{F}^{1/8}L_{R}^{\square}H_{T}^{N}L_{1}^{\square}= (^{\square}R^{V}T^{\otimes}L_{F}^{\square})$
- **3**5% ^CR¥NL®5%¥1/81 V_T − NL5% ^CR √CR V_T® L_F



Application Outlook

- —1/3^LR³/8€¹**3**1/3^LF¹/8^VT‱1/3^LR (€^LF⁵/8¹/3^LF⁵/8^LF
- ■-1/810/00^{1@}Rs
- —o— 1/3—3/8 o5/8 V_T E_R10/001@Rs
- ■^C_RN_{L®1}H_T5/83/8€1/8
- >-3/811/8 R€-10/001@Rs
- ■VT%0Nº1-1%01®Rs
- □1/3^LF^NL^CR15/8-N_L5/8^CR10/001@Rs
- 05/8HT®ER10/001@Rs
- ■HT®NL®1/3000N°10001®Rs
- ■NL®5/8^LR^LF

Regional Outlook

- 01^ER^NL® "Nº5/8^ER€1/81/3
 - o ffiPt-Pt
 - 0 -1/3-1/33/81/3
- , V_TE_R1H_T5/8
 - o ffiPtSMPt
 - o □5/8^CRNº1/3−Rs
 - o O[□]R¹/₃-1/₈5/₈
 - o ‡NL1/3/60Rs
 - o -^HT¹/₃€-
 - o [□]\tr-F-F=1/3
 - \circ † $^{V}_{T}$ - $^{\Theta 1}/_{3}$ $^{\Gamma}_{R}$ Rs

- "L_F€1/3 ■1/31/8€7/8€1/8
 - O TM1/3HT1/3-
 - o —®€-1/3
 - 0 ‡-3/8€1/3
 - O -1 VTNL® SM1 ER5/81/3
 - o "VTLFNLER1/300€1/3
- R¹/₃^NL€- "Nº⁵/₃^CR€¹/₃¹/₃
 - o -^CR¹/₃MD€%0
 - o ●5/8**H**€1/81
 - o "E_{R®5/8}-N_L€-1/3
- • €3/83/80/05/8 >1/3^LF^NL ¶ "7/8^LR€1/81/3
 - o -1^VT^NL® "7/8^ER€1/81/3
 - o ffi">
 - o -1/3 ^VT³/8€ "^ER¹/3²/3€1/3
 - o → ®RsH_TN_L
 - o ‡^LF^CR¹/₃5/₈%₀₀

API in India

The Indian Bulk drug industry or the Active Pharmaceutical Industry is dominated by Chinese players. Companies such as Sun Pharma, Aurobindo Pharma, Laurus Labs, Divis, Jubliant Lifesciences, Biocon are leaders in APIs when one sees the domestic manufacturing for the APIs. However, the quantity is extremely small and only meets about 10–25% of their requirement.



3%5%Nº1%-3%7%1FR HT®1%FRNº1%1%5%VTNL€1%1%3%0 3%FRVT®LF£ ₩®€1%® €- NLVTFR- €LF 1/8[®][□]R¹-€1/8 3/8€LF5/81/3LF5/8LF LF\T1/8® 1/3LF 1/81/3-1/85/8LR£ 3/8€1/32/35/8^NL5/8^LF£ 1/81/3¹F₈8€1 **3**1/3 ¹F₁1/8 ¹T/801/3¹F₈£ -5/8 ¹Y₁F₈1/8 1/9 (181/3) 3/8€-F5/81/3-F5/8-FPt \$\pm\$-3/8€1/3 1/3-3/8 --®€-1/3 1/3-F8/8 N-05/8 N-1/3/6/1-R L-F-V-H-T-H-1/0/€5/8-R-F 17/8 "■‡└F NL1 01└RNL® "Nº5/8└R€1/81/3 3/8 VT5/8 NL1 NL®5/8€□R 001₩ HT□R13/8 VT1/8 NL€1— 1/81/3^HT1/31/8€NL€5%LF£ 0/01/32/31^LR 1/81^LFNL^LF 1/3-3/8 NL®5/8 HT^LR5%LF5%-1/85/8 17/8 1/3 %01/3^LR®5/8 — V_TN°2/35/8^LR 17/8 ®%012/31/3/%0 1/3—3/8 3/81N°25/8^LF^LL€1/8 H_T7%01/3 Rs5/8^LR^LFPt ±— 1^LR3%5%^LR N_L1 1/8 Y_TN_L 3/81₩ — 1 — 5/8₩^HT5% — L_F5%^LF 1/3 — 3/8 € — 1/8^LR5%1/3 L_F5% H_TCR17%€N_LL_F£ 1/81NºHT1/3-€5/8LF ®1/3 **6**5/8 2/35/8®VT- 1VTNLLF1VTCR1/8€-® NL®5/8 1/8CR5/81/3 NL€1- 17/8 "■±LF NL1 N_@5% 3%5% **6**5% %01H_T € − ® 1/81V_T − N_C_R€5% L_F € − "L_F€1/3£ %05/81/33% € − ® N_1 ®C_R1₩N_0 € − N_05/8 "LF€1/3- Nº1/3-R%5/8N_Pt ff@5/8 LF1/37/85/8N_Rs 17/8 Nº5/83/8€1/81/3N_€1- "■±LF 1/3-F8/8 L_{F®}€H_TH_T5/83/8 N₁ @5/8 1/81 VT-NLERRS N_{L®5/8}Rs 1/3 ^CR⁵/8 $^{N}L^{1}P_{t}$ ■®1/3^LRNº1/31/85/8 \(^{\text{N}_L}\)\(\ext{\init}\)1/81/3\%\(^{\text{L}_F}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_F}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_F}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_F}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_F}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_1}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_1}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_1}\)\(^{\text{L}_1}\)\(^{\text{L}_1}\)81/3\%\(^{\text{L}_1}\)\(^{\text{L}_1} ±-3% \runnermath{\tau}-\runnermath{\text{L} $1/_{3} - 3/_{8} \text{ "$^{V_{T}}$^{\Box}_{R}$} 1/_{3} \in -3/_{8}$^{1} 1/_{3}$^{\Box}_{R}$^{5}/_{8} \text{ $^{L_{F}}$} 1N^{95}/_{8} \text{ $^{W_{S}}$}^{6}/_{R}H^{-1}$ $^{W_{S}}$^{1}/_{3}H^{-1}$ $^{W_{S}}$^{1}/_{3}$^{W_{S}}$^{1}/_$



<5/8^HT5/8-3/85/8-N_L 1- -®€-1/3




'R¹'FNL —¹NºHT5%NL€NL€®5% >3%®5%'



API Manufacturers in India

ff"=‡



$$\begin{split} &\text{ff}^{\circledcirc 5/8} \quad 1/8^{1} N^{9} H_{7} 1/_{3} - Rs^{'} L_{F} \quad \Box^{5/8} L_{F}^{5/8} 1/_{8}^{0} \quad \P \quad \sqrt{5/8} \, \textcircled{6}^{5/8} \%^{0}^{1} H_{7} N^{95/8} - N_{L} \quad V_{7} - \textcircled{E}^{N}_{L} \\ &1/8^{N_{7}} L_{R}^{C} L_{R}^{5/8} - N_{L} \%^{0} Rs \quad 1/8^{1} N^{9} H_{7}^{C} L_{R} \textcircled{E}^{L}_{F}^{5/8} L_{F} \quad 1 \textcircled{6}^{5/8} L_{R} \quad @2^{2} \quad L_{F}^{1/8} \textcircled{E}^{5/8} - N_{L} \textcircled{E}^{L}_{F}^{N}_{L} L_{F} \quad \textcircled{44}^{\odot 1} \\ &L_{F}^{H} L_{7}^{5/8} 1/_{8} \textcircled{E}^{1/3} \%^{0} \textcircled{E}^{MD5/8} \quad \textcircled{E}^{-} \quad N_{L}^{\odot 5/8} \quad 1/8^{8} \textcircled{E}^{5/8} \%^{0} 3/_{8} L_{F} \quad 1/7/8 \quad 1/8^{\odot 5/8} N^{9} \textcircled{E}^{1/8} 1/_{3} \%^{0} \quad L_{F}^{R} Rs - N_{L}^{\odot 5/8} L_{F}^{-} \textcircled{E}^{L}_{F}^{C} L_{F}^{C} \\ &1/8^{5/8} L_{R}^{R} N^{95/8} - N_{L}^{1/3} N_{L}^{N} \textcircled{E}^{1} - \pounds \quad \textcircled{E}^{-} \textbf{E}^{-} \textbf$$



‡-3/8€1/3 1/3/001-5/8Pt

 $-V_{T}^{\Gamma}\Gamma_{R}F_{8}-N_{L}\%_{0}R_{S}£ \ \ ^{\Gamma}\Gamma_{R}P_{t} \ \ ^{\Box}5\%_{8}\%_{8}R_{S}'^{L}F \ \ ^{3}65\%_{1}\%_{3}\%_{0}L_{F} \ \ ^{\dagger}\Psi_{C}^{\bullet}N_{L}^{\bullet} \ \ ^{1}3_{-3}\%_{8} \ \ N^{21}3_{-1}\%_{9}^{\bullet}5\%_{8}L_{F} \ \ ^{1}3\%_{9}\%_{8}R_{S}'^{L}F \ \ ^{3}65\%_{1}\%_{9}\%_{0}L_{F} \ \ ^{\dagger}\Psi_{C}^{\bullet}N_{L}^{\bullet} \ \ ^{3}8_{-1}^{\bullet}N_{1}^{\bullet}N_{2}^$

"VTCR12/3€_3/81

—€^HT‰1/3



_1/3_3/81MD

□1/3-2/31/3**1₹R**S

-V_T- ■®1/3^C_RNº1/3

 $-^{V}_{T}- \bullet \bullet 0^{1}/_{3} \Gamma_{R} N^{2}/_{3}' \Gamma_{F} \quad "\bullet \ddagger \quad ^{L}_{T} \Gamma_{R} 1^{1} \bullet \Gamma_{R} 1'_{3} N^{2} \quad ^{2}/_{3} 5'_{8} \bullet 0'_{3} - \quad ^{E}_{-} \quad ^{2} \mathfrak{A} \mathfrak{A}^{2} \quad - \quad ^{L}_{1} 1^{3}/_{8} 1'_{8} Rs \quad ^{L}_{0} 0^{5}/_{8} Rs \quad ^{N}_{1} 0^{5}/_{8} \Gamma_{R} 1'_{8} 1'_{8} 1'_{8} \Gamma_{R} 1'_{8} 1$

‡—¾€¼§└₣ ‡—¼⅓—¼€�¼└₣ ⅙¹¼ √¹№¼└₣¼€⅓ "■‡ ■┗₁¾┗¼¼€¹— —¹Ч‰¾ —Ч¼ —ЧН+₩Rs □€└₣%

 $\bigcirc \in \mathbb{N}_{L} 1 \% = \mathbb{I}_{3} \mathbb{N}_{L} \in -\mathbb{O}^{L}_{F} + \mathbb{O}^{V}_{T} \mathbb{N}^{2} \%^{1} \% = \mathbb{I}_{R} 5 \% + \mathbb{I}_{R$



$$\begin{split} & \text{ff}^{\oplus 5/8} \quad {}^{\oplus 1} \bigoplus 5/8^{\square}_{R} - N^{25/8} - {}^{N}_{L} \quad 1/_{3} - 1^{\vee}_{T} - 1/_{8} 5/8 N^{25/8} - {}^{N}_{L} {}^{L}_{F} \quad 7/_{8} 1^{\vee}_{00} 0^{\vee}_{00} {}^{1} \bigstar \quad {}^{\square}_{R} 5/_{8} 1/_{8} 5/_{8} - {}^{N}_{L} \\ 3/_{8} 5/_{8} \bigoplus 5/_{8} 0/_{00} {}^{1}_{1}^{1}_{T} N^{25/8} - {}^{N}_{L} {}^{L}_{F} \pounds \quad \bigoplus -1/_{8} 0/_{8} 0/_{7} 3/_{8} \bigoplus - \emptyset \quad {}^{1}_{1}^{1}_{1}^{1}_{1}^{1}_{2} - {}^{1}_{1}^{1}_{2}^{1}_{2} + {}^{1}_{1}^{1}_{2}^{1}_{3}^{1}_{3}^{1}_{4}^{1$$



$$\begin{split} &\text{fi}@{\in}\%.5\% \qquad ^{\text{N}}_@{\circ}\% \overset{\text{L}}{\vdash} \text{5\%} \qquad \bigoplus -1\%.5\% - ^{\text{N}}_ \bigoplus 5\%. \overset{\text{L}}{\vdash} \text{1/3} \overset{\text{Q}}{\vdash} \text{N}^2 \qquad ^{\text{N}}_1 \qquad ^{\text{5}}\% - 1\%.1 ^{\text{7}}_1 ^{\text{9}}_3\% \\ & \bigoplus -1\%. ^{\text{L}}_{\text{R}} \text{5\%} \text{N}^{\text{Q}} \text{5\%} - ^{\text{N}}_1 ^{\text{1/3}} \text{5\%} \qquad \bigoplus -2\%.5\%. \overset{\text{L}}{\vdash} \text{N}^{\text{L}}_1 \qquad ^{\text{L}}_1 \qquad ^{\text{L}}_2 ^{\text{L}}_2$$



 $\bigcirc \bigcirc -1/3\% 0 \qquad {}_{0}^{V} T \in 3/85\% 0 \bigcirc \bigcirc -5/8^{L}F \qquad 7/8^{1}^{L}R \qquad 1/3 \qquad {}_{0}^{L} T_{R}^{13}8^{V} T_{1/8}^{N} N_{L} \in 1- \qquad R \in -9/15/83\% 1 + 1/85\% - N_{L} \in 3/85\% 1 + 1/85\% 0 + 1/8$



 $fi@{\in}\%.5\% \bullet {}^{2}1/4{}^{2} \quad N^{2}{\in}\%.0\%.0 {\in} 1- \quad @1/3^{L}{F} \quad 2/35/85/8 - \quad {}^{C}{F}.5\%.{}^{C}{F}.8 \bullet 5/83/8 \quad 7/81^{L}{F} \quad 1/2^{2} \times 35/8 - 5/87/8 {\in} 1/8 {\in} 1/3^{L}{F}.8 \quad 1/81^{N}{}^{2}{H} + 1/3 - {\in} 5/8^{L}{F}.8 \quad {}^{N}{L}1 \quad {}^{N}{L}_{1}/3 {\%}.5\% \quad {}^{N}{L}_{1}/3 {\%}.$



‡NºHT¹□RNL <5/8HT5/8-3/85/8-1/85/8

$$\begin{split} &\text{ff}^{\odot}58 \quad \text{ff}^{\Box}_{R}1/_{3}3/_{8}5/_{8} \quad \blacksquare^{\Box}_{R}^{1}N^{2}1^{N}_{L} \in 1--1^{N}_{T}-1/_{8} \in \% \\ & \text{178} \quad \ddagger-3/_{8} \in 1/_{3} \quad \bot_{F}^{N}_{L}1/_{3}N_{L}5/_{8} \vdash_{F} \quad \ddagger-3/_{8} \in 1/_{3} \\ & \text{end} \quad 1/_{8} \quad$$

$$\begin{split} & & & \text{ff}@^{\Gamma}_{R}{}^{1}{}^{V}_{T}@@ \quad 1/3 \quad {}^{\Gamma}_{R}{}^{5}_{8}{}^{1}_{8}{}^{5}_{8}-{}^{N}_{L} \quad -{}^{1}{}^{N}_{L} \overset{}{\in} 7/8 \overset{}{\in} 1/8}{}^{1}_{3}{}^{N}_{L} \overset{}{\in} 1-\hat{\Sigma} \quad {}^{N}_{L}@^{5}_{8} \quad {}^{5}_{8}{}^{H}_{T}{}^{1}_{3}{}^{\Gamma}_{R}{}^{N}_{L}N^{25}_{8}-{}^{N}_{L} \quad 17/8} \\ & \bullet @^{1}/_{3}{}^{\Gamma}_{R}N^{2}{}^{1}_{3}{}^{1}_{8}{}^{5}_{8}{}^{V}_{T}{}^{N}_{L} \overset{}{\in} 1/8}{}^{1}/_{3}{}^{N}_{0} \overset{}{\leftarrow}_{F} \quad {}^{1}/_{1} \bullet \overset{}{\circ}_{C} \quad {}^{\Gamma}_{1}{}^{1}_{9}{}^{N}_{0} \overset{}{\circ}_{S}{}^{1}_{8} & {}^{1}_{4}{}^{V}_{1}{}^{N}_{L} \quad 3/8}{}^{\Gamma}_{R}{}^{1}/_{3}{}^{7}/_{8}{}^{N}_{L} \quad @^{V}_{T} \overset{}{\in} 3/8}{}^{5}/_{8}{}^{N}_{0} \overset{}{\in} -5/8 \overset{}{\leftarrow}_{F} \\ & 7/8{}^{1}_{\Gamma}_{R} \quad {}^{N}_{L} \overset{}{\otimes}_{S} \quad {}^{8}_{R} \quad {}^{4}_{\Gamma} \overset{}{=} 1/8}{}^{5}/_{8}{}^{8}_{N}{}^{2}/_{8} P_{t} \quad \text{ff} \stackrel{}{@}_{S} \quad @^{V}_{T} \overset{}{\in} 3/8}{}^{5}/_{8}{}^{N}_{0} \overset{}{\in} -5/8 \overset{}{\leftarrow}_{F} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{5}/_{8}{}^{N}_{L} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{1}/_{8}{}^{1}/_{8}{}^{N}_{L} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{1}/_{8}{}^{N}_{L} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{1}/_{8}{}^{1}/_{8}{}^{N}_{L} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{1}/_{8}{}^{N}_{L} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{1}/_{8}{}^{1}/_{8} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^{1}/_{8} \quad {}^{4}_{F} \overset{}{=} 1/8}{}^$$



>NHT5%ERNL —1NºNº€NLNL5%5%



—®5%Nº€1/61/300 ‡—N_5%ERNº5%3%€1/3N_5%LF

 $\bigcirc^{1}\Gamma_{R} \quad {}^{7}\!\!/8^{1}{}^{4}\Gamma_{R} \quad {}^{3}\!\!/8^{\Gamma}_{R}{}^{4}\!\!/9 \quad \bigoplus -\stackrel{N}{\downarrow} 5^{\%}\!\!/8^{\Gamma}_{R}N^{95}\!\!/8^{3}\!\!/8 \stackrel{1}{\downarrow} 3^{N}\!\!/5^{\%}\!\!/F_{E} \quad {}^{2}\!\!/3^{V}\!\!/7^{00}\!\!/9 \quad {}^{1}\!\!/8^{95}\!\!/8 N^{9}\!\!\!-1^{1}\!\!/3^{3}\!\!/9 \cdots {}^{1}\!\!/6^{1}\!\!/9 \cdots {}^{1}\!\!/9^{1}\!\!/9 \cdots {}^{1}\!\!/9^{1}\!\!/9^{1}\!\!/9 \cdots {}^{1}\!\!/9^{1}\!\!/9^{1}\!\!/9 \cdots {}^{1}\!\!/9^{1}\!\!/9 \cdots {}^{1}\!\!/9^{1}\!\!/9^{1}\!\!/9 \cdots {}^{1}\!\!/9^{1$



 $7/8^{5/8} \stackrel{\Gamma}{\Gamma}_R N^{95/8} - \stackrel{N}{\Gamma}_L 1/3^{1} \stackrel{\Gamma}{\Gamma}_L + \frac{1}{2} \frac{1}{3} \frac{1}{3} \stackrel{\Gamma}{\Gamma}_E 5/8^{3/8} \qquad 2/3^{1} \frac{1}{3} \stackrel{\Gamma}{\Gamma}_R 1/9^{1} \stackrel{\Gamma}{\Gamma}_E 1 + \frac{1}{3} \frac{1}{3} \frac{1}{3} \stackrel{\Gamma}{\Gamma}_R 1/9^{1} \stackrel{\Gamma}{\Gamma}_R$

■V_T-%1/3²/3 ■1/3^LR%u

 $-^{N}L^{1/3}N_{L}^{5/8}L_{F} \qquad \qquad ^{N}L^{1} \qquad ^{1/3}N_{L}^{N}L^{\Gamma}_{R}^{1/3}l_{8}^{N}N_{L} \qquad ^{2/3}V_{T}^{5/6}N_{u} \qquad ^{3/8}L_{R}^{\Gamma}V_{T}^{\odot} \\ N^{9}l_{3}-^{V}l_{7}^{8}l_{3}^{1/8}l_{8}^{N}L^{V}l_{T}^{\Gamma}L_{R}^{5/8}L_{F} \qquad ^{9}l_{3}^{2}\Theta^{5/8} \qquad ^{1/3}l_{6}^{1}L_{F} \qquad ^{2/3}l_{8}^{5/8}- \qquad ^{1/3}L_{F}^{5/8}l_{8}^{5/8} \qquad ^{N}L^{1} \qquad ^{1/3}L_{R}^{\Gamma}L_{R}^{1/3}-^{90}l_{8}^{5/8} \qquad ^{7/8}l_{R}^{\Gamma}L_{R}^{1/3} \\ m_{0}^{1}W_{1}^{4}l_{1}^{1}L_{F}^{N}L \qquad ^{9}l_{3}^{1}-^{3/8} \qquad ^{1/3}l_{3}^{3/8} \qquad ^{1/3}l_{3}^{3/8} \qquad ^{1/3}l_{4}^{3/8}l_{1}^{1/3} \\ m_{1}^{4}l_{1}^{5/8}l_{1}^{2}L_{F}^{N}L \qquad ^{9}l_{3}^{5/8}l_{1}^{2}L_{F}^{2}L_{F}^{1/3}l_{1}^{2}L_{F}$

□¹®¼₽; —¹¼€¾€5%º €—⅓%-½€®% └=⅓®%№% ¾¹┗R ‰¹⅓⅓‰ "■‡
№⅓-¼¾⅓⅓¼¼Ч¬Б€-® №¹ ⅓∀¬№ €№Ч¬¹Б₽№Ь





$$\begin{split} &\text{ff}@5\% & @^1 \textcircled{0}5\% \Box_R - N^25\% - N^2 & 1/3\%0 \Box_F 1 & -1^N \Box_F 7/8 \textcircled{0}5\%3 & 1/3 & \Box_F 1/8 @^5\%N^25\% & N_1 & \Box_F \Box_F 1/1 N^2 1^N \Box_F 8/2 \\ &2/3^V T \%0 \% & 3\% \Box_R V_T @ & \Box_T 1/3 \Box_R \% \Box_F 1/2 & \Box_T 1$$

"2/31 \rangle TNL \rangle \rangle 05/8 \rightarrow \rangle 5/8 1\text{\til\}\text{\ti}\text{\texi}\tint{\text{\text{\tex{\text{\text{\text{\text{\text{\texi}\tiex{\text{\ti}\til\text{\t



 $+ \sqrt{100}\% \qquad \bigcirc - \textcircled{5}\% - \mathbb{I}_{\mathsf{N}} \mathbb{I$

ff®5% ●1%%15% €- \pm -3%€1% €-€ N L€ M 5% ₩1%1 \pm %01% M T-1%®5%3% 2%Rs $^{N} L^{\oplus 5/8} \quad ^{\otimes 1} \mathbf{\Theta}^{5/8} \mathbf{^{\square}_{R}} - N^{\underline{\circ}5/8} - ^{N} L \quad \overset{\longleftarrow}{\in} \quad ^{1} \! /_{2} \, ^{\underline{a}\underline{\circ}} \, \mathcal{C} \quad ^{1} \! /_{3} - ^{3/8} \quad ^{\mathbb{C}_{R}} \mathbf{5/8} \, ^{1} \! /_{8} \mathbf{5/8} \, \overset{\longleftarrow}{\bullet} \, \mathbf{5/8} \, ^{1/8} \mathbf{5/8} \, \overset{\longleftarrow}{\bullet} \, \overset{\longleftarrow}{\bullet} \, \mathbf{5/8} \, \overset{\longleftarrow}{\bullet} \, \overset{\longleftarrow$ ^CR5%^LF^HT1^LF5% 7%^CR1N² NL®5% 3%5%**®**5%%01^HT5%3% −1/3N_L€1^LFPt ff®5% ®1**®**5%^CR−N²⁵%−N_L ®1/3^LF 1/3^M0^LF1 1/8^CR^{5/8}1/3^NL^{5/8}3/8 ^LF^HT^{5/8}1/8€1/3^M0 1/3^CR^{5/8}1/3^LF 3/8^{5/8}3/8€1/81/3^NL^{5/8}3/8 ^NL¹ 5%₦HT1^CRNL£ 1/81/3%0%5%3% 5%₦HT1^CRNL¥HT^CR11/85%LF^LF€—® MD1—5%LF ;>■\$LF; -H_T5/81/8€1/30/0 >1/81-1N²€1/8 \$1-5/8^LF ;->\$^LF¿£ N_L1 5/8-1/81 V_T^LR1/3@5/8 7/81 ^LR5/8€@-3%Rs-1/3Nº€1/8 2/31/3-Yu€-® 1/3Wo1-® ₩€NL® ®VT®58 €-7/8^LR1/3^LFNL^LRVT1/8NLVT^LR5/8 $3858 \odot 5800^{1} \times 10^{1} \times 1$ Nº1/3^CR⁰/₂5/8^NL^LF 7/8¹CR Nº1/3 — V_T7/81/3¹/8^NL V_TCR5/8³/8 ®¹¹³/8^LF 1/3 — 3/8 %0¹/3^LR^{®5}/8^LF^NL L=5%^CR⊕€1%5%L=Pt (VT5% N_1 €N_L= ®VT®5% N°1%^CR°V.5%N_ 1%-3% HT1HTVT°%01%N_€1-£ €N_L N_@5/8 ₩1^LR\\038Pt —1-38\\T18_€-\@ 2\3\\T-F\€-58\-F-F €- ‡-38\€1\\3 \@1\3\-F 2\35\\5\\8-3/8€7/87/8€1/8V_T‰N_L 2/35/81/81/3 V_TL_F5/8 17/8 1/81^LR^LR V_TH_TN_L€1−£ 0/01/31/8 % 17/8 €-78^FR13^LF^NL^FR^VT18^NL^VT^FR⁵8£ 1/3-38 €-1/3³8⁵8^FF^VT1/3^NL⁵8 ^LF⁵81/8^VT^FR€^NL**R**s Pt



Global Active Pharmaceutical Ingredients Market





 $38 \in \frac{7}{8}787858^{\Box}_{R}58 - ^{N}_{L} \quad ^{\bot}_{F}R_{S}N^{\Box}_{H}T^{N}_{L}1N^{\Box}_{F} \quad \in - \quad ^{3}8 \in \frac{7}{8}7858^{\Box}_{R}58 - ^{N}_{L} \quad ^{\bigstar}13R_{S}^{\bot}_{F}P_{t} \quad -^{N}_{L}^{\Box}_{R} \in -0588 - ^{N}_{L}$ $F_{F}^{V}_{T}13600 \in ^{N}_{L}R_{S} \quad 18^{1} - ^{N}_{L}^{\Box}_{R}1000 \quad \in ^{\bot}_{F} \quad 13^{3} \quad N^{2}13 - ^{3}813^{3}N_{L}58 \quad ^{\bigstar}058 - \quad \in ^{N}_{L} \quad 18^{1}N^{2}58^{\bot}_{F} \quad ^{N}_{L}1 \quad ^{N}_{L}058$ $N^{2}13 - ^{V}_{T}7813^{3}18^{N}_{L}^{V}_{T}^{\Box}_{R} \in -00 \quad 178^{3} \quad 38^{\Box}_{R}^{V}_{T}00^{\bot}_{F} \quad 13^{\bot}_{F} \quad ^{N}_{L}058 \quad ^{\bullet}_{B} \quad ^{\bullet}_{L}^{\bullet}_{F}58^{\bot}_{F}58 - ^{N}_{L}^{\bot}_{F} \quad ^{N}_{L}058 \quad N^{2}13^{\Box}_{R} = 00 \quad ^{N}_{L}058 \quad ^{\bullet}_{L}^{\Box}_{F}58^{\bot}_{F}58^{\bot}_{F} = 00 \quad ^{N}_{L}058 \quad ^{\bullet}_{L}^{\Box}_{F}58^{\bot}_{F} = 00 \quad ^{N}_{L}058 \quad ^{\bullet}_{L}^{\Box}_{$

 $\bigcirc^{1} \stackrel{\Gamma}{\Gamma}_{R} \quad \bigoplus_{-} \stackrel{\Gamma}{\Gamma}_{F} \stackrel{1}{\Gamma}_{S} - \frac{1}{3} - \frac$



 $\bigcirc ^{1}\Gamma_{R} \quad \longleftarrow ^{1}\Gamma_{R}^{$

■ \[
\begin{align*}
\begin{align*



- —¹⅓HTNL€�5% №¹⅓—ЧТ7%¹⅓¹½NLЧT□R5%□R□F ®5%%0³% NL®5% %0¹⅓□R®5%□FNL □F®1⅓□R5%


 €— 1½®₽Д ¾8ЧT5% NL1 5%¹⅓□FRS 1⅓�1⅓€%0¹⅓²⅓€%0□€NLRS 1₹% □R¹⅓₩

 №¹⅓NL5%□R€¹⅓%0□F
- $\bullet \quad \text{ff}^{@5/8} \quad \mathsf{N}^{$^{25}\!\!/8}^{\mathsf{L}}_{\mathsf{R}}^{1/8}^{@1/3} \mathsf{^{N}}_{\mathsf{L}} \quad \mathsf{N}^{$^{21}\!\!/3} \mathsf{^{V}}_{\mathsf{T}}^{7/8}^{1/3}^{1/8}^{\mathsf{N}}_{\mathsf{L}}^{\mathsf{V}}_{\mathsf{T}}^{\mathsf{L}}_{\mathsf{R}}^{5/8}^{\mathsf{L}}_{\mathsf{R}}^{\mathsf{L}}_{\mathsf{F}} \quad \mathsf{^{L}}_{\mathsf{F}}^{5/8}^{\otimes} \mathsf{N}^{25/8}_{\mathsf{R}} \mathsf{^{N}}_{\mathsf{L}} \quad \mathsf{^{1}}_{\mathsf{G}}^{5/8}^{\otimes} \mathsf{^{N}}_{\mathsf{L}}^{1/3}^{\mathsf{N}}_{\mathsf{L}} = \mathsf{^{1}}_{\mathsf{G}}^{5/8}^{\mathsf{L}}_{\mathsf{R}}^{\mathsf{L}}_{\mathsf{L}}^{\mathsf{$
- $\bullet \quad \text{``$^{-}$_{-}$'_{3}} \quad \bullet \quad \text{``$_{-}$'_{8}$} \stackrel{\bullet}{=} \quad \text{``$_{8}$^{-}$_{F}$} \quad \text{``$_{8}$^{-}$_{F}$} \quad \text{``$_{8}$^{-}$_{8}$} \quad \text{``$_{1}$} \quad \text{``$_{8}$^{-}$_{8}$} \quad \text{``$_{1}$} \quad \text{``$_{8}$^{-}$_{8}$} \quad \text{``$_{1}$} \quad \text$
- -1N°5% 17% N_0°5% % N5%Rs HT%01/3Rs5%ER+F €— N_0°5% "■‡ N°1/3ER%5%NL 1/3ER5%
 Rs%01/3 ○PtffIPt³ ff5% 1/3
 ®01/3ERN°1/31/85%VTNL€1/81/3%00 ‡—3%VTLFNLER€5%LF
 RNL3%Pt³ —15%®ER€—®5%ER ‡—®5%%00°5%€N° ‡—NL5%ER—1/3NL€1—1/3%00
 □N°2/3†³
 "2/32/4ffI€5% ‡—1/8Pt³
 5%ER1/8%U ¶ —1Pt£ ‡—1/8Pt³ —€HT%01/3 ‡—1/8Pt³
 "9/002/35/8N°1/3ER%05% —1ERHT1ER1/3NL€1—3
 ERPt □5/83/83/8Rs1'LF
 R1/32/31ER1/3NL1ER€5%LF
 RNL3%Pt³ —ER€LFNL10%Y Rs5%ERLF —FFVT€2/32/3 —1N°2HT1/3—Rs³
 "VTER12/3€—3%1
 ®01/3ERN°1/3³ 1/3—3% —VT— ®01/3ERN°1/31/85/8VTNL€1/81/3%00 ‡—3%VTLFNLER€5%LF
 RNL3%Pt



Industry Insights

U.S. Active Pharmaceutical Ingredients (API) market size, by type of manufacturer, 2015 - 2027 (USD Billion)



 $+ \frac{1}{3}3/83/8 \in \mathbb{N}_{L} \in 1 - \pounds = \frac{1}{8} \mathbb{E}_{R} 5/81/3 \mathbb{E}_{F} \in -00 \quad \mathbb{H}_{T} \mathbb{E}_{R} 5/8 \frac{1}{3} 0/005/8 - \frac{1}{8}5/8 \quad 17/8 \quad 1/81 - \frac{1}{8} 0/8 - \mathbb{H}_{L} 1/3 0/005/8 = \frac{1}{8} 0/8 0/1005/8 - \frac{1}{8} 0/8 0/1005/8 = \frac{1}{8} 0/8 0/1005/8 - \frac{1}{8} 0/8 0/1005/8 = \frac{1}{8} 0/8 0/1005/8$



 $-^{N}_{L} \Box_{R} 1_{3}^{N} N_{L} 5_{8}^{0} \oplus \bigoplus 1_{8} \quad 1^{V}_{T} N_{L} \Box_{F} 1^{V}_{T} \Box_{R} 1_{8} \oplus \bigoplus_{0} \quad 1_{3}^{3} 0_{0}^{0} 0_{0}^{1} \bigoplus_{F} \quad 1_{8}^{1} 1_{N}^{2} \Box_{T} 1_{3}^{1} - \bigoplus_{5}^{5} A_{L} \Box_{F} 1_{5}^{1} A_{1}^{1} A_{2}^{1} \Box_{F} 1_{8}^{1} A_{1}^{1} A_{1}^{1} A_{2}^{1} A_{1}^{1} A_{2}^{1} A_{1}^{1} A_{1}^{1} A_{2}^{1} A_$



ffRs++5% 17% -Rs-1205%-+€-+ +--+€6001/-+

ffRs^HT⁵/₈ 1⁷/₈ ●1/₃-V_T7/₈1/₃1/₈N_LV_TE_R5/₈E_R ‡-E=⊕®N_LE_F

- ● 5 % $^{\Gamma}$ R 9 1/3 $^{-N}$ L "•‡ € $^{\Gamma}$ 5% $^{\Gamma}$ F N L $^{\Box}$ N 9 1/3 N L 5 8/3% NL1 2/35% NL 95 8 7/81/3 $^{\Gamma}$ F N L 5 8/F N 8/




Application Insights

APIs find application in oncology, cardiology, CNS and neurology, orthopedic, $^{\text{H}}_{\text{T}}^{\text{V}}_{\text{T}}^{\text{O}}_{\text{N}}^{\text{P1}} - 100^{10}\text{Rs}\mathfrak{L}$ $^{\text{O1}}_{3}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{F1}}_{\text{E}}^{\text{F1}}_{\text{E}}^{\text{F1}}_{\text{N}}^{\text{O1}}^{\text{O1}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{F1}}_{\text{N}}^{\text{O1}}^{\text{O1}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{F1}}_{\text{N}}^{\text{O1}}^{\text{O1}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}\mathfrak{L}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{O}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{O1}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{N}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{E}}^{\text{E}}_{\text{O1}}^{\text{O1}}_{\text{O}}^{\text{E}}_{\text{E}}$



Global Active Pharmaceutical Ingredients (API) market share, by application, 2019 (%)



Source: www.grandviewresearch.com

■-1/810/01®Rs €-F 5/8-FN_€Nº1/3N_5/83/8 N_1 2/35/8 N_05/8 7/81/3-FN_5/8-FN_¥@-R1₩€-® L_F5%®N^Q5%−N_L 1**®**5%^L_R N_L®5% 7%1^LR5%1%1%^L_FN_L H_T5%^LR€13%Pt ff®€L_F L_F5%®N^Q5%−N_L €L_F $3\%^{\Box}_{R} \in \textcircled{6}^{5}\% - 2\%^{\Box}_{R} = 7\%^{1}\%^{1}\%^{N}_{L}^{1}^{\Box}_{R}^{L}_{F} \qquad L_{F}^{V}_{T}^{1}\%^{\textcircled{0}} \qquad 1\%^{\Box}_{F} = 0^{\Box}_{R}^{1} + 10^{\Box}_{R}^{5} + 10$ 1/81/3-1/85/8^LR 1/3-3/8 €-1/8^CR⁵/8¹/3^LF€-® %0€7/85/8^LF^NLRs%05/8¥1/3^LF^LF11/8€1/3^NL5/83/8 3/8€^LF5/8¹/3^LF5/8^LFPt -5/8\\$5/8\cap 1/3\%0 1/81\N°HT1/3-€5/8\F 1/3^CR⁵/8 7/8¹¹/8 TL_F€-® 5%₩\L5%-LF€®5% □¶< 7%1LB NL@5% 3%5%®5%%01HTN25%-NL 17% 3%LB\T@LF LFHT5%1%€7%€1% N_L1 —1**@**5%% 2%€1Nº1%^CR°45%^CR^LFPt ff®5%^CR5% 1/3^CR5% — V_TNº5%^CR1V_TL_F "■‡^LF €— N_L®5% Nº1/3^CR°\u5/8^NL 7/8¹^CR 1/8¹/3-1/8⁵/8^CR NL CR5/81/3 NLNº5/8-NL LFVT1/8® 1/3 LF -5/8 1/3 1/8€MD VTNº1/32/3£ $\mathsf{ff}^{\mathsf{C}}_{\mathsf{R}} \mathsf{1}_{3}^{\mathsf{L}} \mathsf{F}^{\mathsf{N}}_{\mathsf{L}} \mathsf{V}_{\mathsf{T}} \mathsf{MD}^{\mathsf{U}}_{\mathsf{T}} \mathsf{N}^{\mathsf{U}} \mathsf{1}_{3}^{\mathsf{U}} \mathsf{2}_{3}^{\mathsf{U}} \mathsf{E} + \mathbb{N}^{\mathsf{U}}_{\mathsf{L}}^{\mathsf{U}} \mathsf{1}_{\mathsf{M}}^{\mathsf{U}} \mathsf{E} \mathsf{N}^{\mathsf{U}} \mathsf{1}_{3}^{\mathsf{U}} \mathsf{2}_{3}^{\mathsf{U}} \mathsf{2}_{3}^{\mathsf{U}} \mathsf{1}_{3}^{\mathsf{U}} \mathsf{1$ 01**@**1/3^ER^NL€^LFPt

Regional Insights



Asia Pacific is expected to be the fastest-growing market over the forecast period. Owing to the availability of affordable labor, major companies in the market are setting up API manufacturing plants in developing countries such as China and India.

Market Share Insights

 $-1N^{25/8} \quad 17/8 \quad N_{L} \otimes 5/8 \quad N_{L} \otimes$



 $+ \bigoplus_{i=1}^{n} \mathbb{P}_{i} \mathbb{P}$



 $-1 - L_F 5\%^F F^V T 5\% - N_L \%0 F8 \cdot L_F 5\% M^2 5\% - N_L \quad \textcircled{L}_F \quad 5\%^L F^N L \overset{\textcircled{1}}{=} N^2 1\%^3 N_L 5\%^3 \% \quad N_L 1 \quad \textcircled{1} \%1\% \overset{\textcircled{1}}{=} - L_F \overset{\textcircled{1}}{=} 0 - \overset{\textcircled{1}}{=} 7\% \overset{\textcircled{1}}{=} 1\%^3 N_L 5\%^3 N_L \quad L_F \overset{\textcircled{1}}{=} 1\%^3 N_L 5\%^3 N_L \quad Y^2 1\%^3 N_L \quad Y^2 1\%^3 N_L 5\%^3 N_L 5\%^3$



ff®5% Nº1/3 ^CR°4.5% NL €- 01 ^CRNL® "Nº5% ^CR€1/81/3 € ^LF H_T ^CR€Nº1/3 ^CR€00 Rs 3% ^CR€**®**5%-2%Rs 1/3 FR1/3HT€3% €-1%FR5%1/3HF5% €- NL®5% ®5%FR€1/3NLFR€1/6 HT1HTVT001/3NL€1-£ ®€®® 1/3/81HTNL€1— 17/8 —5/8₩ 3/8ERVT@EF£ 1/3—3/8 ER€E5/8 €— @ER1VTHT 3/85/8—NL1/3/% H_T□_R1/₃1/₈N_L €1/₈5/₈□_F €- N_L®5/₈ ffiPt-PtPt ff®5/₈ N^Q1/₃□_R%5/₈N_L €- "□_F€1/₃ ■1/₃1/₈€7/₈€1/₈ €□_F H_TC_R1°%5%1%N_L5%3% N_L1 5%**H**⁺H_T1/3—3% 1/3N_L 1/3 C_R1/3H_T€3% H_T1/31/85% 3%V_TC_R€—@ N_L®5% 7/81 CR5/81/81/3 LFN HT5/8 CR€13/8 Pt ‡— "LF€1/3 ■1/31/8€7/8€1/8£ TM1/3 HT1/3— 3/81 Nº€—1/3 N_5/83/8 N_0 5/8 1/31/8^NL€**⊕**5% H_T®1/3^CRN^{Q1}/31/85% Y_TN_L€1/81/3/00 €-®^CR5/83%€5%-N_LL_F N^{Q1}/3^CR^CN5/8 N_L£ ₩®€00.5% $^{N}_{L} @ 5/8 \qquad N^{2} 1/3 ^{\mathbb{L}}_{R} \%_{1} ^{5} 8^{N}_{L} \qquad \textcircled{=} \qquad - @ \textcircled{=} - 1/3 \qquad \textcircled{=} ^{\mathbb{L}}_{F} \qquad 5/8 ^{\mathbb{L}}_{F} ^{N}_{L} \textcircled{=} N^{2} 1/3 ^{\mathbb{N}}_{L} 5/8^{3} 8 \qquad ^{\mathbb{N}}_{L} 1 \qquad 5/8 \overset{\mathbb{N}}{\mathbb{N}}_{T} 1/3 - 3/8 \qquad 1/3 ^{\mathbb{N}}_{L} \qquad 1/3 ^{\mathbb{N}}_{L} 1/3 - 3/8 \qquad 1/3 ^{\mathbb{N}_{L}}_{L} 1/3 - 3/8 \qquad 1/3 ^{\mathbb{N}_$ $^{H_{T}} \Box ^{R} \Box ^{R$ ¹H_T5/₈C_R1/₃N_L€—∞ /X /**€**-X / H_T‰1/3Rs5/8^CR^LF M0/0012/31/30/00 "+®1/3 FRNº1/3 1/85% V+NL€1/81/3%0 €-®FR5/83%€5%-NL F Nº1/3 FR%5%NL €-1/8%0 V+3/85% ff5/8 681/3 [‡]-³/₈ V_T L_F N_L C_R € 5/8 L_F R_N L₃/8 Pt£ "V_T L_R 12/3 € -3/81 ••••1/3 L_R N²1/3 £ ■7/8€MD5/8^CR "□PtPt

$$\begin{split} &\text{ff}^{@5/8} \quad @\%_0^{12/3}1/_3\%_0 \quad 1/_3^{1/8}\text{N}_L \in \textcircled{6}^{5/8} \quad ^{\text{H}}_{\text{T}}^{@1/3}\text{L}_{\text{R}}\text{N}^{21/3}1/_8^{5/8}\text{V}_{\text{T}}\text{N}_L \in 1/_8^{1/3}\%_0 \quad \in - @^{\text{L}}_{\text{R}}5/_8^{1/8} = - ^{\text{N}}_L \\ &\text{N}^{21/3}\text{L}_{\text{R}}\%_0^{15/8}\text{N}_L \quad \in ^{\text{L}}_{\text{F}} \quad 5/_8^{\text{L}}_{\text{F}}\text{N}_L \in \text{N}^{21/3}\text{N}_L^{5/8}3/_8 \quad ^{\text{N}}_L \quad ^{\text{L}}_{\text{R}}5/_8^{1/3}1/_8^{9} \quad \text{ffi}_{\text{-}} \quad 1/_2\phi^2\text{P}_1^{1/2} \quad 2/_3 \in \%_0 \%_0 \in ^{\text{1}}_{\text{-}} \quad 2/_3\text{Rs} \\ &\text{1/2}^{21/2}\phi \quad 7/_8^{\text{L}}_{\text{R}}^{1}\text{N}^2 \quad \text{ffi}_{\text{-}} \quad ^{\text{Q}}_{\text{0}}^{1/2}\text{P}_1^{1/2} \quad 2/_3 \in \%_0 \%_0 \in ^{\text{1}}_{\text{-}} \quad \in ^{\text{L}}_{\text{-}} \quad 1/_2^{29}\text{M}_{\Sigma} \quad 1/_3\text{N}_L \quad 1/_3 \quad -\text{``}_{\text{-}}^{\text{-}} \quad 1/_3\text{N} \quad ^{\text{P}}_1^{1/2} \\ &\text{3/8}^{\text{V}}_{\text{-}}^{\text{L}}_{\text{R}} \in ^{\text{-}}_{\text{-}} \otimes \text{N}_L^{\text{Q}}_1^{1/2} + ^{\text{N}}_2^{1/2} + ^{\text{N$$



-1/3^LF5/83/8 1— N_@5/8 N_Rs H_T5/8 17/8 3/8^LR V_T@£ N_@5/8 "■±L_F N^Q1/3 L_RC/_U5/8 N_L 1/81/3 — 2/35/8 1/80/01/3 - F- F € 7/8 € 5/83/8 € - N_1 N_₩1 L F 5/8 N N S N S N L F H T R 5/8 - F 1/8 R E H T N L € 1 - 3/8 R V T O L F 1/3 - 3/8 1⊕5% CRYNL®5% ¥1/81 VT — NL5% CR ; ■ff—; 3/8 CRVT® LFPt ‡— 1/2 ºº X£ NL®5% HT CR5% LF1/8 CR€HTNL€1— L_F@1/₃C_R5/₈ 17/₈ N_L@5/₈ "■±L_F N^Q1/₃C_RC/_U5/₈N_LPt ff@5/₈ 3/₈5/₈N^Q1/₃—3/₈ 7/₈1C_R 3/₈C_RV_T@L_F ®1/₃L_F €-1/₈L_R5/₈1/₃L_F5/₈3/₈ 7/81/30/00 € - @ V_T - 3/85/8 C_R N_L ® € L_F 1/81/3 N_L 5/8 ® 1 C_R Rs H_TC_R5/8 **3** 1/3 1/3 1/3 C_R 1/8 1/3 C_R 1/8 N_L 1/3 N_L 1 %01/3 R®5/8 LFN LF®1/3 CR5/8 17/8 NL®5/8 HT CR5/8 LF1/8 CR€HTNL€1 — 3/8 CR VT® LF LF5/8 ®Nº5/8 — NL 1/81/3 — 1/30%0^LF1 2/35% 1/3^NLNL^CR€2/3^VTNL5/83% NL1 NL®5% €—1/8^CR5/81/3^LF5/83% 7/811/8^VT^LF 17/8 3/8^LR^VT^{®L}F 1/3−3/8 1/3⁷/8⁷/8¹^LR³/8¹/3²/3 € 0/0 € N_LRs 1⁷/8 ^{®5}/8¹/3 0/0 N_L®1/8¹/3 L_R5/8 Pt N_L@5/8 €NºH_TC_R1**⊕**5/8 1/₃7/₈7/₈1[□]_R3/₈1/₃2/₃€0/₀₀€N_LR_S 17/₈ @5/81/30%0NL@1/81/3^ER5/8£ 5%^L_F^H_T5%¹/₈€¹/₃%0%0Rs €- N_L®5% ffi-£ ®1/₃^L_F 5% H^H_T1/₃-3%5%3% N_L®5% 1/₈1-L_FV_TN^QH_TN_L€1-€-7/8%01/3^NL€1- ®1/3^LF HT%01/3RS5/83/8 1/3 %15/8RS ^CR¹⁰%0⁵/8 €- ⁵/8-[®]1/3-1/8€-[®] C_R5%**⊕**5%−V_T5% 7%C_R1Nº N_C®5% L_F1/3%05%L_F 17% H_TC_R5%L_F1/8C_R€H_TN_C€1− 3/8^LR^VT^{ML}F£ H_T1/₃ E_RN_L €1/₈ V_T‰1/₃ E_R‰Rs L_FH_T5/₈1/₈ €1/₃‰N_LRs 3/₈ E_R V_T®L_FPt "‱ N_L®5/₈ L_F5/₈ 7/₈1/₃1/₈ N_L1 E_RL_F 1/3^CR⁵/₈ 1/8¹⁰/₉₀%₀5/8¹/₈ N_L € **3**5/8 %₀ R_S C_R5/8 L_FH_T1-L_F € 2/3%₀5/8 7/8¹C_R N_L®5/8 %₀1/3 C_R®5/8 L_F®1/3 C_R5/8 17/8 N_®€LF LF5/8®Nº5/8-N_Pt

 $^{5/8} \textcolor{red}{ \textcolor{red}{\mathbb{H}^{1}}} ^{1} \textcolor{blue}{5/8} ^{1/8} \textcolor{blue}{N_{L}} ^{5/8} \textcolor{blue}{1/8} ^{1/8} \textcolor{blue}{1/8} ^{1/8} \textcolor{blue}{1/8} ^{1/8} \textcolor{blue}{1/8} ^{1/8} \textcolor{blue}{1/8} ^{1/8} \textcolor{blue}{1/8} \textcolor{blu$ N @5/8 60 % 12 / 31 / 30 % 12 1 / 20 12 1 / 20 12 $^{$ 1- NLRsHT5/8 17/8 Nº1/3-V₇7/81/31/8N_V₇C_R5/8C_R£ N_0°5/8 "■±L_F Nº1/3C_RC'\u5/8N_L 1/81/3- 2/35/8 3/8€ € € 3/85/83/8 € - N_1 1/81/3 H_TN_L € **3**5/8 "■‡ N^Q1/3 - V_T7/81/31/8 N_L V_T C_R5/8 C_R L_F 1/3-3/8 Nº5/8^CR¹/8®¹/3−NL "**=**± Nº1/3-V_T7/81/31/8N_LV_TC_R5/8C_RL_FPt / /‡// 1/2^{ao}\(\text{Q}\)£ N_L@5/8 1/81/3^HT^NL€**®**5/8 "**=**‡ Nº1/3-V-7/81/31/8N_V-CR5/8CR-F LF5/8®Nº5/8-N_ €LF 5/8#H-5/81/8N_5/83/8 N_1 1/31/81/81V_T-N_ 7/81^CR N_@5/8 %01/3 R@5/8 LFNL LF@1/3 R5/8 17/8 N_@5/8 "■‡LF Nº1/3 R6/U5/8 N_Pt ff@€LF 1/81/3— 2/35/8 N_I 1 1/₃N₁ N₁ □_R€2/₃V_TN₁ 5/₈3/₈ N_L@5/8 7/81/31/8^NL N @1/3 N Nº1LEN 2/3€® "**=**± H_{T®}1/₃^C_RN^Q1/₃1/₈5/₈V_TN_L€1/₈1/₃0/₀₀ 1/81NºHT1/3-€5/8LF H_T1L_FL_F5/8L_FL_F N_{L®5/8}€^CR____ Nº1/3-V_T7/81/31/8N_LV_TC_R€-® 7/81/31/8€000€N_L€5/8L_F 1/3-3/8 1/3C_R5/8 **®**5/8C_RN_L€1/81/300000R





Key Players in the Global APIs Market

■7/8€MD5/8^CR € L_F 1-5/8 17/8 N_®5/8 0/05/81/33/8€ -® H_T0/01/3Rs5/8^CR L_F € - N_®5/8 "■‡ €-38VTLFNLERRSPt ff®5/8 %05/81/33/8€-® HT1LF€NL€1- 17/8 [™]0/00¹²/3¹/3⁰/00 $^{H}_{T} \vdash_{R} ^{13} \not_{S} \lor_{T} / \not_{S} \lor_{L} \\ ^{H}_{T} \vdash_{R} ^{1} \lor_{L} ^{7} \not_{S} ^{10} \lor_{0} \\ \in ^{1}P_{t} \\ \text{ ff} = ^{9} \not_{S} \\ ^{1} \not_{S} \vdash_{R} ^{1} \lor_{S} \\ ^{9} \not_{S} \vdash_{R} ^{1} \not_{S} \\ ^{1} \not_{S} \vdash_{R} ^{1} \lor_{S} \\ ^{1} \not_{S} \vdash_{R} \\ ^{1} \not_{$ €Nº1/3®5/8£ ₩®€1/8® ®€**®**5/8^LF €NL 1/3 1/8¹Nº^L+5/8^NL€NL€**®**5/8 5/83/8®5/8 1**®**5/8^LR 1NL®5/8^LR $^{\text{H}}_{\text{T}}\%^{1/3}\text{Rs}^{5/8}^{\text{F}}_{\text{R}}^{\text{F}}_{\text{Pt}} \quad \downarrow - \quad ^{1}_{\text{F}}^{3/8}^{5/8}^{\text{F}}_{\text{R}} \quad ^{N}_{\text{L}}^{1} \quad ^{\Gamma}_{\text{R}}^{5/8}N^{9/3} \in - \quad ^{1/8}^{1}N^{9}^{\text{H}}_{\text{T}}^{5/8}N_{\text{L}} \in N_{\text{L}} \in \Theta^{5/8} \quad ^{1/3}^{-3/8}$ €NLLF LFN CR5/8-WN P5/8-Nº1/3^ER°/u5/8^NL H_T1L_F€N_I €1-£ N @5/8 1/8¹N⁹H_T1/3−Rs $^{H}_{\mathsf{T}} \Box_{\mathsf{R}} \in \mathbb{N}^{91/3} \Box_{\mathsf{R}} \in \mathbb{N}^{0} \cap \mathbb{R} \qquad ^{7/8} \Box_{\mathsf{F}} \qquad ^{1}_{\mathsf{F}} \Box_{\mathsf{F}} \Box_{\mathsf{F}} \qquad ^{1}_{\mathsf{F}} \Box_{\mathsf{F}} \Box_{\mathsf{F}} \qquad ^{1}_{\mathsf{F}} \Box_{\mathsf{F}} \Box_{$ "H_T1/₃ GRNL - 58 GR - F®€H_T L F£ 1/81900%01/32/31 GR1/3 NL €1 - LF£ H_T GR13/8 V_T1/8 NL 1/3 H_T H_T GR1 **1**3 1/3 90 LF£ 1/3-3/8 1/31/8^FF \rightarrow \text{T} = \rightarrow \text{T} = \rightarrow 1½²⁰ⁿ£ ■7/8€MD5/8^CR 1/31/8^FF^VT€^CR5/83/8 "-1/31/81^CR ■®1/3^CRN^Q1/31/85/8^VT^NL€1/81/30/0^LF£ ‡-1/8Pt %05/81/33/8€-∞ ²/₃€1^HT[®]1/₃^L_RN^Q1/₃1/₈5/₈V_TN_L€1/₈1/₃%₀ :fffi-::£ 1/81NºH_T1/3−Rs 1/3 3%5%**®**5%%01^HT€−® ^LFNº1%3%0%0 Nº10%05%1%^VT%05% ^NL®5%^ER1%^HT5%^VT^NL€1%^LFPt





 $ff^{@5}/8$ "1/8^NL€**®**5/8 ■®1/3^LRNº1/3¹/8^{5/8}VT^NL€1/8¹/3/9/0 ‡-®^LR⁵/8³/8€5/8-N^LL⁻F ;"■‡; ●1/3 ^L_RC/_U5/8 ^NL € ^L_F ^L_F5/8 [©]N ^Q5/8 - N_L5/8 3/8 ¹ - N_L [©]5/8 2/3 1/3 ^L_F€ ^L_F 17/8 "■‡ N_L Rs ^HT 5/8 £ 3/8 ^LR ^VT [©] N_Rs+T5%£ Nº1/3-VT7/81/31/8N_VTER5%ERLF£ N_05/8ER1/3HTRs 1/3ER5/81/3 1/3-3/8 005/8100ER1/3HT0RsPt ■-N_@5/8 2/31/3 F € F 17/8 N_Rs H_T5/8 17/8 "■‡£ N_@5/8 Nº1/3 F R°\u5/8 N_ € F F F 5/8 @ Nº5/8 - N_5/8 3/8 € - N_1 £ —®5%Nº€1/81/30% "■‡ 1/3—3/8 –€10%01®€1/81/30% "■‡Pt ff®5/8 Nº1/3^CR%5/8 NL €LF 7/8 VTCRNL®5/8^CR "1/81/81[□]R3/8€-@ N_L1 N^Q1/3 □ R_S0/8 N_L H_T0/01/3 R_S5/8 □ R □ F£ N_L ® 5/8 Nº1/3^CR°/15/8^N1 €^LF $\frac{1}{3}\%_{0}^{L}_{F^{1}} \xrightarrow{L_{F^{5}}} \frac{N_{25}}{8} \xrightarrow{N_{1}} \frac{5}{8}\%_{8} \xrightarrow{1} \xrightarrow{N_{1}} \frac{95}{8} \xrightarrow{2}_{3} \frac{1}{3} \xrightarrow{L_{F}} \frac{L_{F}}{17} \xrightarrow{N_{1}} \frac{N_{1}}{8} \xrightarrow{N_{1}} \frac{95}{8} \xrightarrow{L_{F}} \frac{17}{8} \xrightarrow{N_{1}} \frac{17}{8$ ■-1/811001®Rs (FRVT®LF£ 01-¥LFNL5/8FR1€3/81/3/00 "-NL€¥€-7/8/001/3NºNº1/3NL1FRRs (FRVT®LF£ —1/3^CR³%€1@1/3^LF1/8^VT001/3^CR < CR^VT^{©L}F£ "—NL€¥3%€1/32/35%NL€1/8 < CR^VT^{©L}F£ 05%VT^CR1001[©]Rs ^{(Σ_RV_T@L_F£ V_TL_F1/8 V_T%₀₀1 L_F%₁5/8%₀₀5/8 N_L1/3%₀} 3/8^CR V_T@L_F 1/3-3/8 ^{1N}L^{®5}/8^ER^LFPt □5/81®□R1/3HT®€1/81/300000Rs£ Nº1/3□R0/15/8NL €LF LF5/8®Nº5/8—NL5/83/8 1/31/8□R1LFLF 7/8¹/_{TR} F_R5/8®€1-L_F -1/3N^{25/8}%0Rs 01^CRNL® "N²⁵/8^CR€1/81/3£ , Y_T^CR1^HT5/8£ "L_F€1/3 ■1/31/8€7/8€1/8 R"●,"Pt ±-1^ER®1/3-€1/8 ®^ER1₩N_® N_®^ER1V_T®® Nº5/8^CR®5/8^CR 1/3-3/8 1/31/8^FF^VT€^LF€^NL€1− 1/3^CR5/8 NL®5/8 CU5/8Rs LFNL^CR1/3NL5/8®€5/8^LF 1/33/81^HTNL5/83/8 2/3Rs NL1^HT €_¾°\r└F^L^RR\$ H7%01/3R\$5%^R\FPt ○1^R €_-\F^\L1/3_1/85%£ □1/3_2/31/3ħR\$ \R5%1/85%_\NL9%R\$ 1/31/8^FF V_T€^CR⁵/8³/8 − V_T − •01/3 ^CRN^Q1/31/8⁵/8 V_TN_L€1/81/3%0£ 1/3 N^Q1 **8**5/8 N_L01/3 N_L 05/8 %0 H_T5/8³/8 N_L05/8 1/81NºHT1/3−Rs 5/8Nº5/8 R®5/8 1/3 F ±-3/8€1/3 F NL1HTNº1 F NL 3/8 F NT® Nº1/3−VT7/81/31/8 N VT R5/8 F NL1HTNº1 F NL 3/8 F NT® Nº1/3−VT7/81/31/8 N VT R5/8 F NL1HTNº1 F NL 3/8 F NT® Nº1/3−VT7/81/31/8 N VT R5/8 F NL1HTNº1 F NL 3/8 F NL 3/8





"- €-N_L5%-L_F5% 7/811/8 V_TL_F 1- 1/81N^QN^Q5/8 L_R1/8€1/3000€MD€-® 3/8 L_R V_T®L_F 1/3-3/8 CR5%3% VT1% €—@ 1HT5% CR1/3 NL €—@ 1/61LFNL F 2/3 Rs 1 VTNL LF1 VT CR1/8 €—@ □¶ < 1/31/8 NL € € € NL € 5/8 LF N₁ @5/8 $1^{\text{L}}_{\text{R}} \otimes 1/_{3} = \text{MD} 1/_{3} \text{N}_{1} = 1 - 1/_{3} \%_{0}$ $5/_{8} 7/_{8} = 1/_{8} \text{Rs}$ €NºH_TC_R1**⊕**5/8 1/81/3-L_FV_T2/₃L_FN_L1/₃ - N_L€1/₃%0%0RsPt ■V_TN_LL_F1 V_TE_R1/₈€ - 1/₈ 1/₈N_L 0%01/₃N_L5/₈E_R L_FN_L1/₃®5/₈L_F 17/₈ 3/85/8 **3**/ H_T1/₃G_RN_L -5/₈G_RL_F 1/₈1/₃ H_T1N_L5/₈ - N_L€1/₃% % Rs €N²H_TG_R1**3**5/₈ 1H_T5/₈G_R1/₃N_L€1 - 1/₃% 6 H_T1^L_RN_L7/81000€1 1/3^H_TH_T^L_R11/31/8[®] [®]15/8^L_F 1/3 0/01−[®] ₩1/3Rs €− 5/8₩H_T1/3−3/8€−[®] L_F1/3005/8^L_F 1/3-3/8 LF€NºVT100NL1/3-5/81VTLF00RS LR5/83/8VT1/8€-® LF€LF00Pt ff®€LF 1/81VT003/8 2/35/8 2/3Rs ^HT1^LF^LF58^LF^LF€-® 23^FR¹3-38⁵838 ®58-58^FR€18 38^FR^VT®^LF£ 23^FR¹3-38⁵838 38^FR^VT®^LF£ 13-38 V_T-2/3^CR¹/3-3/8⁵/8³/8 3/8^CR V_T⁰C_F ₩€N_L⁰€- N_L⁰5/8 L_F1/3 N²5/8 H_T1^CRN_L7/8¹0/0 €1Pt 1/3/8/3/8€NL€1-£ 1/8/05/81/3 FR/9/0Rs 3/85/87/8€-5/83/8 7/81 FR\\1/8 FR/3/8 9/0€-9/1/3/95/8 FF €- N_05/8 L_FV_TH_TH_T000Rs 1/8[®]1/3 € 1/81/3 - [®]1/3 L_R - 5/8 L_R [®]L_R 5/8 L_R N[®]1/3 L_R 3/8€7/87/85/8[□]R5/8-N_ □ □ CR5/8®€1--□ □ 1 € 5/8 □ N_05/8 1/81 VT □ R - F 5/8 17/8 N_05/8 7/81 □ R 5/81/81/3 □ F N_0 H_T5/8^ER€13/8Pt



"└╤€⅓— ⅓¹^VT—_¯R€5%└╤ @¹‱¾ ⅓ ‱⅓¯R®5% ⅙®^VT—¼ ¹७% _®5% ⅓⅓½€**®**5%
└Ţ®⅓¯RNº⅓⅓₺%\\Ţ\\€⅓⅓‰ €—®¯R5%¾€5%—_└= Nº⅓¯R‰5%\\

†€®®5%^ER ®^ER¹₩^NL® €— N₀®5% "■"— 1/31/6N_L€®5% H₇®1/31/65% H₇®1/31/65%

€-N_L@5/8 "**=**"___ ^CR⁵/8[®]€1_ €LF 1/8¹N²H_T1/3^LR1/3^NL€**®**5/8600Rs %01₩£ N_L®5/8 ®^LR1₩N_L® ^CR¹/₃N_L⁵/₈ €– N ®€LF ^C_R5/8®€1− ®1/3 ^L_F 1 ^V_TN_L ^H_T1/3 1/8 5/8 3/8 N_L ®1/3 N_L LFN_CR1/3NL5/8®€1/8 17/8 Nº1/3 N V_T C_R5/8 Nº1/3^CR°/₂5/8^NL^LF €- 01^CR^NL® "Nº5/8[□]R€1/81/3 1/3-3/8 , V_TE_R1H_T5/8P_t ®5/81/30%0NL®1/81/3□R5/8 LFHT5/8—3/8€—® ®1/3 LF %05/83/8 NL1 FF VT1/30%€NLRS ®5/81/30%0NL®1/81/3□R5/8 2/35/81/81Nº€-® 1/31/81/85/8-F-F€2/30/05/8 1/30/01-® ₩€N_® 1/3 ®€®®5/8-R 3/85/8Nº1/3-3/8 7/81 E



 $^{H}T^{\otimes} 1/_{3}^{L} \Gamma_{R}N^{\otimes} 1/_{3}^{1} 1/_{6}^{5} 8^{L} \Gamma_{R}N^{\otimes} 1/_{3}^{1} 1/_{6}^{5} 1/_{6}^{1} 1/_$

01—¥1/81—N_□1000005/83/8 □=\T2/3□=N_1/3—1/85/8□= ®1/3 ®€®® —"□□ 1/3—3/8 1/81/3— 2/35/8
N 1/3□85/8N 5/83/8

 $\circ^{1} - \frac{1}{8} \cdot \frac{1}{8} \cdot \frac{1}{9} \cdot \frac{1}{$



H_T1^C_RN_L€1−L_F 17% 1/3−Rs 3/8^C_RV_T@L_F£ ₩®€1/8® 1/3^C_R5% 2/3€10/01®€1/81/30/00%Rs 1/31/8N_L€**®**5% -1/3 N_ V_TC_R5/8 Pt ff®5/8 "■± L_F ®1/3 **⊕**5/8 L_F€®-€7/8 € 1/8 1/3 - N_ V_TL_F5/8 €-Nº1/3-V_T7/81/31/8^N_V_TC_R€-® 17/8 5/87/87/85/81/8^N_€**®**5/8 1/3-3/8 L_F1/37/85/8 Nº25/83/8€1/8€-5/8 L_FPt 3/8^LR^VT®'^LF 1/3³/8Nº€−€^LF^NL⁵/8^LR⁵/8³/8 3/8¹^LF¹/3[®]5/8£ (5/8^HT5/8−3/8€−® 1− N_L®5/8 C_R5/81/31/8N_L€1-L_F 1/3-3/8 C_R5/8L_FV_T0/00N_LL_F 3/8€7/87/85/8C_R 1/31/81/81^LR3/8€-@ N_L1 N_L@5/8 3/8€LF5/81/3LF5/8LFPt —5/8LRNL1/3€— 3/8LRVT®LF 1/3LR5/8 1/81-NL1/3€—5/83/8 17/8 Nº1 R5/8 NL®1/3-1/31/8N_L€®5% €-®CR5/83%€5%-N_LF N_1 N_CR5/81/3N 1/3 -VTNº2/35/8CR 17/8 1/8° CR1-€1/8 1/3-3/8 €-7/85/81/8NL€1VTLF 3/8€LF5/81/3LF5/8LF LFVT1/8® 1/3LF 3/8€1/32/35/8NL5/8LF£ 1/81/3-1/85/8ER£ 1/3^LRNL®^LR€NL€LF£ 2/31-58 ¶ %1€-NL €-7/85/81/8NL€1-LF£ HT-5/8 VTNº1-€1/3£ 1NL€NL€LF£ H_{T®1/3} CRRs -®€NL€LF£ L_FN_LC_R5/8^H_TN_L11/811/81/81/30%0 1/85/80000 V_T00€ N_L5/8 L_F£ V_TC_R€-1/₃C_RRs N_LC_R1/₃1/₈N_L €-1/₈5/₈1/₈N_L€1-L_FPt +1₩5/₈**3**5/₈C_R£ N_L®5/₈ L_FN_L1/₃-3/₈1/₃C_R3/₈ 1/₈1/₃-**3**⁸/₃ ¹/₈ ¹



05/8₩LF3/4 1/21/4 ●1/3^LR1/8[®] 1/2⁸£ -1/3RS5/8^LR 1/3-3/8 -V_T^LR1/33/85/8 ● ■ ●N_LPt R^NL3/8Pt£ 1/3 3/8 ^C_RV_T® 3/8 € ^L_F1/8 1 **3**5/8 ^C_RRs 1/8 1 N° ^H 1/3 − Rs 2/3 1/3 ^L_F5/8 3/8 € − ± −3/8 € 1/3 £ ® 1/3 ^L_F 2/3 5/8 5/8 − $\frac{1}{3} - - \frac{1}{T} - \frac{1}{8} \frac{5}{8} \frac{3}{8} \qquad \frac{1}{3} \qquad \frac{\Gamma_{R}}{8} \frac{1}{8} \Gamma_{R} \frac{1}{8} \qquad \frac{1}{8} \frac{10}{90} \frac{0}{13} \frac{1}{3} \frac{1}{2} \Gamma_{R} \frac{1}{3} \frac{N}{L} = 1 \qquad \frac{1}{3} - \frac{3}{8} \qquad \frac{1}{3} \frac{1}{8} \frac{1$ 1/3®^CR⁵/8⁵/8N²5/8−N_L 7/8¹C_R -N_L€N²V_T%01/3 N_L1C_R 17/8 ‡-N_L5/8 C_R7/8⁵/8 C_R1- □5/8-5/8 C_F ;-ff‡○□¿ $\frac{1}{3} - \frac{N_L}{3} = \frac{1}{3} = \frac{1}{3} \cdot \frac{1}{3} \cdot \frac{1}{3} = \frac{1}{3} = \frac{1}{3} \cdot \frac{1}{3} = \frac{$ 1/810/00/001/32/31^LR1/3^NL€1- Nº1/33/85/8 NL1 3/8€LF1/81 ⊕5/8 R -5/8 HT 3/8 RVT® 7/81 R NL®5/8 NL CR5/81/3 NL Nº5/8 - NL 17/8 ⊕1/3 CR€1 VT LF 6/0 VT - ®£ 1/81/3 ^CR³/8 €1 **3** 1/3 ^CF1/8 ^VT³/5 ^CR 3/8 € ^CF5/81/3 ^CF5/8 ^CF 1/3 - 3/8 1 ^NC 95/8 ^CR € - 7/8 ³/6 1/3 ^N2 N²1/3 ^NC 1 ^CR Rs N_CR5/8N°5/8-3/81 VT F HT1N_5/8-N_€1/3/00 7/81 CR -5/8₩ N_CR5/81/3 N_N°5/8-N_L F €-1/31/8N_€®1/3N_€-® N_05/8 €--1/3N_5/8 €N°N°N-5/8 FRS-FN_5/8N° 7/81ER 1/3N_1¥ €-78%01/3NºNº1/3NL1^ERRs 3/8€LF5%1/3LF5%LFPt fi€NL® NL®€LF 1/3®ER5%5%Nº5%-NL£ NL®5% -1/3**R**s⁵/8^CR ₩€‰‰ 1/81-N_L€-V_T5/8 N_L1 3/85/8⁵/8^HT5/8- C_R5/8^LF5/81/3^CR1/8[®] 1/31/8^NL€**®**€N_L€5/8^LF ¹— №º%¹%®¹%—€└₣№└₣ ₩€№® ⅔┗₽¹⅓¾۶%┗₽ ╙┰¹№₅№£ ┗₽⅓№£ ┗₽⅓№£ ₩€₽ №®%₽ €-3%€**®**€3%^VT1/3%0 €-3%€1/81/3^NL€1-^LF ₩€^NL® V_T-3%5%^ER^LF^NL1/3-3%€-® $^{H}_{T}1/_{3}^{N}L^{@10}\%0^{10}Rs \in - ^{3}\% \in ^{L}_{F}5/_{8}1/_{3}^{L}_{F}5/_{8} 1/_{3}^{L}_{F} \notin ^{N}L^{@} 0 \in ^{0}\%0^{V}_{T}-N^{9}5/_{8}^{N}L N^{9}5/_{8}^{3}\% \in ^{1}\%1/_{9}^{N}\%0^{V}_{T}$ $-5\%5\%3\% \qquad 1\%3-3\% \qquad 7\%^{V_{T}}\Box_{R}^{N} \underline{)}^{@5}\%\Box_{R} \qquad \Box_{F}^{N} \underline{\Box}_{R}^{5}\%-\underline{\textcircled{0}}^{N} \underline{)}^{@5}\%-\underline{\textcircled{0}}-\underline{\textcircled{0}} \qquad \underline{\textcircled{0}}^{N} \underline{\Box}_{F} \qquad 7\%11\%^{V_{T}}\underline{\Box}_{F}^{F}$ $^{\tiny @5/81/3000}{}^{\tiny N}{}_{\tiny L}{}^{\tiny @1/81/3}{}^{\tiny L}{}_{\tiny R}{}^{5/8} \ ^{17/8} \ ^{\tiny @V}{}_{\tiny T}{}^{\tiny N}{}^{\tiny @1/3}- \ ^{2/3}{}^{5/8}{} {\stackrel{\textstyle \leftarrow}{=}}{}^{\tiny @P_t}$



Global Active Pharmaceutical Ingredient

Market Dynamics

The key factor for growth of global Active Pharmaceutical Ingredient market is the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. $\frac{1}{3}\frac{1}{3}\frac{1}{5}\frac{1}{5}\frac{1}{5}\frac{1}{5}$ $\frac{1}{5}\frac{1}$

 $\bigcirc^{1}\Box_{\mathsf{R}} \ \in_{\mathsf{L}^{\mathsf{L}}}\Box_{\mathsf{L}^{\mathsf{L}}}\Box_{\mathsf{L}^{\mathsf{L}}}^{\mathsf{L}} = 1/2^{\underline{\mathsf{a}}\underline{\mathsf{D}}} \mathfrak{A} \mathfrak{L} \ \ \text{``}\Box_{\mathsf{R}}\Box_{\mathsf{L}^{\mathsf{L}}}^{\mathsf{L}} = 2/3^{5}/8^{5}/8 - 1/3^{1}/8^{\mathsf{L}^{\mathsf{L}}}\Box_{\mathsf{L}^{\mathsf{L}}}^{\mathsf{L}} = 1/8^{5}/8^{3}/8 \ \ \text{``}B_{\mathsf{L}^{\mathsf{L}}}^{\mathsf{L}} = 1/8^{5}/8^{5}/8 - 1/3^{1}/8^{\mathsf{L}^{\mathsf{L}}} = 1/8^{5}/8^{3}/8 \ \ \text{``}B_{\mathsf{L}^{\mathsf{L}}}^{\mathsf{L}} = 1/8^{5}/8^{\mathsf{L}} = 1/8^{\mathsf{L}} = 1/$



Market Regional Analysis

01^L_RN_L® "Nº5/8^L_R€1/81/3 €L_F 5/8**†**H_T5/81/8N_L5/83/8 N_L1 3/81Nº€-1/3N_L5/8 N_L®5/8 "1/8N_L€**®**5/8 Nº1/3^ER°/u⁵/8^NL ■®1/3^CRNº1/31/85/8 V_TN_L€1/81/3‰ [‡]-[∞]^CR⁵/8³/8€⁵/8-N_L ₩€NL® H_T1N 5%=N €1/3%00 F_R1/3N 5% 1/3L_F H_TF_R5%L_F5%=1/85% 17/8 H_T®1/3F_RNº1/31/85% V_TN €1/81/3%00 1/81NºHT1/3-€58LF 7/81LR -5/8₩ 3/8LR/L® 3/8€LF1/81\$5%LRS VTLF€-® 1/33/8\$1/3-1/85/83/8 N_L5/81/8@—10/001@Rs N ®€LF "1/81/81[□]R³/8€—® N₁ 1 €-^L_R5/₈®€1−P_t [‡]-N_L5/8^C_R-1/3 N_L€1-1/3 %₀ O5/83/85/8^CR1/3^NL€1-17/8 ■®1/3^LRNº1/3 1/85/8 V_TN_L€1/81/30/00 ●1/3-V_T7/81/31/8N_LV_TE_R5/8E_RE_F ¶ "L_FL_F11/8€1/3N_L€1-L_F j‡○■●"¿£ N_L®5/8 ffiPt-Pt ®19/03/8L_F ¢2* ®%012/31/30%0 Nº1/3^CR°\u5/8NL LF®1/3^CR5/8 7/81^CR HT®1/3^CRNº1/31/85/8 VTNL€1/81/30%0 1/81NºHT1/3−€5/8LF V_TL_E€_0 N_L®5/8 "1/8 N_L€**6**5/8 €-1/8/00 \rangle T3/8 €-1\text{18} \rangle -5/8 \rangle T \rangle 3/8 \rangle T \rangle T \text{18} \rangle 5/8 \rangle T \rangle T \text{18} \rangle 5/8 \rangle T \rangle T \rangle 1/8 \rangle 5/8 \rangle T \rangle T \rangle 1/8 \ra ■®1/3^LRNº1/31/85/8 \right\rangle TNL €1/81/3\%0 \\ \pm = \text{\mathbb{R}} \\ \frac{1}{8} \\ 2/3€‰061- €- 1/2ª1/2°£ $^{H}\mathsf{T}^{\textcircled{0}} 1/_{3} ^{L} \mathsf{R} \mathsf{N}^{\textcircled{0}} 1/_{3} ^{1} 1/_{8} ^{5} 8 \ ^{U}\mathsf{T}^{\mathsf{N}} \mathsf{L} \overset{\wedge}{\in} 1/_{8} ^{1} 1/_{3} \% 0 \qquad 3/_{8} ^{L} \mathsf{R}^{\mathsf{V}} \mathsf{T}^{\textcircled{0}} \qquad 3/_{8} ^{5} 8 \ \textcircled{0}^{5} 8 \% 0 \ ^{1} ^{H}\mathsf{T} \mathsf{N}^{\textcircled{0}} 5/_{8} - ^{\mathsf{N}} \mathsf{L} \qquad ^{L}\mathsf{F}^{\mathsf{H}} \mathsf{T}^{5} 8 - ^{3} 8 \overset{\wedge}{\in} - ^{\textcircled{0}} \qquad \ \ \, \\ \overset{\mathsf{H}}\mathsf{T}^{\textcircled{0}} 1/_{3} ^{L} \mathsf{R}^{\mathsf{N}} \mathsf{L}^{\mathsf{N}} \mathsf{L}^{\mathsf$ $\frac{1}{2^{2}}\frac{1}{2^{2$ 3/81Nº€-1/3N €-® "1/8NL€\$5/8 ■®1/3^LRNº1/31/85/8 NTNL€1/81/30/00 -1^CR¹-1/3 **3**€^CR^VT^LF£ †‡ffl£ 5/8^NL¹/8Pt

7/81/3^LF^NL5/8^LF^NL¥[®]CR1₩€—[®] CR5/8[®]€1—1/3/00 N[©]1/3^CR^N5/8^NL 3/8 V_T5/8 N^L1 CR1/3 H_T€3/8/00Rs €-1/8^CR5/81/3^LF€-@ N_C®5/8 H_TC_R5/8 **@** 1/3 0/00 5/8 - 1/8 5/8 N_L@5/8^LR¹/3^HT⁵/8 V_TN_L€1/8 17/8 1/8[®]C_R1-€1/8 3/8€L_F5/81/3^L_F5/8^L_F €Pt5/8Pt£ 3/8€1/32/35/8^NL5/8^LF£ 1/81/3-1/85/8^CR 5/8^NL1/8Pt ₩€NL® □R€□F€→® ("T1HT VT0001/3"NL€1→ €→ NL®€□F □R5%®€1→Pt "1/81/81□R3%€→® NL1 fit■£ $1/3^{\Box}_{R} 1^{V}_{T} - 3/8 \quad n^{2}_{+} \quad 17/8 \quad 1/3 \%_{0} \%_{0} \quad 1/8 1/3 - 1/8 5/8^{\Box}_{R} \quad 3/8 5/8 1/3^{N}_{\perp} @^{\Box}_{F} \quad 11/8 1/8^{V}_{T} \Box_{R} \quad \longleftarrow \quad 3/8 5/8 \frac{\bullet}{3} 5/8 \%_{0} 1^{H}_{T} \bigcirc \longrightarrow \quad (1.5)^{1}_{1} - 1/8 1/8^{V}_{1} \Box_{R} \quad 1/8 1/$ $1/_{8}1^{\text{V}} + N_{\text{L}} = 5/_{8} + 1/_{3} - 3/_{8} \quad N_{\text{L}} = 5/_{8} + 1/_{1} - 3/_{8} \quad N_{\text{L}} = 5/_{8} + 1/_{1$ $^{\text{H}}_{\text{T}} \Gamma_{\text{R}}^{10} \%^{5} \%^{1} \%^{\text{N}} \bot^{5} \%^{3} \%^{\text{N}} \bot^{1} \quad \text{$\stackrel{\frown}{\in}$} -1 \%^{\text{E}} \Gamma_{\text{R}}^{5} \%^{1} \%^{\text{E}} \bot^{5} \%^{\text{R}} \times^{2} \Gamma_{\text{R}}^{10} \%^{5} \times^{2} \Gamma_{\text{R}}^{10} \%^{5} \times^{2} \Gamma_{\text{R}}^{10} \times^{5} \times^{2} \Gamma_{\text{R}}^{10} \times^{2} \Gamma_{\text{R}}^$ ₩€^NL® 7/8^CR¹Nº $^{\circ}P_{t}X$ Nº€‱%₀€¹- NL¹ ²⁰Pt² N⁰€‰%o€1− €_7%%^VT5%-1%5%% %Rs ^CR€LF5% €_ 1%1_LFVTNºHTVL€1— 17% VL12%1%1%1%1 VTLF5%£ $\frac{1}{3} - \frac{3}{8} \quad \frac{N_L @5}{8} \quad \frac{@1}{3} \frac{\Gamma_R N^{97} / 8^{V_T} / 90}{1 - \Gamma_R 5} \quad \frac{V_T L_F 5}{8} \quad \frac{17}{8} \quad \frac{1}{3} \frac{9}{0} \frac{1}{8} \frac{1}{9} \frac$



Market Drivers and Key Restraints

The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. $\blacksquare^{N} L @ 5\%^{\square}_{R} \quad ^{N} L @ 1\%_{3} - \quad ^{N} L @ 5\%^{\square}_{F} 5\%_{E} \quad ^{N} L @ 5\%_{R} \quad ^{N} L @ 5\%_{R} = 0 1\%_{3}^{\square}_{R} = 0 1\%_{3$

 $\text{``NL} \quad \text{``H}_{\mathsf{T}} \mathsf{L}_{\mathsf{R}} 5/8 \mathsf{L}_{\mathsf{F}} 5/8 - \mathsf{NL} \mathfrak{L} \quad 1/3 \quad \text{`®} \ \mathsf{V}_{\mathsf{T}} @ 5/8 \quad - \ \mathsf{V}_{\mathsf{T}} \mathsf{N}^{9} 2/35/8 \ \mathsf{L}_{\mathsf{R}} \quad 17/8 \quad 3/8 \ \mathsf{L}_{\mathsf{R}} \ \mathsf{V}_{\mathsf{T}} @ \mathsf{L}_{\mathsf{F}} \quad 1/3 \ \mathsf{L}_{\mathsf{R}} 5/8 \quad \longleftarrow \quad \mathsf{NL} \ \mathsf{@} 5/8$ $^{H}\mathsf{T} \!\in\! ^{H}\!\mathsf{T}^{5}\!\! \% \! \otimes\! \! \in\! -5\% \quad ^{7}\!\! \%^{1}^{\mathsf{L}_{\mathsf{R}}} \quad ^{\mathsf{N}}\!\! \llcorner^{0}\!\! 5\% \quad ^{3}\!\! \%^{5}\!\! \% \! \otimes\! ^{5}\!\! \% \! \! ^{0}^{1}^{\mathsf{H}}\mathsf{T} \mathsf{N}^{2}\!\! 5\% - ^{\mathsf{N}}\!\! \llcorner \quad ^{17}\!\! / \!\! \% \quad ^{\mathsf{N}}\!\! \llcorner^{\mathsf{L}_{\mathsf{R}}}\!\! 5\% \! \! ^{1}\!\! \%^{\mathsf{N}}\!\! \mathsf{L} \mathsf{N}^{2}\!\! \% - ^{\mathsf{N}}\!\! \llcorner^{\mathsf{L}_{\mathsf{F}}} \quad ^{7}\!\! \%^{1}^{\mathsf{L}_{\mathsf{R}}}$ $1/_{3}^{V_{T}} \stackrel{1}{\leftarrow} N^{\circ} N^{\circ} \stackrel{V_{T}}{-} \frac{5}{8} \qquad 3/_{8} \stackrel{C}{\leftarrow} \stackrel{1}{\leftarrow} \frac{1}{R} 3/_{8} 5/_{8} \stackrel{C}{\leftarrow} \stackrel{F}{\leftarrow} \stackrel{F}{\leftarrow} \qquad N^{\circ} 5/_{8} \stackrel{N}{\sim} 1/_{3} 2/_{3} 10/_{00} \stackrel{C}{\leftarrow} 1/_{8} \qquad 3/_{8} \stackrel{C}{\leftarrow} \stackrel{F}{\leftarrow} \frac{1}{R} 3/_{8} \frac{1}{R} \frac{1}{R} 3/_{8} \stackrel{F}{\leftarrow} \frac{1}{R} 3/_{8} \frac{1}{R} \frac{1}{R} 3/_{8} \stackrel{C}{\leftarrow} \frac{1}{R} 3/_{8} \stackrel{C}{\leftarrow} \frac{1}{R} 3/_{8} \stackrel{C}{\leftarrow} \frac{1}{R} 3/_{8} \stackrel{C}{\leftarrow} \frac{1}{R} 3/_{8} \frac{1}{R} \frac{1}{R} 3/_{8} \stackrel{C}{\leftarrow} \frac{1}{R} 3/_{8}$ 1/81/3 - 1/85/8 - Pt ■ - 1/31/81/81 V_T - N_L 17/8 N_L ®5/8 ® € C_U 5/8 € - N_L ®5/8 - V_T N ^{Q2}/₃5/8 - R 17/8 1/81/3 - 1/85/8 - R 1/81/3 LF5% LF£ - VTNº5% CR1 VT LF Nº1/3 - VT7/81/31/8 NL VT CR5% CR LF 1/3 CR5/8 - 1₩ HT CR11/85/85/83/8€-® N_1₩1/3^CR3%^LF 3%5%**®**5%%01^HT€—® ®€®®%0Rs HT1N_5%—NL "■‡^LF 1/3^LF ₩5%%0%0 1/3^LF LFHT5/81/8€1/3000N Rs Nº5/85/8NL "■‡^LF£ €- 1/3 N_{L1} ₩€^N ® N @5/8 2/3€3/8 3/85/8Nº1/3-3/8 7/81□R LFVT1/8® H_TE_R13/8 V_T1/8 N_LL_FP_t 1/3 1/8 1/8 5/8 0/00 5/8 E_R 1/3 N_L 5/8 3/8 ff^{®5}/8^LF⁵/8 7/81/31/8^NL1^CR^LF 1/3^CR5/8 5/8^H+T5/81/8^NL5/83/8 ^NL1 [®]1/3 **®**5/8 1/3 ^CR5/8N^Q1/3^CR°\u1/32/3%05/8 5/87/85/81/8^NL 1- N_@5% Nº1/3 CR°U5%NL @CR1₩NL® €- N_@5% LFV72%LF5%FFV75%-NL Rs5%1/3 CRLFPt



●1/3^LR%15/8^NL -NLYT3/8€5/83/8 -Rs ff1H_T -1N^QH_T1/3-€5/8^LF

 $-15\%^{\circ} \Box_{R} = -05\%^{\circ} \Box_{R} + -05\%^{\circ} \odot_{8} = N^{\circ} \Box_{R} \otimes_{8} \square_{8} = N^{\circ} \Box_{R} \otimes_{8} \square_{8} = N^{\circ} \square_{8} \square_{$

Market Trends

±-1/8^LR5/81/3^LF€-® -1NºH-5/8^NL€N_€1- €- N_05/8 "■± ●1/3^LR%5/8^NL

Market Segmentation



«5%H_T5%-3%€-∞ 1- N_L®5% L_FRs-N_L®5%L_F€L_F£ N_L®5% N^Q1/3 L_RC_N5%N_L €L 1/81-LF€3/85/8^LR5/83/8 7/81^LR LFRS-N_05/8 N_L€1/8 1/3-3/8 2/3€1N_5/81/80£ ₩05/8^LR5/8€- N_05/8 N_@5/8 Nº1/3₦€N°V⊤N° LF®1/3^LR5/8 17/8 N_®5/8 ®\\012/31/3\\00 Nº1/3^LR\\015/8 N_LPt ●5/81/3-₩®€\\05/8\L ®^CR¹₩N_L® H_T1/₃N_LN_L5%^CR- €- ^CR⁵/81/85%-N_L RS⁵/81/3^CR-F£ ₩®€1/8® €-F 5%₩H_T5%1/8N_L5%3% N_L1 L_FV_TC_R®5% 7/8 V_TC_RN_L®5% C_R 1/3 N_L 1/3 C_R5/8 0 0 1/3 N_L € **®** 5/8 0 0 R_S ® € ®®5 8 C_R — "□□ 1 ₩ € - ® N_L1 N_L®5% 1 N_L E_R5/83/8 V_T1/85/83/8 L_F€3/₈5/₈ 5/₈7/₈5/₈1/₈N_LL_F 17/₈ 2/3€1N 5/81/8® LFRS-N ®5/8LF€LFPt $\bigcirc^{V_{\mathsf{T}}\mathsf{E}_{\mathsf{R}}\mathsf{N}} |_{05\%} \mathsf{E}_{\mathsf{R}} \mathsf{N}^{\mathsf{Q}_{\mathsf{T}}} \mathsf{E}_{\mathsf{R}} \mathsf{S}_{\mathsf{R}} \mathsf{E} \qquad \mathsf{N}_{\mathsf{L}} |_{05\%} \mathsf{E}_{\mathsf{R}} \mathsf{N}^{\mathsf{Q}_{\mathsf{T}}} \mathsf{E}_{\mathsf{R}} \mathsf{E} \qquad \mathsf{N}_{\mathsf{L}} |_{05\%} \mathsf{E}_{\mathsf{R}} \mathsf{N}^{\mathsf{Q}_{\mathsf{T}}} \mathsf{E}_{\mathsf{R}} \mathsf{E} \qquad \mathsf{E}_{\mathsf{L}} \mathsf{E}_{$ 1/3-N_L€2/313/8€5/8^LF£ ^CR⁵/8¹/8¹N²²/3€−¹/3−^NL H_TC_R1N₁ 5%€-L_F£ $N^{91}-11/8\%01-1/3\%0$ $\textcircled{6}^{1/3}^{1/8}^{1/8} = -5^{1/3}^{-5/8} + \cancel{1}^{1/3}^{-3/8} + \cancel{1}^{1/2}^{-0.5/8} + \cancel{1}^{1/2}^{-1/2} +$



Market Regional Outlook

The key markets for active pharmaceutical ingredients include $-^{1}V_{T}N_{L}$ $^{\circ}$ $^{\circ}N_{L}^{\circ}=1/81/3$ $^{\circ}N_{L}^{\circ}N_{L}^{\circ}=1/31/3$ $^{\circ}N_{L}^{\circ}=1/31/3$ $^{\circ}N_{L}^{\circ}=1/31/3$ $^{\circ}N_{L}^{\circ}=1/31/3$ $^{\circ}N_{L}^{\circ}=1/31/3$ $^{\circ}N_{L}^{\circ}=1/$






Active Pharmaceutical Ingredients

Market Dynamics

The growing cases of chronic diseases are one of the leading causes of hospitalization, and a majority of the patients with these conditions may need re-admission in $^{@1}L_F^H_T \in ^NL^1/_3\%_0L_F ^{3}_6 ^{N}_{T^5/8} ^{N}_L^1 \in ^{-7}_8^5/_8^1/_8^NL \in ^{1}_L ^{9}_6^5/_3^3/_8 \in ^{-@}_L^1 ^{1}_N^1L_{\oplus 5/8}^{1}_R^2 ^{1}_R = ^{-1}_8^{1}_8^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_R^{1}_R^{1}_R^{1}_R^{1}_R = ^{-1}_8^{1}_8^{1}_R^{$

 $-5\%^{L}_{F} \in 3\%^{5}\%^{L}_{F} \underbrace{C} \quad -(----)^{0}1/_{3}^{L}_{F} \quad 1/_{3}\%_{0}^{L}_{F}^{1} \quad L_{F}^{N}_{L} 1/_{3}^{N}_{L}^{5}\%^{3}\% \quad N_{L}^{0}1/_{3}^{N}_{L} \quad 1^{V}_{T}^{N}_{L} \quad 1^{7}\% \quad N_{L}^{0}5\% \\ N_{L}^{1}N_{L}^{1}/_{3}\%_{0} \quad 1/_{3} - -V_{T}^{1}/_{3}\%_{0} \quad 0^{5}\%^{1}/_{3}\%_{0}^{N}_{L}^{0}1/_{8}^{1}/_{5}^{2}\% \quad 5\%^{H}_{T}^{1}_{5}\%_{8}^{-3}\% \in N_{L}^{V}_{T}^{L}_{R}^{5}\% \underbrace{C} \quad \oplus P_{t}^{5}\%_{8}P_{t}\underbrace{C} \quad 1/_{2}^{0} \\ N_{L}^{L}_{R} \in \%_{0}\%_{0} \in 1^{-}_{L}\underbrace{C} \quad 0^{0}_{*} \quad \oplus L_{F} \quad 7/_{8}^{1}L_{R} \quad N_{L}^{0}5\%_{8} \quad H_{T}^{5}\%_{1}^{1}H_{T}\%_{0}^{5}\% \quad H_{T}^{5}\%_{1}^{1}H_{T}\%_{0}^{5}\%_{8} \quad H_{T}^{5}\%_{1}^{1}H_{T}^{2}\%_{0}^{5}\%_{8} \quad H_{T}^{5}\%_{1}^{1}H_{T}^{2}\%_{0}^{5}\%_{1}^{2}$

□‰¹¾⅓‰ "¹½°\€�⁵% ■®¹⅓¯RNº⅓⅓½⁵% ¬°_€¹½⅓‰ ‡—®¯R⁵%³%€⁵%—°_└; ●⅓¯R‰⁵%°_
-®¹⅓¯R⁵%£ ¾Rs "'H¬H¬‰€¹½⅓¸N_€¹—£ ½²⁰®¡*¿





Market Segmentations

 $-1/3^{\text{L}} = 5\%3\% \qquad 1 - \qquad ^{\text{N}} L \text{Rs} \ ^{\text{H}} = 5\% \qquad 17\% \qquad ^{\text{L}} = \text{Rs} - ^{\text{N}} _{\text{.}} = ^{\text{N}} L = ^{\text{L}} \text{£} \qquad ^{\text{N}} L = ^{\text{N}}$


 $-\frac{1}{3} \stackrel{\mathsf{L}}{\vdash} 5\%8^{3}\% \qquad \stackrel{\mathsf{1}}{-} \qquad \stackrel{\mathsf{II}}{\bullet} \frac{7}{8} \stackrel{\mathsf{1}}{\vdash}_{\mathsf{R}} \mathsf{N}^{2} \stackrel{\mathsf{V}}{\vdash}_{\mathsf{T}} \%_{0} \stackrel{\mathsf{1}}{\cancel{3}} \stackrel{\mathsf{N}}{\vdash}_{\mathsf{L}} = \underbrace{\mathsf{L}}_{\mathsf{L}} \qquad \stackrel{\mathsf{I}}{\bullet} \mathbb{I}_{\mathsf{L}} \frac{1}{3} \%_{0} \qquad \stackrel{\mathsf{II}}{\lor}_{\mathsf{L}} \stackrel{\mathsf{L}}{\bullet} \mathbb{I}_{\mathsf{L}} = \underbrace{\mathsf{L}}_{\mathsf{L}} \qquad \stackrel{\mathsf{II}}{\bullet} \mathbb{I}_{\mathsf{L}} \frac{1}{3} \%_{0} \qquad \stackrel{\mathsf{II}}{\bullet} \mathbb{I}_{\mathsf{L}} \stackrel{\mathsf{II}}{\bullet} \mathbb{I}_{\mathsf{L}} = \underbrace{\mathsf{II}}_{\mathsf{L}} \frac{1}{3} \mathbb{I}_{\mathsf{L}} \frac{1}{3} \mathbb{I}_{\mathsf{L}} = \underbrace{\mathsf{II}}_{\mathsf{L}} = \underbrace{\mathsf{II}}_{\mathsf{L}} \frac{1}{3} \mathbb{I}_{\mathsf{L}} = \underbrace{\mathsf{II}}_{\mathsf{L}} = \underbrace{\mathsf{II}}_{\mathsf{$

 $-1/3^{L}_{F}5\%3\% \qquad 1- \qquad 1/3^{H}_{T}^{H}_{T}\%_{0} \stackrel{?}{\in} 1/81/3^{N}_{L} \stackrel{?}{\in} 1-\underline{\pounds} \qquad N_{L}@5\% \qquad @\%_{0}12/31/3\%_{0} \qquad N^{21}/3^{L}_{R}\%_{1}^{N}_{L} \stackrel{?}{\in} L_{F}5\%0N^{25}_{R} -N_{L}^{5}1\%3\%_{R} \qquad 0 \stackrel{?}{\otimes} 1-1/81/3^{L}_{R}^{3}1\%_{R} \stackrel{?}{\otimes} 1-1/81/3^{L}_{R}^{3}1\%_{R}^{2}_{R} \stackrel{?}{\otimes} 1-1/81/3^{L}_{R}^{2}_{R}^{2}_{R} \stackrel{?}{\otimes} 1-1/81/3^{L}_{R}^{2}$

 $-\frac{1}{3} \stackrel{L}{\vdash} 5\%3\% \qquad 1 - \qquad N^{91}\%0^{5}\%1/8^{V} 7\%0^{5}\% \\ \bullet \stackrel{0}{\lor} 1/3^{E} R N^{91}\%3^{1}\%5 \\ \bullet \stackrel{0}{\lor} 1/3^{E} R^{1}\%3 \\ \bullet \stackrel{0}{\lor} 1/3^{E} R^{1}\%5 \\ \bullet \stackrel{0}{\lor} 1/3$



"└┮€⅓¥■⅓⅓€⅙€⅙ "⅓√Ĺ€∰% ■®⅓└R№⅓⅓⅓%√\∟€⅓⅓‰ ‡–®└R५⅓%€%–\\└┮ ■⅓└R%₺%_ −®⅓└R₺£ ½№® ¡*¿



Market Regional Analysis

$$\begin{split} &\text{ff}^{\otimes 5/8} \quad \text{``N$^{\otimes 5/8}$^{\square}_{R} \in 1/81/3$^{\square}_{F} \quad \in \mathbb{L}_{F}} \quad 5/8 \text{'N}^{\square}_{T} + 5/81/8^{\square}_{L} 5/83/8 \quad \text{``L}_{1} \quad \otimes 1/90/3/8 \quad \text{``L}_{2} \otimes 5/8 \quad \text{``M}_{1} \otimes 1/90/3/8 \quad \text{``L}_{2} \otimes 5/8 \quad \text{``L}_{2}$$



Market Key Players

The prominent players in the global active pharmaceutical ingredients market are $-1/3 - 17/8 \in -$ " $| \bigcirc^{\Gamma} R^{1}/3 - 1/8^{5}/8 | \mathcal{L}$ \cap P_t $| 17/8^{7/8} N^{21}/3 - - + + | 17/8^{7/8} N^{21}/3 - - + + | 17/8^{7/8} N^{21}/3 - - + | 17/8^{7/8} N^{21}/3 - + | 17/8^{7/8} N^{$



Major Five Active Pharmaceutical Ingredients Companies

"Nº-5/81/300 ■®1/3 -RNº1/31/85/8 -TNL€1/81/300 - ±-1/8 Pt

—¹/₃³/8€‰¹/₃ †5/8¹/₃‰^NL®¹/8¹/3^CR5/8 R^NL3/8Pt

 $-1/3^3/8 \stackrel{?}{=} \%0^1/3 \quad \ \ \, \uparrow 5/8^1/3^9\%0^N \stackrel{?}{=} 0^1/3^1 \stackrel{?}{=} 1/3^1/8^1 \stackrel{?}{=} 1/3^1/8^$

RYTHT€- RNL%Pt



 $^{H}_{T}^{\Gamma}_{R}^{13}/_{8}^{V}_{T}^{1}/_{8}^{N}_{L}^{L}_{F} \quad ^{1}/_{3} - ^{3}/_{8} \quad ^{*}_{\blacksquare}^{\bot}_{F}^{F}_{P_{t}} \quad ^{ff@5}/_{8} \quad ^{1}/_{8}^{1}N^{9}_{T}^{H}_{T}^{1}/_{3} - Rs \quad ^{17}/_{8}^{7}/_{8}^{5}/_{8}^{\Gamma}_{R}^{L}_{F} \quad ^{1}/_{3} \quad ^{4}_{\blacksquare}^{\bullet}_{3}/_{8}^{5}/_{8} \quad ^{6}_{R}^{1}/_{3} - ^{9}/_{8}^{5}/_{8}^{\bullet}_{R}^{\bullet}_{A}^{\bullet}_{$

●Rs‰1/3- offI

- - "V_T□_R12/₃€-3/₈1 •®1/₃□_RN[©]1/₃
 - ff5/8 ★ 1/3
 1/3 T_RN^Q1/3 1/85/8 T_TN € 1/8 1/3 0/0 ‡ 3/8 T_T F_TN T_R € 5/8 T_F R_TN T_S 8/F_T R_TN T_R 5/8 T_T R_T 7/8 T_T 7
 - (^CRPt □5/83/83/8Rs§^LF R1/32/31^CR1/3NL1^CR€5/8^LF RNL3/8Pt
 - Rs\\\01/3- \circ PtffIPt
 - "2/32/3ffl€5/8 \$\pmu=-1/8Pt
 - -V_T- •®1/3^LRNº1/31/85/8 V_TN_L€1/81/3/00 ‡-3/8 V_TL_FN_L^CR€5/8^LF RN_L3/8 Pt
 - "2/32/31NLNL
 - -€11/81-
 - —€HT‰1/3 ‡—1/8Pt
 - "Nº05/8- ‡-1/8Pt



$$\begin{split} &\text{ff}@5/8 \quad \textcircled{=}-1/8^{\Box}_{R}5/8^{\dagger}/3^{\Box}_{F} \textcircled{=}-0 \quad 11/8^{\dagger}/8^{\dagger}/^{\Box}_{R}C_{R}5/8 - 1/8^{\dagger}/8^{\dagger}_{F} \quad 17/8 \quad 1/8^{\odot}_{G}C_{R}^{\dagger} - \textcircled{=}1/8 \quad 3/8 \textcircled{=}\Box_{F}5/8^{\dagger}/3^{\Box}_{F}5/8^{\Box}_{F} \textcircled{E} \\ & @^{\Box}_{R}1^{\dagger}_{F}^{\dagger}_{N} \textcircled{=} \quad 0 \qquad 1/3^{2}/3^{2}/3^{\Box}_{R}5/8 \textcircled{\oplus} \textcircled{=}1/3^{\dagger}_{N}^{\Box}_{5/8}3/8 \quad -5/8 \textcircled{\oplus} \quad 3/8^{\Box}_{R}^{\Box}_{F} \textcircled{=} \qquad 1/3^{\dagger}/8^{\dagger}/8^{\dagger}_{N}^{\Box}_{F} - \textcircled{=}1/8^{\dagger}/8^{\dagger}/8 \qquad 1/8^{\dagger}_{R}^{\Box}_{F} - \textcircled{=}1/8^{\dagger}/8^{\dagger}/8 \qquad 1/8^{\dagger}_{N}^{\Box}_{F} - \textcircled{=}1/8^{\dagger}/8 \qquad 1/8^{\dagger}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N} - \textcircled{=}1/8^{\dagger}/8 \qquad 1/8^{\dagger}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N} - \textcircled{=}1/8^{\dagger}/8 \qquad 1/8^{\dagger}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}^{\Box}_{N}$$



Export & Import: All Countries

Export: All Countries

Ampicilline and Its Salts

Unit: KGS

S. No.	Country	Values in Rs. Lacs			Quantity in Thousands		
		2019-2020	2020-2021 (Apr-May(F))	% Growth	2019-2020	2020-2021 (Apr-May(F))	% Growth
1.	AFGHANISTAN TIS	15.64			0.90		
2.	ARGENTINA	259.55	53.65		4.42	1.30	\Box
3.	AUSTRIA	0.00			\ \		111
4.	BANGLADESH PR	35.46	40.82		0.89	0.70	
5.	BRAZIL	275.10	554.66	$\perp \perp \perp$	1.20	2.44	$\backslash \backslash \backslash$
6.	BULGARIA		0.00				
7.	BURUNDI	4.61	11.16		0.20	0.50	$\perp \perp \perp$
8.	BELARUS	193.75	A = A + A + A + A + A + A + A + A + A +		8.45		///
9.	TAIWAN	56.32	30.51		3.13	1.60	
10.	COLOMBIA	114.42			4.26		
11.	CYPRUS	115.76	39.85		2.30	0.80	
12.	DOMINIC REP	2.21			0.05		
13.	EGYPT A RP	767.48	188.40		32.71	7.39	
14.	ETHIOPIA	361.72	0.00		20.00	0.01	
15.	FRANCE	101.75	$XX \cap Y$	$\perp \downarrow \downarrow \downarrow$	0.98	XX////	
16.	GEORGIA	3.23	$\mathcal{M}\mathcal{M}$		0.08	X <i>X</i> /X///	ШЦ
17.	GERMANY	7.06			0.17	X / X / / /	ЩЩ
18.	GHANA	502.75	192.23		32.40	11.00	



		// // // // // // //	 		++++++++++++++++++++++++++++++++++++	+
19.	HUNGARY	11.15	///////////////////////////////////////	0.60		
20.	INDONESIA	352.68	0.00	20.27		()
21.	IRAN	312.10		10.50	00	
22.	ISRAEL	8.02		0.30		
23.	ITALY	12.74	MMMIII	0.52		
24.	COTE D' IVOIRE	53.40		2.55		
25.	JAPAN	58.14		1,60		
26.	KENYA	1,415.12	81.27	87.82	5.10	\prod
27.	KOREA RP	377.86	126.55	6.61	2.14	
28.	LEBANON	26.30		0.75		
29.	MALAYSIA	38.58	18.47	2.20	0.80	
30.	MYANMAR	0.99		0.04		
31.	MEXICO	915.90	202.33	9.00	2.00	
32.	NEPAL	131.46	3.80	7.63	0.20	
33.	NETHERLAND	400.63	209.74	20.18	9.30	
34.	NIGERIA	3,511.61	505.50	219.90	31.00	/ '
35.	PAKISTAN IR	116.73	20.34	2.99	0.50	
36.	PARAGUAY	2.03	2.10	0.04	0.03	
37.	PERU	0.03				
38.	PHILIPPINES	28.34		0.60		
39.	POLAND	91.80		0.82	\////XX	
40.	PORTUGAL	21.59	11.34	0.20	0.10	
41.	ROMANIA	428.06	155.82	4.55	1.50	\mathcal{M}
42.	RUSSIA	367.60	64.12	7.65	1.50	
43.	SERBIA	0.01		1 1 1 1 1 1 1 1 1 1 1	X/////////	Ш
44.	SINGAPORE	3.73	6.03	0.20	0.30	



			+++++			
45.	SOUTH AFRICA	0.08		0.00		
46.	SPAIN	461.35	207.06	4.66	2.00	
47.	SRI LANKA DSR	9.98	MMII	0.26		
48.	SUDAN	338.15	NNN	19.73		
49.	SYRIA	53.48	149.58	3.50	8.20	
50.	TANZANIA REP	43.95		2.60		
51.	THAILAND	2,834.46	1,179.35	136.65	54.50	
52.	TUNISIA	0.00				
53.	TURKEY	486.99	42.24	14.01	1.00	
54.	UGANDA	60.36		3.50		
55.	U ARAB EMTS	52.40		2.70		
56.	UKRAINE	81.70	40.90	1.00	0.45	
57.	USA	2.39		0.04		
58.	UZBEKISTAN	48.15		1.30		
59.	VIETNAM SOC REP	422.15	32.86	21.85	1.10	
60.	YEMEN REPUBLC		8.48		0.40	
61.	ZAMBIA		2.31		0.08	
	Total	16,399.00	4,181.46			
India	's Total	221,985,418.10	22,345,384.17			
%Sha	re	0.0074	0.0187			



Cephalexin and Its Salts

Unit: KGS

+	the the telephone	H H H H	NNHH	++++		++++	Unit: KGS
S. No.	Country	Valu	Values in Rs. Lacs Quantity in		tity in Thou	sands	
B		2019-2020	2020-2021 (Apr-May(F))	% Growth	2019-2020	2020-2021 (Apr- May(F))	% Growth
1.	ALGERIA	1,896.09	193.67	XX///	52.75	5.00	
2.	ARGENTINA	299.14	23.31		8.57	0.60	
3.	AUSTRALIA	3.26			0.05		
4.	BANGLADESH PR	6.03			0.15		
5.	BRAZIL	4,599.65	1,077.86		133.93	28.77	
6.	CAMBODIA	68.86			2.00		
7.	CANADA	113.28	230.85		2.10	5.70	
8.	TAIWAN	810.61	105.69		24.81	3.05	
9.	ECUADOR	4.33			0.10		
10.	EGYPT A RP	353.98	13.50		10.30	0.30	
11.	GERMANY	2.84			0.05		
12.	IRAN	2,775.77			73.00		
13.	JAPAN	318.36			3.64		
14.	JORDAN	607.47	36.79		18.50	1.00	
15.	KENYA	148.47			4.30	XX////	
16.	KOREA RP	192.03	MMM		4.10	XXX///	/////
17.	LEBANON	57.34	24.72		1.60	0.60	
18.	MACEDONIA	6.84	WWW.		0.15	MMM	
19.	MALAYSIA	519.63	351.76		15.50	9.40	



20.	MEXICO	275.52		8.00		
21.	NEPAL	6.54		0.17		46
22.	NIGERIA	116.20		3.20		
22.	NIGERIA	116.20		5.20		(X,Y)
23.	PERU	5.22		0.13		
24.	PHILIPPINES	592.35	MMMM	17.70		
25.	SERBIA	68.09	885000XXX	1.83		
26.	SPAIN	835.87	242.27	19.05	6.00	
27.	SRI LANKA DSR	818.30	221.01	21.65	5.50	
28.	SUDAN	855.42	218.02	24.05	5.00	
29.	SYRIA	19.98		0.50		
30.	THAILAND	857.14	559.82	25.30	14.00	
31.	TURKEY	0.23		0.00		
32.	U ARAB EMTS	1,168.52		34.15		
33.	UK	88.63		2.00		
34.	VIETNAM SOC REP	2,096.79	153.33	63.23	4.00	
35.	YEMEN REPUBLC	4.52		0.10		
1	Total	20,593.27	3,452.59	11111111		
India	's Total	221,985,418.10	22,345,384.17			
%Sha	re	0.0093	0.0155			



Ibuprofen with or without Paracetamol or other Compounds

Unit: KGS

11.	1	<u> </u>				Un	it: KGS
S. No.	Country	Values in Rs. Lacs			Quantity in Thousands		
H	MAMA	2019-2020	2020-2021 (Apr-May(F))	% Growth	2019-2020	2020-2021 (Apr-May(F))	% Growth
1.	AFGHANISTAN TIS	375.10	20.01	X////	54.49	1.79	
2.	ANGOLA	639.89	48.53		133.31	4.86	
3.	ARMENIA	2.66			0.02		$ \cdot \cdot $
4.	AUSTRALIA	4,844.22	1,111.70		209.27	22.11	
5.	BAHAMAS	14.74	0.11		0.39	0.01	
6.	BANGLADESH PR	23.01			1.00		$\backslash \backslash \backslash$
7.	BELIZE	39.06	23.88		1.14	0.74	$(\ \) \ \)$
8.	BELGIUM	341.57	80.55		20.16	6.22	$\backslash \backslash \backslash$
9.	BENIN	430.55	1.07		30.48	0.04	$\backslash \backslash \backslash \backslash$
10.	BHUTAN	10.97	11.90		0.39	0.54	
11.	BOLIVIA	222.38	124.80		23.88	8.72	$\backslash \backslash \backslash$
12.	BOTSWANA	85.78			2.62		
13.	BULGARIA	0.02			0.00		
14.	BURKINA FASO	311.41	72.64		10.73	3.83	
15.	BURUNDI	136.66	20.72		10.28	1.51	
16.	BELARUS	248.65	44.48		3.59	0.39	
17.	CAMBODIA	134.74	26.61		10.48	1.88	
18.	CAMEROON	651.21	48.09		75.90	3.12	
19.	CANADA	5,570.12	990.72		133.43	7.33	
20.	CAPE VERDE IS	11.20	$I \vee I \vee I \vee I$		0.26	/	



/ //						
21.	CAYMAN IS	0.11	0.10	0.00	0.01	
22.	C AFRI REP	25.11	1.87	1.58	0.16	1.6
23.	CHAD	21.99		2.49		
24.	CHILE	2,299.79	419.28	135.80	23.43	
25.	CHINA P RP	0.23	NINNI	0.01		
26.	COMOROS	3.11		0.92		
27.	CONGO P REP	500.66		24.99		
28.	COSTA RICA	715.97	177.54	37.43	1.31	
29.	CROATIA	5.57		0.25		$ \cdot $
30.	CZECH REPUBLIC	5,302.29	1,345.84	225.27	15.04	\\\
31.	DENMARK	815.63	446.76	40.65	6.02	
32.	DJIBOUTI	8.13		1.13		$\backslash \backslash \backslash$
33.	DOMINIC REP	766.90	48.79	25.43	4.09	
34.	ECUADOR	571.48	48.76	25.07	2.57	
35.	EGYPT A RP	47.48		1.37		
36.	EL SALVADOR	656.71	137.04	15.44	1.92	
37.	ETHIOPIA	386.55	47.46	43.20	3.00	
38.	EQUTL GUINEA	3.00	20.77	0.06	1.66	
39.	FIJI IS	4.94	21.43	0.16	0.26	
40.	FRANCE	4,016.55	820.08	352.84	44.39	
41.	GABON	0.01		0.00		
42.	GAMBIA	83.74	1.74	3.94	0.30	//X/X
43.	GEORGIA	150.31	77.16	3.28	1.97	
44.	GERMANY	1,773.21	480.75	63.11	9.55	
45.	GHANA	610.88	22.84	43.38	4.20	
46.	GUATEMALA	4,285.89	69.30	106.40	0.48	



		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	- 			
47.	GUINEA	456.53	7.70	60.31	1.60	
48.	GUINEA BISSAU	6.92	MHHH	1.73		
49.	GUYANA	19.72	2.67	2.86	0.38	
50.	HAITI	93.97	93.31	6.44	3.84	
51.	HONDURAS	1,717.94	32.84	59.01	2.71	
52.	HONG KONG	6.08	0.04	0.20	0.00	\\\
53.	HUNGARY	4,343.31	799.89	89.44	6.50	
54.	ICELAND	17.65	17.69	0.20	0.16	
55.	IRAN	0.06		0.00		
56.	IRAQ	404.36	41.98	51.25	1.81	
57.	IRELAND	136.10		16.44		
58.	ISRAEL	31.84		2.00		
59.	ITALY	19.31		1.54		
60.	COTE D' IVOIRE	0.22	0.36	0.01	0.03	\\\
61.	JAMAICA	31.04	2.60	1.52	0.09	
62.	JORDAN	787.83	56.33	40.90	3.06	
63.	KAZAKHSTAN	163.05		6.51		
64.	KENYA	865.20	130.79	49.97	7.73	
65.	KIRIBATI REP		4.31		0.06	
66.	KYRGHYZSTAN	41.62	9.09	2.25	0.40	
67.	KOREA RP	2.67		2.46		
68.	LAO PD RP	3.37		1.53	X/////	
69.	LATVIA	36.00	51.77	1.03	0.40	///X)
7 0.	LEBANON	73.82	MM	3.60	$\chi \chi / / / /$	
71.	LESOTHO	70.02	2.28	2.39	0.19	
72.	LIBERIA	242.95	52.27	14.59	3. <mark>50</mark>	



73.	LIBYA	2.99	7//////		0.11		
74.	MADAGASCAR	542.87	58.12		49.08	4.97	
75.	MALAWI	258.76	9.27		13.96	0.77	
76.	MALAYSIA	0.39	4.21		0.01	0.01	
77.	MALDIVES	2.46	1.15		0.19	0.09	
78.	MALI	265.08	40.88	V////	33.97	2.49	
79.	MALTA	481.20	47.63	(X/// <u>/</u>	27.76	2.90	
80.	MAURITANIA	35.07			4,47		
81.	MAURITIUS	40.33	7.36		2.87	0.42	
82.	MYANMAR	500.94	107.58		30.38	3.82	\\\
83.	MOLDOVA	2.02		· X \	0.01		
84.	MONGOLIA	6.37			0.56		
85.	MOROCCO	0.07		$ \cdot \cdot $	0.00		
86.	MOZAMBIQUE	206.89	30.51		16.09	1.55	$\setminus \setminus \setminus$
87.	NAMIBIA	130.92	\mathcal{M}		6.31		
88.	NEPAL	1,365.44	203.52		139.37	16.01	
89.	NETHERLAND	1,741.69	204.86		64.41	3.66	
90.	NETHERLANDANTIL	43.65			2.63		
91.	NEW ZEALAND	1,016.53	248.63		40.37	3.73	
92.	NICARAGUA	2,445.08	33.47		82.43	1.75	
93.	NIGER	33.98	94.84		2.50	3.07	
94.	NIGERIA	2,835.73	648.65		308.61	28.11	
95.	OMAN	1.79	M = M + M + M + M + M + M + M + M + M +		0.23	<u> </u>	
96.	PANAMA REPUBLIC	1.83			0.00	M///	
97.	PAPUA N GNA	80.64	27.20		3.89	0.95	ШШ
98.	PERU	88.72	10.41		6.22	0.24	



99.	PHILIPPINES	60.84	4.64		4.81	0.26	
7///		11 11 11 11	4.04			0.26	
100.	POLAND	145.36			3.62		X
101.	PORTUGAL	31.70	++++++++++++++++++++++++++++++++++++		1.50		7. \
102.	QATAR	12.37			0.22		
103.	RUSSIA	13,098.71	1,999.82		624.72	11.73	
104.	RWANDA	552.64	1.77	<u> </u>	29.51	0.26	
105.	SAUDI ARAB	1.79		(X/// <u>//</u> /	0.13		
106.	SERBIA	16.48			0.04		
107.	SENEGAL	340.52	64.84		35.10	5.18	
108.	SEYCHELLES	0.40	0.09		0.03	0.01	\\\
109.	SIERRA LEONE	226.01	81.92		22.60	7.83	
110.	SINGAPORE	48.51	20.42		7.14	0.26	$\backslash \backslash \backslash$
111.	SOMALIA	207.59	11.51		32.84	0.73	
112.	SOUTH AFRICA	5,326.25	883.49		209.01	29.18	
113.	SPAIN	1,089.71	287.22		44.96	3.54	
114.	SRI LANKA DSR	240.36	17.71		24.22	1.06	
115.	ST KITT N A	0.30			0.01		
116.	ST LUCIA	0.97			0.05		
117.	SUDAN	34.29	9.94		1.60	0.75	
118.	SURINAME	7.11			1.00		
119.	SWAZILAND	15.05	0.66		0.66	0.05	
120.	SYRIA	14.37	0.50		0.20	0.02	
121.	TAJIKISTAN	124.89	13.94		22.81	0.60	//X)
122.	TANZANIA REP	722.57	118.14		78.59	5.14	
123.	THAILAND	192.18	59.46		9.41	0.45	ШШ
124.	TOGO	152.24	0.87		9.45	0.07	



140.	ZAMBIA Total	283.92 155,124.89	97.58 29,692.14		101.50	21.03 4.86	
139. 140.	YEMEN REPUBLC	465.75 1,265.99	49.50		77.68	2.39	
138.	SAMOA	1.46		$\backslash \backslash \backslash \backslash$	0.06	+++	
137.	VIETNAM SOC REP	53.01	26.18		5.59	0.31	
136.	VENEZUELA	62.54	14.18		2.20	1.46	
135.	VANUATU REP	13.80	104.20		0.40	2.76	
134.	UZBEKISTAN	1,787.30	164.20		115.99	2.78	
133.	USA	59,005.97	13,361.14		1,841.77	173.84	$ \cdot \cdot $
131.	U K UKRAINE	8,271.63 961.82	1,825.43		6.31	35.70	+ + +
130.	U ARAB EMTS	351.67	76.01	X///	28.44	1.78	$\left \cdot \right \left \cdot \right $
129.	UGANDA	554.86	27.60		67.79	3.27	
128.	TURKMENISTAN	358.34	27.87		31.80	2.30	
127.	TURKEY	143.39	29.65		15.17	12.62	
126.	TRINIDAD	21.52	16.14		1.46	0.86	NG
125.	TONGA	5.51			0.25		



Other Cyclic Amides and Thr Drvtvs And Salts

Unit: KGS

11/1	M M M M				Unit: KGS				
S. No.	Country/Region	Value	Values in US\$ Million			Quantity in Thousands			
M		2021-2022	2022- 2023(Apr-Jan)	%Growth	2021-2022	2022- 2023(Apr- Jan)	%Growth		
1.	AFGHANISTAN	0.00	0.00	V////	0.13	0.13			
2.	ALBANIA	0.00		$\langle X \rangle / Z$	0.03				
3.	ALGERIA	0.61	0.46	XXXX	5.44	0.88			
4.	ANGOLA		0.02			1.45			
5.	ARGENTINA	2.56	2.05		23.44	13.50			
6.	AUSTRALIA	0.07	0.03		10.16	2.26			
7.	AUSTRIA	4.50	3.62		38.10	25.00			
8.	BANGLADESH PR	1.06	1.75		15.57	23.36			
9.	BELGIUM	3.82	7.17		403.69	616.26			
10.	BHUTAN	0.01	0.01		0.50	0.25			
11.	BOLIVIA	0.02	0.02		0.23	0.14			
12.	BOSNIA-HRZGOVIN	0.00	0.09			0.03			
13.	BRAZIL	9.91	9.62		51.38	49.31			
14.	BULGARIA	8.00	3.14		5.78	2.96			
15.	BURKINA FASO	M/M		1111	11111				
16.	BELARUS	0.05	0.28		0.03	0.43			
17.	CAMBODIA	0.00		1111	0.03				
18.	CAMEROON	MMM	0.00		111W	0.01	/XXX		
19.	CANADA	3.50	1.69		44.26	12.30	///X/		
20.	CHILE	0.04	0.03		1.51	1.70			
21.	TAIWAN	9.37	4.09		422.52	22 <mark>8.46</mark>	ЩШ		
22.	CHINA P RP	16.08	10.57		866.03	391.43			



23.	COLOMBIA	0.71	0.19	22.53	8.54	
24.	COSTA RICA	0.02	0.02	0.33	0.17	
25.	CROATIA	0.37	0.44	0.42	0.68	
26.	CUBA	0.27		1.10		
27.	CYPRUS	0.65	1.03	3.14	8.82	
28.	CZECH REPUBLIC	0.14	0.44	1,34	2.68	
29.	DENMARK	0.00	0.00		0.00	
30.	DJIBOUTI	0.00	0.00	0,25	0.00	
31.	DOMINIC REP	0.02	0.05	0.31	0.65	
32.	DOMINICA	0.03		0.01		
33.	ECUADOR	0.02	0.03	0.43	0.63	\ \
34.	EGYPT A RP	2.48	2.18	47.55	43.59	
35.	EL SALVADOR	0.02		0.10		\ \
36.	ESTONIA		0.02		0.00	
37.	ETHIOPIA	0.03	0.04	0.26	0.77	\ '
38.	ERITREA	0.00				
39.	FINLAND	0.04	0.08	0.01	0.33	\
40.	FRANCE	1.95	1.46	61.15	56.88	
41.	GABON	$\times \langle \cdot \rangle \langle \cdot \rangle$			0.01	
42.	GERMANY	6.24	12.26	415.65	312.62	1
43.	GHANA	0.13	0.10	2.43	1.35	X
44.	GREECE	1.74	3.61	21.01	56.73	
45.	GUATEMALA	0.02	0.04	0.12	0.24	
46.	HONDURAS	0.00		\\\\\ <i>XX</i> X	///////X	
47.	HONG KONG	0.05	0.01	0.52	0.06	X
48.	HUNGARY	0.46	0.55	1.78	2.41	
49.	INDONESIA	8.43	1.13	305.27	92.83	



		W/ W/ W/ /	IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII			\bot
50.	IRAN	0.03	0.00	0.08	0.04	
51.	IRAQ	0.07	0.09	0.12	0.26	5
52.	IRELAND	12.00	5.80	16.00	7.14	
53.	ISRAEL	1.26	0.78	14.18	11.34	
54.	ITALY	1.90	0.90	43.28	19.03	
55.	COTE D' IVOIRE	0.09	0.20	3.51	8.00	
56.	JAPAN	10.82	14.27	179.35	192.15	
57.	JORDAN	0.28	0.44	2.54	4.18	
58.	KAZAKHSTAN	0.01	0.02	0.40	0.57	$ \cdot \cdot $
59.	KENYA	0.17	0.08	20.02	8.13	$\backslash \backslash \backslash$
60.	KOREA RP	11.49	6.64	182.43	91.14	
61.	LATVIA	0.04	0.01	0.55	0.10	$\backslash \backslash \backslash$
62.	LEBANON	0.13	0.15	1.57	2.33	$ \cdot \cdot \cdot $
63.	LIBYA		0.13		9.00	///
64.	LITHUANIA		0.00		0.03	$\backslash \backslash \backslash \backslash$
65.	MACEDONIA	0.29	0.36	0.87	1.05	
66.	MADAGASCAR	0.00	0.01	0.03	0.32	$\backslash \backslash \backslash$
67.	MALAWI	0.00	0.00	0.03	0.13	
68.	MALAYSIA	0.07	0.73	0.78	1.76	
69.	MALTA	1.12	0.62	11.08	0.19	
70.	MYANMAR		0.00	///////////////////////////////////////	0.03	
71.	MEXICO	5.54	5.21	96.77	108.64	
72.	MOLDOVA	0.00		0.01		$\times\!\!\times\!\!\times\!\!\times$
73.	MOROCCO	0.33	0.06	1.87	0.49	//X/X
74.	MOZAMBIQUE	0.04	0.01	0.09	0.03	///X
75.	NEPAL	0.11	0.10	3.00	6.21	
76.	NETHERLAND	7.17	13.04	451.54	36 <mark>2.06</mark>	



77.	NEW ZEALAND		0.00		0.12
78.	NICARAGUA	0.01	7111111111	0.05	4.5
79.	NIGERIA	0.37	0.11	14.90	6.15
80.	NORWAY	58.62	57.27	3,905.13	3,770.32
81.	OMAN	2.27	0.68	46.27	15.96
82.	PAKISTAN IR	1.38	0.82	27.73	17.70
83.	PANAMA REPUBLIC	0.02	\$QX/X/X/X/ <i>X///</i>	0.42	
84.	PARAGUAY	0.09	0.08	0.78	0.83
85.	PERU	0.38	0.83	4.88	6.49
86.	PHILIPPINES	0.08	0.09	10.08	1.86
87.	POLAND	1.34	0.88	13.62	11.50
88.	PORTUGAL	0.16	0.28	1.86	2.22
89.	PUERTO RICO		0.08		0.35
90.	QATAR	0.00		0.02	
91.	ROMANIA	0.05	0.06	0.70	0.52
92.	RUSSIA	2.25	3.52	75.04	40.13
93.	RWANDA	0.01		0.50	
94.	SAUDI ARAB	2.76	1.11	37.72	8.92
95.	SERBIA	0.02	0.02	0.12	0.10
96.	SIERRA LEONE	0.01		1.00	
97.	SLOVAK REP	0.00	11/1///	11/////	
98.	SINGAPORE	0.18	0.06	41.66	16.52
99.	SLOVENIA	0.44	0.46	6.16	7.05
100.	SOMALIA	11/1///////////////////////////////////	0.01	1	0.71
101.	SOUTH AFRICA	0.32	0.01	19.29	0.23
102.	SPAIN	3.55	2.29	177.03	77.35
103.	SRI LANKA DSR	0.06	0.02	13.31	0.34



%Share		0.0673	0.0639	111111XX	()/////////////////////////////////////	$\mathbb{X}\mathbb{X}$
India's Total		422,004.40	372,117.75		(//////////////////////////////////////	
	Total	283.90	237.62		//////	
124.	ZIMBABWE	0.01	0.01	0.01	0.03	
123.	ZAMBIA	0.02	0.01	0.82	0.65	
122.	CONGO D. REP.	0.02	0.04	1.50	2.83	
121.	YEMEN REPUBLC	0.01	0.05	0.25	0.79	
120.	VIETNAM SOC REP	0.37	0.41	5.01	3.64	
119.	VENEZUELA	0.02	0.01	2.42	0.17	
118.	UZBEKISTAN	0.03	0.03	0.26	0.15	
117.	URUGUAY	0.21	0.17	3.08	2.30	
116.	USA	40.98	27.06	2,571.48	1,981.22	
115.	UKRAINE	0.01	0.00	0.05	0.01	
114.	UK	2.59	2.33	102.96	83.67	
113.	U ARAB EMTS	2.89	3.43	34.05	54.69	
112.	UGANDA		0.00		0.00	
111.	TURKEY	1.96	1.68	91.03	13.59	
110.	TUNISIA	0.13	0.02	2.30	0.30	\square
109.	TRINIDAD	MANNO.	0.00	/////X/XX	0.02	
108.	THAILAND	0.78	0.67	22.29	22.19	
107.	TANZANIA REP	0.29	0.19	40.33	30.13	
106.	SWITZERLAND	22.68	14.84	821.24	464.10	X.
105.	SWEDEN	0.18	0.01	12.10	0.22	6
104.	SUDAN	0.00	0.01	0.03	0.22	



Import: All Countries

Ampicilline and Its Salts

Unit: KGS

S. No.	Country	Valu	Values in Rs. Lacs				Quantity in Thousands			
1		2019-2020	2020-2021 (Apr-May(F))	% Growth	2019-2020	2020-2021 (Apr-May (F))	% Growth			
1.	CHINA P RP	327.69			12.77					
2.	HONG KONG	308.85			3.00					
3.	RUSSIA		66.99			1.00				
4.	TURKEY	32.33			0.50					
5.	USA	0.75			0.00					
	Total	669.62	66.99							
India's Total		336,095,445.61	29,848,219.32							
%Sha	are	0.0002	0.0002							



Cephalexin and Its Salts

Unit: KGS

S. No.	Country	Valu	Values in Rs. Lacs			Quantity in Thousands			
H		2019-2020	2020-2021 (Apr-May(F))	% Growth	2019-2020	2020-2021 (Apr- May(F))	% Growth		
1.	BELGIUM	269.55			6.60				
2.	CHINA P RP	1,002.75			27.40				
3.	ITALY	0.03							
4.	NETHERLAND	1,948.78	179.79		48.00	4.40			
5.	SPAIN	10,603.89	3,209.00		290.31	78.90			
	Total	13,825.01	3,388.79						
India	's Total	336,095,445.61	29,848,219.32						
%Sha	%Share (0.0114						



Ibuprofen with or without Paracetamol or other Compounds

Unit: KGS

S. No.					Quantity in Thousands			
H	HHH	2019-2020	2020-2021 (Apr-May(F))	% Growth	2019-2020	2020-2021 (Apr- May(F))	% Growth	
1.	FRANCE	0.52	300000	XX///	0.00			
2.	GAMBIA	3.39			0.03			
3.	GERMANY	185.49			0.86			
4.	NAMIBIA	0.07			0.00			
5.	SPAIN	0.03			0.00			
6.	TURKEY	49.74			0.40			
7.	UK	102.81			0.31			
8.	USA	0.38			0.01			
1	Total	342.44						
India	's Total	336,095,445.61	29,848,219.32				///	
%Sha	re	0.0001					///	



Other Cyclic Amides and Thru Drvtvs and Salts

Unit: KGS

S. No.	Country/Region	Value	es in US\$ Mi	llion	Quantity in Thousands			
M		2021-2022	2022- 2023(Apr- Jan)	%Growth	2021-2022	2022- 2023(Apr- Jan)	%Growth	
1.	ARGENTINA	0.23		XX///	0.39		111	
2.	AUSTRALIA	0.00	(XXXXX	XXXX//	46	XX	1///	
3.	AUSTRIA	0.03	$\times\times\times\times$	\bigcirc	0.44		1///	
4.	BELGIUM	0.01	0.08		1.94	7.14	///	
5.	BRAZIL	0.03			0.69	1///	1111	
6.	BRUNEI	0.41	0.20		81.98	31.10	1//	
7.	CANADA	0.00	0.00		0.00	0.01	////	
8.	TAIWAN	0.00	0.00		0.06	0.00		
9.	CHINA P RP	137.42	132.36	1///	15,592.43	10,963.91	111	
10.	DENMARK						1//	
11.	FINLAND		0.15	1///	+ + +	1.67	////	
12.	FRANCE	0.93	0.71		52.80	31.40		
13.	GERMANY	3.55	2.64	1///	697.27	336.04	///	
14.	GREECE	0.67	0.44	$\cap \cap$	1.49	1.02	////	
15.	HONG KONG	4.43	2.09	1///	31.02	7.24	////	
16.	INDÓNESIA	0.00	////	\Box	0.03	\		
17.	IRELAND	0.16	0.03	1111	1.42	0.01		
18.	ISRAEL	0.22	0.21	1111	34.00	8.44	//XXX	
19.	ITALY	11.45	10.84		45.99	40.25	///X	
20.	JAPAN	1.17	2.60		102.77	265.18	/////	
21.	KOREA RP	0.14	0.04	1111	13.86	3.70	//////	
22.	LATVIA	0.02	0.01		1	0.00	HHH	
23.	LUXEMBOURG	0.00	YYYY		0.26			



%Sha	re	0.0291	0.0274			1//
India'	s Total	613,052.05	602,430.49			////
11	Total	178.49	165.01			
40.	USA	5.66	7.78	69.80	70.92	
39.	UKRAINE	0.00		0.00		
38.	UK	0.69	0.51	0.46	4.38	////
37.	TURKEY	0.03	0.00	16.00		
36.	THAILAND		0.31		0.11	
35.	SWITZERLAND	2.32	0.40	3.84	1.40	1///
34.	SPAIN	0.88	1.69	12.60	13.31	
33.	SLOVENIA		0.00	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	0.00	
32.	SINGAPORE	1.84	0.05	12.39	1.05	
31.	SAUDI ARAB	0.06		44.00		
30.	PORTUGAL	0.00	5500	XX/// ///XX		
29.	POLAND	0.44	0.31	3.33	2.62	
28.	NORWAY	4.30	0.81	53.02	9.91	
27.	NETHERLAND	0.00	0.10	0.01	9.68	(V)
26.	MEXICO	0.08	MM	0.50		
25.	MALTA	1.25	0.67	0.07	0.03	AG
24.	MACEDONIA	0.06		0.20		



Financials & Comparison of Major Indian Players/Companies

Source: CMIE



About Financial Statements of CMIE Database

A reasonably comprehensive list of all the information is listed in this flattened structure. The list reflects the usual disclosures made by companies. It is long as it tries to capture as much of granular information as possible.

Separately, CMIE database captures the disclosures made by companies in their Annual Reports according to the various Accounting Standards specified by the Institute of Chartered Accountants of India and according to the stipulations of the Reserve Bank of India.

There is an overlap of information presented and the disclosures as per the Accounting Standards and RBI stipulations. The data is normalised as per the CMIE database methodology and the rest is captured without normalisation since these presentations are highly standardised.



Profits & Appropriations

Description:

There are various measures of profits of companies. These are either gross or net of depreciation, amortisation, interest payments, direct taxes, prior-period and extra-ordinary transactions, etc. All measures of profits are essentially derived from the entries made under income and expenses in the CMIE database. Since all sources of income and all heads of expenses are captured comprehensively in CMIE database, it is possible to derive the various measures of profits from these.

Profit after tax is an atomic indicator in CMIE database. The rest of the profit measures are all derived indicators. The profits after tax and all other measures of profits as derived from the database may differ from the profits as presented by the company. The most likely cause for this difference is the treatment of transactions pertaining to prior periods or because of extra-ordinary transactions during a year.

As mentioned earlier, profit after tax is an atomic Indicator in CMIE database. All other measures of profits are derived Indicators and these are presented in Measures of Profits under Derived Indicators of Profits. Some of these are applicable only to finance companies. These are PBPDTA and PBPT and their variants. PBDITA and its variants are applicable only to non-finance companies. The other two derived measures of profits used in CMIE database are PBT and Cash profits. These are applicable to all kinds of companies like PAT and its variants.

The term "variants" used earlier refers to the various income and expense items that are netted out to derive measures of profits that are often more useful than the profit measures gross of these.



For example, one of the variants is the suffix "net of P&E". "P&E" is prior period and extra-ordinary transactions. Profits are reduced by the net income from prior period and extra-ordinary transactions to ensure that the profits reflect transactions of the current year. Other variant suffixes are "net of P&E&OI", which is net of prior period and extra-ordinary transactions and net of other income; and, "net of P&E&OI&FI", which is net of prior period and extra-ordinary transactions, net of other income and net of financial services incomes.

All these variants for the various profit measures are presented under Measures of Profits.

Derived Indicators of Profits includes one set of measures under Distribution of Profits. There are distributions of four measures of profits. These are - PBDITA, PBPDTA, PBPT and PAT. While the distribution of PAT shows the share of dividends and retained profits, the rest show the share of PAT and other components of the measures of profits. For example, PBDITA consists of provisions, write-offs, depreciation, amortisation, interest and PAT.

Profitability ratios are derived Indicators based on measures of profits, income and assets and liabilities. Over 35 such measures are provided in the CMIE database. These are divided into two parts - profit margins of income and returns over investments.

A number of Indicators that are used in the derivation of the sources of growth in profits are presented under the sub-part Sources of growth in profits. There are three measures of profits for which these Indicators are provided - PBDITA, PBT and PAT. Growth itself is computed at run-time and is not stored in CMIE database. However, these Indicators are used to understand the sources of growth in the three measures of profits. This understanding is based on a simple but useful arithmetical construct.



Total Liabilities

Description:

Total liabilities of a company are the sum of all the resources deployed by it. It includes all sums it owes to the shareholders in the form of share capital and reserves and surpluses, all sums it owes its lenders in the form of secured and unsecured loans and all current liabilities and provisions. It includes deferred tax liability.

In the CMIE database, total liabilities balance total assets and, total liabilities is the sum of the following:

- 1. Paid up shares and similar capital such as, forfeited equity capital, paid up preference capital, capital contribution, convertible warrants and minority interest reserves.
- 2. Reserves and funds, net of accumulated losses, if any. These include premium reserves, capital redemption reserves, revaluation reserves, employee stock option reserves, general reserves and balance as per profit and loss statement. While revaluation reserves is included here, in most presentations of CMIE database, it is netted out.
- 3. Borrowings
- 4. Current liabilities & Provisions
- 5. Deferred tax liability

The Annual Report provides a lot of information besides a structured presentation as outlined above. For example, it provides details of the authorised capital, issued and subscribed capital, number of shares issued, details of buy-backs, etc. All of this is covered under the Addendum information of Liabilities.



CMIE database makes fine distinctions in defining share holders funds and net worth. It defines free and specific reserves and capital employed clearly so that the same definitions apply to all companies. All of this some more Indicators are presented in Derived Indicators of Liabilities.

Derived Indicators also include an entire section "Secured & unsecured borrowings". This section helps in the selection of Indicators relating to borrowings directly. The presentation in the main listing of all Indicators has one list of secured borrowings with its detailed break-up and another list of unsecured borrowings with its detailed break-up.

As a result, the selection of total bank borrowings implied always adding secured bank borrowings and unsecured bank borrowings. To avoid the tedium, the Derived Indicators of Liabilities includes this section that provides the secured and unsecured borrowings for most of the frequently used borrowing items.



Total Assets

Description:

Total assets is a sum total of all the assets held by a company as on the last day of an accounting period. An asset is recognised in the balance sheet when it is probable that the future economic benefits associated with it will flow to the enterprise. As per Part I of Schedule VI of Companies Act 1956, assets are required to be disclosed under the heads Fixed Assets, Investments, Current Assets, Loans and Advances and Miscellaneous Expenditure no written off. This data field is broadly the sum of the amounts disclosed under each of these assets. Computationally and more precisely, this is the sum of the following data fields:

- Net fixed assets
- Capital work in progress and net pre-operative expenses pending allocation, if any
- Investments
- Inventories
- Receivables
- Loans & advances
- Cash & bank balances
- Deferred tax assets
- Miscellaneous expenses not written off



Net Cash Flow from Operating Activities

Description:

Cash flow from operating activities is the cash generated from the main or primary business activities of the company. A company can present the cash flow statement under the direct or indirect method of presentation. This data field provides the amount of cash flow generated from operating activities, which is calculated, under the indirect method.

Under indirect method, the net profit or loss before tax and extraordinary income is used to calculate the amount of net cash flow generated from operating activities. In other words, the indirect method adjusts net income for items that affected reported net income but did not affect cash. Since income statement is prepared on an accrual basis, in which revenue is recognized when earned and not when received, net income does not represent the net cash flow from operating activities and it is necessary to adjust it for those items which affect net income although no actual cash has been paid or received against them.

To compute net cash flows from operating activities, non cash charges in the income statement are added back to net income, and non cash incomes deducted. Further, cash flows on account of changes in the working capital of the company are included.

When accounts receivable increase during the year, revenues on an accrual basis are higher than on a cash basis because goods sold on account are reported as revenues. In other words, operations for the period led to increased revenues, but not all of these revenues resulted in an increase in cash. Some of the increase in revenues resulted in an increase in accounts receivable. To convert net income to net cash flow from operating activities, the increase in accounts receivable must be deducted from net income.



When accounts payable increase during the period, expenses on an accrual basis are higher than they are on a cash basis because expenses are incurred for which payment has not taken place. To convert net income to net cash flow from operating activities, the increase in accounts payable must be added back to net income.

Cash flows from operating activities are obtained, broadly, by the following method:

Add: Net Profit before tax and extraordinary incomes Add: Non-cash Expenses (Depreciation, Amortization, Provisions made, write offs) Less: Non-cash Incomes (provisions written back) Add: Non-operating Expenses (Interest paid) Less: Non-operating Incomes (Interest, dividend income) Add: Non-operating Losses (Loss on Sale of Non-Current Assets, Foreign exchange losses) Less: Non-operating Gains (Gain on Sale of Non-Current Assets, Foreign exchange gains)



Section -I

This section comprises of selected companies with their contact details. These companies have major market share in their respective field.



Name of Company with Contact Details

1 1 1 1 1 1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1/1 1/1 1/1	H H H						
Company	$M \mid M \mid M$	$X \mid X \mid X$	MM			Telephone	Fax		Web
Name	Address 1	Address 2	City	Pin code	State	Number	Number	Email	Address
DIN IX	65,	MMM	X X				Y // \	atulsbarha	
Alpha	Dharampeth	A M M L	$X \mid X \mid X$	X I X I	Maharas	3 1 1 A 1 Y	$\Lambda/Y + 1$	te@gmail.	\sim
Remedies Ltd.	Extn.,	Shandinagar,	Nagpur	440010	htra	2249574	$Y \wedge A \wedge V$	com	
MNN	NNN	Link Road,	MMM	MM	VIII.	/// // X	M = M	srane@an	www.anku
Ankur Drugs &	C-306, Crystal	Andheri	NAL	/NN	Maharas	$////\chi$		kurdrugs.c	rdrugs.co
Pharma Ltd.	Plaza, Andher		Mumbai	400053	htra	40682300	40682323	om	m
Aurobindo	Plot No.2,	690000VVV	DALASLAS	/ X / X /	Telangan	/////		info@auro	www.auro
Pharma Ltd.	Maitrivihar	Ameerpet,	Hyderabad	500038	/ 1/ / 7/ /	23736370	23747340	bindo.com	bindo.com
PROVINI	Milkat	CS	WXX	XX	X/X/X			1111	
	No,3339,	No.227/2+3	(MX/X/	$\langle X \rangle \langle X \rangle \langle X \rangle$	$/ \times / \times \times$				
	Block No.1,	A Harpale		/X/X/				cianhealth	
Cian	From South	Park, Opp.			Maharas			care@yah	www.cian.
Healthcare Ltd.		Bergerpaint,	Duno	412308		26982792	26982792	oo.co.in	co.in
nealthcare Ltu.	Side,		rulle	412300	liua	20982792	20302732	00.00.111	CO.III
	Cipla House,	Ganpatrao			$\langle \cdot \rangle$	Μ \		contactus	
		Kadam	\ \ \ \				1 1 1	contactus	.\\\\.
Challa Lt.d	Peninsula	Marg, Lower	Na	400043	Maharas	24026000	24026420	@cipla.co	www.cipla
Cipla Ltd.	Business Park,	Parel,	Mumbai	400013	ntra	24826000	24826120	m	.com
Dr. Reddy'S								shares@dr	
Laboratories	8-2-337, Road				Telangan	\ \ \ \ \	1 /	reddys.co	www.drre
Ltd.	No.3,	Banjara Hills,	Hyderabad	500034	a	49002900	49002999	m	ddys.com
Farmson	Plot No. 14,						\ \ \	1 / /	
Pharmaceutica	1 1 1 1			. \ \	\ \ \		\	finance@f	
Gujarat Pvt.	Industrial			\ \ \	1	1111	\ \	armson.co	www.farm
Ltd.	Estate,	Nandesari,	Vadodara	391340	Gujarat	2840612	2841377	m	son.com
Glaxosmithklin					/ / /			\ \ \ \ \	
e	Dr. Annie		7 / /	\ \ \			\ \		
Pharmaceutica	Besant Road,				Maharas	1111	1 1	askus@gsk	www.gsk-
s Ltd.	Worli,		Mumbai	400030	htra	24959595	24959494	.com	india.com
	Indoco House	Kalina.	111		1 / /			sunil.joshi	
Indoco	166, C S T	Santacruz	1 1 1	1 1 1	Maharas		111	@indoco.c	www.indo
	Road,	(East),	Mumbai	400098		26541851	26520787	om	co.com
	167-168 GIDC	(=0.0 5))	1 1 1	\ \	1	7 / 1 7	7 1 1	info@pan	www.pand
	Industrial	1 1 1 1 1	1 1 1		/ / / /			drugsltd.c	rugsltd.co
Pan Drugs Ltd.		Nandesari,	Vadodara	3013//	Gujarat	3062020	3062500	1 / / / / / /	m
Tan Drugs Ltu.	Piramal	ivariuesari,	vauouara	331340	Gujarat	3002020	3002300	0111/	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	Ananta,	Kamini	IIIII	1 1			$ \setminus VX $	(//////	/X/X/
Diramal	Ananta, Agastya Corp.		1111				$1 \times X \times X$	//////	I/MM
Piramal Enterprises	- 15 1/ 1/ 1/	D D D D D	IMI	1 / /	Maharas		[\/ \/ \/]	//////	///X/X
Enterprises	Park, Opp.	Marg, Kurla	N (1	400070	Maharas	20022000	20022004	//////	M/M
Ltd.	Fire Brigade,		Mumbai	400070	ntra	38023000	38023084	HHH	HHA
1/1/1/1/1	/////////	L&T	1/1/1/	$\langle N 1 \rangle$			Y	V / / / / /	
1 1 1 1 1 1	11111	Business	1 1 1 1	MM			$\Lambda/V\Lambda/V$		www.sano
Sanofi India	Sanofi House,		$\Lambda \Lambda \Lambda \Lambda$	1 / . /	Maharas		[V_A]/V_A	igrc.sil@sa	fiindialtd.c
Ltd.	CTS No.117-B,	Vihar Road,	Mumbai	400072	htra	28032000	28032939	nofi <mark>.com</mark>	om



		Powai,	$M \cap M$	1111					
Sri Krishna Pharmaceutica	C-4, Industrial	MM	MM		Telangan			1 7 1 1	www.srikri shnaphar
s Ltd.	Area, Uppal,	$X \mid X \mid X$	Hyderabad	500039	a	27201101	27204470	ma.com	ma.com
Inds. India Pvt.	Commerz II,		Mumbai	400063	Maharas htra				
3. 1 13. 1 3. 1	8-3-1066, Plot No. 11,	Srinagar Colony,	Hyderabad		Telangan a	3748834			



Name of Director(S)

Company Name	Date	Director Name
<i>4 H H H H H H H H H</i>	NNNN	
Alpha Remedies Ltd.	3/31/2018	ANIL DIVAKARAN NAIR
		ATUL S BARHATE
MMMMMMM	MNNNNN	MANJIT SINGH SAWHNEY
	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	PREETIINDER SINGH B SETHI
N N N N DLDGGGGGGGG		RAJESH GOVINDRAM BHATIA
Ankur Drugs & Pharma Ltd.	3/31/2012	ANIL KUMAR KHADKE
2745075073507350750750800800808080		DILEEP H SHINDE
234.04.754.650.050.54.754.754.654.65		GIRRAJ VIJAYVARGIYA
		PURNANDU JAIN
1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		RAMESH BATHAM
		S C RANE
Aurobindo Pharma Ltd.	3/31/2019	AVNIT BIMAL SINGH
		B ADI REDDY
		K NITYANANDA REDDY
		K RAGUNATHAN
		M MADAN MOHAN REDDY
		M SITARAMA MURTHY
		M SIVAKUMARAN (DR.)
		N GOVINDARAJAN
		P SARATH CHANDRA REDDY
		P V RAMAPRASAD REDDY
	1//////////////////////////////////////	SANTHANAM SUBRAMANIAN
		SAVITA MAHAJAN
Cian Healthcare Ltd.	3/31/2019	CHANDRA PRAKASH SINGH
		JAYANT V TILLOO
		PADMANABHAN BALASUBRAMANIAM
	11 1 1 1 1 1 1 1	PANKAJ SHRINIWAS ZANWAR
		RIYAZ B KHAN
<u> </u>	11/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1	SMITA KHANNA
<i>0.00.00.00.00.00.00.00.00.00.00.00.00.0</i>		SURAJ SHRINIWAS ZANWAR
//////////////////////////////////////	$T \cap T \cap$	USHA JASWANI
Cipla Ltd.	3/31/2019	ADIL ZAINULBHAI
XXXXXXXXXXXXXXXX	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ASHOK SINHA
474744444444		IREENA VITTAL (MS.)



	\\\\\\\	KEDAR UPADHYE
KIKIKI KIKIKI KATURI BERM		M K HAMIED
	\mathcal{M}	NAINA LAL KIDWAI (MS.)
		PETER LANKAU
ANN KIKIKIN NINA	NNHH	PETER MUGYENYI (DR.)
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	NNN	PUNITA LAL (MS.)
		RAJENDRA CHOPRA
		S RADHAKRISHNAN
	350 0 / / / / / / / /	SAMINA VAZIRALLI (MS.)
		UMANG VOHRA
	/ 	Y K HAMIED (DR.)
Dr. Reddy'S Laboratories Ltd.	3/31/2019	ALLAN OBERMAN
Dr. Neddy 3 Edbordtories Etd.	3/31/2013	ANUPAM PURI
		BHARAT N DOSHI
		BRUCE LA CARTER
		G V PRASAD
		HANS PETER HASLER
		K SATISH REDDY
		KALPANA MORPARIA
		LEO PURI
		OMKAR GOSWAMI (DR.)
		PRASAD R MENON
	11111	SANDEEP PODDAR
		SAUMEN CHAKRABORTY
		SHIKHA SHARMA
		SRIDAR IYENGAR
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	ANJU SINGH
	1 1 1 1 1	ANNIE RATHOD
		HARISHCHANDRA NAGJIBHAI PATEL (DR.)
	11111	KAVITA SHUKLA
	1 1 1 1	KOMAL SAMIR PATEL (MRS.)
		N K PATEL
		SAMIR K PATEL
X		SHEELA G NAIR
		SHUBHANGINI MAHATRE
A A A A A A A A A A A A A A A A A A A	IIIIIIII	SUCHI BHATT
<u> </u>	4.4.4.4.1.1.1.1	SUDHESH A MISHRA
A A A A A A A A A A A A A A A A A A A	A = A + A + A + A + A + A + A + A + A +	VINIT S MENON



Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019	A A NADKARNI
	$M \cap M \cap M$	A BANSAL
	MMMM	A N ROY
	NNIIIII	A VAIDHEESH
		D S PAREKH
	MMMMILL	D SUNDARM
	INNINNIL	MARC JONES
		NIHAL KAVIRATNE
	3 3330 X / X / X / X / X	P THAKUR
		P V BHIDE
	XXXXXXX	R C SEQUEIRA
		R KRISHNASWAMY
		R R BAJAAJ
		R S KARNAD
		SUBESH WILLAMS
Indoco Remedies Ltd.	3/31/2019	ADITI KARE PANANDIKAR
		ANAND NADKARNI
		ANIL M NAIK
		D M GAVASKAR
	$\cdot \lambda \lambda \lambda $	JAYSHANKAR MENON
		MANDAR BORKAR
		RAJIV KAKODKAR
		SHARAD P UPASANI
		SUNDEEP V BAMBOLKAR
		SURESH KARE
Pan Drugs Ltd.	3/31/2013	ATUL PANDYA
		HEMANT UPADHYAY
		KAMAL N PANDYA
		PARAG VAMANRAY RAVAL
Piramal Enterprises Ltd.	3/31/2019	AJAY G PIRAMAL
		ANAND PIRAMAL
		ARUNDHATI BHATTACHARYA (MRS.)
		DEEPAK SATAWALEKAR
	1/1/1/1//	GAUTAM BANERJEE
	1111111	GOVERDHAN MEHTA (PROF.)
	VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV	KEKI DADISETH
		LEONARD D'SOUZA
		N VAGHUL



		NANDINI PIRAMAL
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN		R A MASHELKAR
XIXININININININI		S RAMADORAI
A IN		SIDDHARTH METHA
U N N N N N N N N N N N N N		SWATI A PIRAMAL (DR.)
A HANN N NAKKAKA	NNHH	VIJAY SHAH
A MININI MININI MININI M	NNII	VIVEK VALSARAJ
Sanofi India Ltd.	12/31/2019	A SOOD
	X/X/X/X	ADITYA NARAYAN
	(XXXX)	CHARLES BILLARD
	XXXX	CHERIAN MATHEW
	$(\times\times\times\times$	CYRIL GRANDCHAMP
	$\times \times $	GIRISH TEKCHANDANI
		N RAJARAM
		RANGASWAMY R LYER
		SHAILESH AYYANGAR (DR.)
		THOMAS ROUCKOUT
		USHA THORAT
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	C GOPALA KRISHNAN MURTY
		PRANESH RAJ MATHUR
		SHILPA BUNG
		V SATYAVATHI
		V V SUBBA REDDY
		VEMPALLI VENKATA KRISHNA REDDY
		VENKATESWAR RAO SARVEPALLI
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3/31/2019	GAURAV MATHUR
		PRAMOD GHORPADE
		RAGHUNATHAN ANANTHANARAYANAN
Triton Laboratories Ltd.	3/31/2000	C KRISHNA PRASAD
VIII XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	1111	C UMA DEVI (SMT.)



Plant Capacity

Company Name	Product/Raw Material name	Year ended	Capacity	Capacity Unit	-Producti on	Producti on - Unit	Sales	Sales quantity - Unit	Sales value
company rame	Wateriarriame	cnaca	Capacity	V	OII	on onic	quarretty	- Olive	Rs.
	MMNNNN	Date	units		units	/V/V/V	units		Million
Alpha Remedies		MM	NNN	NNI	111111	7 AV X A			
Ltd.	INTEREST	200903	MNI	NN		(/X/V)			0.1
MMM	PARACETAMOL	200903	NOON/	X/X/X	/////	//X/\		M	185.5
Ankur Drugs & Pharma Ltd.	BULK DRUGS	201203		\times	X///				22.8
Filalilla Llu.	CAPSULES	201203	XXX	(X/X/X)	XX			+++	22.0
25025036036	FORMULATION	201203			$\times \times$		$\wedge \setminus \setminus$	1/ / / /	64.9
	DRY POWDER			XXX					
	INJECTABLE	201203							0.7
	DRY SYRUPS					\		1 1	
	FORMULATION	201203	+			\	-	\perp	200.2
	EFFERVESCENT TABLETS	201203							77.5
	FORM FILL & SEAL	201203				\ \		///	16.5
	INTEREST	201203				//	1 / 1	1///	1.6
	JOB WORK	201203			///	///	//	////	112.1
11/1/2	LIQUID FORMULATION	201203							384.7
AAK.	LIQUID INJECTABLE	201203			1 / /	1 / / /	\		5.9
	OINTMENTS	201203	1//	1//	1//	1//		111	27.4
11/1/1/1/	ORAL POWDER	201203			111		\	////	2.1
	ORAL STRIP/PATCHES	201203							2
	TABLETS FORMULATION	201203							706.4
Aurobindo Pharma Ltd.	BULK DRUGS & INTERMEDIATES	201903	\Box	///	$\backslash \backslash \backslash$				
	CAPSULES & TABLETS	201903	111				\ \ X		119226.3
	DIVIDEND	201903	$\perp \perp \perp$				ΔXX	4/////	790.8
	INJECTABLES	201903	IIIII				XNX	//////	MXM
	INTEREST	201903	MM				VXNX	[/////	114.4
AAAAA	OTHERS	201903	NNN				<u> </u>	M/M	WUN
AAAAA	SCRAP	201903	IMAI			$\setminus \setminus V$	X/V X/	111111	154.7
NN XXX	SERVICES	201903	VVV			$\square \square \Lambda$	/ Y /\ / Y /		160.7
VV V <u>V V V</u>	SYRUPS	201903	MM	M M = M		1 1/1	AIVAI		



	TRADING GOODS	201903	/////	1///					
Cian Healthcare Ltd.	PHARMACEUTICALS MEDICINAL CHEM & BOTANICAL PROD	201903							693.1
Cipla Ltd.	AEROSOLS	201903							
ZMMM	AEROSOLS/INHALATI ON DEVICES	201903							
MMM	ANDA & OTHER PRODUCT LICENCE	201903	MM	M		I/XX/			720
MINNI	BULK DRUGS	201903		\sqrt{X}	/////	$1/N \chi$			
	BULK DRUGS (TRADED)	201903		\times	X///				
	CORPORATE GUARANTEE COMMISSION	201903							199.2
2000 CONTRACTOR	CREAMS	201903							
	CREAMS (TRADED)	201903					111		///
	DIVIDEND	201903			λ			1///	2415
	INJECTIONS	201903				/ /	1///		///
	INJECTIONS/STERILE SOLUTIONS	201903							
	INTEREST	201903				///	///		596.3
	LIQUIDS	201903			///	///			
111/	LIQUIDS (TRADED)	201903		///	//	////		///	
111111	OTHERS	201903	$\mathcal{M} \setminus \mathcal{M}$	//	///	1///			///
	OTHERS (TRADED)	201903	///	///	///	1//			
	PROFIT ON SALE OF INVESTMENTS	201903							1074.1
	RENT	201903	///	/ / /	///	///		///	53.5
AAAA	ROYALTY	201903	$I \cup I \cup I$	////		////	/ /		506.8
	SCRAP	201903							319
	SERVICES	201903	///			/ / /			64.8
	TABLETS & CAPSULES	201903							119684.4
	TABLETS & CAPSULES (TRADED)	201903							
	TECHNOLOGY KNOW-HOW/FEES	201903	IIII				XXX		410.2
Dr. Reddy'S Laboratories Ltd.	BIOTECHNOLOGY (GRAMS)	201903					XXXX		
AAAAA	BULK DRUGS	201903	$\Lambda \Lambda \Lambda \Lambda$				$(\Lambda/Y\Lambda/)$		
WWW	COSTOM PHARMACEUTICAL SERVICES(KILOGRA	201903							



	MS)	MI	1111						
	FORMULATIONS	201903	NIII						104667
11/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1	INTEREST	201903	IMII						812
	LICENSE FEES	201903	NN			N I N			559
HININ	PROFIT ON SALE OF MUTUAL FUNDS	201903	MM			MAX	$M \setminus M$		448
MAN	SALE OF SPENT CHEMICALS	201903	MM	W		/X/V			356
NNNN	SCRAP	201903	ANI	NN		$//\lambda/\gamma$			161
MMM	SERVICE INCOME	201903	MMM	XXX	I/I/I	//X/Y		$M \cap M$	503
Farmson Pharmaceutical Gujarat Pvt. Ltd.	DILUTE ACETIC ACID	201903				SQ.	46304.9	Tonnes	289
	ACID	201903		$\times \times \times$			6443.09	Tonnes	39.5
1	INTEREST	201903						111	15.4
	PARACETAMOL	201903	1			\	20246.52	Tonnes	6755.8
	RENT	201903			170	/		1//	0.4
Glaxosmithkline Pharmaceuticals Ltd.	INTEREST	201903							764.4
	LIQUIDS: ORALS, TOPICALS, PARENTALS & MALT	201903	3						30894.8
11111	OTHER SERVICES	201903	$\times \setminus \setminus$						\\\
I AAA	OTHERS	201903				1 / /		$\backslash \ \backslash \ \backslash \ \backslash$	
11111	RENTAL INCOME	201903	111	///		///	/	///	4.8
(SERVICE INCOME	201903		111	1 / / 7				256.2
	SOLIDS INCL. POWDERS & OINTIMENTS	201903							
	TABLETS & CAPSULES	201903	$\backslash \backslash \backslash$						
	VACCINES	201903		1 / 1	1 / /	1 1 1			$\times \times \times$
Indoco Remedies Ltd.	ANALYTICAL & TESTING INCOME	201903					\ \ <i>X</i> /		486.5
	BULK DRUGS	201903	III				LVXX/	[]]]]]	$(\chi\chi\chi)$
MANN	CAPSULES	201903	I V	111			NXN	//////	XXX
	INJECTIBLES & EYE PREPARATION	201903	W				XXXX		
111111111111111111111111111111111111	INTEREST	201903	$\Lambda \Lambda \Lambda I$				$\Delta / \Delta / \Delta / \Delta $		15.6
XXXXXX	LIQUID ORALS	201903	VVV				IYAIYI		8927.2
M/M/M/M	OINTMENTS	201903		(1 1 1/	MANA		



	&LOTIONS	MM	////						
	OTHERS	201903	MIII						
	POWDERS	201903	IMI						
	SCRAP	201903	NN			ALL AL	1/1/1/		3.5
PINIXI	TABLETS	201903	XX			LVAIV	M = M + M		
VI M M I	TOOTHPASTE &		NXX	NH		$I \wedge I \wedge I \wedge I$			
JNNN	MOUTH GEL	201903	MM	VXL		IXAIX	$\Lambda + V$		
MMM	DICLOFANIC		NNN	NNI		/ /V X /1			
Pan Drugs Ltd.	SODIUM	201303			1.5	Tonnes	1.43	Tonnes	0.7
HHHH	DILUTED ACETIC ACID	201303	XXXXX	MM	460.04	Tonnes	460.94	Tonnes	0.1
	GUAIACOL	201303	INNN	*////	460.94	Tonnes		Tonnes	0.1
		PINN PN	$\wedge \wedge \wedge \wedge$	$\frac{(X(X))}{(X)}$			0.6	1 1 1 1	
PALEMANDAVONO	GUAIPHENESIN GUAIPHENESIN DC	201303	$\times \times \times$	XXXX	141.6	Tonnes	145.45	Tonnes	39.3
	95	201303	$\times\!\!/\!\!\times\!\!/\!\!\times$		66.05	Tonnes	66.05	Tonnes	37.3
	METHACARBAMOL	201303	XXV/V		- VXV	Tonnes	0.28	Tonnes	0.2
	PAMABROM	201303				Tonnes	0.62	Tonnes	1.5
	PARA AMINO	201303			9.52	Tormes	10.02	Tomics	1 1 1 1 1 1
	PHENOL	201303					0.54	Tonnes	0.1
	PARACETAMOL	201303					10	Tonnes	2
	PARACETAMOL	/ / /			///		1//	///	/ / /
	POWDER	201303			491.26	Tonnes	494.71	Tonnes	112
	PNPNA	201303		$\backslash \backslash \backslash$	\ \ \	$\setminus \setminus \setminus$	3.68	Tonnes	0.3
Piramal	BULK DRUGS				$ \cdot \cdot $	111	\ \	1 1	\.\.\.
Enterprises Ltd.	INTERMEDIATES	201903		+		+++		-	18182.4
	DIVIDEND	201903	1 / /	1 / /	1 / /	///	/ /	$\backslash \backslash \backslash \backslash$	1298
	FACILITY FEES	201903			1///	$\perp \perp \perp$	(189.2
	INCOME ON INSTRUMENTS MANDATORILY MEASURED	201903							940.7
AAAA	INTEREST	201903	////	///					15724.1
	LIQUIDS	201903	111	1 / 1	1 / /			///%/	
	LIQUIDS, DROPS & SOLUTIONS	201903							
	OTHER FINANCING ACTIVITIES	201903	III				\XX	7////	9
MANN	OTHERS	201903	$I \setminus I \setminus I$				NXN	//////	77X/X
MAR	PERSONAL CARE PRODUCTS - TRADED	201903	M				XXXX	//////	W///X
MMM	PROCESSING CHARGES	201903	MM			$ \setminus \setminus X $	N(N)		2.1
MMA	PROFIT ON SALE OF INVESTMENTS	201903	MM	MM					1.3



	SERVICES	201903	IIIII						2921.5
	TABLETS	201903	$M \cap M$						
	TRADE IN TABLETS & CAPSULES	201903	W						X
PH W	VITAMIN A IN VARIOUS FORM	201903				MM	M = M + M		
Sanofi India Ltd.	BULK DRUGS	201912	INN	NHI		ΔM			
	FORMULATIONS	201912	NN	MMI	HHH	/ A/ Y A			28427
	INCOME FROM SERVICES	201912			/////				1676
MMMA	INTEREST	201912		(XXX)	$\langle I/II \rangle$	$//\chi_{\Lambda}$			910
	RENT	201912	$\mathbb{Z}\mathbb{Z}\mathbb{Z}$	$X \times X \times X$	\times				3
XXXXXXXXXXX	SCRAP	201912	$\times\times$		XXX			1111	15
Sri Krishna Pharmaceuticals Ltd.	D C GRANULES	201903							
	DOMPERIDONE	201903	1					1 1	///
	FOLIC ACID	201903			170	/		1//	1
	FRUSEMIDE	201903					111	111	///
	GLIBENCLAMIDE	201903			/ / /	//	///	1111	111
	INTEREST	201903			///	//	1//	///	6.2
	OTHERS	201903	, V				//		///
1////	PARACETAMOL IP	201903			111	111	//	///	5288.6
	TIE MONIUM SULPHATE	201903							
11111	TRADED GOODS	201903		1			\ \	\\\	\ \ \
Teva Pharmaceutical 8 Chemical Inds. India Pvt. Ltd.	DRÚGS INTERMEDIATES	201903							1990
1 1 2 2 3	INTEREST	201903				1//		17	33.7
	MARKETING SERVICES	201903							37.3
Triton Laboratories Ltd.	ACTIVATED CARBON	200003					0.51	Tonnes	
	PARACETAMOL	200003	250	Tonnes	1892.12	Tonnes	1860.63	Tonnes	282.6
	SODIUM BI SULPHATE	200003	1 K		$\backslash \backslash \backslash$		0.69	Tonnes	
	SPENT ACID	200003		Tonnes	34.5	Tonnes	34.5	Tonnes	IIIN
$I \times I \times I \times I$	SULPHURIC ACID	200003	XXX				0.45	Tonnes	



Location of Plant

Company Name	State	District	Location	Product
Ankur Drugs & Pharma Ltd.	Daman & Diu	Daman	Daman	Capsules Formulation
NNNNNN	NNNN	KNNII		Dry Powder Injectable
	KIKIKIKI	INNNII	77777 NX7	Dry Syrups Formulation
MMMMMM	MANA		[//////X.	Effervescent Tablets
		20X X X X X X X X	////////	Form Fill & Seal
	KANDADKOX X			Liquid Formulation
		\mathbb{Z}^{1}		Liquid Injectable
				Ointments
				Oral Powder
				Oral Strip/Patches
				Tablets Formulation
	Himachal Pradesh	Solan	Solan	Capsules Formulation
				Dry Powder Injectable
				Dry Syrups Formulation
				Effervescent Tablets
				Form Fill & Seal
				Liquid Formulation
				Liquid Injectable
				Ointments
				Oral Powder
				Oral Strip/Patches
				Tablets Formulation
	7//////////////////////////////////////		Pydibheemavar	
Aurobindo Pharma Ltd.	Andhra Pradesh	Srikakulam	am	Capsules & Tablets
	Andhra Pradesh	Visakhapatnam	Parwada	Capsules & Tablets
	Rajasthan	Alwar	Bhiwadi	Capsules & Tablets
	Telangana	Medak	Bollaram	Capsules & Tablets
	Telangana	Medak	Borapatla	Capsules & Tablets
	Telangana	Medak	Chitkul	Capsules & Tablets
	Telangana	Medak	Goddapothara m Village	Capsules & Tablets
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	Telangana	Medak	Medak	Capsules & Tablets
4/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1	Telangana	Medak	Pashamylaraam	Capsules & Tablets
$\Lambda\Lambda\Lambda\Lambda\Lambda\Lambda\Lambda\Lambda\Lambda$	Telangana	Rangareddi	Bachupalli	Capsules & Tab <mark>lets</mark>
Cian Healthcare Ltd.	Uttarakhand	Hardwar	Bhagwanpur	Pharmaceuticals Medicinal



	MMMM			Chem & Botanical Prod
Cipla Ltd.	Goa	South Goa	Verna	Tablets & Capsules
	Himachal Pradesh	Solan	Baddi	Tablets & Capsules
	Madhya Pradesh	Dhar	Pithampur	Tablets & Capsules
MMMMNNNN	Sikkim	East Sikkim	Rangpoo	Tablets & Capsules
NNNNNN	Sikkim	East Sikkim	Rorathang	Tablets & Capsules
Dr. Reddy'S Laboratories Ltd.	Andhra Pradesh	Srikakulam	Srikakulam	Formulations
	Andhra Pradesh	Visakhapatnam	Vishakhapatna m	Formulations
	Himachal Pradesh	Solan	Baddi	Formulations
	Puducherry	Yanam	Yanam	Formulations
	Telangana	Medak	Bollaram	Formulations
	Telangana	Rangareddi	Bachupally	Formulations
Farmson Pharmaceutical Gujarat Pvt. Ltd.	Gujarat	Vadodara	Vadodara	Dilute Acetic Acid
				Paracetamol
Glaxosmithkline Pharmaceuticals Ltd.	Maharashtra	Nashik	Nashik	Liquids: Orals, Topicals, Parentals & Malt
Indoco Remedies Ltd.	Goa	South Goa	Verna	Liquid Orals
	Himachal Pradesh	Solan	Baddi	Liquid Orals
	Maharashtra	Aurangabad (MAH)	Aurangabad	Liquid Orals
	Maharashtra	Mumbai	Mumbai	Liquid Orals
	Maharashtra	Raigarh (MAH)	Raigarh	Liquid Orals
Pan Drugs Ltd.	Gujarat	Vadodara	GIDC Area	Diluted Acetic Acid
			$ \cdot \cdot \cdot \cdot $	Guaiphenesin
				Paracetamol Powder
Piramal Enterprises Ltd.	Gujarat	Ahmadabad	Ahmedabad	Bulk Drugs Intermediates
	Madhya Pradesh	Dhar	Pithampur	Bulk Drugs Intermediates
	Maharashtra	Mumbai	Mumbai	Bulk Drugs Intermediates
	Maharashtra	Raigarh (MAH)	Mahad	Bulk Drugs Intermediates
	Tamil Nadu	Chennai	Ennore express highway	Bulk Drugs Intermediates
	Telangana	Sangareddy	Digwal village	Bulk Drugs Intermediates
Sanofi India Ltd.	Goa	Goa	Goa	Formulations
	Gujarat	Bharuch	Ankleshwar	Formulations
Sri Krishna Pharmaceuticals Ltd.	Telangana	Rangareddi	Nacharam	D C Granules
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	Telangana	Rangareddi	Uppal	D C Granules
Triton Laboratories Ltd.	Telangana	Medak	Bonthapally	Paracetamol
///////////////////////////////////////	1/	$I \cap I \cap I \cap I$		Spent Acid



Credit Ratings

Company		M	MMMM					Company/Iss uer not co-
Name	Date	Agency	Instrument	Grade	Rating	Status	Amount	operating
MMA	MM	M		MMIII		/////	(Rs. Million)	
Aurobindo	NN	MM	Working capital	NNNII		$\bigvee \bigvee \bigvee$		
Pharma Ltd.	10/23/2019	IND-RA	loan	High Safety	AA+(ind)	Rating Watch	50000	N
	1000000	IND-RA	Non-fund based working capital limit	Highest Safety	A1+(ind)	Rating Watch	14940	N
Cipla Ltd.	1/7/2020	A PARA PA	Bank Guarantee	Highest Safety	A 1+	Reaffirmed	900	N
Cipia Lta.	1/1/2020	CARE	Packing Credit	Highest Safety	A 1+	Reaffirmed	30020	N
	1/21/2020		Commercial paper	Highest Safety		Reaffirmed	10000	N
1	1/21/2020	IIND-KA	Non-convertible	nighest safety	А1+(пии)	Reallillieu	10000	IN
		IND-RA	unsecured debentures/bonds /notes/bills	Highest Safety	AAA(ind)	Reaffirmed	10000	N
Dr. Reddy'S Laboratories Ltd.	11/8/2019	ICRA	Non-government debt	High Safety	AA+	Reaffirmed	5000	N
(/ / /	////	/ / /	Non-government		///			
7 / / /		ICRA	debt	Highest Safety	A 1+	Withdrawn	$\setminus \setminus \setminus$	N
1 111	\\\\		Working capital		\\.\.\			
1111	2/11/2020	IND-RA	loan	High Safety	AA+(ind)	Initial Rating	5000	\ N
IJJJJ	$X \setminus X \setminus X$	INID DA	Working capital	High Cofoty	A A . (ind)	Dooffirmod	90	\ \ \ \
		IND-RA	Non-fund based working capital limit	High Safety Highest Safety		Reaffirmed Reaffirmed	920	N N
	4/30/2020	IND-RA	Working capital loan	High Safety	AA+(ind)	Reaffirmed	100	N
		IND-RA	Working capital loan	High Safety	AA+(ind)	Reaffirmed	4700	N
		IND-RA	Commercial paper	Highest Safety	A1+(ind)	Initial Rating	8000	//\/N\//\/
		IND-RA	Non-fund based working capital limit	Highest Safety	A1+(ind)	Reaffirmed	1200	N
Farmson Pharmaceuti cal Gujarat Pvt. Ltd.	7/17/2019	ICPA	Cash Credit	Adequate Safety	A-	Withdrawn	100	Z
rvi. Liū.	7/17/2019	11 11 11	1 1/ 1/ 1/ 1/ 1/ 1/ 1/		A-			
/ // // //	1	ICRA	Bank Guarantee	High Safety	A 2+	Withdrawn	150	N
Indoco	8/30/2019	ICRA	Cash Credit	Adequate	Α	Downgraded	84	N



Remedies			Safety				
_td.	11/1/1/1/	$X \mid X \mid$					
	1 1 1 1 1 1 1	1 K 1 K 1 K 1 K 1 K	Adequate				
	ICRA	Cash Credit	Safety	Α	Downgraded	120	N
	MMM	MMMMM	Adequate				
P V V V	ICRA	Cash Credit	Safety	Α	Downgraded	90	N
THHA	MINIM	Fund based	VNIII		MVMNV		
MININI		financial	Adequate		//////		
AMMV	ICRA	facility/instrument		A/A2+	Downgraded	100	N
NNN	MINN	Fund based	UN WW	77777	/X/VX		
MMM	NNNN	financial	Adequate	//////			
NNNN	ICRA	facility/instrument	Safety	A/A2+	Downgraded	150	N
Library WY	1150,9130,9134,917	Non-fund-based	MMMM	N//L/			111
7407417408	KONONUKU	financial	Adequate				
	ICRA	facility/instrument	Safety	A	Downgraded	126.6	N
22 22 22 22 22	8008888888888	Non-fund-based	XXXXX	///////		1 1 1	
		financial	Adequate			1	
	ICRA	facility/instrument	Safety	A	Downgraded	117.1	N
		Non-government	Adequate		1 / /		
	ICRA	debt	Safety	A/A2+	Downgraded	600	N
			Adequate			111	111
	ICRA	Term loans	Safety	A	Downgraded	550	N
	1 / 1 /		Adequate	/ / / /		/ / /	
	ICRA	Term loans	Safety	Α	Downgraded	550	N
			Adequate	(/	1 1 1	1/1	. \ \ \
7 / / / ,	ICRA	Term loans	Safety	Α	Downgraded	550	N
11111			Adequate	1 / /	111	/ / /	111
11/1/	ICRA	Term loans	Safety	Α	Downgraded	350	N
111111			Adequate	/ / / /	/ / /		/ / /
11111	ICRA	Term loans	Safety	Α	Downgraded	500	N
11111	ICRA	Commercial paper	High Safety	A 2+	Withdrawn	///	N
WIAAA		Fund based	o Jaicty	 		//	111
1111		financial		11/1		\ \	
	ICRA	facility/instrument	High Safety	A 2+	Downgraded	100	N
		Fund based	g carety	17			
11/17/1		financial	1111	111			
1816	ICRA	facility/instrument	High Safety	A 2+	Downgraded	100	N
	7 / / /	Non-fund-based	3 25.00,		3,223	1/////	XXX
Value V	NNNNN	financial	1 1 1 1			/////	
	ICRA	facility/instrument	High Safety	A 2+	Downgraded	52.5	//N//
11/1/1/1/	111/1/1/	Non-fund-based	1	+++	1 1 V X /	(/////	///X/
MAAAA	(XXXX)	financial	1 1 1 1 1			V////	
X N N N N	ICRA	facility/instrument	High Safety	A 2+	Downgraded	30	/ / _N / /
111111	11111	Non-fund-based	\\			X/////	HHH
$1 \wedge 1 \wedge 1 \wedge 1 \wedge 1$	MMM	financial	$(I \mid I \mid I)$		$V \setminus V X / V X$	// / / []	
1111111	ICRA	facility/instrument	High Safety	A 2+	Downgraded	50	N
AMAA.	ANTALA.	Non-fund-based	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		- 3.4		
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	ICRA	financial	High Safety	A 2+	Downgraded	70	N



			facility/instrument					
Piramal		11	IMNNNI					
Enterprises		1 // /	MMMMM					
Ltd.	7/9/2019	CRISIL	Commercial paper	Highest Safety	A 1+	Reaffirmed	120000	N
	MNN	$X \mid X \mid$	Non-convertible		\square			
	NNN	M	unsecured					
	MNN	001011	debentures/bonds	.N. N. J. J. J		V. I., A., A., A.	G F 1000	
AMN	MND	CRISIL	/notes/bills	Highest Safety	A 1+	Initial Rating	15000	N
	MMX	NI	Non-convertible	NNNII	M/M	$V \wedge V \wedge V$		
		NN	unsecured debentures/bonds	VXVXII	7/////	VX/		
	12/30/2019	CARE	/notes/bills	High Safety	AA	Initial Rating	25000	N
L. 2007973000	12/30/2019	CARE	Non-convertible	riigii Salety	AA	illitial Nating	23000	111
	SCASCASIA X	axku	unsecured	/X/X/X/			1 1 1 1	
	PSKAKAKA	XXXX	debentures/bonds	$\times\times\times\times\times\times$				
		CARE	/notes/bills	High Safety	AA	Reaffirmed	1000	N
- CO.		CARE	Term loans	High Safety	AA	Reaffirmed	32000	N
		CARE	Commercial paper	Highest Safety	A 1+	Reaffirmed	30000	N
		CARE	Commercial paper	Highest Safety	A 1+	Reaffirmed	90000	N
. / / /		//	Fixed deposits			1 1 1		111
	/ / / /		(including		/ / /	\ \\	1 1 1 1	
		1 /	intercorporate			1 1		
		CARE	deposits)	Highest Safety	A 1+	Reaffirmed	2500	N
			Fund based		1	/ / /	$\langle \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	
	\ \ \ \		financial				/ / / /	
1 111	$\perp \setminus \setminus$	CARE	facility/instrument	Highest Safety	A 1+	Reaffirmed	26000	N
	\ \ \ \		Non-convertible	\ \ \ \ \ \	/ / /			
	$\mathcal{N} \cap \mathcal{N}$		unsecured		111	\ \ \	/ / /	
		CARE	debentures/bonds	Lichart Cafety	. 1.	Deaffines ad	F000	/ // /
 		CARE	/notes/bills Non-fund-based	Highest Safety	A 1+	Reaffirmed	5000	N
			financial		1 / /		\ \	
		CARE	facility/instrument	Highest Safety	A 1+	Reaffirmed	2000	N
///// /		N/	Non-convertible	g.rest sarety	1.1			
MMM			unsecured		/ / /		1	
		AA	debentures/bonds		1 1 1		///2	
	3/30/2020	CARE	/notes/bills	High Safety	AA	Initial Rating	10000	X N X
	MMM	111	Non-convertible				//////	/X/X/
	11/1//	11 11.	unsecured	1			//////	
MIN	AAAI	1/1/	debentures/bonds			$\cup \cup \cup \vee X$	V/////	
MAA	4/24/2020	1/ 1/	/notes/bills	High Safety	AA	Initial Rating	30000	/ N/
MAX	4/28/2020	11 11	Commercial paper	Highest Safety	A 1+	Reaffirmed	60000	N
<u> </u>	4/29/2020	CRISIL	Commercial paper	Highest Safety	A 1+	Reaffirmed	60000	N
	MMM_{I}	MMM	Non-convertible	M = M + M			/	
	IMIII	MA	unsecured	$(\ \ \ \ \ \ \ \ \ \ $		1 \ /\/ X /\/		
	NNNN	CDICII	debentures/bonds	High oct Cafat	A 1.	\A(ith dan	15000	N.
1 1 1 1	I = I = I = I	CRISIL	/notes/bills	Highest Safety	A 1+	Withdrawn	15000	IN



	5/28/2020	ICRA	Debentures / Bonds / notes / bills	High Safety	AA	Reaffirmed	3300	Y
		ICRA	Debentures / Bonds / notes / bills	High Safety	AA	Reaffirmed	1700	C, C
		ICRA	Non-convertible unsecured debentures/bonds /notes/bills	High Safety	AA	Reaffirmed	141000	Y
	MA	ICRA	Non-government debt	High Safety	AA/A1+	Reaffirmed	3000	Υ
	F\$7FQ9FQ	ICRA	Term loans	High Safety	AA	Reaffirmed	24950	Υ
CHANKE	MOMON	ICRA	Commercial paper	Highest Safety	A 1+	Reaffirmed	90000	Υ
		ICRA	Fund based financial facility/instrument	Highest Safety	A 1+	Reaffirmed	21200	\ \ \ \
		ICRA	Non-fund-based financial facility/instrument		A 1+	Reaffirmed	2000	Y
Sri Krishna Pharmaceuti cals Ltd.	11/22/2019	ICRA	Term loans	Moderate Safety	BBB	Downgraded	213.3	N
		ICRA	Working capital loan	Moderate Safety	A 3+	Downgraded	710	N
1 112		ICRA _	Working capital loan	Moderate Safety	BBB	Downgraded	1280	N



Name of Raw Material(S) Consumed with Quantity &Cost

Company Name	Product/Raw Material name	Year Ended	Raw material quantity	Unit of raw material qty	Raw material value
		Date	Units	//////	Rs. Million
Alpha Remedies Ltd.	RAW MATERIAL	200903		$MM \cap M$	135.1
Ankur Drugs & Pharma Ltd.	RAW MATERIALS	201203	//////////////////////////////////////		941.6
Aurobindo Pharma Ltd.	RAW MATERIALS	201903	////XA		57559.2
Cian Healthcare Ltd.	RAW MATERIALS	201903	/////X/		405.4
Cipla Ltd.	RAW MATERIALS	201903	1/4/6		10237.8
Dr. Reddy'S Laboratories Ltd.	RAW MATERIALS	201903	XXXX		21032
Farmson Pharmaceutical Gujarat Pvt. Ltd.	ACETIC ANHYDRIDE	201903			1329.6
	ACTIVATED CARBON	201903		1///	89.9
	HYDRO SULPHITE OF SODA	201903	$\mathbb{Y} \setminus \mathbb{Y}$		18.3
	OTHERS	201903			30.5
	PHENOL	201903	\ \ \ \ \		3606.4
Glaxosmithkline Pharmaceuticals Ltd.	RAW MATERIALS	201903			6820.7
Indoco Remedies Ltd.	RAW MATERIALS	201903		\ \\	2400.9
Pan Drugs Ltd.	ACETIC ANHYDRIDE	201303	378060	Kgs	22.1
	ACTIVATED CARBON	201303	6170	Kgs	\ \ \ \1
	EPICHLOROHYDRIN	201303	92475	Kgs	11.4
	GUAIACOL	201303	105900	Kgs	32.9
	OTHERS	201303			8.1
	PARA AMINO PHENOL	201303	406599	Kgs	74.1
Piramal Enterprises Ltd.	RAW MATERIALS	201903			7672.7
Sanofi India Ltd.	RAW MATERIALS	201912		\ \ \ <i>X</i> /	8636
Sri Krishna Pharmaceuticals Ltd.	RAW MATERIALS	201903		\	3673.2
Triton Laboratories Ltd.	A.CARBON	200003	69133	Kgs	5.2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	ACETIC ANHYDRIDE	200003	1430044	Kgs	51.9
//////////////////////////////////////	C.S.FLAKES	200003	61537	Kgs	0.8
VVIIVIVIVIVIVI	C.S.L.Y.E.	200003	3619479	Kgs	20.9



AN ISO 9001	: 2015 CERTIFIED	COMPANY
-------------	------------------	---------

	EDTA	200003	2334.5	Kgs	0.3
	HCL	200003	5515	Kgs	
	HYDROS	200003	49613	Kgs	3
PINNIN W	IRON POWDER	200003	2069311	Kgs	19
UNUNNN	LIQUID AMMONIA	200003	HIMX	MXM	0.2
MMMMM	P.N.C.B.	200003	2465641	Kgs	76.7
HNMMMM	SODA ASH	200003	1691	Kgs	
	SODIUM BIO SULPHATE	200003	695	Kgs	
	SULPHURIC ACID	200003	1141850	Kgs	3.3
	ZINC DUST	200003	173625	Kgs	0.1



Section-II

This section provides comparative financial performance of companies given in Section – I. This comparison will be helpful to analysis the companies on the basis of their financials viz... Assets, Cash Flow, Cost as % Ge of Sales, Forex Transaction, Growth in Assets & Liabilities, Growth in Income & Expenditure, Income & Expenditure, Liabilities, Liquidity Ratios, Profitability Ratio, Profits, Return Ratios, Structure of Assets & Liabilities (%), Working Capital & Turnover Ratios, etc.....


P.S: Blanks or 0 in the data in above tables is due to non-disclosure of the data by the company.



Assets

		Rs.	Rs.	M				Rs.	Rs.	Rs.	Rs.
1 1 1 1 1 N 1 N 1	Date	Million	Million	AAA			Million	Million	Million	Million	Million
MMM	MMM	IXIX	N N	MM.	((cash_ba	1 1 1		$I \times N$. \ \ \		
NUNN	MM	Cross	Conital			tories-	HM	Evnanca	Loans		
A M IM N	NNN			$1 \times 1 \rightarrow 1$	prevy(cas	. / /		Expense		Tundo	Total
Company Name	Year	fixed assets	1 3 1 3 1 1		h_bank_b al)))	1 1 1 1 1	6 1 6 37	advance		payables	Total
Alpha Remedies	Teal	assets	progress	(3)	ai)))	1163]]]	bies	auvance	E2	payables	assets
Ltd.	3/31/2018	164.2	97.YXY	114.4	////	$\langle ////$	13.3		7.8	11.6	135.7
Ankur Drugs &	3/31/2010	104.2	NININ	W 71.7	$\forall \lambda \lambda \lambda$	X///			7.0	11.0	15383.
Pharma Ltd.	3/31/2012	13512 5	2664.8	11586.8	-8 4	-1476.7	317.6	1.6	76	1482.4	1 1
Aurobindo	3/31/2012	/\/ /\/ /\/	X / / / / /	//////	X/X/X	X/X	55252.	1	16930.	1102.1	18651
Pharma Ltd.	3/31/2019	54461.5	7308.9	41497	-1701.3	5620.3		5131.1		19669.8	1 1 1
Cian Healthcare		282282	\$\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	800	VXX	1			/ /	111	1
Ltd.	3/31/2019	312.1	63.7	234.8	17.4	1.2	206.2	\ \ \ 2	69.4	53.3	798.8
	1 / /	//	/ / /				33614.		20294.	111	18966
Cipla Ltd.	3/31/2019	60932.3	2973.3	41274.6	-563.4	-1695.7	/\ \ 5	5924.6	3	15286.1	5
Dr. Reddy'S	/ / /	///	/ / /			7 \	//		111	111	16471
Laboratories Ltd.	3/31/2019	97741	4001	46827	438	1588	39592	5218	13102	11094	0
Farmson		/ / /				//	///	\	//	///	///
Pharmaceutical						. \ \	\ \	\ '		111	\ \
Gujarat Pvt. Ltd.	3/31/2019	2330.5	16.3	1460.6	337.9	17.6	780	61.5	494	899.5	3250.7
Glaxosmithkline		/ /	1110			1 1	\ \ \	\	//		\ \ \
Pharmaceuticals	\\\\						/ /	\ \	44511.	1 1	/ /
Ltd.	3/31/2019	5590.8	10026.4	4300.1	-1206.4	-136.9	2332.6	42487.5	4	4796.1	
Indoco Remedies	\ .\ .\ .			\ \ \	1 / /	1 /					13050.
Ltd.	3/31/2019	9344.9	1854.3	4675.1	130.5	-98.6	2141.2	674.8	1945.2	1707.1	8
Pan Drugs Ltd.	3/31/2013	122.3	\ \ 0	64.3	-0.3	-0.6	39.1	111	24.7	65.3	193.7
Piramal			1 1 1	1 1 1		/ / /			166607	$\backslash \ \backslash \ \ \backslash$	43183
Enterprises Ltd.	3/31/2019	22330	979.5	18236.3	-4977.4	-159.1	9568.7	56780.5	.9	5633.6	4.8
11/1/1/	12/31/201	$ IA\rangle$	1 1 1 1		1 1 1 1		1 1 '		\	/ /	
Sanofi India Ltd.	9	8171	174	4987	2952	-197	2635	21390	27075	3856	52966
Sri Krishna	1111	111	$\langle \rangle$	111			1 / /	111	1	///X	
Pharmaceuticals		11111	IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	1.1	\ \ \ \	1.1.	/ _ / _ /		\ //		73.0X
Ltd.	3/31/2019	2678.2	20.5	1469.4	-13.2	53.8	2039.4		96.5	749	4427.3
Teva	MMM	1111	X X X		111	1			$\chi \chi / /$	/////	XXX
Pharmaceutical &	AAA	AA	MM	111					(XN)	/////	/X/X
Chemical Inds.	2/21/2010	////	1111		274.6	2.0	1126 7	20.4	X AL	1427	1050.0
India Pvt. Ltd. Triton	3/31/2019	2.3	AAA	0.8	274.6	3.8	1136.7	28.4	66.6	143.7	1959.9
Laboratories Ltd.	3/31/2000	101.7	0.1	60.2	1.2	10.3	61.6		22.5	63.3	172 6
Laboratories Ltd.	3/31/2000	101./	0.1	60.2	1.2	10.3	01.0	0.4	22.5	05.3	173.6







Cash Flow


		D. 1 D. 1	Rs.	2 4:11:	D 14:11:	D 14:11:	D 44:11:	D 4:11	
HIMI	Date	Million	Million	Rs. Million	KS. Million	Rs. Million Net cash inflow or	Rs. Million	Rs. Million	Rs. Million
Alpha Remedies		Net cash flow from operating	ed from operatio	extraordin	inflow or (outflow) from investmen	(outflow) due to net increase or (decrease) in cash and	cash equivalent s as at the beginning	cash equivalent s as at the end of the	from
Ltd. Ankur Drugs &	XXXXXXXX 2002-00-00			$\langle XXX \rangle$			$A \rightarrow A$	+++	+
Pharma Ltd.	3/31/2012	32	45	32	239.6	2.4	10.4	12.8	-269.2
Aurobindo Pharma Ltd.	3/31/2019		10088.3	117			1//		$I \setminus I \setminus I$
Cian Healthcare Ltd.	3/31/2019	128	128	128	-83.2	174	5.9	23.3	27.4
Cipla Ltd.	3/31/2019		19194.3			1 / / 1			1 1 1 1
Dr. Reddy'S						////	\ \	1111	
Laboratories Ltd. Farmson Pharmaceutical	3/31/2019				-5509			1132	
Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals	3/31/2019								
Ltd.	3/31/2019	4010.7	6207.1	4164.5	-1443.3	-1016.2	1994	977.8	-3583.6
Indoco Remedies Ltd.	3/31/2019	1321.4	1357.6	1321.4	-1037.6	122.3	84.9	207.2	-161.5
Pan Drugs Ltd. Piramal Enterprises Ltd.	3/31/2019	67605.8	69393.1	67605.8	-93289.1	-4344.8	4578.7	233.9	21338.5
Sanofi India Ltd.	12/31/2019	4123	6406	4123	657	2948	8251	11199	-1832
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	-101.2	-77.3	-101.2	-81.7	-11.8	23	11.2	171.1
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3/31/2019	242	545.6	242	33	274.5	475.1	749.6	-0.5
Triton Laboratories Ltd.	XXXX	MM	XXX	MMM			MMM	YALL	



Cost as % Ge of Sales

	77/1/	Rs. Million	Rs.	Rs. Million	Rs. Million	Rs. Million	Rs. Million		Rs. Million	Rs. Million
MMM	Date	MM	Stores,	IVIIIION			MIN			
HHHH		Raw materials, stores &	spares, tools consume	Raw material	Power, fuel & water	Compen sation to employe	$\langle \wedge \rangle \langle $		Marketi ng expense	tion expense
Company Name	Year	spares	d	expenses	N 1 1 1 1	es	duty	S	5	S
Alpha Remedies Ltd.				ĎXXX			XA			1//
Ankur Drugs & Pharma Ltd.	3/31/2012	1172.2	28.5	1143.7	152.3	188.1	8.8	1.1	26.1	2.2
Aurobindo Pharma Ltd.	3/31/2019	61327.8	4979.1	56348.7	5062.8	11981	7		652.6	2953.6
Cian Healthcare Ltd.										
Cipla Ltd.	3/31/2019	22819.4	1004.9	21814.5	2649.3	18400.9)	/ / /	6337.8	1706
Dr. Reddy'S Laboratories Ltd.	3/31/2019	22394	4242	18152	2786	16165		56	9022	2587
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	5126.4	51.8	5074.6	5 282	2 208.7	7		33.1	6.9
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019								1398.5	
Indoco Remedies Ltd.	3/31/2019		11	///			111	399.3	111	305.2
Pan Drugs Ltd.	3/31/2013	172.6		172.6	13.8	17.3	3 2.5	\	2.2	2.9
Piramal Enterprises Ltd.	3/31/2019		111	7672.7	1//			698	309.2	388.5
Sanofi India Ltd.			1 1		111	1 / 1	111	\		\ \ \
Sri Krishna Pharmaceuticals Ltd.										
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.										
Triton Laboratories Ltd.	XXXX	N N N	N.N.					XXX		////}







Forex Transaction

	7/////	IML	ALAL							
	1 1 7 1 1	Rs. Million	10 1 10 1	Rs. Million	Rs. Million		Rs. Million	Rs. Million		
HHH	Date	Million	IVIIIIOII	IVIIIION			HIMA	Y // \ \		((imported
HHH		Total forex	Export of goods	Export of	Total forex spendin		Import of finished	capital	port_ear	_rawmat/ rawmat_p urchased)
Company Name	Year	earnings		N IN IN	g	s (cif)	(cif)	7 //	sales))	*100)
Alpha Remedies Ltd.						X///				
Ankur Drugs & Pharma Ltd.	3/31/2012		XXX		8.9	7.5	30	0	0	18.94
Aurobindo Pharma Ltd.										
Cian Healthcare Ltd.										
Cipla Ltd.		/ /						1 1		
Dr. Reddy'S Laboratories Ltd.										
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	1926.7	1926.7		364.7	355.8			26.83	7
Glaxosmithkline Pharmaceuticals Ltd.										
Indoco Remedies Ltd.										
Pan Drugs Ltd.	3/31/2013	72.7	72.7	1 1 1	5.8	5.8		\ \	33.3	3.69
Piramal Enterprises Ltd.										
Sanofi India Ltd.		11/1	1 / /	111	1 / /	111	111		\	
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	2329.8	3 2329.8		2410.8	2349.2		1.6	42.81	63.87
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.										
Triton Laboratories Ltd.			11/1							




Growth in Assets & Liabilities

til til til til	11/11/	Date	NNA						Rs. Million
Company Name	Growth (gross_fixe d_assets,pr ev(gross_fix		ev(net_fix	(current_a ssets,previ current_as	(total_ass ets,prev(t otal_asse	(use_borro wings,prev (use_borro	bilities,pr	Growth (net_wort h,prev(net	Total
Alpha Remedies	ed_assets))	rear	20010XVV	sets))	ts))	wings))	labilities))	_worth))	assets
Ltd.		3/31/2018		$y \times x$	$\langle X \rangle / c$	$///\Lambda$			135.7
Ankur Drugs & Pharma Ltd.	KUYKUKU	3/31/2012	WXX	XXXX	/X/X/	00	-13.55	-65.96	1111
Aurobindo Pharma Ltd.	26.89	3/31/2019	22.3	14.5	14.92		14.92	13.7	186518.2
Cian Healthcare Ltd.	22.92	3/31/2019	17.4	-7.36	4.32		4.32	27.7	798.8
Cipla Ltd.	5.88	3/31/2019	-4.46	9.68	6.79	16.41	6.79	11.82	189665
Dr. Reddy'S Laboratories Ltd.	5.97	3/31/2019	-0.73	-2.72	-5.33		-5.33	7.42	164710
Farmson Pharmaceutical Gujarat Pvt. Ltd.	47.5	3/31/2019	69.27	19.66	i 19.19		19.19	49.38	3250.7
Glaxosmithkline Pharmaceuticals Ltd.	37 74	3/31/2019	33.21	-6.4	1.86	34.43	1.86	3	78808
Indoco Remedies Ltd.		3/31/2019		/ / /	///		1.79	1111	
Pan Drugs Ltd.	17.82	3/31/2013	26.33	-8.51	-2.96		-2.96	///	193.7
Piramal Enterprises Ltd.	7.02	3/31/2019		-13	3.17		3.17	-1.93	431834.8
Sanofi India Ltd.	-22.42	12/31/201 9		33.62	10.1		10.1	10.05	52966
Sri Krishna Pharmaceuticals Ltd.	3.91	3/31/2019	-4.13	14.9	7.26		7.26	-2.72	4427.3
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	15	3/31/2019	60	45.2	47.76		47.76	70.88	1959.9
Triton Laboratories Ltd.	4.52	3/31/2000	-0.99	53.07	27.27	, \ \ \	27.27	95.08	173.6



growth(total_assets,prev(total_assets))





Growth in Income & Expenditure

	Date	1111						MMM	Rs. Million
				Growth	Growth (compensa tion_to_e				X
			(rawmat_e	(stores_spa res_consum	mployees, prev(comp	(selling_dist ribution_ex p,prev(selli	Growth	Growth	
						ng_distribut		(pat,prev(Total
Company Name	Year))	consumed))	ees))	ion_exp))	a))	pat))	assets
Alpha Remedies Ltd.	3/31/2018	11////	/////						135.
Ankur Drugs & Pharma Ltd.	3/31/2012	-81.61	-76.88	-27.11	-8.02	-22.83			15383.
Aurobindo Pharma Ltd.	3/31/2019	(////	//X/\				$\forall \land \land$	-15.61	
Cian Healthcare Ltd.	3/31/2019	/X//	///\\		29.95		////	111	798.
Cipla Ltd.	3/31/2019	/X/X/	/					1 1	18966
Dr. Reddy'S Laboratories Ltd.	3/31/2019	3241	\					///	16471
Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline	3/31/2019								3250.
Pharmaceuticals Ltd.	3/31/2019	8.09	33.67	34.48	3.46	31.37	22.54	20.84	7880
Indoco Remedies Ltd.	3/31/2019	-7.71	-13.68	5.96	4.96	5 -7.42	-39.09		13050
Pan Drugs Ltd. Piramal	3/31/2013	-2.89	10.01	_ / /	-2.81	183.33			193
Enterprises Ltd.	3/31/2019	7.05	-5.24	-3.76	-8.42	8.68	-55		431834.
Sanofi India Ltd.	12/31/201 9	10.83	7.82	19.15	9.58	3 2.24	-3.3	8.83	5296
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	43.15	73.13	54.81	14.81	-5.76	-32.6		4427.
Teva Pharmaceutical & Chemical Inds.									
India Pvt. Ltd. Triton	3/31/2019	36.95		\ <i>X</i> //	35.66	11.11	61.98	61.16	1959.
Laboratories Ltd.	3/31/2000	16.37	18.81	/////10	6.67	62.16	48.25	336.36	173



Income & Expenditure

		Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
	Date	Million	Million	Million	Million	Million	Million	Million	Million		Million
Company Name	Year	1 1 1 1 1	/ 6 / 1/ 8	Change	Raw material s, stores & spares	extra- ordinary	Power, fuel &	bonus, ex gratia pf & gratuitie	tion expens		Depreciation (net of transfer from revaluation reserves)
Alpha Remedies Ltd.	XXX	/////	/////								
Ankur Drugs & Pharma Ltd.	3/31/2012	1523.7	0.3	-204.9	1172.2	407.3	152.3	182.4	29.4	468.3	611.9
Aurobindo Pharma Ltd.	3/31/2019	122578.9	90.9	2898	61327.8	99.9	5062.8	11732.8	3606.2	1266.5	3789
Cian Healthcare Ltd.	3/31/2019	676.3	9.5	2.4	416.2	· X	1.5	E4.7	2 2	53.8	20.2
500000000000V	3/31/2019	XXX			22819.4		1.5	54.7 17076.6	1 1 1		29.2 5620.4
Cipla Ltd. Dr. Reddy'S Laboratories Ltd.	3/31/2019							111	11	///	
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	7182.1	7	9.9	5126.4	2.9	282	202	40	42.4	161.4
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019		92.2	-255.6	6903			5055.2	2028	5.5	485.9
Indoco Remedies Ltd.	3/31/2019	, //		-133.3	11	///	//		11	///	
Pan Drugs Ltd.	3/31/2013	218.3	///	1.4	172.6	15.6	13.8	17.2	5.1	0.4	5.2
Piramal Enterprises Ltd.	3/31/2019	21816.5	498.9	-97.4	8097.5	152.6	676.9	3634.2	1395.7		1311.8
Sanofi India Ltd. Sri Krishna	12/31/2019	30709	11	-23	8692		423	4220	2004	3	999
Pharmaceuticals Ltd. Teva	3/31/2019	5442.4		41.5	3792.4	. 2	281.8	623.2	57.3	64.2	166.6
Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3/31/2019	2027.3				5.1	. 0.2	31.9	3	1.8	0.2
Triton Laboratories Ltd.	3/31/2000	287.9		5.7	183	0.1	19.9	9.4	6	5.9	4.9



	Date	Rs. Million	11 1 1 1		Rs. Million		1 1 1 1	7 / /	Rs. Million
			Reserves	Porrowi	bank	Unsecure d Bank borrowin	&	Total	Trade
Company Name	Year	Net worth		3 3 3	ngs	gs		liabilities	
Alpha Remedies Ltd.	3/31/2018			1 1 1			47.3		11.6
Ankur Drugs & Pharma Ltd.	3/31/2012	MMM						15383.7	
Aurobindo Pharma Ltd.	3/31/2019	113506.2	112920.3	45198	1797		67812.3	186518.2	19669.8
Cian Healthcare Ltd.	3/31/2019	175.2	45.7	487	321.8	20.6	334.5	798.8	53.3
Cipla Ltd.	3/31/2019	157819.1	156207.7	111			24629.9	189665	15286.3
Dr. Reddy'S Laboratories Ltd.	3/31/2019	126835	126011	10646			30887	164710	11094
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	1743	1714.1	460.9	381.9		1140	3250.7	899.5
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019	21424.2	19730.1	5.9			28159	78808	4796.2
Indoco Remedies Ltd.	3/31/2019	6610.8	6426.5	2958.7	1350.2	470	4548	13050.8	1707.3
Pan Drugs Ltd.	3/31/2013	-84.5	-115.9	196.6	188.4	.	264.7	193.7	65.3
Piramal Enterprises Ltd.	3/31/2019	144439.3	161244.6	208338	20630.8	17389.5	138059.6	431834.8	5633.6
Sanofi India Ltd.	12/31/2019	24423	24193	//	///	///	16786	52966	3856
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	2065.9	1946.7	1374.2	993.8		1864.9	4427.3	749
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3/31/2019	1750.7	1750.6				202.9	1959.9	143.7
Triton Laboratories Ltd.	3/31/2000	35.7	\	48.2	40.3	1 / /	70.2	173.6	



Liquidity Ratios


	Times	Times	Times	Times	Times	(%)	Rs. Million
Company Name	Cash to current liabilities (times)	Quick ratio (times)	Current ratio (times)	Debt to equity ratio (times)	Interest cover (times)	Interest incidence (%)	Total assets
Alpha Remedies Ltd.	0	0.28	0.28			0	135.7
Ankur Drugs & Pharma Ltd.	0	0.05	0.09	12.26		6.08	15383.7
Aurobindo Pharma Ltd.	0.01	0.83	1.44	0.4	16.52	3.07	186518.2
Cian Healthcare Ltd.	0.07	0.69	1.17	2.78	1.22	10.86	798.8
Cipla Ltd.	0.95	2.42	3.73	0	146.03	19.45	189665
Dr. Reddy'S Laboratories Ltd.	0.73	2.03	2.72	0.08	26.32	3.51	164710
Farmson Pharmaceutical Gujarat Pvt. Ltd.	0.15	0.89	1.02	0.26	20.36	7.71	3250.7
Glaxosmithkline Pharmaceuticals Ltd.	0.41	0.98	1.16	0	1136.2	69.62	78808
Indoco Remedies Ltd.	0.05	0.53	0.96	0.45	0.56	8.06	13050.8
Pan Drugs Ltd.	0.07	0.22	0.31		///	0.2	193.7
Piramal Enterprises Ltd.	0.08	0.15	0.19	1.44	15.06	0	431834.8
Sanofi India Ltd.	0.67	1.41	1.79	0	2204.67	/ / / /	52966
Sri Krishna Pharmaceuticals Ltd.	0.02	1.11	1.55	0.67		5.18	4427.3
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3.72	9.49	9.62	0	567.83		1959.9
Triton Laboratories Ltd.	0.04	0.78	1.08	1.35	2.02	16.3	173.6



Profitability Ratio

///////////////////////////////////////	Date	(%)	(%)	(%)	(%)	(%)	(%)	(%)
Company Name	Year	PBDITA as % of total income	PBT as % of total income	PAT as % of total income	income net	as % of total	Net profit	Operating profit margin of non-financial companies
Alpha Remedies	Teal	income	income	total income	OFFAL	HEL OF PAL	Illargili	Companies
Ltd.			IVA/1					1 1 1 1
Ankur Drugs & Pharma Ltd.	3/31/2012	-6.9	-150.7	' -159.08	-26.59	-119.32	-219.28	-26.63
Aurobindo Pharma Ltd.	3/31/2019	20.8	15.77	12.28	19.3	15.86	12.29	19.6
Cian Healthcare Ltd.	3/31/2019	14.28	1.54	0.96	13.06	0.38	1.17	13.25
Cipla Ltd.	3/31/2019	24.18	19.39	14.55	20.3	19.24	14.21	21.06
Dr. Reddy'S Laboratories Ltd.	3/31/2019	23.19	15.6	11.72	20.82	15.05	11.11	21.21
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	15.81	. 12.91	7.95	14.95	12.8	7.92	15.07
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019	21.88	20.25	12.98	18.84	19.31	12.08	19.3
Indoco Remedies Ltd.	3/31/2019	1	$X \land Y$		1111	///		///
Pan Drugs Ltd.	3/31/2013	1.28	-1.15	-1.15	-6.12	-8.35	-8.35	-6.14
Piramal Enterprises Ltd.	3/31/2019	20.44	-19.11	-20.81	4.21	10.59	9.96	7.96
Sanofi India Ltd.	12/31/2019	21.85	18.64	13.09	21.14	20.91	15.34	21.78
Sri Krishna Pharmaceuticals								
Teva Pharmaceutical & Chemical Inds.	3/31/2019							
India Pvt. Ltd. Triton	3/31/2019	49.95	49.63	35.15	48.19	49.52	34.99	48.99
Laboratories Ltd.	3/31/2000	5.85	1.87	1.66	5.78	2.08	1.87	5.8







Profits							
	Date	Rs. Million	Rs. Million	Rs. Million	Times	Rs. Million Change in PBT net of P&E&OI because of change in financial service income	
Company Name	Year	PBDITA	РВТ	Operating profit of non-financial companies	PAT net of P&E / total income net of P&E (times)		
Alpha Remedies Ltd.		I I W X W					
Ankur Drugs & Pharma Ltd.	3/31/2012	-133.3	-2912.9	-405.7	-2.19	376.8	
Aurobindo Pharma Ltd.	3/31/2019	25908.1	19646.2	24022.1	0.12	40648.61	
Cian Healthcare Ltd.	3/31/2019	98	10.6	89.6	0.01		
Cipla Ltd.	3/31/2019	31373.2	25154.3	26207.9	0.14	12758.53	
Dr. Reddy'S Laboratories Ltd.	3/31/2019	25274	17007	22539	0.11	-1635.46	
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	1145.6	935.3	1082.5	0.08	745.26	
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019	7172.2	6637.1	6021.1	0.12	1493.84	
Indoco Remedies Ltd.	3/31/2019	897.2	-92.4	667.6	0	226.22	
Pan Drugs Ltd.	3/31/2013	3	-2.7	-13.4	-0.08	5.44	
Piramal Enterprises Ltd.	3/31/2019	8466.9	-7915.8	1735.8	0.1	180.74	
Sanofi India Ltd.	12/31/2019	6914	5898	6689	0.15	437.01	
Sri Krishna			////				
Pharmaceuticals Ltd.	3/31/2019	183.4	-84.8	175.5	-0.01	-52.68	
Teva Pharmaceutical & Chemical Inds. India							
Pvt. Ltd.	3/31/2019	1032	1025.4	993.2	0.35	567.22	
Triton Laboratories Ltd.	3/31/2000	16.9	5.4	16.7	0.02	1.3	



Return Ratios


$M \cap M \cap M$	Date	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	
Company Name	Year	Return on net worth	PAT as % of net worth	Return on capital employed	PAT as % of capital employed	Return on total assets	PAT as % of GFA excl reval	PAT as % of total assets excl reval	PAT net of P&E as % of GFA excl reval	
Alpha Remedies			MM						1 1 1 1	
Ltd.		$IIII\Lambda$						M		
Ankur Drugs & Pharma Ltd.	3/31/2012	-207.89	-191.08	-26.75	-24.59	-20.74	-22.75	-19.06	-24.76	
Aurobindo Pharma Ltd.	3/31/2019	14.35	14.34	10.35	10.35	8.77	31.42	8.77	31.43	
Cian Healthcare Ltd.	3/31/2019	5.12	4.23	1.23	1.01	1.08	2.33	0.89	2.83	
Cipla Ltd.	3/31/2019	12.27	12.63	12.2	12.56	9.99	31.88	10.28	30.96	
Dr. Reddy'S Laboratories Ltd.	3/31/2019	9.82	10.43	8.54	9.08	3 7.1	13.45	7.54	12.66	
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	39.45	39.6	28.63	28.74	19.2	29.47	' 19.28	29.35	
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019	18.28	20.15	18.28	3 20.14	1 4.94	88.16	5.45	80	
Indoco Remedies Ltd.	3/31/2019		-0.42	-0.39	-0.3	3 -0.29	////			
Pan Drugs Ltd.	3/31/2013			-16.3	-2.41	-9.31	-2.39	-1.37	-16.19	
Piramal Enterprises Ltd.	3/31/2019	2.82	-5.91	1.19	-2.5	5 1.01	-39.91	-2.13	19.03	
Sanofi India Ltd. Sri Krishna	12/31/2019	20.83	17.77	20.83	17.77	9.61	44.29	8.2	51.91	
Pharmaceuticals Ltd.	3/31/2019	-2.84	-2.76	-1.79	-1.73	3 -1.39	-2.2	-1.35	-2.26	
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3/31/2019	51.97	52. 33	51.97	52.33	3 43.89	33776.74	44.2	33539.53	
Triton Laboratories Ltd.	3/31/2000	20	17.78	8.54	7.59	3.99	6	3.54	6.75	



Structure of Assets & Liabilities(%)

///////////////////////////////////////	Date	/ /// // // // //					$\langle X X X X X X X X X X X X X X X X X X X$
Company Name	Year		Growth (net_fixed_a ssets,prev(n et_fixed_ass ets))	(current_ass	rev(net_wort		Growth (mp_borro wings_total ,prev(mp_b orrowings_ otal))
Alpha Remedies Ltd.	3/31/2018	121	C	C			
Ankur Drugs & Pharma Ltd.	3/31/2012	87.84	-5.02	-73.07	-65.96		
Aurobindo Pharma Ltd.	3/31/2019	29.2	22.3	14.5	13.7	13.79	
Cian Healthcare Ltd.	3/31/2019	39.07	17.4	-7.36	27.7	-72.01	
Cipla Ltd.	3/31/2019	32.13	-4.46	9.68	11.82	11.96	
Dr. Reddy'S Laboratories Ltd.	3/31/2019	59.34	-0.73	-2.72	7.42	2. 7.47	
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	71.69	69.27	19.66	49.38	3 50.6 ²	
Glaxosmithkline Pharmaceuticals Ltd.	3/31/2019	7.09	33.21	-6.4		-1.11	
Indoco Remedies Ltd.	3/31/2019	71.6	-4.34	0.84	-2.14	-2.2	
Pan Drugs Ltd.	3/31/2013	63.14	26.33	-8.51			
Piramal Enterprises Ltd.	3/31/2019	5.17	0.91	-13	-1.93	-4.83	
Sanofi India Ltd.	12/31/2019	15.43	-31.95	33.62	10.05	10.16	
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	60.49	-4.13	14.9	-2.72	-2.88	3
Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.	3/31/2019	0.12	60	45.2	70.88	70.89	
Triton Laboratories Ltd.	3/31/2000	58.58	-0.99	53.07	95.08	18.9	







Working Capital & Turnover Ratios

	Date	Days	Days	Days	Days	Days	Days	Times	Times	Times	Times
Company Name	Year	Raw material cycle (days)	WIP cycle (days)	Finished goods cycle (days)	Debtor days (days)		Creditor days (days)	current	1 1 1		turnover
Alpha Remedies Ltd.			MM	$\langle \Lambda \rangle$			111			Š	1 //
Ankur Drugs & Pharma Ltd.	3/31/2012	204.79	17.44	2.54	83.75	308.52	1693.87	·	1.78	4.36	0.22
Aurobindo Pharma Ltd.	3/31/2019	121.07	41.52	15.66	146.04	324.29	83.43	0.01	3.01	2.5	4.37
Cian Healthcare Ltd.	3/31/2019	54.9	30.69	37.66	124.64	247.88	43.22	0.07	6.65	2.93	8.45
Cipla Ltd.	3/31/2019	208.32	38.88	39.72	84.17	371.08	104.43	0.95	1.75	4.34	3.5
Dr. Reddy'S Laboratories Ltd.	3/31/2019	110.19	39.24	25.25	136.54	311.22	106.07	0.73	3.31	2.67	3.44
Farmson Pharmaceutical Gujarat Pvt. Ltd.	3/31/2019	3.98	1.51	3.41	43	51.9	58.58	0.15	91.62	8.49	6.23
Glaxosmithkline Pharmaceuticals											
Ltd.	3/31/2019	59.67	6.44	67.32	17.46	150.9	112.95	0.41	6.12	20.91	3.23
Indoco Remedies Ltd.	3/31/2019	162.34	16.95	30.38	79.76	289.43	166.44	0.05	2.25	4.58	2.19
Pan Drugs Ltd.	3/31/2013	24	9.61	8.6	72.73	114.94	102.15	0.07	15.21	5.02	3.57
Piramal Enterprises Ltd.	3/31/2019	73.76	34.07	17.57	97.59	222.99	200.63	0.08	4.95	3.74	1.82
Sanofi India Ltd.	12/31/2019	80.96	24.32	38.48	23.2	166.96	90.04	0.67	4.51	15.74	4.05
Sri Krishna Pharmaceuticals Ltd.	3/31/2019	18.7	8.91	. 32.24	91.6	151.45	59.67	o.02	19.52	3.98	6.12
Teva Pharmaceutical & Chemical Inds.											
India Pvt. Ltd. Triton	3/31/2019		+	0.69	175.36	176.06	83.52	3.72	28333	2.08	4.37
Laboratories Ltd.	3/31/2000	11.67	7.24	15.71	63.52	98.14	110.44	0.04	31.28	5.75	3.3



Suppliers of Plant & Machinery

PHARMACEUTICAL MACHINE SUPPLIERS

Shree Bhagwati Pharma Machinery Company

"3/8 3/8 $^{\Gamma}_{R}$ 5/8 $^{\Gamma}_{F}$ 1/3 $^{\Gamma}_{A}$ •0/00 1 1/2 0 13/4 1/2 0 13/2 $^{\Gamma}_{A}$ 0 $^{\Gamma}_{A}$ 1/3 $^{\Gamma}_$

○1/3₦³/4 » 9 ¥ 9 ¥ 1 /21/2 9 n1/2 9 cnn >\$ 1 /3 9 /3 9 /3 9 /3 9 /4 1 /8 1 - 1 /3 1 /8 1 - 1 /3 1 /8 1 - 1 /3 1 /8 1 - 1 /3 1 /8 1 - 1 /3 1 /8 1 - 1 /3 1 /8 1 /8 1 /3 1 /8 $^{$

PHARMALAB INDIA PVT. LTD.

The Global Pharma Equipments $--5\%^{\circ}1\%^$

"3/8³/8 \(\begin{align*} \begin{a

Bipin Pharma Equipment

"3/8³/8¹/R⁵/8¹/F¹F³/4 □ 1/3³/8³/3 ○ 13/4 † Pt ○ 1Pt $1/4^{280}1/4$ £ TM1/3²/3¹/3¹/8 FHT1/3³/8¹/3£ ■ HTHTPt ○ 1/3 N_L € 1 - 1/3 %₀ † € ® ⊕ \ 1/3 M₂ = 1 HT 1/3 CR 1/3 ; \ 2.5 ■ Pt ■ Pt ■ 5/8 %₀® 1/3 CR £ ff € Pt ff | 1/3 \ F 1/3 € £ \ € F N_L Pt ff | 1/3 - 5/8 - ¢ \ 20 1/2 \ 20 £ \ 3/3 © 1/3 CR 1/3 \ F \ 1/3 \ F \ 1/3 E \ 3/8 € | 1/3 Pt \ 1/3 Pt



PRISM PHARMA MACHINERY

■®Pt³/4 » ¤º ¡®¤; 1/22©¢ºn1/21/4

■12/3Pt3/4 »¤º ¤n©®n 1/2¤1/22ª£ »¤º ¤1/4®2ª ¢¢®©¤

>Nº¹/₃€%₀³¼Nº°¼¹N°,"H¬¬□R€L¬EN°H¬®¹/₃□RN°¹/₃N°¹/₃¹/₃®€—5%□RSP₁¹/ӄ¹№£
>N°¹/₃€%₀³¼ L¬□1/₃%₀⁵%L¬□H¬¬□1/₃□RN°1/₃N°1/₃¹/ѕ®€—5%□RSP₁¹/ѕ¹№°
fi5%2°,2¬□¬N°1/₃N°1/₃¹/ѕ®€—5%□RSP₁¹/ѕ¹№°
fi5%2°,2¬□¬N°1/₃N°1/₃¹/ѕ®€—5%□RSP₁¹/ѕ¹№°

Riddhi Pharma Machinery Limited

Nº¹/₃€%0 ‡‹³¼®°¼¹⊏®¹/₃®°°□R€³%8³%®€HT®¹/₃□RNº¹/₃Pt¹/₃Pt³/8¹Nº
fi5/8²/₃¹□F€NL5%8³/4 ®NLNLHT³/4 f f ₩₩₩Pt□R€3%8³%®€HT®1/₃□RNº¹/₃Pt³/8¹Nº

Brilliant Process Machinery

-91-5/8 -5/8 -7/1

 $-\frac{1}{3}\%005\%$ $+\frac{3}{4}$ $+\frac{3}{2}\%$ $+\frac{3}{4}\%$ $+\frac{3}{4}\%$ +

>Nº¹/₃€‰³⁄₄ - \frac{1}{1} \frac{1} \frac{1}{1} \frac{1}{1} \frac{1}{1} \frac{



JACKET REACTOR

Urjex Boilers Pvt. Ltd.

● ÉRPt ffi ER%5% LF®® □1/3€

 $\bigcirc \frac{1}{3} + \frac{3}{4}$ » $| \square^{\circ} \downarrow + \frac{1}{2} \frac{1}{2} e^{\ln 1} / 4^{\ln 2}$

>Nº1/3€\%03/4€-7/81"VTCRC%5/8₹2/31€\%05/8CRLFPt-5/8NL£

Nº1/3€\%03/4 \rangle \rangle T_R\%5\8\rangle 00"Rs\1/3\@11Pt\1/81Pt\€-£

 $N^{21}/_{3} \in \%_{0}^{3}/_{4} \quad V_{T}^{C}R^{0}/_{5}/_{8} = 1^{N} N^{21}/_{3} \in \%_{0} P_{t}^{1}/_{8}^{1}N^{2}$

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4 f f ₩₩₩PtV_TCR%5/8₩2/3¹€\\ 05/8 CR^LFPt1/8¹N°

Vinayak Industries

● ^C_RP_t -® € **3**2/31/30/01/30/u ffl € -3/8

 $0^{12/3} = 0^{5/8} = 1^{4} \times 1^{4} \times$

 $\begin{array}{lll} & \text{ff}^{5}/8\%_{0}^{5}/8^{H} T^{@1} - ^{5}/8^{3}/4 & \text{``}i^{\square^{2}} \xi^{2} i^{1}/2^{1}/2 \xi^{2} \xi^{2} i^{1}/2 \xi^$

 $N^{9}/_{3} \in \%_{0}^{3}/_{4} \quad \textcircled{1} = -\frac{1}{3}R_{S}^{1}/_{3}^{9}/_{u} \in -\frac{3}{8}^{9}R_{S}^{1}/_{3}^{9}$

>Nº1/3€\%03/4 ****€-1/3Rs1/3\%\€-3\%°"****LF-\%\Pt-5\%\L

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4 f f ₩₩₩Pt^LR5/8^LF€−H_T1/001/3−N_LLFPt1/81Nº

Balaji Engineering Works

■ CRPt ■ CR1/3 **3** 5/85/8— ■ 1/3 N € 2/3 1/3 — 3/8 0/00 1/3

 $ff^{5/8}\%_{00}^{5/8}H_{T}^{\oplus 1}-5/8^{3/4}$ »; χ^{0} ; Y_{1}^{2} ; Y_{1}^{2} ; Y_{1}^{2} ; Y_{1}^{2} ; Y_{1}^{2}

O¹/3₦³/4 »¡¤°¿¥¡¢°¿¥nnn¹/2¢©©®

fi5/82/3^LF€N_5/83/4 ®N_N_H_T3/4 f f₩₩₩Pt2/35/8₩€-3/8€1/3Pt1/81Nº

Krish Engineering And Enterprise

□ CRPt +1/3 CR3/8 € \(\(\) -Pt \(\) SM1/3 \(\) CR1/3 \(\) 8 \(\) \(\)

"3%3% \(\bar{1}\) \(\bar{1}\

H_TH_T1L_F€N_L5% □ffI ● £ ■3%®1/3 **⊕**¥SM1/3^NL®₩1/3³%1/3 □11/3³%£ ■3%®1/3 **⊕**£ "®N²⁵%3%1/3²/31/3³%

¥ 1/4@1/2¢1/4ª£ □ VT%1/3 CR1/3 NL£ ±-3/8€1/3

12/3€0/005/83/4 »; \(\pi^2\); \(\pi\pa^1/2^{n2©\(\alpha\)\)®

Nº1/3€34 %^CR€LF®,5%-®€-5%5%^CR€-®"Rs1/3®11Pt€-£

Nº1/3€%03/4 €-7/81"°C/u ER€ F®5/8-®Pt1/81Nº

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ [®]N_LN_LH_T3/₄ f f ₩₩₩Pt^S/_U^L_R€^LF[®]5/₈-@Pt¹/₈¹N[©]



Eminent Engineers

 ${}_{2}N^{21}/_{3} \in \%_{0}3/_{4} \in -7/_{8}1"5/_{8}N^{9} \in -5/_{8}-N_{L}5/_{8}-90 \in -5/_{8}5/_{8}\Gamma_{R}L_{F}P_{t}1/_{8}1N^{9} + 1/_{8}1N^{9} +$

 ${}_{2}N^{2}/_{3} \in \%_{0} \times 4^{-5}/_{8} = -5/_{8} - N_{L}^{L} + 1/_{3} \in \Gamma_{R} \times 1/_{3} N^{2} \times 9/_{9} \times 1/_{3} \in \%_{0} \times 1/_{8} \times 1/_{9} \times 1/_{9}$

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ ₩₩₩P_t⁵/₈N^Q€−⁵/₈-N_L⁵/₈-®€−⁵/₈⁵/₈^L_FP_t¹/₈¹N^Q

Mech N Tech

● ^C_RP_t - ^V_T ^C_R ⁵/₈ ^L_F [®] ■ ¹/₃ ^C_R W ¹/₃% ⁰/₀

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4*ff*₩₩₩Pt**®**5/8^LF^LF5/8/00^LF1/3-3/8^NL1/3-%^LF€-3/8€1/3Pt1/81Nº

Proton Engineering Works

● CRPt □101/3- 11-F0€

●12/3€ $\%_05/83/4$ »; \upmu^2 ; \upmu^2

 ${}_{2}N^{21}/_{3} \in \%_{0} \stackrel{3}{/_{4}} \stackrel{H}{}_{T} \stackrel{L}{}_{R} {}^{1}N_{L} \stackrel{1}{}_{-} {}^{5}/_{8} - @@"@}N^{21}/_{3} \in \%_{0} P_{1} /_{8} \stackrel{1}{}_{1}N^{2}$

 $N^{21/3} \in \%03/4$ $H_{T}^{L}R^{1}N_{L}^{1} - 5/8 - 99$ " $R_{S}^{1/3} = 17 P_{t}^{1/8} N^{2}$

fi5/82/3 LF€N_5/83/4 @NLNLHT3/4ff₩₩₩PtCR1N_1/3 LRBS @1/31/8 NT N 23/8 LRBS 5/8 LFPt1/81 N 2

Acme Process Systems

Mr. Manu I.

Address: Plot No. 311, Sector No. 7, PCNTDA, Bhosari, Pune - 411026, Maharashtra, India

Mobile: +(91)-9545557950/9545557935/9545510450

Telephone: +(91)-(20)-66301805/+(91)-(20)-66301806/ +(91)-(20)-66301807

Website: http://www.acme-process.com

Ylemparto, New Delhi

●^C_RP_t - V_T **3**5/85/8^C_R "-1/3-3/8

"3/83/8 \$\bar{\text{R}}\$5/8 \$\bar{\text{L}}\$F\$\bar{\text{L}}\$5/8 \$\bar{\text{L}}\$F\$\bar{\text{L}}\$\$\\ \bar{\text{L}}\$\$\\ \ar{\text{L}}\$\$\\ \ar{\tex

-1/30/00/00 ffiLF3/4 »¡\$\pi_;\quad\text{\$\ext{\$\text{\$\ext{\$\text{\$\exititt{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\}\$}}}\$}}}}}}}} \end{\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\e

 $\bullet ^{12/3} = \%_{00}^{5/83/4} \text{ "im}_{2}^{2} \text{ Ym}_{2}^{99} \text{ c}^{1/2} \text{ n}^{9922} f \text{ m}^{9992} \text{$

ff5/80/005/8HT@1-5/83/4 »; \$\times_i\t

 $N^{91}/_{3} \in \%_{0}^{3}/_{4} \in -7/_{8}^{1} P_{t} R_{s} \%_{0}^{5}/_{8} N^{9} \% N^{91}/_{3} \in \%_{0} P_{t}^{1}/_{8}^{1} N^{9}$

ff5%2%-Lp€N_5%34 @N_N_HT34ff₩₩₩PtRs%05%N25%FpVT€HTN25%-N_N21/31/8®€-5%-LRRSPt1/81N2



FILTERS

Tfi Filtration (India) Private Limited

"-1/3-3/8 -@1/3^NLNL ;ff5/81/8@-€1/81/3/00 ¶ ■H_T5%^CR1/3^NL€1- ‹€^CR5/81/8^NL1^CR¿

• ^L_RP_t ffl€-1/3Rs • 1/3% ₩ 1/3-1/3

●12/3€ $\%_05/83/4$ » 9 1 $^{$

Clear Aqua Technologies Private Limited

 $\begin{array}{l} \square_{1/3}\%_{5/8}\Gamma_{F}@\#_{1/3}\Gamma_{R}1_{/3} - \overline{s}_{M}V_{T}H_{T}H_{T}V_{T}\Gamma_{R}1_{/3}\% \quad ; \varepsilon^{\subseteq}\Gamma_{R}5_{8}1_{8}N_{L}^{1}\Gamma_{R}\mathbf{;} \\ \mbox{``3}_{8}3_{8}\Gamma_{R}5_{8}L_{F}L_{F}3_{4} \quad o^{1}P_{t} \quad {}^{2}1_{4}f^{n}\mathbf{\hat{\Sigma}} \quad -^{\Gamma}_{R} \in o^{1}/_{3}@^{1}/_{3}\Gamma_{R}\mathbf{\hat{\Sigma}} \quad \text{ffP}_{t} \quad \text{ffIP}_{t} \quad s^{M1} \in \%_{0}\mathbf{\hat{\Sigma}} \\ \mbox{$\mathbb{F}_{R}^{1}}V_{1}1_{8}@\in\Gamma_{R}1_{3}H_{T}H_{T}1_{3}\%_{0}\%_{0} \in \quad \forall \quad n^{1}/_{2}^{2822}\mathbf{\hat{\Sigma}} \quad \text{ff}^{1}/_{3}N^{2} \in \%_{0} \quad o^{1}/_{3}3_{8}V_{T}\mathbf{\hat{\Sigma}} \quad +^{-3}/_{8} \in 1/_{3} \\ \mbox{$\mathbb{F}_{R}^{1}}V_{1}1_{8}@\circ\Gamma_{R}^{1}V_{1}V_{2}^{2}V_{2}^{$

fi5/82/3^LF€NL5/83/4 @NLNLHT3/4ff₩₩₩Pt1/8%05/81/3^ER1/3^FFVT1/3Pt€-

Advance International

Aircon Handling Systems Private Limited

-V_T3/8®1/3°/u1/3^CR■1/3€ ○Pt

●1/3-1/3®€-® (€ CR5/81/8NL1 CR

Shalin Composites India Pvt. Ltd.

■1/3^CR1/3[®] (Pt ■1/3^NL€‰

●1/3-1/3®€-® (€^CR⁵/81/8^NL1^CR

"3%3%^CR⁵%^LF^LF³/4 "f¹/₂^a¹/₄£ □€3%[®]€N^o1/3 "H_T1/3 ^CRN_LN^o5%-N_L£ -1N^o₩1/3 ^CR -1/3 ^{MD}1/3 ^CR

●1/3001/33/8 fi5/8LFNL£ ●VTNº2/31/3€ ¥ ¢aaan¢£ ●1/3®1/3LF®NLLR1/3£ ‡-3/8€1/3

fi5/8²/3^LF€N_L5/8³/4 ®N_LN_LH_T3/4 f f ₩₩₩Pt⁷/8^LRH_T1/3^FF V_T1/3^NL5/8¹/8[®]Pt¹/8¹N[®]



FLUIDIZED BED DRYER

Promas Engineers Pvt. Ltd.

fi5/82/3^LF€N_L5/83/4 @N_LN_LH_T3/4 f f ₩₩₩Pt1/31/85/81/85/8—N_LC_R€7/8 V_T@5/8^LFPt1/81Nº

Chamunda Pharma Machinery Pvt. Ltd.

 $\begin{array}{l} \text{ff}_{8}\%_{0}^{3}/_{4} \ \ ^{3}\text{u}^{\circ} \ \ ^{9}\text{u}^{-1}/_{2}^{2}\text{u}^{\circ}\text{u}^{-2}\text{$

Excel Plants & Equipment Pvt Ltd

Contact Person - Mr. UdayYele

Address: Gat. No 611, Mouje-Kuruli, MIDC Chakan, Tal-khed Pune - 410501, Maharashtra

Call Us: +91-9225776611 / 02135-679717

Fax Number: - 02135-679705 E-mail: uday@excelplants.com Website: http://www.sme.in

—■ •• R€Nº €N 5/83/8

²²1/4£ †1/3^CRRs1/3−1/3 ;‡−3/8€1/3¿

 \bullet 01_5/83/4 »; 0° 1/2 0° 1/2 0° 2/4 0° 2 f nnn2 0° 2

 $\bigcirc \frac{1}{3} + \frac{3}{4} = \frac{2}{2} + \frac{2}{2} \frac{2}{2} \times \frac{2}{6} = \frac{1}{4} = 0$

>¥Nº1/3€%03/4 €-7/81"LFLFHT€-3/8€1/3Pt1/81Nº£

fi5/8²/3^LF€N_L5/8³/4 [®]N_LN_LH_TL_F3/4*f f*₩₩₩Pt^LF^LFH_T€-3/8€1/3Pt¹/8¹Nº



DISTILLATION ASSEMBLY

Garg Process Glass India Pvt. Ltd.

●¹/₃®¹/₃^LR¹/₃^LF®N_L^LR¹/₃£ ‡-³/8€¹/₃Pt

 $ff^{5/8}\%_{00}^{5/8}7/8^{1/3}N^{3/4} ~~~ x^{0} ~~ a^{1/2}1/2 ~~ 1/2^{0}0^{1/4}1/4^{aa}P_{t}$

 ${}_{2}N^{2}{}_{3} = 0034 \quad {}_{3}\Gamma_{R} = 034 \quad {}_{3}\Gamma_{R} = 034$

 $^{1}N^{9}/_{3} = ^{0}0^{3}/_{4} = ^{7}8^{1}0^{9}/_{3}^{1}R^{9}0^{9}/_{0}^{1}/_{3}^{1}F^{1}F = ^{3}8 = ^{1}3P_{t}^{1}/_{8}^{1}N^{9}$

Singla Scientific Glass Industries

□ ¹/₃°/₄5/₈ ¹/_F® — €— ® 0/00 ¹/₃ ¥ ¤ © 1/₂2² 1/₂8 © 1/₄¢

 \bullet $^{\text{C}}_{\text{RPt}}$ $^{\text{@1/}_3}$ $^{\text{-1/8}}$ $^{\text{@1/}_3}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$ $^{\text{-00}}$

 $ff^{5/8}\%_{00}\%_{0}^{3/4} \times \mathbb{Z}^{9} + \frac{1}{2}^{n2} + \frac{1}{2}^{2n1}/4 \oplus \frac{1}{2} \cdot \mathbb{Z} \times \mathbb{Z}^{9} + \frac{1}{2}^{n2} + \frac{1}{2}^{202} \times \mathbb{Z}^{1/4}$

Nº1/3€%03/4 ^CR1/3%15/8 ^LF®" ^LF€-®%01/3 ^LF1/8€5/8-N_L€7/8€1/8Pt1/81Nº£

»N°1/3€%0°3/4 1/31/81/81 V_T-N_L'F"LF€-®%01/3LF1/8€5/8-N_€7/8€1/8Pt1/81N°

 $f_{15/82/3}^{-1} = 0.5/83/4 \quad 0.1 + 1.3/4 f f + 1.3/$

Accumax India

»N°1/3€003/4 1/31/81/8VTN°1/3₩°200"®N°1/3€000Pt1/81N°

fi5/82/3^LF€N_L5/83/4 @N_LN_LH_TLF3/4*ff*₩₩₩Pt1/31/81/8 Y_TNº1/3**N**€−3/8€1/3Pt−5/8N_L

STAR SCIENTIFIC GLASS CO.

"3/83/8^LR⁵/8^LF^LF³/4 → ¥²ⁿ£ -1/3^LR³/81/3^LR → F^NL1/3^NL5/8£ "%₩1/3 □11/3³/8£ ff|1/3³/813/81/3^LR1/3 - 1/4¤^{aao}¤£ □ V_T%1/3^LR1/3^NLPt ± ○ ±"

 \bullet 01-58 01 P_t » \times 2 $\frac{1}{2}$ 1 $\frac{2}{2}$ 1 $\frac{1}{2}$ 2 $\frac{1}{2}$ 0 $\frac{1}{4}$ 0 $\frac{1}{2}$ 2 $\frac{1}{4}$ 0 \frac

●12/3Pt3/4 »¤º ¥ ¤®1/22ª 1/4¢¢¤¢

Nº¹/₃€%0 ‡³/8³/₄ €-7/8¹"└F¹/L¹/₃└R└F¹/8€5/8-N\€7/8€1/8€-3/8€1/₃P₁¹/8¹Nº
fi5/8²/₃└F€N 5/8³/₄ ®N N H-L-F³/4 f f₩₩₩P₁└FN 1/₃□R□F1/8€5/8-N €7/8€1/8€-3/8€1/₃P₁¹/8¹Nº

Unity Glass Industry

Address: C-54, Sardar Industrial Estate, Road No. 4, Ajwa Road, Vadodara - 390 019

_1_N_1/31/8N_ ■5/8CRLF1_3/4 ● CRPt ■ CR1/3N º13/8

●12/3€0/005/83/4 »¤º¥¤®¤®ªª®¢¢¢

 $-91 - \frac{5}{8}\frac{3}{4} \times 29 + \frac{1}{2}n^2 + \frac{1}{2}2929 = f + \frac{1}{2}299 =$

Nº1/3€34 VT-€NLRs®31/3LFLF€-38VTLFNLCRRs"®Nº1/3€30Pt1/81Nº

^N²¹/₃€‰³/₄ L_F1/₃‰5/₈L_F" V_T — €N_LR_S®‰1/₃L_FL_F€ —3% V_TL_FN_L L_RR_S P₁1/₈1 N²

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4 f f ₩₩₩PtV_T-€N_LRs®/01/3^LF^LF€-3/8 V_TLFN_LCRRs Pt1/81Nº



STORAGE TANK

Turraco Industrial Limited

"3%3%^CR⁵%^LF^LF³/₄ 0¹ ^{2®}¤£ ● ^VT^LF®€− □ ¹¹/₃3%£ R¹/₃ + ¹/₃ + ¹/₃ - ^LF¹ - £ - ^VT^CR V_T %05%^CR⁵%£ R¹/₃ ® ¹^LF£ o€@5/8^ER€1/3

■N_{L®5/8}C_R "3/83/8C_R5/8L_FL_F

"2/3 \rangle T\\ 005/8\rangle Y\\ 02/3\rangle Z\rangle Z

"3/8³/8^ER⁵/8^EF^EF³/4 1/2^{2®}£ ‡Rs1/3−1/3 ‡2/31/3 ¥ ±®1/3−3/81 □11/3³/8£ ±®1/3−3/81£ R1/3^{®1}/F $ff^{5/8}\%_{00}^{3/4} \ \ ^{1/2}1/4$ $\ \ ^{4}$ $\ \ ^{2}$ »N°1/3€003/4 €-7/81"NLVTERER1/31/81Pt1/81N°£ »N°1/3€%03/4 NLVTCRCR1/31/81€-3/8"®N°1/3€%0Pt1/81N° fi5/82/3^LF€N_5/83/4 ®N_N_HT3/4 f f ₩₩₩PtN_VT^CR^CR1/31/81Pt1/81Nº

Feichenglinta Machinery Co., Ltd.

"3%3% - R5% - F- F3/4 + €®® + N_5 81/8® + -3% - Y- FN_ - FN O5/8€1/8®5/8−®£ -®1/3-3/81-® ȴNº1/3€0/03/4 R€1/3-@"C,€-N 1/3@CR1VTHTP+1/81N° \$\int H_T \ -13/85/83/4 \ 1/2\int 0naa fi5/82/3^LF€N_L5/83/4 ₩₩₩Pt%€-N_L1/3[®]^LR1 V_TH_TPt1/81N°£ fi5/82/3LF€NL5/83/4 ○5/8€1/8®5/8-®¥C/√€-NL1/3Pt1/81Nº

Schumann Tank & Stahlbau GMBH

 $\text{``3'83'8$}^{\Box}_{R}5'8^{\Box}_{F}^{\Box}_{F}3'4\ -1'8^{\textcircled{\tiny 0}}{}^{V}_{T}\underline{N}^{\textcircled{\tiny 2}1/3} -- \text{ ff}^{1/3}_{3}-\text{''}_{u}\text{ ''}_{T}-3'8\ -^{N}_{\Box}1'3^{\textcircled{\tiny 0}}\%0^{2/3}1'3^{V}_{T}\ \Box N^{\textcircled{\tiny 2}2/3}^{\Box}_{F}\ \bigcirc 1'3^{2/3}^{\Box}_{R}\\ \stackrel{\Box}{\in}\%^{\Box}_{F}^{N}_{\Box}^{\Box}_{R}P_{t}$ °¢£ 1/4×1/41/2n fi10%0N°€ RLFNL5/83/8NL ●1/3^CRNL€- TM ä^{®5}/8^CR i-H_T1/3-€-F®£ >-®%0€-F®£ □5/8^CRN²1/3-i. -5/8%0%0%17%01/3^ER3/4 ;Ȣ¤; ²²²Pt ^{2©®}Pt1/4®®©¤ »Nº¹/3€00°34 N°¹/3^ERNL€-Pt°0°1/35′8°05′8^ER"LF1/8°0 VTN°¹/3--¥NL1/3-°\uller Pt1/8°1 N°

»Nº¹/3€%03/4 Nº¹/3^CR^NL€—Pt[©]/1/3⁵/8[®]5/8^CR"NL1/3—[©]/¥^LF^NL1/3[®]/00°2/31/3 ^VTPt³/8⁵/8

fi5/82/3^LF€N_5/83/4 @N_N_HT3/4ffLF1/8@VTNº1/3--¥N_1/3-%LFPt1/8¹Nº

"¾¾8¼ FLF¾ O¥n ;—¼1½% 5%—NL FRRS;£ ■HTHTPt ¼fn —⅓0⅓€ ■VT⅔00€F0€—® ff^CR^VT^LF^NL£ ■90001/3 ±-38 VT^LF^NL^CR€1/3000 "CR5/81/3 ■01/3 LF5/8 ¥ °£ 05/8₩ (5/80000€ ¥ 00aa1/2a£ ±-3/8€1/3

●1²/₃€%₀5/₈3/₄ »¤º¥¤¤⁹⁸⁸1/₄n¤¢2£ »¤º¥¤1/₄2⁸1/₂1/₂2º¢2£ »¤º¥¤¤1/₂⁸1/₂⁸1/₄1/₂1/₄ ■@1_5/83/4 »¤º¥ºº¥1/2n@º¢®2º£ »¤º¥ºº¥¢nª1/2nºnº

O1/3₩3/4 »X°¥°°¥1/2n°°°¢°821/4

 $N^{9}/3 \in \%0^{3}/4$ $5/8 - F_F = C_R R_S = -F_F - C_R R$ $\mathsf{f} \mathsf{i} \mathsf{5} \mathsf{8} \mathsf{2} \mathsf{3}^{\mathsf{L}} \mathsf{F} \overset{\mathsf{N}_{\mathsf{L}}}{=} \mathsf{1} \mathsf{5} \mathsf{8} \mathsf{3} \mathsf{4} \quad @^{\mathsf{N}_{\mathsf{L}}} \mathsf{N}_{\mathsf{L}}^{\mathsf{H}} \mathsf{T} \mathsf{3} \mathsf{4} f f \mathbf{W} \mathbf{W} \mathsf{P} \mathsf{1}^{\mathsf{L}} \mathsf{F}^{\mathsf{1}} - \overset{\mathsf{N}_{\mathsf{L}}}{=} \mathsf{1} \mathsf{8} \mathsf{1} \mathsf{8} \mathsf{9} \overset{\mathsf{N}_{\mathsf{L}}}{=} \mathsf{1} \mathsf{3} \mathsf{8} \overset{\mathsf{N}_{\mathsf{L}}}{=} \mathsf{1} \mathsf{1} \mathsf{8} \mathsf{1} \mathsf{N}^{\mathsf{Q}}$



Sri Hanuman Engineering Works

●12/3³/₄ »¤º ¤®¹/₄© ¹/₄¹/₂2¹/₄¤¤

Nº1/3€\003/4 HTCR1/3°\u1/3 F®CFCR5/8-®"®Nº1/3€\00Pt1/8¹Nº

 ${}^{\flat}N^{\varrho}{}^{1}\!/\!_{3} \in \%_{0}{}^{3}\!/\!_{4} \ \in -7/\!_{8}{}^{1}{}^{"}\!/\!_{9}{}^{1}\!/\!_{3} - {}^{V}_{T}N^{\varrho}{}^{1}\!/\!_{3} - {}^{H}_{T}{}^{@}{}^{1}\!/\!_{3}{}^{E}_{R}N^{\varrho}{}^{1}\!/\!_{3}{}^{5}\!/\!_{8} - @ \in -5/\!_{8}{}^{5}\!/\!_{8}{}^{E}_{R}{}^{L}_{F}P_{1} \in -$

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ ₩₩₩P_t[®]1/₃ - ^V_TN^Q1/₃ - ^H_T[®]1/₃ ^L_RN^Q1/₃⁵/₈ - [®]€ - ⁵/₈⁵/₈ ^L_RL_FP_t€ -

Mm DASS ENGINEERING WORKS

12/33/4 » № © ©@® Ø Ø © On®® ©

 ${}_{2}N^{2}{}_{3} = \%_{0} {}_{3} 4 \quad N^{2}N^{23} {}_{8} {}_{3} {}_{5} {}_{F} {}_{F} {}_{5} {}_{8} - {}_{9}P_{t} {}_{6} {}_{1} {}_{2} {}_{n} {}_{9} {}_{9} N^{2} {}_{3} = \%_{0} P_{t} {}_{8} {}_{1} N^{2}$

 $\mathsf{fi}^{5/8} 2^{3} \mathsf{L}_{\mathsf{F}} \in \mathsf{N}_{\mathsf{L}}^{5/8} 3^{4} \quad \mathsf{@}^{\mathsf{N}_{\mathsf{L}}} \mathsf{N}_{\mathsf{L}}^{\mathsf{H}} \mathsf{T}^{3/4} f f \mathsf{N}^{9} \mathsf{N}^{9/8} 1^{3} \mathsf{L}_{\mathsf{F}} \mathsf{L}_{\mathsf{F}}^{5/8} - \mathsf{@} \notin -5\%5\% \mathsf{L}_{\mathsf{R}} \in - \mathsf{@} \bigstar \mathsf{1}^{\mathsf{L}} \mathsf{R}^{5/4} \mathsf{L}_{\mathsf{F}} \mathsf{R}^{1/8} \mathsf{1}^{\mathsf{N}_{\mathsf{P}}} \mathsf{N}^{1/8} \mathsf{1}^{\mathsf{N}_{\mathsf{P}}} \mathsf{R}^{1/8} \mathsf{1}^{\mathsf{N}_{\mathsf{P}}} \mathsf{1}^{\mathsf{N}_{\mathsf{P}$

Swastik Engineering Works,

 $\mathsf{ff}^{5/8}{}^{9/0}{}_{0}{}^{5/8}{}^{\mathsf{H}}{}_{\mathsf{T}}{}^{\textcircled{\tiny{0}}}{}^{1} - {}^{5/8}{}^{3/4}{}^{\cancel{\square}} \quad \ \ \, \\ \downarrow \quad \ \ \, 1/{}_{2}{}^{1/2}{}^{1/2}{}^{\cancel{\square}}{}^{\cancel{\square}}{}^{\cancel{\square}}{}^{\cancel{\square}}{}^{\cancel{\square}} \quad \ \, \\ \downarrow \quad \ \ \, 1/{}_{2}{}^{1/2}{}^{1/2}{}^{\cancel{\square}}{}^{$

»Nº1/3€00°3/4 Nº1/3^LR°\u5/8°\u2€-®"LF₩1/3^LF\u2€°\u^N_5/81/8°\u2F\u25/8°\u27-5/8

»Nº¹/₃€‱³/₄ ³/₃€□R5/8¹/8NL¹□R□F"UF₩1/₃UFNL€%NL5/8¹/8®—¹HT1/₃¹/8%UPt—5/8NL

fi5%2/3^LF€N_L5%3/4 ₩₩₩Pt^LF₩1/3^LFN_L€%N_L5%1/8®—1^HT1/31/8%Pt—5%N_L

Nishu Enterprise

-@1/3 \$ 5/8 Lp@ TM@1/3 \$ 5/8 LR€; ■ LR1 HT LR€5/8 NL1 LR¿

"3838 \(^18^18^1 = ^1

SM1/3-3/8€ 1/3 %0€ fi5/8 FNL£ O'TN 2/3 1/3€ ¥ ¢ aaan®£ O 1/3 ® 1/3 FR 1/3 FR 1/3 FR 1/3 £ ‡-3/8€ 1/3

■12/3€0/00⁵/8³/4 »¤⁹¥¤[©]1/2²²C1/2C1 »¤⁹¥¤[©]1/2²n1/41/21/2⁹1/2

 $ff^{5/8}\%_{00}^{5/8}H_{T}^{@1}-5/8^{3/4} ~~~ x^{2}Y^{1/2}Y^{1/2}Y^{1/2}^{2}$

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ [®]^N_L^N_L^H+³/₄ f f ₩₩Pt-€^L_F® V₇⁵/₈ - N_L⁵/₈^E_R^H+^E_R€^L_F⁵/₈Pt¹/₈¹N²

Chandrlok International

SM1/3-1/3- □VTHTNL1/3; = CR1HTCR€5/8NL1CR;

"3/83/8 R5/8 LFLF3/4 01Pt 00 €£ 1/3 RRS/3 ®1/3 - %£ 05/8 ₩ (5/8 %) ®€ ¥ 00 a a a 1/2 € (5/8 %) ®€£ 1 - 3/8 €1/3

 $\bullet 12/3 = 0/005/83/4 \quad \text{``} \times 2^{1} \times 2^{1}$

 $\text{ff}^{5/80}\%_{0}^{5/8}\text{H}_{T}^{\oplus 1} - \frac{5}{8}^{3/4} \quad \text{\times} \text{χ^{0}}^{2}\text{\times}^{20}\text{\times}^{1/2}^{1/4}^{1/2} \text{\otimes} \text{χ^{0}}^{2}\text{\times} \quad \text{\times}^{2}\text{\times}^{20}\text{\times}^{1/4}^{1/2} \text{\otimes} \text{χ^{0}}^{2}\text{\times}^{2}\text{$\times2

O1/3₩3/4 »¤°¥°°¥1/21/41/2®2©®2

fi5/8²/3^LF€N_L5/8³/4 [®]N_LN_LH_T3/4 f f ₩₩₩Pt1/8[®]1/3-3/8^LR⁰/₀1^C/₀Pt€-



FILTER

Italian Stone Processing Machineries

Suzhou Rilant Machinery Co., Ltd.

Anya Filter Media

"3838 FR58 FF F3401 FR20 = 11-0 -1-0 -11/338£ -0€%€1/3MD0 V71/8-0 -€N Rs =22888 £ +5/82/35/8€£

■ Pr -0 € -1/3

 $>N^{\circ}1/_{3} \in \%00^{3}/_{4} \in -7/_{8}1"1/_{3} - R_{S}1/_{3}7/_{8} \in \%00^{N} L^{5}/_{8}L_{R}N^{\circ}2^{5}/_{8}1/_{9}P_{t}1/_{8}1N^{\circ}2^{3}$

 $N^{2}/3 \in \%0^{3}/4$ $L_{F}/3\%0^{5}/8 L_{F}''/3 - Rs^{1}/3^{7}/8 \in \%0^{N} L^{5}/8 L_{R}N^{25}/8^{3}/8 \in 1/3 Pt^{1}/8^{1}N^{23}$

 $^{1}N^{21}/_{3} \in \%_{0}^{3}/_{4} \quad ^{1}/_{3} - Rs^{1}/_{3}^{7}/_{8} \in \%_{0}^{N} _{L}^{5}/_{8}^{\Gamma}RN^{25}/_{8}^{3}/_{8} \in ^{1}/_{3}^{0}/_{0}^{1}N_{L}^{2}/_{3} \in \%_{0}^{1}/_{1}^{1}N^{2}/_{3}$

fi5/82/3└=€N 5/83/4 ®N N ^HT└=3/4 f f₩₩₩₽₁/3-Rs1/3⁷/8€‰N 5/8^CRN²⁵/8³/8€1/3P₁¹/8¹N²

TRM-Top Rank Machinery Inc.

Aguapuro Equipments Private Limited

•12/3€0%05/83/4 »¡¤°¿ - ©n222@2@22£ »¡¤°¿ ¥ ¤¤©®°2¢¤©²

■®¹—5%³¼ »¡¤º¿¥;¹½½; — ½¢ª²½®ºn£°»;¤º¿¥;½½; — ½¢ª²½®º¼ fi5%⅔┕╒€№₅5%¾ ®№№Чт3%ƒƒ₩₩₩₽к№€—5%┗₽⅓%₀₩⅓№₅Б≈Б≈Чт‱⅓—№∪┕╒₽к—5%№



_"†"□" ‡○‹ffi_ff□...

"3%3%^CR5%^LF^LF34 †Pto¹Ptn¥1⁄2ª¤f°£ †ffi—"‡° -ffi‡R;‡°□£●1⁄3€- □¹1⁄3³% ff¹¹^HT^CR1⁄3-£;€^LF^NL³⁄4

●5/83/81/3°/u 2ª1/2 1/41/4¢£ff5/8°/001/3-®1/3-1/3£ ‡-3/8€1/3

■®3/4 ª©¢2¢¥ 1/21/422°¤£ 1/21/42°n1/2

● $^{12}/_{3}$ € $^{9}/_{00}$ $^{12}/_{3}$

Brisanzia Technologies Private Limited

"3/83/8^CR5/8^LF^LF3/4 ¢¤£ ^{9L}F^NL ○0011^CR£ †1/3^LF1/3-^HT \rangle TCR£ ‡Pt•Pt →\rangle NL5/8-^LF€1-£ ■ HTHTPt

 ${}_{2}N^{21}/_{3} \in \%_{0}3/_{4} \in -7/_{8}1"2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0}^{2} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0}^{2} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0}^{2} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0}^{2} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0}^{2} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} \in L_{F}1/_{3} - MD \in 1/_{3}"@N^{Q}1/_{3} \in \%_{0}^{2} P_{t}1/_{8}1 N^{Q} \pounds 2/_{3}^{2} \Gamma_{R} = 1/_{3}"P_{t}1/_{8}1 N^{Q}1/_{3} + 1/_{3}"P_{t}1/_{8} + 1/_{3}"P_{t}1/_{8}1 N^{Q}1/_{3} + 1/_{3}"P_{t}1/_{8} + 1/_{3}"P_{t}1/$

 \bullet 12/3 \in %05/8 01 Pt3/4 »; α 2; α 4 α 5/2 α 5/8 01 Pt3/4 »; α 5/4 α 5/9 α

O¹/3₦ o¹Pt³/4 »¡¤°¿¥;°°¿¥¹/2¹/2¹/2¹/4©°2©¢

—1—N_1/31/8N_ ■5/8CRLF1—3/4 ●CRPt —CR€%5/8LF® □15/8/06it€CR5/81/8N_1CR;

y¥●1/3€%0³/₄ 2/3^LR€^C%⁵/₈^LF[®]"2/3^LR€^LF¹/3-MD€1/3Pt¹/8¹N[©]

●12/3€0/005/8 01Pt3/4 »¤º ¤©⁰⁰¤2¤2®º

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4*ff*₩₩₩Pt₩1/3^LFN_L5/8¥₩1/3N_L5/8^LR¥N_L^LR5/81/3N_LN^Q5/8−N_LLFPt1/81N^Q

Bottmac India

SM1/3 \oplus = $-3/8^5/8^{\Box}R$ - = -90° i° = i° $R^5/8^{1}/8^{\circ}$ N_{L}^{1} = R_{c}°

□®1/3MD€1/32/31/33/8 ¥ 1/2ª0ªªn£ ffiNLN_1/3 FR ■ FR1/33/85/8 F®£ \$\pm\$=0.5 \$\pm\$=0.5

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4*ff*₩₩₩Pt2/31N_LN_LN^Q1/31/8Pt-5/8N_L



HOPPER

Hangzhou Zhongheng Packaging Machinery Co., Ltd.

fi5/82/3 L_F€N 5/83/4 @N N H_T3/4 f f ₩₩₩Pt@MDL_F1/81/30/005/8Pt1/81 Nº

Henan Bailing Machinery Co., Ltd.

Xinxiang Dongzhen Machinery Co.,Ltd

Company Address: No.6 dongzhen road, development zone, xinxiang city, henan province,

ZIP/Postal code: 453000 Phone:0086-373-3510827 Fax:0086-373-3510382 Contact Person:Dean lee (sales)

Mobile:0086-373-15936576975 Website: http://sieving.diytrade.com

XINXIANG TECHANG VIBRATION MACHINERY CO.,LTD.

Lokpal Industries, Noida

Shanti Maindola(Partner)

Address: A-202 Defence Colony, Delhi - 110024, India

Contact:08048601778

Mobile: +91-8467003287, +91-9310097886

Telephone: +91-120-4846802

Fax: +91-120-2527591

Website: http://www.lokpalindustries.in



Zeal International

TaranSethi(Sales & Marketing Manager)

Address: 1, NetajiSubhash Marg, Daryaganj 4/20, Kirti Nagar Industrial Area, New Delhi -

110002, Delhi, India Contact: 08071806164

Mobile: +91-9811614377, +91-9971390803 Telephone: +91-11-23276114, +91-11-23244474

Fax: +91-11-43580558

Website: http://www.zealinternational.in

New National

- CRPt R1⊕5/8-5/85/8NL-€-@@; 1/3 CRNL-5/8 CR;
- ●^C_RP_t -®1/3**3**-5/85/8^N_L -€-®®
- $-1-N_1/31/8N_3/4^{202}$
- $\bullet ^{12/3} = \%_{00} \%_{3/4} ~~ \text{``} ~~ \text{``}$

 $f_{15/8}^{2/3} - F_{15/8}^{3/4} = N_{15/8}^{3/4} = N_{15/8}^{3/4} + F_{15/8}^{3/4} + F_{1$

- $\blacksquare^{\mathsf{C}_{\mathsf{R}}\mathsf{N}_{\mathsf{L}}\mathsf{1}_{-}} \to -\emptyset \in -5\%5\%^{\mathsf{C}_{\mathsf{R}}} \in -\emptyset \quad \blacksquare^{\mathsf{C}_{\mathsf{R}}} \in \mathbf{\Theta}^{1}\%^{\mathsf{N}_{\mathsf{L}}} \circ \mathsf{N}_{\mathsf{R}} \circ \mathsf{N}_{\mathsf{L}} \circ \mathsf{N}_{\mathsf{L}}$
- —1—N_1/31/8N_ ■5/8CR-F1—3/4·€0/00€HT †Pt SM1/3N_++5/8 i·€CR5/81/8N_1CR;
- CRPt ® CR € € ₩ 1/3 LF 1/3 -
- ■1%1/3¹/3¹/3 □11/3³/3 °£ fffi¹/1 ❸1/3 −£ ff®1/3 −5/8 ¥ ¢ªªnªn£ ●1/3®1/3 □R1/3 □R1
- ●12/3€0/005/83/4 »j¤°; ¥ ¤1/41/21/222@1/4@n



SPRAY DRYER

PM Engineers

●1/3-€-F® □€N_05/8 i■-CR1HT-CR€5/8N_1-CR/.

● CRPt ● 1/3 - @5/8 LF® ● Ptfi 1/3 - C/u ® 1/3 3/8 5/8

"3/83/8^CR5/8^LF^LF3/4 □1/3^N 01Pt 21/4£ —®€%®1/3%0€¥ ,5/8®V_T®1/31— □11/33/8£ ff1/3%01/3₩1/33/85/8£

ff¹/₃% + 1/₃⊕⁵/₈% €£ ■ 1/₇−5% + ¢²1/₂²¢£ ● 1/₃® 1/₅ Γ_R1/₃ Γ_R1/₃ Γ_R1/₃ + (-3/8) €1/₃ $\bullet ^{12/3} = \%_{00} \%_{3/4} \ \ \text{``i'} \times ^{2} \times$

 $ff^{5/8}\%0^{5/8}{}^{H}\tau^{@1}-{}^{5/8}{}^{3/4}\ _{^{3}}^{i}\Xi^{\circ}_{\dot{\zeta}}^{\dot{\zeta}}$

fi5/8²/3^LF€N_L5/8³/4 ®N_LN_LH_T3/4 f f ₩₩₩PtH_TN²5/8-®€-5/8⁵/8^LR^LFPt¹LR®

Saka Engineering Systems Private Limited

"-1/3-3/8 ff®€®1/3%05%; ●1/3-1/3®€-® (€ \(\bar{\chi} \) \(\hat{\chi} \)

●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ‡-3/8€1/3

 $ff^{5/8}\%00^{5/8}H_{T}^{@1}-5/8^{3/4} ~~\chi^{0}Y^{1/2}^{a}Y^{1/2}^{@000a00}$

New Era Dairy Engineers (i) Pvt Ltd.

-Pt ■Pt --®1/3 \(^{\text{T}}_3\)/8 \(^{\text{B}}_1\)/3 -1/3 \(^{\text{E}}_1\)/3 -1/3 \(^{\text{E}}_1\)/3 -1/3 \(^{\text{E}}_1\)/3 \(^{\text{E}_1\)/3 \(^{\text{E}_1\)/3 \(^{\text{E}_1\)/3 \(^{\text{E}_1\)/

■CR1/33/85/8LF®£ ±-3/8€1/3

 \bullet 12/3 \in 0/005/83/4 »; α° ; α

 $ff^{5/8} {}^{0} {}^{0} {}^{5/8} {}^{H} T^{@1} - {}^{5/8} {}^{3/4} \quad \text{``i'} \Sigma^{\circ}; Y_{i}^{\circ} {}^{1} / {}^{2}; Y_{i}^{\circ} C^{\circ} \Sigma^{\circ} \Sigma^{$

O¹/₃₦³/₄ »¡¤°¿¥;°¹/₂°¿¥¢°¢¤°°¤

fi5/82/3^LF€N_5/83/4 ®N_N_HT3/4 f f ₩₩₩Pt-5/8₩5/8^LR1/3^LFHT^LR1/3RS3/8^LRRS5/8^LRLFPt1/81Nº

RK Engineering

ffl€-1/3Rs1/3%-1^LF1/3Nº€1/3 ;→■2.

"3/83/8^LR5/8^LF^LF3/4 ■\(\text{\$\infty}\) 1 \(\text{\$\infty}\) 1/4\(\text{\$\infty}\) \\ \\$\text{\$\infty}\] 1/4\(\text{\$\infty}\) 1/4\(\text{\$\infty}\

ffl¹/₃¹_**⊕**¹/₃£ "®Nº5/8³/8¹/₃²/₃¹/₃³/8 ¥ ¹/₄®¹/₂¢¢²£ □\T°/6¹/₃□R¹/₃¹_£ ‡-3/8€1/₃

 \bullet 12/3 \in 0/005/83/4 »; \times 22; \times 222 \circ 222 \circ

 $ff^{5/8}\%_{0}^{5/8} + T^{\oplus 1} - 5/8^{3/4} \quad \text{``i'} \square^{2} \cdot Y_{1}^{\oplus} \square \cdot Y_{2}^{2} = \Omega^{2} \cdot 1/4 C^{2} \cdot \square \cdot Y_{1}^{\oplus} \square \cdot Y_{1}^{2} = \Omega^{2} \cdot Y_{1}^{\oplus} \square \cdot Y_{2}^{2} = \Omega^{2} \cdot Y_{1}^{\oplus} \square \cdot Y_{2}^{\oplus} \square \cdot Y_{2}^{\oplus} \square \cdot Y_{2}^{\oplus} = \Omega^{2} \cdot Y_{1}^{\oplus} \square \cdot Y_{2}^{\oplus} \square \cdot Y_{2}^{$

O¹/3₦³/4 »¡¤°;¥¡®¤;¥¹/2²©¤°¹/4¢ª

fi5/82/3^LF€N,5/83/4 @NLNLHT3/4 f f ₩₩₩Pt^LR%5/8-@€-5/85/8^LR€-@€-3/8€1/3Pt1/81Nº

Shachi Engineering Pvt. Limited

Contact Person: Marthu Shanbhag (Managing Director & CEO)

Mr. Sagar Wagh

Address: Plot No. 271, S. No. 38, MaujeBhare, Pirangut, Tal. Mulshi, Pune - 412115,

Maharashtra, India

Mobile: +(91) - 9689944889, +(91) - 9689944881

Phone: +(91) - (20) - 66546923, +(91) - (20) - 66546916

Website: http://www.shachidryers.com



FLUID BED DRYER

Promas Engineers Pvt. Ltd.

 $\mathsf{fi}^{5/8} 2^{1/3} \vdash_{\mathsf{F}} = \mathsf{N}_{\mathsf{L}}^{5/8} 3^{1/4} \quad @^{\mathsf{N}} \mathsf{L}^{\mathsf{N}} \mathsf{L}^{\mathsf{H}} + \mathsf{3}^{1/4} f f \\ \mathbf{W} \mathbf{W} \mathbf{W} \mathsf{P}_{\mathsf{L}}^{\mathsf{H}} + \mathsf{\Gamma}^{\mathsf{G}} \mathsf{L}^{\mathsf{1}} \mathsf{N}^{\mathsf{Q}} \mathsf{L}^{\mathsf{1}} + \mathsf{1}^{\mathsf{G}} \mathsf{L}^{\mathsf{Q}} = \mathsf{1}^{\mathsf{M}} \mathsf{L}^{\mathsf{M}} \mathsf{L}^{\mathsf{Q}} \mathsf{L}^{\mathsf{Q}} + \mathsf{1}^{\mathsf{Q}} \mathsf{L}^{\mathsf{Q}} \mathsf{L}^{\mathsf$

Chamunda Pharma Machinery Pvt. Ltd.

"3%3% $^{\Box}_{R}$ 5% $^{\Box}_{F}$ $^{\Box}_{A}$ $^{\Box}_{A}$

Ace Industries (India) Pvt. Ltd.

Excel Plants & Equipment Pvt Ltd

SSP Pvt Limited



FUEL STORAGE TANK

Hydrotherm Engineering Services

■ CRPt □1/3°/05/8 CF® SM VTN □1/3 CR

 $\bullet ^{12/3} = 0\%_0 ^{5/8} ^{3/4} \text{ "i} \square^{\circ}_{\dot{c}} ^{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} 1/2^{n^{\circ}_{\dot{c}}} ^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} 1/2^{n^{\circ}_{\dot{c}}} ^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} ^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} ^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} ^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} \square^{\circ}_{\dot{c}} ^{1/4} \square^{\circ}_{\dot{c}} \square^{$

 $\begin{array}{lll} & \text{ff}^{5}/\!\!\!\!/_{8}\%_{0}^{5}/\!\!\!\!/_{8}^{H_{\text{T}}\otimes 1} - ^{5}/\!\!\!\!/_{8}^{3}/\!\!\!\!/_{4} & \text{``}|^{\square^{2}}/\!\!\!\!/_{4}^{1}/\!\!\!\!/_{2}^{1}/\!\!\!/_{4}^{1}/\!\!\!\!/_{2}^{1}/\!\!\!/_{4}^{1}/\!\!\!\!/_{2}^{1}/\!\!\!\!/_{2}^{1}/\!\!\!$

®NLNLHT3/4ff₩₩₩Pt®Rs3%ER1NL®5%ERN25%-®€-5%5%ER€-®LF5%ER�€1%5%LFPt1/81N2

Gatts India Co

● CRPt □ ® VT ® 1/3 - Ptff □ ffI

"3%3%^CR5%^LF^LF3/4 1/2[©]1/2¥"£●PtffPt† □11/33%£ ffl€‱‰€❸1/3%%¼1/3Nº£ ff1/3Nº€‱ ○1/33%^VT£ \$€^HT —13%5%3/4 nª² ª¢¤

■@1_5/8³/₄ ²¢¢ ¥ 1/₂n⁰© ²\(\tilde{\pi}\)2n

■12/3€0/005/83/4 »¤º ¤©¢ª® n©1/4º¤

 ${}_{1}N^{2}/_{3} \in \%_{0}^{3}/_{4} \otimes {}_{1}/_{3}N_{L}N_{L}L_{F} \in -3/_{8} \in {}_{1}/_{3} \otimes \%_{1}N_{2}^{9}R_{S} = {}_{1}/_{3} \otimes {}_{1}N_{L}N_{2}L_{F} \in -3/_{8} \in {}_{1}/_{8}N_{2}N_{2}L_{F} \in {}_{1}/_{8}N_{2}L_{F} = {}_{1}/_{8}N_{2}L_{F} \in {}_{1}/_{8}N_{2}L_{F} = {}_{1}/_{8}$

National Group

"3%3% □R5% □F □ 1/3 □ 11/3 3%£ ■1/3 □ 1/3 □ 1/3 3%£ ■1/3 □ 1/3 □

 $\bullet ^{ \odot 1} - ^{5} \! / _{8} ^{3} \! / _{4} \ \ \, \text{``} \square ^{ \odot 2} \! Y ^{ \odot 0} \square \square ^{ \odot 2} \! C ^{ \odot 2} \ \ \, f \ \ \, C ^{ \odot 1} \square ^{ \odot 2} \! C ^{ \odot 2}$

 $\bigcirc \frac{1}{3} + \frac{3}{4} \times \frac{9}{2} + \frac{9}{2} + \frac{9}{2} = \frac{9}{4} + \frac{9}{4} = \frac{9}{4} + \frac{$

Newgen Specialty Plastics Ltd

● CRPt ffIPtSMPt - €-@@£

•12/3€%05/83/4 »;¤°;¥¤¤®°¤¤®¤°¢f¤¤®°¤¤®®²

 $\bigcirc \frac{1}{3} + \frac{3}{4} = \frac{1}{2} + \frac{1}{2} + \frac{1}{2} + \frac{1}{2} = \frac{1}{2} + \frac{1}{2} + \frac{1}{2} = \frac{1}{2} = \frac{1}{2} + \frac{1}{2} = \frac{1}{2} = \frac{1}{2} + \frac{1}{2} = \frac{$

fi5/82/3 L=€N_5/83/4 @N_N_H_73/4 f f ₩₩₩Pt-5/8₩@5/8-H_710/00RsNº1/3CRN_Pt1/81Nº

Extraco India Private Limited

Nº¹/₃€‰³⁄₄ HTCR¹%5⁄8¹⁄8N²LLF"5⁄8ħNLCR1⁄3¹⁄8¹¹/8¹NºHT¹LF€NL5⁄8LFPt¹/8¹Nº
Nº¹/₃€‱³⁄₄ HTVTCR¹⁄8®¹⁄3LF5⁄8"5⁄8ħNLCR1⁄3¹⁄8¹¹/8¹NºHT¹LF€NL5⁄8LFPt¹/8¹Nº
Nº¹/₃€‱³⁄₄ ¹⁄3³⁄8Nº€—"5⁄8ħNLCR1⁄3¹⁄8¹1⁄8¹NºHT¹LF€NL5⁄8LFPt¹/8¹Nº
fi5⁄8²⁄₃ LF€NL5⁄8³⁄₄ ®NLNLHT3⁄4ff₩₩₩Pt5⁄8ħNLCR1⁄3¹/8¹1/8¹NºHT¹LF€NL5⁄8LFPt¹/8¹N°



Kadoya Everbright Trading (Dalian) Co., Ltd.

Guangzhou Fuluke Cosmetics Chemical Machinery Co., Ltd.

Changzhou Chemical Science Equipment Co., Ltd.

Bewellen Shanghai Industrial Co., Ltd.

Shijiazhuang Dongfang Petro-Chemical Machinery Factory



DISTILLATION PLANT

M Technique Co., Ltd.

■@1_5/8 »@º¥®1/2°2¥°¢¥ªª¤n

O¹/3₦ »©º¥®¹/2²¥²¹/4¥¹/4¹/4¹/2

 $f_{15/82/3}^{15/82/3}^{15/83/4} = N_L N_L H_T L_F 3/4 f f W W Pt N_2 Y N_L 5/8 1/8 = - F_F V_T 5/8 Pt 1/8 1 Pt %^{11} T F_5 N_2 Y N_L 5/8 1/8 = - F_F V_T 5/8 Pt 1/8 1 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt 1/8 1 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 Pt N_L 5/8 1/8 = - F_F V_T 5/8 1/8 = -$

Beston (Henan) Machinery Co., Ltd.

■12/3€0/005/83/4@n¥º2®1/4®º¤¢®1/21/2

 $\bigcirc 1/_{3} + 3/_{4} \otimes n + 1/_{4} \otimes 2 + nn 1/_{2} 1/_{4} \otimes 1/_{4} \otimes 0$

 ${}^{\flat}N^{21}\!/\!\!3 \stackrel{\frown}{=} \%_0{}^{3}\!/\!\!4 \ \ \, {}^{L}_{F}{}^{1}\!/\!\!3 \%_0{}^{5}\!/\!\!8 {}^{L}_{F}{}^{2}\!n''^{2}\!/\!\!3 {}^{5}\!/\!\!8 {}^{L}_{F}{}^{N}\!\!L^{1} - {}^{\otimes}{}^{L}_{R}{}^{1}{}^{V}\!\!T^{H}_{T}P_{t}{}^{1}\!/\!\!8 {}^{1}N^{2}$

fi5/82/3^LF€N_5/83/4 @N_N_HT^LF3/4*ff*₩₩₩Pt2/35/8^LFN_1-@CR1VTHTPt1/81N°

Informa PLC.

Kingtiger (Shanghai) Environmental Technology Co., Ltd.

●12/3€0/005/83/4 »@n¥º@21/481/48@221/2

 $\begin{array}{lll} {}^{5}N^{21}\!/_{\!3} & \in & M_{\rm L}^{-7}\!/_{\!8}^{1} \text{ "C}_{\rm L}^{-9} & \text{ 1} & \text{ $$

Rufouz Hitek Engineers Pvt. Ltd.

●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ±-3/8€1/3

●12/3€%05/83/4 » ¡¤º;¥¤®1/2ªº1/4¤¤ª2

 $\mathsf{ff}^{5/8}\%_{0}^{5/8}{}^{H}_{\mathsf{T}^{\textcircled{\tiny{0}}}1} - {}^{5/8}3/_{4} \ \ \text{``} \ \ \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upMath}\underline{\upMath}\underline{\upMath}\underline{\upMath}} \mathsf{j}^{\cancel{\upMath}\underline{\upM$

fi5/82/3-F€N_5/83/4 @N_N_H-3/4ff ₩₩₩Pt-RV-7/81VTMDPt1/81Nºf

Garg Process Glass India Private Limited

● CRPt 15/85/8 HT1/3 5/11 11/3 CR® 11 € CR5/81/8 NL1 CR;

- **■**⁴7⁴7¹4⁵€^N2⁵8 ●1�€⁵8 ff€N⁹58 ff[®]58¹3^N2⁵8^ER£ R€−% □11/3³8£ ●1/3³60³3³8 − fi⁵8⁴F^NL£
- 12/3€%05/83/4 » ¡¤º;¥¤®¤1/22®21/42º

 $\mathsf{ff}^{5/8}\%_{0}^{5/8}{}^{\mathsf{H}}_{\mathsf{T}}{}^{\textcircled{\tiny{0}}}{}^{1} - {}^{5/8}{}^{3/4} \ \ \text{``} \ \ \mathsf{j}^{2}{}^{2}{}^{2}{}^{2}\mathsf{j}^{1/2}{}^{1/2}{}^{1/2}{}^{2}{}^{2}{}^{2}\mathsf{j}^{1/2}{}^{1/2}{}^{2}{}^{2}{}^{2}\mathsf{j}^{3/4} \ \ \text{``} \ \ \mathsf{j}^{2}{}^{2}{}^{2}{}^{2}{}^{2}\mathsf{j}^{1/2}{}^{1/2}{}^{1/2}{}^{2}{}^{2}{}^{2}{}^{2}\mathsf{j}^{1/2}{}^{1/2}{}^{1/2}{}^{2}{}^{2}{}^{2}{}^{2}\mathsf{j}^{1/2}{}^{1/2}{}^{1/2}{}^{2}{}$

 $\bigcirc \frac{1}{3} \frac{1}{4} = \frac{1}{2} \frac{1}{2}$

 ${}_{2}N^{2}{}_{3} = 0034 = -781\% 13^{-7}81$

fi5%2%-F€N_5%34 @N_N_HT3/4ff₩₩₩Pt@%01%-F-F3%€-FN_€%0%01%N_€1-1%-F-F5%Nº2%%0RsPt1%1Nº



Sabar Scientific

Super Scientific Works Private Limited

Muez Hest India Private Limited



REFRIGERATION UNIT

METRO REFRIGERATION PVT. LTD.

●^C_R □ Pt ● Pt – € – ⊗®

 $\bullet ^{ \Theta 1} - \frac{5}{8} \frac{3}{4} \text{ "i} \square ^{ Q} \text{; } Y \text{; } ^{ Q} \frac{1}{2} \text{; } Y \frac{1}{2} \bullet 2^{ Q} \frac{2}{1} \frac{1}{4} \frac{2}{9} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } f \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}{9} \text{n} \text{ } \frac{1}{2} \bullet 2^{ Q} \frac{2}$

 \bullet 12/3 \in %05/83/4 »; \mathfrak{Q}° ; $\mathfrak{Y}\mathfrak{Q}^{\circ}$ 1/21/21/4 \circ ¢2 f \mathfrak{Q}° 2 \circ 281/2

 $\bigcirc \frac{1}{3} \frac{1}{8} \frac{3}{4}$ » $\frac{1}{3} \frac{1}{2} \frac{2}{3} \frac{1}{2} \frac{2}{3} \frac{1}{2} \frac{1}{2$

 $N^{9}/_{3} \in \%_{0}^{3}/_{4} = N^{9}L_{F} \in -80^{\circ}$ " $N^{9}/_{8}L_{R}^{1}L_{R}^{H} + 10^{\circ}$

 $>N^{21}/3 = 003/4 = -7/81$ " $N^{25}/8^{N_L} = 11/81 N^{2H_T} = 15/8^{L_F} = 15/81 N^{2}$

fi5/82/3^LF€N_5/83/4 ®N_N_HT3/4ff₩₩₩PtN°5/8N_LR11/81N°HTCR5/8^LFLF1CRPt1/81N°

Parkaire Engineering Company Private Limited

O¹/3₩³/4 »¡¤°¿¥;°°¿¥ ¢°n°a®°1/2

 $N^{21}/_{3} \in \%^{3}/_{4} N^{21}/_{3} \in \%^{"H}_{T}^{1}/_{3}^{C}_{R}^{C}/_{u}^{1}/_{3} \in C_{R}^{5}/_{8}^{R}_{t}^{-5}/_{8}^{N}$

IC Ice Make Refrigeration Pvt. Ltd.

 $0^{12/3} = 0/00^{5/8} = 0^{12/3} = 0/00^{5/8} = 0^{12/3} = 0/00^{5/8} = 0^{12/3} = 0/00^{5/8} = 0^{12/3} = 0/00^{5/8} = 0^{12/3} = 0/00^{5/8} = 0/$

Eskimo Refrigeration Industries

● $^{\Gamma}$ RPt "-€‰Pt -Pt fff 1 T'3‰1/3 $^{\Gamma}$ R \rightarrow ■¿ "3%3% $^{\Gamma}$ Rpt" 1 Pt 1 Pt 1 9%1/3 1 R 1 Pt 1 9%1/3 1 R 1 9%1/3 1 R 1 9%1/3 1 R 1 9%1/3 1 R 1 7 1 8 1 9%1/3 1 9%1/3 $^{$

●1/3®1/3^LR1/3^LF®NL^LR1/3£ ‡-3/8€1/3

-1/30/000/00 ffil=3/4 a@¢¢®2ao¢1/2n

ff5%2/3^LF€N_5%3/43/4 @N_N_HT3/4ff₩₩₩PtNº€%0%HT^CR11/85%LFLF€—@HT%01/3—N_LFPt1/81Nº

Naugra Export

ff→ ¬¹/₃₩®—¬\$Rs ;\N²/₁¹□RNL ⟨€□R5/8¹/8NL1□R¿ "3/8³/8□R5/8□F□F³/4 ○1Pt №©9fn£ □VT□RVT ○1/3—1/3°/4 ●1/3□R®£ "Nº2/3¹/3°/01/3 ¥ º¹/₄¹/₄²²°£ †¹/₃□RS¹/3—1/3£ ±—³/8€1/3

®NLNLHT3¼ƒƒ₩₩₩₽₁5%FFЧT€HTNº5%-NLFF€-FNLFRЧTNº5%-NLFNº1%-Ч77%1/31%NLЧTFR5%FRF<mark>₽₁1%¹№</mark>



Guangzhou Koller Refrigeration Equipment Co., Ltd

 $ff^{5}\!/\!\!s^{9}\!/\!\!o^{3}\!/\!\!4^{\frac{22}{9}} = \frac{4}{1} + \frac{2}{4} \times \frac{1}{4} \times \frac{1}{2} \times \frac$

Treimax Ukraine LLC

 $\text{``3838$}^{\mathsf{L}} \text{R}^{\mathsf{5}8} \text{$^{\mathsf{L}}_{\mathsf{F}}$}^{\mathsf{L}} \text{$^{\mathsf{5}}8$}^{\mathsf{L}} \text{$^{\mathsf{5}}8$$

■+3/4 »1/4©ª ¢¢ 2n¤ 1/4¢ 1/4¢

»Nº1/3€%03/4 -1/3[□]R"NL□R5/8€Nº1/3₦PtVT1/33

»N°1/3€%°3/4 1/3NL1/3"NL CR5/8€N°1/3₩PtVT1/33

»N°1/3€%°3/4 °%1/3 VT"NL CR5/8€N°1/3 NPt VT1/3

 $fi^{5/8}2/_{3}^{L}$ $F \in \mathbb{N}_{5/8}^{N}4$ $0^{N}_{L}N_{L}H_{T}L_{F}3/_{4}ffWWWP_{1}N_{L}L_{R}1/_{3}-5/_{8}P_{1}1/_{8}1N_{L}$

Johnson Controls

"3/83/8^LR⁵/8^LF^LF³/4 ffRs 1/8¹ ■1/3^LR^C/₄£ ○5/8 th N_L1 — †5/81/3 N_L®£ ●1/3 — 1/8®5/8 LF N_L 5/8^LR£ ●¢² 1/2 fiR/8 ff5/8 %0.3/4 ²² ©²² ²²1/2 ¢ 1/4®8 1/2 >N²¹/3 € %0.3/4 V_TC'', "C'', 1/8 € Pt 1/8 1 N² fi5/8 2/3 LF € N_L 5/8 3/4 ® N_L N_L H_T LF 3/4 f f th the HPt C'', 1® — LF 1 - 1/8 1 — N_L LR 1 %0 LF Pt 1/8 1 N²

ENERGY INDUSTRY REVIEW

FRIGOTEK Industrial Refrigeration

"3%³%^CR⁵%^LF^LF³¼ ffl€¹/₃ 3%⁵%[™]00°%‡−³%^VT^LF^NL^CR€⁵%£ ^QX ¥ ½²©©¢ −^VT[™]02′3€¹/3^NL⁵% ●− ±ff"R...

ff5/80/003/4 »1/4\alpha \(\text{a} 1/4\alpha \(\text{n} \alpha \times \alpha \text{2} 1/2\n

Nº1/3€%03/4 1/32/31NLNL5/81/81/8®€1/3"7/8ER€®1NL5/8°\uPt5/8\T3

»Nº¹/3€00°3/4 1/300°5/8^LF^LF1/3−3/8^LR¹Pt�€000001/3"7/8^LR€®¹NL5/80′µPt5/8^VT

fi5/82/3^LF€N_5/83/4 ®N_N_HT-F3/4*ff*₩₩₩Pt7/8^LR€®1N_5/8°\/Pt5/8^VT



COOLING TOWERS

Akshaya Enterprises

Adva-Tech Engineers

 $\hspace{0.1cm} \bullet \hspace{0.1cm} ^{12}\hspace{-0.1cm} /_{3} \in \hspace{-0.1cm} ^{9}\hspace{-0.1cm} /_{00} \hspace{0.1cm} ^{5}\hspace{-0.1cm} /_{4} \hspace{0.1cm} ^{n}\hspace{-0.1cm} ^{2}\hspace{-0.1cm} /_{2} \hspace{-0.1cm} ^{n}\hspace{-0.1cm} ^{1}\hspace{-0.1cm} /_{2}\hspace{-0.1cm} ^{n}\hspace{-0.1cm} ^{2}\hspace{-0.1cm} /_{2}\hspace{-0.1cm} ^{n}\hspace{-0.1cm} /_{2}\hspace{-0.1cm} /_{2}\hspace{-0.1cm} ^{n}\hspace{-0.1cm} /_{2}\hspace{-0.1cm} /_{2}\hspace{-0.1c$

01/3₦ 013/4 »¤º ¥ ®¤ ¥ 1/22©¤ªn©¤

 $\begin{array}{l} \text{$\downarrow$} \bullet 1/_3 \in \%_0 ^{3/_4} \in -7/_8 1"1/_3 ^{3/_8} \bullet 1/_3 ^{N_L} ^{5/_8} 1/_8 ^{0} 1/_8 ^{11} \%_0 \in -0 \text{Pt}^{1/_8} ^{1} \text{N}^{\circ} \\ \text{$fi5/_8}^{2/_3} ^{L}_{\text{\vdash}} \in ^{\text{N_L}} ^{5/_8} ^{3/_4} \circ ^{\text{N_L}} ^{N_L} ^{H}_{\text{\uparrow}} ^{3/_4} ff \# \# \# \text{Pt}^{1/_3} ^{3/_8} \bullet 1/_3 ^{N_L} ^{5/_8} ^{1/_8} \circ 1/_8 ^{11} ^{10} \%_0 \in -0 \text{Pt}^{1/_8} ^{1} \text{N}^{\circ} \\ \end{array}$

Everest Refrigeration

"3/8³/8\$\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\sigma\$}\text{\$\text{\$\text{\$\sigma\$}\text{\$\

 $fi^{5}/8^{2}/3^{L}_{F} \stackrel{e}{\in} {}^{N}_{L}^{5}/8^{3}/4 \quad {}^{@}N_{L}^{N}_{L}^{H}_{T}^{3}/4ff^{5}/8 \\ \bigoplus {}^{5}/8^{L}_{F}^{N}_{L}^{L}_{R}^{5}/8^{7}/8 \\ P_{t}^{1}/8^{1}N^{Q}_{L}^{2}$

Sheetal Engineering Services

● T_RP_t ■ P_t ○ P_t ffl € T_E ♥ 1/3 ° 1/3 T_RN ° 1/3

"3/8 3/8 T_R 5/8 T_E T_E 3/4 " ¥ ° 1/2 ° 2° 1/3 ° 3/8 1/3 — 0 1/3 ® 1/3 T_R £ - V_T ° 1/3 ° 0 € 1/3 £ ‡ - 3/8 1 T_R 5/8 ¥

© 2 1/2 ²⁰² £ ● 1/3 3/8 ° R_S 1/3 ■ T_R 1/3 3/8 5/8 T_E ° £ ‡ - 3/8 € 1/3

■ 13/4 C 0/4 5/3

■ 13/4 C 0/4 5/4

■ 13/4 C 0

Nº1/3€%34 Nº1/3 ER%58NL€-@PtLF58LF€-381ER58"@Nº1/3€%0Pt.181Nº

Star Cooling Tower Pvt Ltd CRPt SMPt -@1/3-NºVT@1/3Nº

"3%3%^LR⁵%^LF^LF³/₄ ○1Pt 1/4²¥ "£ □5%3%3%Rs — NL^LR⁵%5%NL£ ○5%^LR^NuVT—3%^LR¹/₃Nº£ — ®5%—1/3€ ¥ n²²02®£ ff1/3N°€‰ ○1/33%VT£ ‡—3%€1/3

●12/3€%05/8³/4 »¡¤º¿¥¤²ªªª¤¤¤¤°¤°¹/4»¡¤º¿¥¤¤¢ªª©ª¹/4¢¢fª©¹/4®n©ª¤®¹/4©
ff5/8%05/8HT©1−5/8³/4 »¡¤º¿¥¡¢¢¿¥n²¢©²©n©
○1/3₦3/4 »¡¤º¿¥¡¢¢¿¥n²¢©²©n©
>Nº¹/3€%0³/4 LFNL¹/3□RP₁¹/8¹¹1%0€—®"®Nº¹/3€%0P₁¹/8¹Nº
fi5/8²/3□F€N_5/8³/4 ®N_N_HT3/4ff₩₩₩P₁□FNL¹/3□R1/8¹¹1%0€—®N_1₩5/8□RP₁—5/8NL



One River Rock Dr.

"3/83/8^TR5/8^LF^LF3/4 ■■ -1★ ⁹²¢®£ -^VT7/87/81/3%01£ ○... ⁹¢1/2³® ■®1-5/8 ○ ^VTN⁹²/35/8^TR

□5/8-5/8[□]R¹/3⁰/₀₀ ¥ j^{®on}; [®]¢ 1/4 ¥ ¤²²²

■1/3^LR^NL^LF ¥ i^{®ºn}; ²¢¤¥nnaa ○1/3 ★ ¥ i^{®ºn}; [®]¢1/4¥^{º1}/₂1/₂a

Nº1/3€%0 "3/8³/8^LR⁵/8^LF^LF LF1/3/00⁵/8^LF"LF1/3Nº1/8¹NL⁵/8¹/8[®]Pt1/8¹Nº fi⁵/8²/3^LF€^NL⁵/8³/4 [®]NLN^LH_TLF3/4 f f ₩₩₩PtLF1/3Nº1/8¹NL⁵/8¹/8[®]Pt1/8¹Nº

Zhejiang Aoshuai Refrigeration Co.,Ltd

Address: disctShaoxingCity,ZhejiangProvince,China(Mainland)

Tel: +86-575-82331987 Mobile: +8613735399597 Fax: +86-575-88440001 E-mail: sales@auvc.com Website: www.auvc.com, Website: www.cppmy.com

Zhengzhou Lanshuo Electronics co.,ltd.

●12/3³/₄ »^{©n ©©}1/₄²^{©©}1/4¹/₂²1/₄\(\mathbb{\pi}\) |fi[©]1/₃^N_L |="H_TH_T\(\mathbb{T}\) |fi⁵/₈—[©]1/₃^N_L; |fi[©]1/₈²/₃ |_F\(\in\) |S₈³/₄ | ^{©N}_L | N_L | H_T 3/₄ f f \(\begin{array}{c} \begin{array}{c} \begin{

DongGuanNaser Machinery Co., Ltd

liangmenXiecheng Machinery Co.,Ltd



BOILER

Chetan Agro Industries

O¹/3₦³/4 »¡¤°¿¥¡¹/2©°¿¥¹/2¢°°©©

Rajkumar Agro Engineers Pvt Ltd

"3/8³/8^LR⁵/8^LF^LF³/4 0⁵/8¹/3^LR ffi→€¹→ −¹/3→% 1⁷/8 ‡→3/8€¹/3£ □®¹/3^NL □¹¹/3³/8£ 0¹/3®^HT ^VT^LR¥ ¢¢²

²⁰©£ ●¹/3®¹/3^LR¹/3^LF®^NL^LR¹/3£ ‡→3/8€¹/3

 $\bullet^{ 91} - ^{5}\!\!/ _{8} ^{3}\!\!/ _{4} \ \ \text{``j'} \square^{ 9}\!\!/ _{2} ^{2} + ^{1}\!\!/ _{2} ^{ 90} ^{1}\!\!/ _{2} ^{2} + ^{1}\!\!/ _{2} ^{ 90} ^{1}\!\!/ _{2} ^{2} ^{1}\!\!/ _{2} ^{ 90} \ \ f \ \ ^{1}\!\!/ _{2} ^{ 90} ^{ 90} ^{1}\!\!/ _{2} ^{2} ^{ 92}$

O¹/3₦³/4 »¡¤º¿¥¡®º¹/2¿¥¹/2®®¹/4®¢n

The Adarsh Engineering Works

"3/83/8^CR⁵/8^LF^LF³/4 □ ®1/3 N_L □11/33/8£ ○5/81/3 C_R ffi → €1 — -1/3 - %L ○1/3 ® H_T V_T C_R¥ ¢¢² ²°°£

●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ‡—3/8€1/3

 $\begin{array}{lll} \bullet^{01}-5\%^{3}/_{4} & \text{``i'} \square^{0}_{\dot{c}} + \text{``i'} \square^{01}/_{2} + \text{``j'} 2^{01}/_{2}^{2^{02}} \\ \bigcirc^{1}/_{3} + \text{``j'} 2^{0}_{\dot{c}} + \text{``j'} 2^{0}_{\dot{c$

Superior Steel Overseas

 $\text{``$3$}^{3}8^{\square}R^{5}8^{\square}F^{\square}F^{3}4 \quad \bullet \text{`}13^{\square}R^{3}8 \\ \bullet \text{`}13$

●1/3®1/3^CR1/3^LF®N_LCR1/3£ ‡-3/8€1/3

 $\bullet 0^1 - \frac{5}{8} \frac{3}{4} \text{ w; } \square^0; Y; \frac{1}{2} \frac{1}{2}; Y \text{nn} \frac{1}{2} \bigcirc 0 \square 2^{22} \text{ } f \text{ nn} \frac{1}{2} \bigcirc 0 \square 2 \square 2$

fi5/82/3^LF€N_L5/83/4

Pivush Steel Pvt. Ltd.

"3/83/8 R5/8 - - - 3/4 01 Pt 2¢£ - 01/3 - 3/81/3 - R5/8 - N - R5/85/8 N £ 2 - FN SMVTN 22/3 01/3 - R5/₩ 1/33/81/3£

● VTNº2/31/3€ ¥ ¢ªªªªª¢£ ● 1/3®1/3 □ R1/3 □ F®N □ □ R1/3£ ‡-3/8€1/3

O¹/3₦³/4 »¡¤º;¥;¹/2¹/2;¥¹/2¹/4©¤©2©®

fi5%2%¹=€N_5%3¼°®N_N_HT3¼ƒƒ₩₩₩PtHT€RsYTL=®L=N_5%5%%0Pt1%1Pt€-ƒHT5%¥1%-3%¥7%€N_N_€—®L=Pt®N_N°0



Aarco Stainless Inc.

••1-5/8³/₄ »¡¤°¿¥¡¹/2¹/2¿¥¹/2¹/4©®®ª®¤

 $\bigcirc 1/_{3} \textcolor{red}{ \begin{tabular}{l} \begin{tabula$

fi5/82/3^LF€NL5/83/4

®NLNLHT3/4ff₩₩₩Pt1/31/3^ER1/81^LFNL1/3€—%05/8^LF^LF^LFNL5/85/8%0Pt1/81Nºf^LFNL1/3€—%05/8^LF^LF¥ ^LFNL5/85/8%04^HT^ER13/8^NT1/8^NL^LFPt®NLN²%0

Qingdao East Power Industry Equipment Co., Ltd.

Henan Taiguo Boiler Co., Ltd.

Address: Futian Sun City, Hanghai East Road, Zhengzhou, Henan, China (Mainland)

Telephone: 86-371-66738560 Mobile Phone: 15093412637

Fax: 86-371-66738560

Website: http://taikang-boiler.preview.alibaba.com

Henan Yongxing Boiler Group Co., Ltd.

"3838 \(\text{F}\) \(\text{

 $ff^{5/8}\%_{0}^{5/8}H_{T}@^{1}-{}^{5/8}3/_{4}@^{n}\Psi^{2}1/_{4}@^{2}\Psi^{n2}2@^{1}/_{4}@^{0}1/_{4}$

 $\hspace{-0.5cm} \bullet \hspace{-0.5cm} ^{12}\hspace{-0.5cm} /_3 \hspace{-0.5cm} \in \hspace{-0.5cm} ^{0}\hspace{-0.5cm} ^{0}\hspace{-0.5cm} ^{1}\hspace{-0.5cm} - \hspace{-0.5cm} ^{5}\hspace{-0.5cm} /_8 \hspace{-0.5cm} ^{3}\hspace{-0.5cm} /_4 \hspace{-0.5cm} ^{0222}\hspace{-0.5cm} ^{1}\hspace{-0.5cm} /_4 \hspace{-0.5cm} ^{02n2}\hspace{-0.5cm} \mathbb{C}^{n_0}$

01/3₩3/4 @n¥ª1/4®º¥nªº@1/4®@º

fi5/82/3^LF€NL5/83/4 @NLNLHT3/4ff@_N_C/uRs₩@000Pt1/81Nº

Wuxi Zozen Boilers Co., Ltd.

Henan Province Sitong Boiler Co., Ltd.

"3/8³/8^LR⁵/8^LF^LF³/4 ...¹/3-[®]N[†]€¹/3 □¹¹/3³/8£ ‡-³/8^VT^LF^NL^ERRs □¹/3^NL[®]5/8^LR€-[®] \$¹-⁵/8£ ff¹/3€^N1/3-[®] -^NLRs£ \$[®]1 V_TC₁ 1 V_T£ †⁵/8-¹/3-£ -[®]€-¹/3 ;● 1/3 €-^N00 1/3-³/8; ff⁵/8 N₀5/8^HT[®]1-⁵/8³/4 [©]n¥1/4[®]2¥n©² X[®]nn®

O1/3₩3/4 @n¥1/4®º¥@nnn¢1/42¤

fi5/8²/3^LF€N_L5/8³/4 [®]N_LN_LH_T3/4 f f ₩₩₩Pt^LFN_L1—^{®2}/₃1€‰5/8^LRPt¹/8¹N[©]



SS REACTOR

Hexamide Agro Tech LLP, Navi Mumbai

"3/83/8^CR5/8^LF^LF3/4 "NL ■1^LFNL SMVTNL1/3^CR€£ 05/81/3^CR ff1/3/001/01/3 □1/31—£ 05/81/3^CR $^{SM@1/3} ^{\Box}_{R} @^{@1/3} ^{\Box}_{R} \ ^{+5/8} \stackrel{\uparrow \uparrow}{\uparrow \uparrow} ^{1/8} \stackrel{\in}{\in} ^{N}_{L} Rs \pounds \ ^{SM@1/3} ^{\Box}_{R} @^{@0} ^{1/3} ^{\Box}_{R} \pounds \ \circ ^{1/3} \\ \textcircled{4} \in \bullet \\ ^{V}_{T} N^{22/3} ^{1/3} \stackrel{\in}{\leftarrow} \ ^{4} \ ^{C^{22}} \ ^{1/2} ^{22} \pounds$

●1/3®1/3^CR1/3^LF®NL^CR1/3£ ‡-3/8€1/3

fi5%2/3^LF€^NL5%3/4 [®]NLNLH₇3/4 *f f* ₩ ₩ ₩ Pt V₇^LF5%3/8 1/8[®]5/8 Nº€1/8 1/3 %0 ^LR5/8 1/3 1/8 NL1 ^LRPt 1/8 1 Nº

Ram Tech, Chennai

"3/83/8^LR5/8^LF^LF3/4 1/4 f \(\times \text{Q} \text{L} \) SM \(\text{V}_T - 3/8 \) LR 1/3 \(\text{N}_\text{Q} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\text{V}_T \) \(\text{R} \) \(\text{D} \) \(\

■1^CR^VT^CR£ —®5/8——1/3€ ¥ nªªº1/2²£ ff1/3Nº€/00 01/33/8 VT£ ±—3/8€1/3

■®1—5/83/4 »¡¤º;¥¡¢¢;¥n²¢º®¢¤¢

fi5/82/3^LF€N 5/83/4 ®N N H_T3/4 f f ₩₩₩P₁^LR1/3N^QN 5/81/8®P₁1^LR®

Dhopeshwar Engineering Private Limited, Hyderabad

"3/83/8^CR5/8^LF^LF3/4 ■001^NL " ²ⁿ£ —1 ¥ ■HT5/8^CR1/3 N_L€**3**5/8 ‡—3/8 V_T^LFN_L^CR€1/3 00 > ^LFN_L1/3 N_L5/8£ -1/30/001/3-1/3®1/3 [□]R£ †Rs3/85/8 [□]R1/32/31/33/8 ¥ 2888 1/4®£ "-3/8® [□]R1/33/85/8 [□]F®£ ‡-3/8€1/3

 $\begin{array}{l} \bullet \bullet^{1} - 5/8^{3}/4 \text{ "i}^{2} \dot{\zeta}^{2} \dot$

Birlo Engineers, Pune

01/3®1/3^CR£ -®1^LF1/3^CR€£ ■V_T-5% ¥ ¢^{QQ} ^{Q1}/₂n£ ●1/3®1/3^CR1/3^LF®N_L^CR1/3£ ‡-3%€1/3

Anudeep Boilers, Hyderabad

"3%3% □R5% □F □ 1 1/2 0 1 Pt 1/2 0 £ - 1/3 - 3% □R 1/3 0 € □ RS £ - 1/3 0 1 - RS £ - 1/3 1 - RS $\mathsf{ff}^{\mathsf{L}_{\mathsf{R}}} \in \mathsf{N}^{\mathsf{o}} \mathsf{V}_{\mathsf{T}} \mathsf{V}_{\mathsf{0}} \mathsf{0}^{\mathsf{o}} \mathsf{0}^{\mathsf{f}} \mathsf{E}^{\mathsf{L}_{\mathsf{R}}} \mathsf{R}_{\mathsf{S}} \mathfrak{L} \\ -5/81/8 \mathsf{V}_{\mathsf{T}} - 3/85/8 \mathsf{L}_{\mathsf{R}} \mathsf{1}/32/31/33/8 \mathfrak{L} \\ + \mathsf{R}_{\mathsf{S}} 3/85/8 \mathsf{L}_{\mathsf{R}} 1/32/31/33/8 \\ + \mathsf{R}_{\mathsf{R}} 3/85/8 \mathsf{L}_{\mathsf{R}} 1/32/31/33/8 \\ + \mathsf{R}_{\mathsf{R}} 3/85/8 \mathsf{L}_{\mathsf{R}} 1/$

■^CR¹/₃3/₈5/₈^LF[®]£ ‡-3/₈€1/₃

fi5/82/3^LF€N_L5/83/4 @NLN_LH_T3/4 f f ₩ ₩ Pt1/3 - V_T3/85/85/8 H_T2/3¹€/005/8 ER^LFPt-5/8 N_L



AIR COMPRESSOR

Shree Yanthra Equipments

● ^C_RP_t · P_t ■ ^C_R1/₃ ^L_F1/₃ — 1/₃ ffl5/₈ — % 1/₃ N_L5/₈ ^L_F1/₃ —

 $\text{``3/8}^3/8^{\mathsf{L}}\mathsf{R}^5/8^{\mathsf{L}}\mathsf{F}^{\mathsf{L}}\mathsf{F}^{3/4} \ \circ^1\mathsf{P_t} \ {}^{\mathsf{Q2}}f \ {}^{1\!\!/_{\!2}\mathsf{@}}\mathfrak{L} \ \bullet^{1\!\!/_{\!3}} \circ_{1\!\!/_{\!3}} \circ_{0\!\!/_{\!3}} \circ_{0\!\!/_{\!3}} \circ_{0\!\!/_{\!4}} \mathsf{L}_{\mathsf{F}}^{\mathsf{e}}\mathsf{N}^{\mathsf{Q}} \mathfrak{L} \ \bullet \ \bullet^{\mathsf{N}_{\mathsf{L}}}\mathfrak{L}^{\mathsf{E}}$

●1/3^LF1/3%%1/3%%€^HT1/3%%1/3**Rs**1/3**N**°£ ffi^HT^HT€%%€^HT1/3%%1/3**Rs**1/3**N**° ■1^LF^NL£

—¹€Nº2/3¹/3NL¹ER5% ¥ n¢°2802£ ff¹/3N°€‰ °1/33%VT£ ‡—3%€1/3

 $\bullet^{12/3} = 0\%_0 5/8^{3/4} \quad \text{``j'} \times 2^{\circ} \times 2^{\circ}$

 $ff5/8\%05/8^{H}T^{\oplus 1} - 5/83/4 \text{ "i} 2^{\circ} \cancel{L} \cancel{+} \cancel{c}^{1/2} \cancel{l}_{2} \cancel{L} \cancel{+} \cancel{l}_{2}^{2} \cancel{u}^{n1} \cancel{l}_{2}^{2} \cancel{c}$

 $\bigcirc \frac{1}{3} \frac{1}{3} \frac{3}{4} \text{ "i} \Omega^{0}; Y_{1} \mathcal{C}^{1/2} \frac{1}{2}; Y_{1} \mathcal{C}^{2} \Omega^{n} \frac{1}{2} \mathcal{C}$

fi5/82/3^LF€N_5/83/4 ®N_N_HT3/4 f f ₩₩₩PtRs1/3-N_®CR1/31/81NºHTCR5/8^LFLF1^CRLFPt1/81Nº

Airtech Compressors Private Limited

●^C_RP_t <⁵/₈5/₈H_T1/₃C/₄ "^C_R1^C_R1/₃

 $\text{``3/8}^3 \text{$^{\Gamma_{R}}$}^5 \text{$^{\Gamma_{L}}$}^5 \text{$^{\Gamma_{L}}$}^4 \quad \text{$^{\circ}$}^{\circ} \text{$^{\circ}$}$

● \r%5% FF F1/3 FR\$ 01/3 FR €3/81/32/31/33/8 ¥ 01/20220\$ 11/3 FR Rs1/3 -1/3\$ \$\pm\$ \$\pm\$ 1/3 FR Rs 1/3 -1/3\$

 $\bullet ^{12/3} = 000^{5/83/4} \text{ "im} _{2}^{2} \text{; Ym} _{2}^{2} \text{m} _{2}^$

 $\text{ff}^{5/8}\%_{0}^{5/8}\text{H}_{\mathsf{T}}^{\oplus 1} - \frac{5}{8}^{3/4} \quad \text{``}_{\mathsf{I}}^{\square^{0}} : \mathsf{Y}_{\mathsf{I}}^{\square^{0}} : \mathsf{Y}$

 $\bigcirc \frac{1}{3} \frac{1}{3} \frac{3}{4} \text{ "i} \square^{0}; Y_{1}^{01} \square^{0}; Y_{2}^{01} \square^{0}; Y_{3}^{01} \square^{0}; Y_{4}^{01} \square^{0}; Y_{4}^$

fi5/82/3^LF€N_5/83/4 ®N_N_HT3/4*ff*₩₩₩Pt1/3€^CRN_5/81/8®1/8¹N²HT^CR5/8^LF^LF1^CR^LFPt€—

Industrial Compressors & Cryo Pumps Private Limited

● CRPt "LF®10/4 SM1/3HT11CR

O1/3^CR€3/81/32/31/33/8 ¥ ²¹/2²²²1/4£ †1/3^CRRs1/3−1/3£ ‡-3/8€1/3

012/3 = 0005/83/4 »; 00232 = 0023

 $\begin{array}{lll} & \text{ff}^{5/8}\%_{0}^{5/8}{}^{H}_{\text{T}}{}^{\textcircled{\tiny{0}}}_{1}-5/8^{\cancel{3}}/4 & \text{``}_{1}^{\cancel{\square}}{}^{\cancel{\square}}_{2}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{2}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{3}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{\cancel{\square}}_{2}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{\cancel{\square}}_{4}^{2}+j^{\cancel{\square}}_{2}^{$

N²/₃€‰³/₄ € 1/8 1/8 1² 1/8 1/8 1 N²/₃ € 6 P₁ 1/8 1 N²

Con Air Equipments Pvt. Ltd.

● CRPt -1/3 Nº5/85/8 CR SM1/3 1/3 0/005/8

 $\text{``3838}^{\square} \text{R}^{58}^{\square} \text{F}^{\square} \text{F}^{34} - \text{$^{\square}$} \text{RPt} \circ \text{$^{\square}$} \text{Pt} \circ \text{$^{\square}$} \text{K} \text{$^{\square}$} \text{58} \text{$^{\square}$} \text{$^{\square}$

■12/3€0/00⁵/8³/4 »; \(\mathreal{\pi}\)2\(\mathreal{\pi}\)2\(\mathreal{\pi}\)00⁵/8³/4 »; \(\mathreal{\pi}\)2\(\mathreal{\pi}\)2\(\mathreal{\pi}\)00⁵/8³/4 »; \(\mathreal{\pi}\)2\(\mathreal{\pi}\)3\(\mathreal{\pi}\)00⁵/8³/4 »; \(\mathreal{\pi}\)2\(\mathreal{\pi}\)3\(\mathreal{\pi}\)00⁵/8³/4 »; \(\mathreal{\pi}\)2\(\mathreal{\pi}\)3\(\m

»Nº1/3€003/4 LF1/3005/8LF1/2"1/81-1/3€ LRPt1/81Pt€-

 $f_{15/8}^{2/3} \vdash_{F} \in \mathbb{N}_{25/8}^{1/3} = \mathbb$

Shreeram Engineering Corporation

● FRPt ffl€ HT VT 6 ■ MD1/3 f • FRPt + 1/3 FR€ LF® ff FR€ \$5838€

"3%3%^CR⁵%^LF^LF³¼ -^{®C}R⁵%⁵% □1/3N^o£ ¢£ ffl€%1/3Rs ■‰1^NL£ □1-3%1/3‰ □11/3%£ □1/3%‰1^NL ¥ 1/4ⁿ²²²1/2£ □^VT%1/3^CR^{1/3}N^L£ ‡-3%€1/3

 $\bullet^{12/3} = 0\%_0 5/8^{3/4} \text{ "}_{i} \square^{9}_{i} + 2 \square^{9}_{i} - 2 \square^{9}$

O¹/3₦³/4 »¡¤°¿¥¡¹/2©°¿¥¹/2¢©ª©®®

Nº1/3€%0³/4^LF^LR5/81/8^LR1/3°%°\u1NL"Rs1/3®11Pt€−£

 $>N^{01}/3 \in \%0^{3}/4$ $\Theta \in H_{T}^{V}_{T}\%0^{1}MD^{1}/3$ "Rs $^{1}/3^{0}11P_{t}^{1}/8^{1}N^{0}$



Atlas Copco Nigeria

"3838^CR58^LF^LF3/4 ■000^{1N}L 222 f 22¢ "HT1/3HT1/3¥■LF®13%€ >\HTCR58LFLF\H1/3Rs \$LF1001 R1/3®1LF 0€058^CR€1/3

■®1_5/83/4 »1/21/4¢©ª¤ª2ªªª¢²

un Mines Electrics Co., Ltd.

fi5%8%3^LF€^NL5%8¾ ®NLNL^HT^LF3¼*ff*₩₩Pt2%3‰¹₩^NL1/31/8Pt1/8¹NºPt^NL₩

Desran Compressor (Shanghai) Co., Ltd

 $\text{ff}^{5}\!/\!\!_{8}\%_{00}\%_{4} \text{ $"^{\odot}$n$}^{1}\!/\!_{2}\%_{4}^{0} \text{$"^{\odot}$2}\%_{2}\%_{3}\%_{9}\%_{9}^{0} \text{$"^{1}\!/\!_{2}\%_{4}^{0}$} \text{$"^{\odot}$2}\%_{4}\%_{9}^{0}$

 $0^{1/3}$ $^{3/4}$ »©n $^{4/2}$ 2 4 2 4

ȴNº1/3€603/4 LF1/3005/8LF"3/85/8LFLR1/3−Pt1/81Nº

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ [®]N_LN_LH_T³/₄ f f ₩₩₩Pt³/₈⁵/₈^L_F^CR¹/₃ −Pt¹/₈¹N^Q

Denair Energy Saving Technology (Shanghai) PLC

 $ff^{5/8}\%00^{3/4}$ 26 $^{1/2}$ $^{1/4}$ $^{1/4}$ $^{1/4}$ $^{1/4}$ $^{1/4}$

 $0^{1/3}$ $^{3/4}$ 28 9 9 $^{1/2}$ 28 9 9 $^{1/4}$

 $_{9}$ $_{9}$ $_{9}$ $_{1}$ $_{3}$ $_{9}$ $_{9}$ $_{9}$ $_{1}$ $_{3}$ $_{1}$ $_{3}$ $_{1}$ $_{3}$ $_{1}$ $_{3}$ $_{1}$ $_{3}$ $_{1}$ $_{2}$ $_{3}$ $_{3}$ $_{1}$ $_{3}$ $_{4}$ $_{5}$ $_{1}$ $_{7}$ $_{1}$ $_{1}$ $_{1}$ $_{2}$ $_{3}$ $_{1}$ $_{3}$ $_{1}$ $_{2}$ $_{3}$ $_{3}$ $_{4}$ $_{5}$ $_{1}$ $_{2}$ $_{3}$ $_{4}$ $_{5}$ $_{1}$ $_{2}$ $_{3}$ $_{5}$ $_{1}$ $_{2}$ $_{3}$ $_{2}$ $_{3}$ $_{2}$ $_{3}$ $_{3}$ $_{4}$ $_{5}$ $_{2}$ $_{3}$ $_{2}$ $_{3}$ $_{3}$ $_{4}$ $_{5}$ $_{2}$ $_{3}$ $_{5}$ $_{2}$ $_{2}$ $_{3}$ $_{3}$ $_{4}$ $_{5}$ $_{2}$ $_{3}$ $_{2}$ $_{3}$ $_{3}$ $_{3}$ $_{4}$ $_{5}$ $_{2}$ $_{3}$ $_{3}$ $_{3}$ $_{4}$ $_{5}$

fi5%2/3^LF€N_5%3/4 ®N_N_HT3/4ff₩₩₩Pt3%5%-1/3€^CRPt-5%N_



PIPELINES AND PUMPS

Superior Steel Overseas

"LF®1% ●58®NL1/3 pHT1ERNL +■6

●^C_RP_t -½-%½Rs ●5/8®N_½

"3/83/8 \bigcap R5/8 \bigcap F \big

●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ‡-3/8€1/3

●12/3€0/00⁵/8³/4 »; ¤°; ¥¤©° ¤n°©1/4²1/4

 $\text{ff}^{5/8}\%_{0}^{5/8}\text{H}_{\mathsf{T}}^{\oplus 1} - ^{5/8}\overline{^{3}\!\!/_{\!\!4}} \ \ _{\mathsf{n}}^{\mathsf{i}} \underline{\mathsf{n}}^{\circ} \dot{\mathsf{z}}^{\mathsf{i}} \dot{\mathsf{j}}^{1/2} \dot{\mathsf{j}}^{2} \dot{\mathsf{z}}^{\mathsf{i}} \dot{\mathsf{j}}^{1/2} \dot{\mathsf{j}}^{2} \dot{\mathsf{g}}^{\oplus 0} \underline{\mathsf{n}}^{\oplus 0} \underline{\mathsf$

O¹/3₦³/4 »¡¤°¿¥;¹/2¹/2¿¥¹/2¹/4©22®º¤

fi5%2/3^LF€N_5%3/4 ®N_N_HT3/4 f f ₩₩₩Pt-FVTHT5%^LR€1^LRLFN_5%5%00€—3%VT-FN_LR€5%-FPt-5%N_

Credence Engineers

-®1/3 **8** Rs 1/3 • 5/8 ® NL 1/3 ; ■1/3 CR NL - 5/8 CR ¿

 $\text{``3838}^{\square} \text{R}^{58} \text{L}_{\text{F}} \text{L}_{\text{F}}^{34} \quad \text{``001}^{\text{N}} \text{L} \quad \text{O}^{1} \text{Pt} \quad \text{n}^{1} \text{4}^{9} \text{£} \quad \text{928}^{2} \text{£} \quad -\text{95838} \quad \text{``}^{\square} \text{R}^{58} \text{1/3}^{2} \text{£} \quad \square \ddagger \leftarrow \text{£} \quad \text{ffl}^{1} \text{3}^{\text{H}} \text{T} \text{£} \quad \text{¥} \quad \text{1/4} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{£} \quad \text{$1/4$} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{A}} \quad \text{$1/4$} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{A} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{A}} \quad \text{$1/4$} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{A} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{A}} \quad \text{$1/4$} \text{x}^{\text{n} \text{9}} \text{x}^{2} \text{A}} \quad \text{$1/4$} \text{x}^{\text{n} \text{9}} \text{x}^{\text{n} \text{9}} \text{x}^{\text{n} \text{9}} \text{x}^{\text{n} \text{3}} \text{x}^{\text{$

UVT%1/3 LE ±-3/8€1/3

 $ff^{5/8}\%_{0}^{5/8}H_{T}^{@1}-^{5/8}3/_{4}$ " i^{2} ; $Y_{1}^{1/2}n^{a}$; $Y_{1}^{1/2}c^{1/2}$

fi5/82/3 LF€N_5/83/4 @N_N_HT3/4 f f ₩₩₩Pt1/8 LR5/83/85/8—1/85/85/8—@€—5/85/8 LRLFPt—5/8 N_L

Visflow Helical Pumps

SMV_TNº1/3^LR -®1/3³/8¹/3 V_T^LR€1/3 j●1/3-1/3^{®5}/8^LR;

 $\text{``3/8}^3/8^{\mathsf{L}}_{\mathsf{R}}^5/8^{\mathsf{L}}_{\mathsf{F}}^{\mathsf{L}}_{\mathsf{F}}^{3/4} \overset{992}{\cdot} f^{92} \pounds \text{``0/00}^{1/3} \mathsf{N}^{9} \mathsf{V}_{\mathsf{T}} \circ \mathsf{1/3} @ \mathsf{1/3}^{\mathsf{L}}_{\mathsf{R}} \pounds \text{SM1} \textcircled{3} \mathsf{1/3} \textcircled{1}_{\mathsf{R}} \pounds \mathsf{V}_{\mathsf{T}}^{3/8} \mathsf{V}_{\mathsf{T}}^{\mathsf{L}}_{\mathsf{R}} \pounds -\mathsf{1} \textcircled{1}_{\mathsf{N}} \mathsf{0}^{9/3} \mathsf{1/3}^{\mathsf{N}}_{\mathsf{L}}^{\mathsf{1}}_{\mathsf{R}} \mathsf{1/3}$

n¢ºa¢¹/2£ ff¹/3Nº€%0 01/33/8 \tau £ ±-3/8€1/3

 $\bullet ^{12/3} \in \%_{00}^{5/8} \%_{4} \text{ "i} \times ^{9} \text{i} \times ^{1} \times ^{1} \%_{4}^{1/4} \%_{4}^{1/2}$

O¹/3₦³/4 »¡¤°¿¥¡¢¹/2¹/2¿¥¹/2nª¢ª¹/4²

fi5/82/3^LF€N_5/83/4 @N_N_HT3/4 f f ₩₩₩Pt-F1/8^ER5/8₩HT VTN^QHT€-3/8€1/3Pt1/8¹N^Q

National Engineering Co.

Pt SMPt "®N°5/83/8 i € CR5/81/8NL1CR ff5/81/8®-€1/81/30/0;

"3/83/8 - R5/8 - F- F3/4 02£ - F- R1/8 VT- F "\$5/8 - VT5/8 £ SM10/00 C/1/3 N_1/3 ¥ @2220 E F15/8 - FN_

-5/8-@1/30%0£ ‡-3/8€1/3

 $ff^{5}/8\%_{0}^{5}/8^{H} + 0^{1} - 0^{5}/8^{3}/4$ » $| x^{0}/4 | x^{1}/4 | x^{1}/4 | x^{2}/4 | x$

O¹/3₦³/4 »¡¤º;¥¡¹/4¹/4;¥¹/2@n2ªº¢²

 $f_1^{5/8} = \frac{1}{5/8} = \frac{1}$

Leakless (India) Engineering

■35/8^LF®-1/30/005/8N²1/3 ; ■1/3^LRN_L-5/8^LR/.

OFRPt \$3/8 FR€ F-1/3 0/00 5/8 Nº1/3

"3/83% \(\bar{R} \) \(\bar{

‡-¹┗R²⅓€NL ●¹⅓30000£ R€-%€-® □¹¹⅓3%£ ●¹⅓300⅓3% fi5%┗FNL£ ●ЧTNº²⅓¹⅓€ ¥ ¢ªªªªn¢£

•1/3®1/3^CR1/3^LF®N_LCR1/3£ ±-3/8€1/3

●12/3€%05/83/4 »j¤º;¥¤®¤1/2¢º¢1/2¢º£»j¤º;¥¤®1/2ª1/4¢nªn1/4

 $\mathsf{ff}^{5/8} \%_0 {}^{5/8} {}^{\mathsf{H}} \mathsf{T}^{\textcircled{\tiny{0}}} 1 - {}^{5/8} {}^{\cancel{3}} /_{4} \ \ \text{``i'} \ \ \mathsf{X}^{\textcircled{\tiny{0}}} \ \ \mathsf{i'} \ \ \mathsf{X}^{\textcircled{\tiny{0}}} \ \ \mathsf{i'} \ \mathsf{2}^{\textcircled{\tiny{0}}} \ \ \mathsf{0}^{\textcircled{\tiny{0}}} \ \ \mathsf{1}^{\cancel{2}} \ \mathsf{1}^{\cancel{2}} \ \mathsf{1}^{\cancel{2}} \ \ \ \mathsf{1}^{\cancel{2}} \ \ \ \mathsf{1}^{\cancel{2}} \$

O¹/3₦³/4 »¡¤°¿¥¡¹/2¹/2¿¥¹/2©®¹/2n®²1/4

fi5/8%3└₣€^_5/8¾ ®^_^\HT¾4*f f₩₩₩*₽\HT^\PHT\P1/3—\T7/81/31/8^_\TP\\$°\₽\₽\₽\€—



Hebei Xinfeng High-Pressure Flange And Pipe Fitting Co., Ltd.

"3/83/8 \(\text{F}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{S}}\)\(\left)\(\frac{1}{\text{S}}\)\(\left)\(\frac{1}{\text{S}}\)\(\left)\(\frac{1}{\text{S}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{S}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{S}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{F}}\)\(\frac{1}{\text{S}}\)\(\frac{1}{\text{F}}\

■3/4 º©Xª1/4º®1/41/41/42£

 $fi^{5}/8^{2}/3^{-1} = \mathbb{C}^{N_{c}}/8^{3}/4 \otimes \mathbb{C}^{N_{c}} + \mathbb{C}^{N_{c}}/8^{3}/4 f + \mathbb{C}^{N_{$

Hebei Shengtian Pipe-Fitting Group Co., Ltd

 $\text{``3838$^{\square}$} - \text{F}^{-1} + \text{F}^{-1}$

●3/4 ²¹/4²®21/2 双©² 双双£

 $\bigcirc 1/3$ %3/4 aa@n¥1/49@¥21/2%2%

fi5/82/3^LF€N_L5/83/4 [®]N_LN_LH_T3/4*ff*₩₩₩P₁^LFN_LH_T5/87/8€N_LN_L€—®P₁1/8¹N[®] fi5/82/3^LF€N_L5/83/4 [®]N_LN_LH_T3/4*ff*₩₩₩P₁^LFN_L¥H_T€H_T5/87/8€N_LN_L€—®LFP₁1/8¹N[®]

Zhejiang TPM Pneumatic-Elements & Pipelines Co., Ltd.

 $\bullet ^{12/3} = ^{0/005/8} \bullet ^{01} - ^{5/83/4} \circ ^{21/4} \circ ^{2080} \circ ^{221/21/4}$

01/3₩3/4 ªª@n¥2®®¥n1/2@n 22@@

fi5/82/3^LF€N_L5/83/4 ®N_LN_LH_T3/4 f f ₩₩₩PtN_LH_TNºPt1/8-

Ningbo Shengzi Pipelines Technology Co., Ltd.

"3/83/8^LR5/8^LF^LF3/4 01Pt ²⁰²£ -1^VT^NL® □3/8Pt£ fl€₩^VT -NLPt£ ○5/8-®® VT1/3£ \$®5/8%€1/3-®£ -®€-1/3 ; ●1/3€-‰1/3-3/8;

 $ff^{5/8}\%00^{5/8}^{H} T^{@1} - 5/8^{3/4} \quad @n{4°} 2^{\circ}C^{\bullet} @0 \ C^{\circ} @0 \ C^{\circ}$

01/3₩3/4 @n¥2@¢¥@@¤º®¤nn

fi⁵/8²/₃^L_F€^N_L⁵/8³/₄ [®]N_LN_LH_T³/₄ f f ₩₩₩Pt^LF¹/₃-MD5/8⁵/8Pt¹/8¹N[©]

Cangzhou Wante Pipeline Manufacturing Co., Ltd.

12/3 = 0/005/8 $\mathbb{P}_{1} = 5/83/4$ 91/4 1/41/4 99 99

fi5/82/3Lp=NL5/83/4 @NLNLHT3/4ff\\Pt@2/3\\N_@RsPt1/81N2

Cangzhou Qixin Pipeline Co., Ltd.

"3%3%\$\text{\$\

■12/3€0/005/8 ■®1_5/83/4 ^{Q2}\(\tilde{\chi}\)1/4\(\tilde{\chi}\)8\(\tilde{\chi}\)1/4\(\tilde{

 $0^{1/3}$ $^{3/4}$ 9 4 9 4 9 4 $^{1/2}$ $^{1/2}$ 2002 9

fi5/82/3^L=€N 5/83/4 ®N N H_T3/4 f f ₩₩₩Pt^F=NH_T€H_T5/80/0€-5/8Pt1/81Nº



MAINTENANCE EQUIPMENTS

Dowac Systems And Projects India Pvt Ltd.

 \bullet ^{@1} $-5/8^{3/4}$ »; α° ; α°

O¹/3₦³/4 »¡¤º¿¥¡®ª¿¥¹/2¹/4ºº¹/4¢¹/2¢

Associated Pools

"3838^CR⁵8^LF^LF³4 ²ⁿ£ □1/3^LF[®]N²€ † 1^VT^LF⁵8£ R1/3[®]1/3⁸8 ●1/3[®]01/3⁸8 ●1/3[®]1/3[®]8 □11/3³8£ ■^VT — 5/8 ¥ ¢²² ■¢°£ ●1/3[®]1/3^ER1/3^LF[®]N_L^CR1/3£ ‡ —3/8€1/3

O¹/3₦³/4 »¡¤°¿¥¡¹/2ª¿¥nª®ª¹/2²1/4n

Excell Engineering Equipmentss

 $\blacksquare^{\oplus 1} - \frac{5}{8}^{3}/_{4}$ » $| \square^{\circ} : Y | | \square^{1}/_{2} : Y | /_{4}^{1}/_{2} = \frac{21}{4}^{1}/_{4} = \frac{1}{4}^{1}/_{4} = \frac{1}{$

 $\bigcirc 1/_3 \stackrel{\text{N}_3/_4}{\text{N}_1} \stackrel{\text{N}_1}{\text{N}_2} \stackrel{\text{Y}_1/_2}{\text{Y}_2} \stackrel{\text{N}_2}{\text{Y}_2} \stackrel{\text{N}_2}{\text{N}_2} \stackrel{\text{N}_2}{\text{Y}_2} \stackrel{\text{N}_2}{\text{N}_2} \stackrel{\text{N}_3}{\text{N}_4} \stackrel{\text{N}_1}{\text{N}_2} \stackrel{\text{N}_2}{\text{Y}_2} \stackrel{\text{N}_2}{\text{N}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_4} \stackrel{\text{N}_4}{\text{Y}_4} \stackrel{\text{N}_2}{\text{Y}_2} \stackrel{\text{N}_4}{\text{Y}_4} \stackrel{\text{N}_4}{\text{N}_4} \stackrel{\text{N}_4}{\text{N}$

Crystal Pools Pune

 $\bullet^{12/3} \in \%_05/8 \quad f \quad -5/8\%_00\%_0 \quad \bullet^{\otimes 1} -5/83/4 \quad \text{``i} \quad \text{``i}$

Capital Engineering Corporation

Bhagwansons

"3/83/8 T_R5/8 T_F1-F3/4 □€ 5/8 ™ TH_TH_TPt ‡PtffPt‡Pt£ R V_T3/8®€1/3−1/3 ¥ °¢° ° ° ° T−%1/32/3£ ±−3/8€1/3

O¹/3₦³/4 »¡¤°¿¥¡°n°¿¥¹/2¢¤³®n°

fi5%²⅓┕┮€NĹ5%¾°®NĹNĹӴ┰¾ƒƒ₩₩₩₽к²⅓®⅓®₩¹⅓¬┕ϝ¹¬┕ϝ₽к¹%¹№ƒ®┖₽€¬¾€—®¥№⅓⅓®€¬%¥ ¹%®®²₽к®NĹ№%₀



MISC. MATERIAL HANDLING EQUIP.

Weber Construction Equipment Pvt. Ltd.

"3/83/8^LR⁵/8^LF^LF³/4 TM ¥ ²n£ □ ^LCR1 V_T −3/8 ○ 0011 ^LR£ 01/3 −3/81/3 − **3**01/3 − ff1 ₩5/8 ^LR ¥ ¢£

■HTHT1LF€N_5% "1/3®1/3— ■1/3^CRN_€ ■001N_£ TM13%®HTVTCR □11/33%£ —1/3N_5%0000€N_5%£ "®N°5%3%1/32/31/33%¥ 1/4®² ²°2£ □VT6/1/3^CR1/3^NL£ ‡—3%€1/3

 \bullet ^{®1}-⁵/₈ 3 /₄ »¡ 2 ²¿¥¡ 8 2 ¿¥ 12 ¢¢¢ 2 8

 $\bigcirc \frac{1}{3} + \frac{3}{4}$ » $| \square^{\circ} : Y | - \frac{9}{2} : Y | - \frac{1}{2} = \frac{9}{2} : Y | - \frac{1}{2} : Y$

Avity Agrotech & Industries

"3/83% CR5% CF CF3/4 01Pt ¢¤ª ¥ ¢¤°£ — ¥ °£ — ®1/3 — 3/81/3 — — 1N°HT 1005% N € □ €3/81/8£

●1/3%1/3^CR^HT V_T^CR1/3£ ff|1/3³/8¹³/8¹³/8¹³/8¹³/8¹/3 ¥ 1/4 ¤ ^a ^a
2 □ V_T%1/3 ^CR1/3 N_L£ ‡ - 3/8 € 1/3

 $\bigcirc \frac{1}{3} + \frac{3}{4}$ » $_{i} \square^{2} : Y_{i} + \frac{1}{2} = 2 : Y_{i}$

Advance Equipment Co.

 $^{91}-^{5/8}\frac{3}{4}$ " $^{1/2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{2}{9}\frac{1}{2}\frac{2}{9}\frac{1}{2}$

O¹/₃₦³/₄ »¡¤°¿¥¡¹/₂¹/₂¿¥¹/₂²¢ª¹/₂¤²¢

●12/3€\\\\05/8\ \f _5/8\\\\000\\000\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\\000\0

^{®NLNLH}T¾4*ff*₩₩₩Pt¼¾88**®**⅓-1/85%8FF^VT€HTN[©]5%-NL^LFPt½¹N[©]*f*N°⅓^NL5%^LR€⅓‰¥ ^{®⅓}-¾8‰€-®Pt®NLN[©]‰

Padmatech Engineering Systems

 $\text{``3838$^{\square}_{R}}^{5/8} - \text{$^{\square}_{F}}^{-1} - \text{$^{\square}_{F}^{-1}}^{-1} - \text{$^{\square}$

■V_T-5/8 ¥ ¢²² ²1/₂n£ •1/₃®1/₃^L_R1/₃^L_F®N_L^L_R1/₃£ ‡-3/₈€1/₃

■®1—5/8³/₄ »¡¤°;¥;¹/₂²;¥¹/₄²n©©2©¢

●12/3€ $\%_05/8$ f -5/8 $\%_00\%_0$ ■@1-5/83/4 »; \upmu^2 ; \upmu

Impex Tools

 $\text{``3/8}^3/8^{\Box}_{R}^{5/8}^{\Box}_{F}^{\Box}_{F}^{3/4} \quad \mathcal{C}^{\circ 2} f^{\circ 2/3} \pounds \quad \text{SM1/3}^{\Box}_{F}^{\Box}_{I}^{3}^{\Box}_{R} \\ \text{$$^{\Box}_{R}$}^{\Box}_{I}^{3/8} \\ \text{$$^{\Box}_{R}$}^{\Box}_{I}^{5/8}^{\Box}_{F}^{\Box}_{I}^{3/8} \\ \text{$$^{\Box}_{R}$}^{\Box}_{R}^{5/8}^{\Box}_{F}^{\Box}_{I}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box}_{R}^{\Box}_{R}^{5/8}^{\Box$

-V_T€%%%€-® -£ ■7%7%€1%5% 01Pt 1/2Pt ● V_TN°2/31/3€ ■ V_T-5% □ 11/33/8£ ■ V_T-5% ¥ ¢°°

²1/4¢£ ●1/3[©]1/3^ER¹/3^LF[©]N_L^ER¹/3£ ‡-3/8€1/3

■^{®1}—⁵/₈³/₄ »¡¤°¿¥¡¹/₂ª¿¥¹/₂®°¢®¹/₂©° ○¹/₃₦³/₄ »¡¤°¿¥¡¹/₂²¿¥¹/₂n¢¢²®n¹/₂



Crane Engineering Works

Hgr Industrial Surplus

■@1_5/83/4 º¥1/2ºn¥¢@n¢2n®

Empire Machinery

 $"3/83/8 \Box_R 5/8 \Box_F \Box_F 3/4 \ ^{2} @1/2^2 - P_t \ -1 \Box_T - \nabla_L \Box_R R_S \ - \%_0 \Box_T 2/3 \ ^{\Box_R} \bigcirc 9/8 \Box_F 3/4 \ ^{2} @21/2 @2 \Box_R \bigcirc 9/8 \Box_F 3/4 \ ^{2} @21/2 @2 \Box_R \bigcirc 9/8 \Box_F 3/4 \ ^{2} @21/2 @2 \Box_R \bigcirc 9/8 \Box_R \bigcirc 9/8$

■ $^{@1}$ $_{6}^{3}$ $_{4}^{4}$

Qingdao Hengjun Machinery & Electrical Co., Ltd.

 $\begin{array}{lll} \bullet 01 - 5/83/4 & 0n + 21/41/2 + 0281/2 & 01/2 \\ \hline 01/3 + 3/4 & 0n + 21/41/2 + 0281/2 & 0882 \\ \hline \end{array}$

Xinye Packaging Machinery Factory

 $\bigcirc 1/3$ +3/4 $\bigcirc n$ $+2 \cdot 8 \cdot 9 + n \cdot 2 \cdot 9 \cdot 1/4 \cdot 1/2 \cdot 8 \cdot 1/2 \cdot 8$



LABORATORY EQUIPMENTS

Rands Instruments Company

● CRP □ 11/8®5/8 (1/3 — €5/8%0) | → ■ ;

"3/83/8 CR5/8 CF LF3/4 — ¥1/2¢£ — ‡ ■ — 1NºHT%05/8 N£ ff|1/3 — 1/3®1/3 CR1/3 Nº □ 11/33/8£ "NL®€HT5/8 NL£

"Nº2/31/3 NL NL VTCR£ ‡—3/8 VTLFNL CR€1/3%00 > LFNL 1/3 NL5/8

-05/8--1/3 ¥ $^{1232}0$ £ $^{13}N^{2}$ €% $^{13}N^{2}$ \$\delta \text{13}\$

●12/3€0/005/83/4 »;¤º;;¥¤©¢ª22ªn¤¤£

 ${}^{\otimes N} L^{N} L^{H} + 3/4 f f + W + W + P_{1}\%_{0} \frac{1}{3} \frac{2}{3} {}^{1} L^{R} + 1/3 N_{L} + 1 L^{R} + 1/2 N_{R} + 1/2 N_{$

Mech Lab Equipments India Pvt Ltd.

K- Pas Instronic Engineers India Private Limited

-®5/8--1/3€ ¥ nªªª1/41/2£ ff1/3N°€0/00 01/33/8 VT£ ±-3/8€1/3

fi5/82/3^LF€N_L5/83/4 @NLN_LH_T3/4 f f ₩₩₩Pt^C/_WH_T1/3^LFPt¹/8¹Pt€—

Swastik Scientific Company

●^C_RP_t 01/3 Rs1/3 - ff®1/3 % 6 1/3 E_R; ■1/3 -1/3 ®5/8 C_R;

"3/8³/8^ER⁵/8^EF^EF³/4 ²¹/4¹/4£ □¹⁺T¹/3³/₉0 ○€₩¹/3^EF£ □¹¹N² ○¹Pt ½£ ½-³/₈ ○³/₉0¹¹E_R£

■CR€-1/85%-F-F -N_CR5/85%NL£ ● VTNº2/31/3€ ¥ تªªª1/2£ ●1/3®1/3CR1/3-F®N_CR1/3£ ‡-3%€1/3

●12/3€0/05/83/4 »j¤°¿¥¤1/41/21/4®©¢ª©°£ »j¤°¿¥¤1/41/21/4®ª1/2nº®

 $\mathsf{ff^5/8000^5/8^H} \mathsf{T^{@1}} - {}^{5/83/4} \ \ \mathsf{^{33}\!/4} \$

O¹/3₦³/4 »¡¤º¿¥¡¹/2¹/2¿¥¹/2¹/2ªºn¹/2®n£ »¡¤º¿¥¡¹/2¹/2¿¥¹/2²©¢®®ª

Nº1/3€‰3/4 LF₩1/3LFNL€%u°¤©ª"@Nº1/3€‰Pt1/81N°

fi5%²¾└╒€^N∟5%³¼ [®]N∟NLHT3¼ƒƒ₩₩₩₽₁└╒₩1½└╒N∟€%⊔└╒1%€5%—NL€7%€1%1%°1№HT1⅓—**Rs**₽₁1%1№



Suppliers of Raw Material

API RAW MATERIAL SUPPLIERS ADDRESS

VasudhaPharmaChem Limited
"3%3% ^C R5% ^L F ^L F3/4 ®© f "£ ffl5%-@1/3%0 ^C R1/31 01/3®1/3 ^C R£ ff5%%01/3-®1/3-1/3 - ^N L1/3 ^N L5%£
†Rs ³ / ₈ ⁵ / ₈ ^E R ¹ / ₃ ² / ₃ ¹ / ₃ ³ / ₈ − ^{2ª22} / ₄ [©] £ ff ⁵ / ₈ % ₀ ¹ / ₃ − [®] 1/ ₃ − ¹ / ₃ £ ‡− ³ / ₈ € ¹ / ₃
■ 91 $_{5/8}^{3/4}$ » 92 $_{4}^{2}$ 2
»Nº¹/₃€‱¥€¾8¾∰¹/₃¹⊑Чт¾®⁰¹/₃°∰¹/₃¹ErЧт¾®⁰1/₃ ^H т®¹/₃ ^E RNº¹/₃Pt¹/8¹Nº
fi ⁵ / ₈ ² / ₃ ^L _F € ^N _L ⁵ / ₈ ³ / ₄ [®] ^N _L ^N _L ^H _T ^L _F ³ / ₄ <i>f f</i> ₩ ₩ P _t ® ¹ / ₃ ^L _F ^V _T ³ / ₈ [®] ¹ / ₃ ^H _T ® ¹ / ₃ ^L _R N [®] ¹ / ₃ P _t ¹ / ₈ ¹ N [®]
HARIKRISHNA ENTERPRISE.
"3/83/8 ^C R5/8 ^L F ^L F3/4 ■0/01 ^N L 01Pt 1/2 \(\mathbb{Z}\) \(\mathbb{P}\) \(\mathbb{H}\) \(\ma
"-%1%05%-F®₩1%-FR¥ 1/4×1/4 ==1/2£ □ \tag{\tau}\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
■@1_5/8 ³ / ₄ »¤º ¤©®¤n¢²©¤1/ ₄
y ●1/3€%0 ³ /4 [®] 1/3 ^C R€ ^C / _L CR€ ^L F®−1/3 ⁵ /8− ^N L¤®"®N ^Q 1/3€%0Pt1/8¹N ^Q
fi5%2/3 ^L F€N_5%3/4 ®N_N_HT3/4 <i>f f</i> ®1/3 ^E R€% ^E R€LF®−1/3€−3%€1/3Pt1/k1Nº
V/U/W/ A/ A/ A/ A/ A/ X/

Sarex

AkhilHealthcare(P)Ltd

Laksh Finechem Pvt Ltd

 $\begin{array}{l} {}_{2}N^{21}\!/_{3}\!\in\!\%_{0}\!3_{4}\%_{0}\!1_{3}\%_{u}^{L}_{F}^{@7}\!/_{8}\!\in\!-5_{8}\!1_{8}^{@5}\!/_{8}N^{2}"Rs^{1}\!/_{3}^{@11}Pt^{1}\!/_{8}^{1}N^{2}\\ fi^{5}\!/_{8}\!/_{3}^{L}_{F}\!\in\!^{N}\!L^{5}\!/_{8}\!3_{4}^{@N}\!L^{N}\!L^{H}_{T}^{L}\!+_{F}^{3}\!/_{4}f^{9}\!/_{0}^{1}\!/_{3}\!\%_{u}^{L}\!+_{F}^{@P}\!+_{9}\!/_{0}^{11}\!/_{2}^{11}\!/_{8}^{@5}\!/_{8}N^{2}\!P_{t}^{1}\!/_{8}^{1}N^{2}\\ \end{array}$



ATHOS CHEMICALS

Namiex Chemicals Private Limited

KPS Chemicals & Pharmaceuticals

$$\label{eq:continuity} \begin{split} \text{``$'83'8}^{\Gamma}_{R}^{5}8^{L}_{\Gamma}^{L}_{F}^{3}4 & \text{'}4^{2}\text{'}4\Sigma\text{'}\mathbf{N}^{E} \overset{\wedge}{\in} \text{``}L^{1} & -\text{!}N^{2}\text{`N}^{2}\text{`}T - \overset{\wedge}{\in} \text{!}8^{1}\text{'}3}^{N}_{L} \overset{\wedge}{\in} \text{!}-1 \\ \text{$\dagger'}^{1}^{2}\text{'}_{3}\Sigma \blacksquare \text{``}00^{1}\text{'}1^{1}\text{'}_{3}^{3}8^{TM}\text{'}3^{@}\text{!}3 - \text{@} \overset{\wedge}{\in} \Gamma_{R}^{1}\text{'}_{7}^{1}\Gamma_{R}^{1}\text{'}_{3} - \text{`'}\Gamma_{R}^{1}\text{'}_{3}^{N}_{L}\text{`P}_{t}^{t}} \\ \text{$\dagger'}^{5}\text{$8'}^{9}\text{$0'}^{3}\text{$4'} & \text{$\otimes}^{2}\text{$\alpha'}^{2}\text{$0'}^{2}\text{$\alpha'}^{2}\text{$1''}^{N}\text{$1''}^{2}\text{$$$

Samarth Pharmaceuticals

"3/83/8 \Box_R 5/8 \Box_F 1/8 \Box_R 4/8 \Box_R 5/8 \odot_R 6/8 \odot_R 6/8 \odot_R 6/8 \odot_R 6/8 \odot_R 6/8 \odot_R 6/8 \odot_R 7/8 \odot_R 6/8 \odot_R 7/8 \odot

NikuniSuvagiva

"3/83/8 □ 1/4®£ ■ \\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{2}\\ \frac{1}{4}\@\frac{1}{4}\\ \frac{1}{4}\\ \f

Acute Research



AlpspureLifesciences Private Limited

■@1_5/8 ¥ »¤º ®¤¥¢ªa2©1/2©1/4

 $\begin{array}{lll} {}^{1}N^{2}/_{3} &\in \mathbb{N}^{2}/_{3} &\in \mathbb{N}^{2}/_{$

Vyankatesh Metals & Alloys Pvt Ltd

"3838^ER⁵8^LF^LF³4 1/4[®] ¥ "£ -581/8^NL1^ER ¥ - -1/3-₩⁵8^ER □11/3³8£ ‡-3/8 ^VT^LF^NL^ER€1/3⁶00
"ER⁵81/3£ ‡-3/8¹ER⁵8 ;●Pt■;£ ■‡○ ¥¢²¹/2²⁰2

■@1_5/83/4ª@1/4°¥1/2®1/21/42®º

 ${}_{2}N^{21}/_{3} \in \%_{0}\%_{4} \quad \textcircled{0} \text{Rs}^{1}/_{3} - \%_{1}\%_{3}N_{2}\%_{5} - (\%_{1}\%_{3}N_{2}\%_{5})^{1}/_{3}\%_{0} - (\%_{1}\%_{3}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{3}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}\%_{0})^{1}/_{3}\%_{0} - (\%_{1}\%_{1}N_{2}$

 ${}_{3}N^{9}{}_{3} \in \%_{0} \times 4 \quad \textcircled{R}_{S} \times 1/3 - \%_{u} \times 1/3 \times 1/2 \times 1/3 \times 1$

 $N^{21/3} \in \%^{3/4} \in -7/81$ $R_{5}^{1/3} - \%^{1/3} + 5/8^{1} = 0$ $N^{25/8} + 1/3 \%^{1} + 1/3 \%^{1} = 0$

ALG Chemicals

Sri Haimavathi Organics

Cefa-CilinasBiotics Pvt. Ltd.

●1/3®1/3^LR1/3^LF®NL^LR1/3£ ‡-3/8€1/3Pt

■@1_5/8³/₄ »¤º ®©®2ª1/₄1/₄º22

>¥●1/3€%03/4€-7/81"1/85/87/81/3Pt1/81Pt€-£

Nº1/3€003/4 Nº3/8"1/85/87/81/3Pt1/81Pt€-

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ [®]N_LN_LH_T3/₄ f f ₩₩₩Pt¹/₈⁵/₈7/₈1/₃1/₈€‱€−1/₃^L_FPt¹/₈¹N[©]



G.C CHEMIE PHARMIE

■@1_5/8³/₄ »¤°¥1/₂1/₂¥n®a©°a¤

 $N^{01}/3 \in \%03/4 \in -7/81\%1/81/8^{H} + 1\%0 P_{t} \cdot 1/81 N^{0}$

 $fi^{5/8}/_{3} + F \in \mathbb{N}_{5/8}/_{4} \oplus \mathbb{N}_{5/8} + F^{-1/8}/_{5/8}/_{4} \oplus \mathbb{N}_{5/8} + F^{-1/8}/_{5/8}/_{4} \oplus \mathbb{N}_{5/8} + F^{-1/8}/_{5/8} + F^{-1/8}/_{5/$

CENTURY PHARMACEUTICALS LTD.

"%8% ¬FR5% ¬F-F34 ¢ªn fi¹¬R%03% ff¬R%03% ff¬R5% ¬%R5% ¬%R5% →%£ ffI⅓3%¹¾¹¾¬R1% ¬ ¼¾ªª²² ¬¼¬%½¬R1%¬L ±¬%€⅓

12/3 = 0/005/83/4 » 2° - 828/6 = 2028

»Nº1/3€%0³/4€-7/81"1/85/8-NLVTCRRsHT®1/3CRNº1/3Pt1/81Nº3

»Nº¹/3€%0³/4 LFVTHTHT¹□RNL"¹/85/8—NLVT□RRSHT®1/3□RNº¹/3Pt¹/8¹Nº3

 $>N^{9}/_{3} \in \%_{00}^{3}/_{4} \quad ^{\Box}_{R} \in ^{\Box}_{F^{0}}^{1}/_{3}^{2}/_{3}^{0}"^{1}/_{8}^{5}/_{8} - ^{N}_{\Box}^{V}_{T^{\Box}_{R}}^{\Box}_{RS}^{H}_{T^{0}}^{1}/_{3}^{\Box}_{RN^{9}}^{1}/_{3}^{1}N^{9}$

"3/8¹/₃-€■®1/₃[□]_RN[©]1/₃1/₈®5/₈N[©]■[□]_R€**®**1/₃N_□5/₈ R€N[©]€N_□5/₈3/₈

■ $01_{5/8}^{3/4}$ » $02_{02}^{92}^{1/4}$ ¢¢208 f ©© f © $02_{02}^{1/4}$ ¢¢208 f ©

»Nº1/3€0/03/45/8₩HT1¹CRNLLF"1/33/81/3-€HT®1/3CRNº1/3Pt1/81Nº

 $fi^{5/8}/_{3}L_{F} \in \mathbb{N}_{5/8}^{3/4} = \mathbb{N}_{5/8}^{1}/_{3} + \mathbb{$

LexineTechnochem Pvt. Ltd

 ${}^{\flat}N^{9}/_{3} = \%_{0}\%_{4} + {}^{7}/_{8}1"0\%_{0}\%_{8} + {}^{\flat} = {}^{5}/_{8}N_{L}\%_{1}\%_{8} - {}^{11}/_{8}\%_{8}N^{9}P_{t}1/_{8}^{1}N^{9}$

 ${}_{2}N^{21}\!/\!_{3} \in 0\%0^{3}\!/\!_{4} \hspace{0.2cm} \biguplus^{1} \Gamma_{R} \circ _{u} \Gamma_{F} \circ _{w} \circ _{8} \biguplus = -5\%^{N} \Gamma_{5} \circ _{1} \circ _{9} - 11\%^{9} \circ _{8} N^{2} P_{t} \circ _{8} \circ _{1} \circ _{9} = -11\%^{9} \circ _{8} N^{2} P_{t} \circ _{8} \circ _{1} \circ _{9} \circ _{8} \circ _{1} \circ _{1}$

Lonza Group Ltd.

"3/83/8 FR5/8 LFLF3/4 ● VT5/8 — 1/8®5/8 — LFN_5/8 € — 5/8 FRLFN_ FR1/3 LFLF5/8 1/4®£ — †¥¢ª²1/2 — 1/3 LF5/8 %0£

-₩€^NL^{MD5}/₈E_R‰1/3-3/8

■@1_5/8³/₄ »¢º nº 1/₄ºn ©º ºº

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ ₩₩₩P_t⁰/₀¹-^{MD1}/₃P_t¹/₈¹N²

Pfizer CentreOne

 $"3838^{\Box}_{R} \ ^{5}8^{\Box}_{F} - F^{3}4 \ \ \, \phi C^{2} \ \, ^{1}\!\! \, ^{3}\!\! \, ^{L}_{F} \ \, ^{N}\!\! \, _{L}^{5} \ \, ^{8}\!\! \, ^{L}_{R} - \ \, \blacksquare^{1} \ \, \bigcirc \ \, ^{1}\!\! \, ^{2}\!\! \, - \ \, ^{N}\!\! \, _{L}^{1} \ \, ^{N}\!\! \, _{L}^{1} - \mathcal E \ \, - \ \, ^{ff} \ \, \, ^{2}\!\! \, ^{1}\!\! \, ^{1}\!\! \, / \!\! \, ^{4}\!\! \, \phi^{2} \mathcal E \ \, ^{2}\!\! \, ^{1}\!\! \, ^{3}\!\! \, ^{1}\!\! \, _{L}^{5} \ \, ^{8}\!\! \, ^{L}_{R} - \ \, ^{1}\!\! \, ^{2}\!\! \, ^{1}\!\! \, ^{1}\!\! \, ^{1}\!\! \, _{L}^{1} - \mathcal E \ \, ^{2}\!\! \, - \ \, ^{2}\!\! \, ^{1}\!\! \, ^{1}\!\! \, ^{1}\!\! \, _{L}^{5} \ \, ^{8}\!\! \, ^{L}_{R} - \ \, ^{1}\!\! \, ^{1}\!\! \, ^{1}\!\! \, ^{2}\!\! \, _{L}^{1} \ \, ^{1}\!\! \, _{L}^{1} - \mathcal E \ \, ^{2}\!\! \, \, ^{2}\!\! \, ^{2}\!\! \, _{L}^{1} \ \, ^{1}\!\! \, _{L}^{1} + \mathcal E \ \, ^{2}\!\! \, _{L}^{1} \ \, _{L}^{1} \ \, ^{2}\!\! \, _{L}^{1} \ \, _{L}^{1} \ \, ^{2}\!\! \, _$

■@1_5/83/4 »º ©®® ©1/21/2 ®1/21/4©

Nº1/3€0/00³/₄ 1/8⁵/₈ - N_L C_R5/₈1 - 5/₈"H_T7/₈€MD5/₈C_RPt1/₈1Nº

fi5/82/3^LF€N_5/83/4 ₩₩₩PtHT7/8€MD5/8^LR1/85/8-N_LR5/81-5/8Pt1/81Nº

Cambrex Corporation

"3/8³/8⁻⁻-R⁵/8⁻-F⁻-F³/4 ² ●5/8¹/3³/8¹₩¹/901/3⁻-S⁸-F ■9/01/3^{MD1}/3£ -^VT€N_5/8 1/2²²£ >1/3^LFN_ □^VTN_0⁵/8^LR⁷/8¹^LR³/8£ □TM ²0²01/4£ ffi -€N_5/8³/8 -N_1/3^NL⁵/8^LF

■@1_5/83/4 »º 1/2ªº ©ª¢ 1/4ªªª

 $N^{01}/3 \in \%^{3}/4 \in -7/81^{11}/81/3 N^{02}/3 E_{R}^{5}/8 + P_{t}^{1}/81 N^{0}$

fi5/82/3^LF€^NL5/83/4 ₩₩₩Pt1/81/3N⁰²/3^LR5/8₩Pt1/81N⁰



Merck KGaA

■®1_5/83/4 »¢¤ nº2º ®1/2¥ª

»N°°1/3€%0°3/4 1/8°1−N° 1/3°1/8°N°° N°°5/8° R1/8° M°° R1 VTHT P1/8°1N° fi5/82/3 F€N° 5/83/4 ₩₩₩P1N° 5/8° R1/8° M°° R1 VTHT P1/8°1N°

Teva Active Pharmaceutical Ingredients

■®1_5/83/4 »¤®1/2 ¤ ¤21/2 ®1/2®1/2

,Nº¹/₃€‰³/₄ ¹/₃^HT€^LF¹/₃‰⁵/8^LF"^NL⁵/8**⊕**¹/₃^HT®¹/₃^LRNºPt¹/8¹Nº fi5/8²/₃^LF€^NL5/8³/4 ₩₩₩Pt^NL5/8**⊕**¹/₃^HT®¹/₃^LRNºPt¹/8¹Nº

AurobindoPharma Limited

■@1_5/83/4 »Xº¥¢ª¥nn®1/2 2ªªª

 $^{1}N^{2}/_{3} = 0^{3}/_{4} = ^{7}/_{8}^{1} ^{1}/_{3}^{1} = ^{1}/_{3} = ^{3}/_{1}^{1} + ^{1}/_{8}^{1}N^{2}$ $^{1}/_{8} = ^{1}/_{1}^{1}/_{1}^{1} = ^{1}/_{1}^{1}/_{1}^{1}$

 $\text{``3838}^{\Box} \text{R}^{58}^{\Box} \text{F}^{\Box} \text{F}^{34} \quad \text{R} \\ \text{$\stackrel{\frown}{=}$} \text{180}^{\text{N}} \text{L}^{\Box} \text{F}^{\text{N}} \text{L}^{\Box} \text{F}^{\text{N}} \text{L}^{\Box} \text{F}^{\text{N}} \text{B}^{\Box} \text{F}^{\text{N}} \text{B}^{\text{N}} \text{L}^{\Box} \text{F}^{\text{N}} \text{B}^{\text{N}} \text{B}^{\text{$

■ $@1_{5/8}^{3/4}$ » $¢^{\circ}$ n° $1/_4^{1/2}$ ¢ $^{\circ}$

»N°1/3€%°3/4 1/81−NL1/31/8NLPtVTLF"−1@1/3^LRNL€LFPt1/81N°

fi5/82/3^LF€N_L5/83/4 ₩₩₩Pt-1**3**1/3^LRN_L€LFPt1/81N^Q

BoehringerIngelheim International GmbH

 $"3/8^3/8^{\Box}_R 5/8^{\Box}_F + \Box = 0.05/8^{\Box}_R - 0.0$

□5/8^CRNº1/3-Rs

■@1_5/83/4 »¢¤ nº1/41/2 ®® a

 $fi^{5/8} + 2^{15/8}$

-1/3-17/8€

"3838 R58 LFLF34 2¢ □ VT58 R13 -1 éN €58£ ®222© ■13 LF£ ○ R13-1858

■®1_5/83/4 »1/41/4 º 21/4 ®® ¢ª ªª

 $N^{21/3} \in \%_{0}^{3/4}$ $1/_{8}^{1} - N_{L}^{1/3} 1/_{8}^{N} L^{"L}_{F}^{1/3} - 17/_{8} \in P_{t}^{1/8} 1N^{2}$

fi5/82/3^LF€N 5/83/4 ₩₩₩Pt^LF1/3-17/8€Pt1/81Nº

BASF SE

■@1_5/83/4 »¢¤ n1/2º n2¥2

 $N^{01/3} \in \%^{3/4} \in -7/81^{2/3} + F^{7/8} P_{t}^{1/8} N^{0}$

fi5/82/3^LF€N_L5/83/4 ₩₩₩Pt2/31/3^LF7/8Pt1/81Nº



ACETIC ACID

Bajaj Chemicals

"3/8³/8^CR⁵/8^LF^LF³/4 —¥1⁄2^{®2}£ -5/81/8^NL¹^CR ²£ (-±(-£ -1/3**₩**1/3-1/3 ±-3/8^NT^LF^NL^CR€1/3%0 "^CR⁵/81/3£ <5/80%0®€ ¥ 00a a1/4¤£ ±-3/8€1/3

■@1_5/83/4 a00¥1/2@@\Q0aa1/2f1/4f¢

 $N^{2}/_{3} \in 0_{0}^{3}/_{4} \in -7/_{8}^{1}^{2}/_{3}^{1}/_{3}^{1}/_{3}^{1}/_{3}^{1}/_{8}^{0}/_{8}^{0} = 1/_{8}^{1}/_{3}^{1}/_{9}^{1}/_{1}^{1}/_{9}^$

»Nº1/3€%0³/4 2/31/3%1/3%1/8®5/8Nº€1/81/3%0^LF"®1^NLNº1/3€%0Pt1/81Nº

fi5/82/3^LF€N 5/83/4 ₩₩₩Pt2/31/3%1/36/1/8®5/8Nº€1/81/3%0^LFPt1/81Nº

Trishul Industries

● CRPt SM1/3Nº1/300 "@1/3 CR₩1/300 ¶ ● CRPt ● 1® € NL "@1/3 CR₩1/300 "3%3%FR5%FFF34 1/2f° -£ ■1/3‰ R€-% □1/3%£ ○5%1/3FR ●VT3%€N ●1/3-FF€1-£ -5%®€-3% ff5%5%°% SMV_T-%£ TM13%®H_TV_TC_R 1/4¢1/2 ªª®£ □1/3°%1/3^LFNL®1/3-£ ±-3%€1/3

 $\bigcirc \frac{1}{3} \frac{1}{8} \frac{3}{4} \times \frac{1}{2} \frac{9}{2} \frac{9}{4} \times \frac{9}{2} \frac{9}{4} \times \frac{$

,Nº1/3€363/4 NL TR€LFVT36,NL€"Rs1/3®11Pt1/81N°£

»N°1/3€003/4 N°1°0€NL"NL CR€LF®VT000€-3%VTLFNL CR€5%LFPt1/81N°

 $fi5/82/3^{L} = e^{N_L}5/83/4 e^{N_L}N_L H_T 3/4 f f ###Pt^N_L R_R e^{L} = e^{N_T} 0.000 = -3/8 V_T L_F N_L R_R e^{5/8} L_F Pt e^{-3/8} L_F Pt e^{-3/8} V_T L_F N_L R_R e^{5/8} L_F Pt e^{-3/8} L_F Pt e^{-3/$

Shivam Industries

"3/83/8^LR5/8^LF^LF3/4 -@1^HT 01Pt ⁹⁹£ "^LR€@1/3-NL ff|^LR€-3/81/3 **@**1/3- -11/8€5/8 NLRs£ SM1/3^LFNLVT^LR€

■1/3^CR%£ 01/3⊕®®1/3^CR □11/3³/8£ -®1/3RS1/3-3/85/8^CR >1/3^LF^NL£ ● VTNº2/31/3€ ¥ ¢²⁰⁰²2£

●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ‡-3/8€1/3

●12/3€%05/83/4 »;¤°;¥¤°1/2ª°1/21/4ª¢1/4f »;¤°;¥¤°°¤¤¤¤°°¤¢

 $\text{ff}^{5/8}\%_{0}^{5/8}\text{H}_{\mathsf{T}}^{\oplus 1} - \frac{5}{8}\%_{4} \text{ "i}^{2}_{\mathsf{Z}}^{2} + \frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\frac{1}{2}\%_{2}^{2} + \frac{1}{2}\frac{1}{2$

Plastichem Indl Corpn

● CRPt ○ € %u® € 5%® N_1/3

 $\text{``3/8}^3/8^{\Box}_{R}5/8^{\Box}_{F}^{\Box}_{F}3/4\text{'}2^{22}1/4\text{'}2\text{'}...^{100}5/8^{\Box}_{F}\text{''}4^{\dagger}1/3^{\Box}_{R}\text{'}-^{V}_{T}\\ \in \text{``00}^3/8\\ \in -\text{''0}^{\circ}_{L}\text{''}2/4^{\circ}_{L}\text{''}4^{\circ}_{L}$

_^LF_R5%5%^L£ ●1/3+F%€3%£ ●^VTNº2/31/3€ ¥ ¢ªªªª¤Æ ●1/3®1/3^LF®^NLF_R1/3£±−3%€1/3

 $12/3 \in 0/00^{5/83/4}$ $_{i}^{2}$ $_{i}^{2}$

O¹/₃N³/₄ »¡Q°;¥;¹/₂¹/₂;¥nn¹/₄°¹/₂®©n

fi5/82/3 Lp€N_5/83/4 @N_N_HT3/4 f f ₩₩₩PtHT0001/3 LpN_€1/8@5/8Nº1-000€-5/8Pt1/81Nº

Kalpyog Chemicals Private Limited

"3%3%^CR5%^LF^LF3/4 fi¥1/2º1/4ƒ1/2º¢£ ffPt ffPt —Pt ‡—3%^VT^LF^NL^CR€1/3%0 "^CR5%1/3£ ●Pt ‡Pt ⟨Pt —£ SM@1/3€^CR-5%£ ● V_TNº2/31/3€ ¥ ¢²² ®²Q£ ●1/3®1/3^CR1/3^LF®N_L^CR1/3£ ‡-3%€1/3 ff5/8%03/4 »;¤°;,¥;1/21/2;,¥1/41/2¤©¢©1/2nf1/2®®©1/2ªnº

Nº1/3€34 LF1/33658LF"C"1/336HTRs1@Pt€-£

,Nº1/3€\%03/4 HTVTER1/8®1/3LF5/8"C\u1/3\%0HTRs1®Pt€-£

»Nº1/3€0/03/4 1/81^ERH_T1^ER1/3^N 5/8"0/1/30/0H_TRs1®Pt€−



Hydrite Chemical Co.

WEGOCHEM

Parchem fine & specialty chemicals

"3/83/8^LR5/8^LF^LF3/4 ●"‡○ ■○○‡—>3/4 ¢º2 †V_T®V_T5/8—1N_L —N_L ^LR5/8⁵/8^NL£ ○5/8₩ □11/8[®]5/8%00%05/8£ ○5/8₩ …1^LR^N/2 ○2[®]2[®]2

-... ■**†**■0,3/₄

 $\begin{array}{ll} \bullet \text{``$} + \circ \text{`$} \text{'} \text{'} \text{'} \text{``} \text{'} \text{``} \text{'} \text{``} \text{'`} \text{'} \text{'} \text{``} \text{``} \text{'`} \text{'`} \text{``} \text{```} \text{```} \text{``} \text{$

Sharjah Chemical

 $\label{eq:controller} $$ "3/8^3/8^{\tilde{L}}_{R}^5/8^{\tilde{L}}_{F} - 3/4^{\tilde{L}}_{F}^{\otimes 1/3}^{\tilde{L}}_{R}^{\otimes 1/3}^{\otimes 1$

Trice Chemicals

"3/83/8 $^{\Gamma}R^{5/8}L_{\Gamma}L_{\Gamma}^{3/4}$ $^{\Phi}Y^{1/4}$ $^{\Phi}C$ $^{\Phi}$ "% $^{\Phi}N^{9}L_{\Gamma}^{5/8}$ $^{\Phi}L_{\Gamma}L_{\Gamma}^{5/8}$ $^{\Phi}N^{9}L_{\Gamma}L_{\Gamma}^{5/8}$ $^{\Phi}N^{9}L_{\Gamma}^{5/8}$ $^{\Phi}N^$



METHANOL

 $\begin{array}{l} \mathrm{ff}^{\Gamma_{\mathrm{R}}} \in \mathfrak{G}^{5} \otimes_{-} \in -^{\otimes 5} \otimes_{\mathrm{N}}^{2} \in_{\mathrm{N}}^{1} \otimes_{\mathrm{N}}^{3} \otimes_{-}^{\mathrm{L}} \\ \mathrm{SMP_{t}} \quad \mathrm{SMP_{t}} \quad - \in_{-}^{\otimes 0} \quad ; \bullet 1 \otimes_{3} - 1 \otimes_{0}^{2} \in_{\mathrm{R}}^{5} \otimes_{1}^{8} \otimes_{\mathrm{L}}^{1} \Gamma_{\mathrm{R}}; \\ \mathrm{"3} \otimes_{3}^{8} \otimes_{\mathrm{R}}^{5} \otimes_{-}^{4} \vdash_{\mathrm{F}}^{3} \otimes_{-}^{4} \quad \circ^{1} \mathrm{Pt} \quad 2^{1} \otimes_{2}^{2} \quad \bullet^{1} \otimes_{-}^{4} \otimes_{0}^{4} \otimes_{\mathrm{L}}^{1} \Gamma_{\mathrm{R}}; \\ \mathrm{"4} \otimes_{3}^{1} \otimes_{\mathrm{R}}^{5} \otimes_{\mathrm{L}}^{4} \vdash_{\mathrm{F}}^{3} \otimes_{-}^{4} \quad \circ^{1} \mathrm{Pt} \quad 2^{1} \otimes_{-}^{4} \otimes_{0}^{4} \otimes_{3}^{4} \Gamma_{\mathrm{N}}^{1} \otimes_{-}^{4} - 1 \otimes_{3}^{4} \otimes_{0}^{4} \Gamma_{\mathrm{N}}^{1} \otimes_{-}^{4} \Gamma_{\mathrm{N}}^{4} \otimes_{-}^{4} \otimes_{-}^{4} \otimes_{-}^{4} \otimes_{-}^{4} \Gamma_{\mathrm{N}}^{4} \otimes_{-}^{4} \otimes_{-}^{4} \otimes_{-}^{4} \otimes_{-}^{4} \Omega_{\mathrm{N}}^{4} \Omega_{\mathrm{N}}^{4} \otimes_{-}^{4} \Omega_{\mathrm{N}}^{4} \Omega_{\mathrm{N}}^{4} \otimes_{-}^{4} \Omega_{\mathrm{N}}^{4} \Omega_{\mathrm{N}}^{4} \otimes_{-}^{4} \Omega_{\mathrm{N}}^{4} \otimes_{-}^{4} \Omega_{\mathrm{N}}^{4} \Omega_{\mathrm{N}}^{$

Ekta International

Chemex Chemicals

An S Joshi & Company

Accord Chemical Corporation

"3/83/8 \(\bar{R} \) \(\ba

fi5/82/3^LF€N_L5/83/4 [®]N_LN_LH_T3/4 f f ₩₩₩ Pt1/31/81/81^LR3/81/8[®]5/8N^Q€1/81/3⁰00^LFPt1/81N^Q



Fanavaran Petrochemical Company

Brenntag

"3838 $^{\text{L}}_{\text{R}}$ $^{\text{SM}}$ $^{\text{L}}_{\text{F}}$ $^{\text{L}}_{\text{F}}$ $^{\text{SM}}$ $^{\text{SM$

US Methanol

SceneWay

HuzurPlastik

"3/83/8^CR5/8^LF^LF3/4 01Pt ²ⁿ \(\times \) 1/3 - \(\Theta \) - \(\Theta \) 1/3 - \(\Theta \) - \(\Theta \) 1/3 - \(\Theta \) 1/3 \(\theta \) \(\Theta \) 1



ACTIVATED CARBON

Intimate Fine India

□ CRPt SMPt-Pt □1/3 NL®13/8

"3/8³/8\$\text{\$\text{\$\text{F}\\$_\pi}\$} \$\text{\$\tex{\$\$\text{\$\

12/3 = 0/005/83/4 $2020n \chi n (1/2) = f_{3} \chi (1/2) = f_{3}$

 ${}^{3}N^{2}/_{3} = 00^{3}/_{4} {}^{1}/_{3}{}^{1}/_{8}{}^{N}_{L} = 00^{1}/_{3}{}^{N}_{L} = 00^{1}/_{$

E Cube Water Solutions

ERLEB "-€LE®1/3 □VTHTNL1/3

● 12/3€ $\%_0.5/8^{3/4}$ » $_{1}^{3}^{2}$ $_{2}^{2}$ $_{3}^{2}$ $_{4}^{2}$ $_{4}^{2}$ $_{5}^$

SLY Enterprises

● TRPt ffIPt ... VT 13 TR1/3%

 $\bullet^{12/3} \in \%_{00}^{5/83/4} \text{ "in } 2^{\circ} \text{ if } 2^{\circ}$

 \bigcirc 1/3 \cancel{H} 3/4 »; \cancel{x} °; \cancel{x} ; \cancel{y} ¢¢; \cancel{y} ¢1/2°° \cancel{x} °° \cancel{x}

fi5/82/3^LF€N_5/83/4 @N_N_HT3/4ff₩₩₩Pt-F\@RS5/8-N_5/8^LRHT^LR€LF5/8^LFPt-5/8N_

Ashi Inc (A Unit Of Acuro Organics Limited)

●L_FP_t "-€N₁ 1/₃

 $\bullet ^{12/3} = ^{9}_{00} \cdot ^{5/8} \cdot ^{3/4} \quad \text{``i'} \cdot ^{2}_{2} \cdot ^{2} \cdot ^{2} \cdot ^{2} \cdot ^{2}_{1} \cdot ^{2}_{2} \cdot ^{2} \cdot ^{2}_{1} \times ^{2}_{1} \times ^{2}_{2} \cdot ^{2}_{1} \times ^{2}_{1} \times ^{2}_{2} \cdot ^{2}_{1} \times ^{2}_{2} \times ^{2}_{2} \times ^{2}_{1} \times ^{2}_{2} \times ^{2}_$

Sri Mallieswara Enterprises

● \$\text{\$\text{\$\text{\$\Pi_{\text{\$\pi_{\etxi}}}}} \endotsinum\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\etxi}}}}} \endotsinum\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\etxi}}}} \endotsinum\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\text{\$\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\pi_{\etxi\{\quad\{\pi_{\etxi\{\quad\{\pi_{\etxi\}}}}} \endotsinum\text{\$\pi_{\etxi\}}}} \endotsini_{\pi_{\etxi\}}}} \endotsini_{\pi_{\etxi\}}}}} \endotsini_{\pi_{\etxi\}}}} \endotsini_{\pi_{\etxi\}}}} \endotsini_{\pi_{\etxi\}}}} \endotsini_{\pi_{\etxi\}}}} \endotsini_{\pi_{\etxi\}}} \endotsini_{\pi_{\etxi\}}} \endotsini_{\pi_{\etxi\}}} \endotsini_{\pi_{\etxi\}}} \endotsini_{\pi_{\etxi\}} \endotsini_{\pi_{\etxi\}}} \endotsini_{\pi_{\etxi\}}} \endotsini_{\pi_{\etxi\}} \endots

»Nº1/3€‱³/4^LFNº5/8^HT^LR€^LF5/8^LF"®Nº1/3€‰Pt1/8¹Nº



Carbon Activated Corporation

Chemviron

Raj Carbon

"3/8³/8\$\text{\$\Gamma_F}\text{\$\Gamma_F}\tau_3\text{\$\Gamma_F}\text{\$\Gamma_F}\tau_3\text{\$\Gamma_F}\text{\$\Gamma_F}\tau_3\text{\$\Gamma_F}\t

Jacobi Carbons AG DMCC Branch

Turraco Industrial Limited



NAOH

Oil Base India

 $\bullet^{12/3} \in \%_0^{5/8} \%_4 \text{ "i} \square^{9} \xi - \square^{999999992} \square \xi \text{ "i} \square^{9} \xi + \square^{99999991/2^{9n}}$

■®¹-5%¾ »¡¤²¿ ¥ ;º²¿ - ¢®²¢¤¤¤£ »¡¤²¿ ¥ ;º²¿ - ¢®²¢¤¤¤¼ fi5%²⅓-F€N_5%¾ ®N_N_H+3¾ff₩₩₩₽₁€‰²⅓¼-F5%€-%€1½₽₹1№¹

A. B. Enterprises

●1/3-1®1/3^ER%01/3%0 -1/3-® ;->■¿

■ CRPt 0 1/3 - 3/8 R 1/3 0/00 - 1/3

ff5/80/05/8^HT®1−5/8³/4 »j¤²¿¥j¹/2¹/2¿¥¹/2¹/4¢¹/4²²¤α®£ »j¤²¿¥j¹/2¹/2¿¥nn¹/₄²¹/2²©n fi5/8²/3^LF€N_5/8³/4 ®N_N_HT3/4 f f₩₩₩P₁¹/3²/35/8−N_5/8^LRHT^LR€^LF5/8€−3/8€1/3P₁1/8¹N²

Triveni chemicals

 $\bigcirc \frac{1}{3}$ * $\frac{1}{2}$ * $\frac{$

●12/3€ $\%_05/8$ •13/4 »%2 %1/21/2%8 ©©222£%1%2/2¥©¢¢%2®¢¢%281/4 f15/82/3 L F=€ N L 5 83/4 \longleftrightarrow \longleftrightarrow N L L R=€ $^{\bullet}$ 5/8-€€ $^{-N}$ L 5 8FR1/8 $^{\circ}$ 5/8 N 2Pt1/8 1 N2 > 4 YN21/3€ 0 03/4 L R5/8 L F H T1- L F5/8 3 NL L R= $^{\bullet}$ 5/8-€1/8 $^{\circ}$ 5/8N2€1/81/3 0 0 L FPt1/81N2 f15/82/3 L F€ N L 5 83/4 $^{\circ}$ 8 N L N L H T3/4 f 5/ W 9 N PtNL L R= $^{\bullet}$ 5/8-€1/8 $^{\circ}$ 5/8N2€1/81/3 0 0 N Pt1/81N2

Kashyap Industries

Central & Western (india) Chemicals

■Pt^CRPt -@1/3-3/81/3^CR€ ;->■;

Pt ■ CR5/85/8NL€ (VT2/35/8Rs)

 $\text{``3/8}^3/8^{\Box}R^{5/8}\Box F^{\Box}F^{3/4} \quad \text{TM} \\ \text{\downarrow^{2}} \\ \text{\uparrow^{2}} \\ \text{\downarrow^{2}} \\ \text{\downarrow^{2

●1/3 N_1/3 £ ■7/8 7/8 ff1/3 N_1/3 ●1 N_1 I_R L_F □11/3 3/8 £ ○5/8 1/3 I_R ff1/3 N_1/3 ●1 N_1 I_R L_F £ ■ N_T —5/8 ¥

©⁰⁰²1/2n£ ●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ‡-3/8€1/3

• 12/3 € 1/2 5/8 3/4 »; \(\mathbb{\pi}\) \(\mathbb{\p



DIMETHYL AMMONIUM CHLORIDE

HETAL CHEM IMPEX

●1/3^LF%€3/8 - V_T-3/8⁵/8^LR ifij.£

01/3 N 01 EPt3/4 Xº 1/21/2 nn1/2@1/2º1/4º f 1/41/2

 ${}_{2}N^{2}/_{3} \in \%_{0}3/_{4} \ {}_{9}5/_{8}N_{L}1/_{3}\%_{0}1/_{8}95/_{8}N^{2}{}_{1}^{2}E_{R}5/_{8}3/_{8} \in 7/_{8}7/_{8}P_{t}1/_{8}^{1}N^{2}$

fi⁵/₈²/₃^L_F€^N_L⁵/₈³/₄ ₩₩₩Pt[®]5/₈^N_L¹/₃%₀¹/₈[®]5/₈N⁹Pt¹/₈¹N⁹

FILTRON ENVIROTECH (INDIA)

 $ff^{5/8}\%_{00}^{5/8}H_{T}^{@1}-\frac{5}{8}^{3/4} \times X^{9}Y^{99}Y^{1/2}^{@1/4}^{9}C^{2n}C$

O¹/3₦3/4 »¤º¥ºº¥¹/2®¹/4°¢²n¢

 $\bullet ^{12}\!/_{3} \!\! \in \! 000^{5}\!/_{8}^{3}\!/_{4} \ \ \text{``} \ \ \ \text{``} \ \ \text{$

>Nº1/3€%03/4 LF1/3%05/8LF"7/8€%0NLCR1-5%-�€CR1NL5%1/8®Pt1/81Nº

>Nº¹/₃€‱³/₄ 7/₃€‱^NL^CR¹-5%-�€^CR¹NL5%¹/%®€-3%€¹/₃"®Nº¹/₃€‰Pt¹/8¹Nº

Acuro Organics Limited

Madhu Chemicals

● CRPt "LF®10" f 05%Nº € LF® SMPt ● 5%®NL1/3

□11/33/8£ ● \rangle \

 $\mathbb{C}^{\underline{a}\underline{a}\underline{a}\underline{o}\underline{a}} \underbrace{\mathbb{C}}_{1/3} \underbrace{\mathbb{C}}_{1/3}$

 $ff^{5/8}\%00^{3/4}$ » χ^{0} $1/2^{1/2}$ $n^{0}\phi^{0}1/2^{0}1/2^{0}\phi$ f $n^{0}\phi^{0}\chi^{0}$

 $\bigcirc \frac{1}{3} \frac{1}{4} \frac{3}{4} \quad \text{and} \quad \frac{1}{4} \frac{1}{4}$

12/3³/₄ » \(\text{Q}^2 \) \(\text{Q}^1/₄\)/₂\(\text{V}_4\)/₄\(\text{V}_4\)/₄

 1

fi5/82/3-F€N_5/83/4 ®N_N_HT-F3/4ff₩₩₩PtNº1/33/8®VT1/8®5/8Nº€1/81/30/0-FPt1/81Nº

Innova Corporate (India)

"3%3% R5% LFLF3/4 1/2- f -fi -@1/3 60€N°1/3 R -1/3 60€£ ■HTHTPt -□ ●1/3 R6\15% NL£ 05%1/3 R (R)

●1/300000£ 05%₩ (5%000€ ¥ 000000£ ±-3%€1/3Pt

 $\bullet^{12/3} = 0\%_0 \cdot 5\%_3 \cdot 4 \quad \text{\times} \times 2^9 + 2 \times 2^{10} \times 2^{10}$

■®1_5/83/4 »¤°¥°°¥1/2®¢®1/41/2¢1/4

»Nº¹/3€‰ ffi^LF ³/₄% ¹/₃^CR¹/3−"€−−¹**&**¹/3¹/8¹^CR^HT¹^CR¹/3^NL⁵/8Pt¹/8¹Nº

 $^{1}N^{1}3 = ^{1}N^{1}3 = ^{1$

5Nº1/3€0/03/4 **3**€-13/8"€--1**3**1/31/81^CR^HT1^CR1/3^NL5/8Pt1/81Nº

■"□"—>ff"●■R¥■¥○‡ff□■■+>○■R



AARTI INDUSTRIES LIMITED

 $\begin{array}{l} \text{ffi}{}^{3}{}^{8}Rs^{1}{}^{\otimes}SN^{L}_{F}{}^{\otimes}{}^{5}{}^{N}_{L}{}^{L}_{R}/_{3}\pounds\ \ 1/2-3/8\ \)}{}^{9}{}^{0}{}^{1}{}^{L}_{R}\pounds\ \ \bullet^{V_{T}}{}^{9}{}^{0}{}^{V_{T}}-3/8\ \ |\text{fii}{}^{5}8^{L}_{F}{}^{N}_{L}_{;}£\ \ \bullet^{V_{T}}N^{\circ}{}^{2}{}^{3}{}^{3}{}^{\Box}_{F}+2/3 + 2/3 +$

Dhanlaxmi Chemicals

Central Drug House

Bharat Chemicals



Alpha Chemika

ff¹/3−Nº¹/3Rs ●¹/3®¹/3%¹/3−

● V_TNº2/31/3€£ ● 1/3®1/3 E_R1/3 L_{F®}N_LE_R1/3 ¥ ¢^{aaa21}/4£ ‡-3/8€1/3

12/3 = 0/005/83/4 $x^2 + x^1/4892 = 1/4$ $x^2 + x^2 + x^3/4$ $x^2 + x^3/4$ $x^3 + x$

»Nº¹/₃€‱³/₄ 5%₦HT¹┖RNLLF"1/3‱HT®1/31%®5%Nº€%1/3Pt1/8¹Pt€−

fi5%2/3^LF€N_L5%3/4®N_LN_LH_T3/4 f f ₩₩₩P_t1/3000^HT®1/31/8®5%Nº€0/1/3¥^LF1/%€5%-N_L€7/8€1/%P_t1/%1Nº

Universal aromatic

 $"3/83/8 \Box_{R}^{5/8} \Box_{F}^{1} \Box_{F}^{3/4} = \%_{0}^{1} \Box_{L}^{1} \bigcirc_{1}^{1} P_{t} \qquad 2 \Box_{R}^{1} \Box_{R}^{1}$

□\rangle 1/3 \rangle 1/3 \ran

 \bullet ⁰¹ $-5/8^3/4^2$ » \times ⁰ \times 1/2ⁿ \times 0° \times 1/2¹/2¹/2¹/2²1/4² ; \bullet 7/8⁷/8 \times 1/8⁵/8;

ff5/80/003/4 »¤°¥1/2n¢n¥1/21/2°21/42 j□5/8LF€3/85/8-1/85/8;

ff5/80/003/4 »¤°¥¤1/21/2®¢¢1/41/4©° ;●12/3€0/005/8;

 $\bigcirc \frac{1}{3} \frac{1}{4} \times \frac{3}{4} \times \frac{9}{2} \frac{1}{2} \frac{n c}{n} \frac{1}{2} \frac{1}{4} \frac{1}{4} \frac{1}{4} \frac{2}{4} \frac{1}{4} \frac{1}$

>¥N°1/3€%03/4€-7/81"V_T-€**®**5/8^CR^LF1/3%01/3^CR1N°1/3^NL€1/8Pt1/81N°

■V_TC_R1/8[®]1/3^LF⁵/8³/4 V_T-€**®**5/8^LR^LF¹/3[®]/00²V_T"Rs¹/3[®]11Pt¹/8¹N[®]

 $^{L}_{F} ^{1} \! /_{\! 3} \! /_{\! 00} ^{5} \! /_{\! 8} ^{L}_{F} ^{3} \! /_{\! 4} \ \, ^{\circ} \! /_{\! 5} ^{R} \! /_{\! F} ^{\otimes H}_{T} ^{1} \! /_{\! 3} ^{N} \! /_{\! 5} ^{8} \! /_{\! 00} ^{1} \! /_{\! 4} ^{1} \! /_{\! 4} ^{\otimes 2} ^{"} \! @ \! N^{21} \! /_{\! 3} \! \in \! \! /_{\! 00} \! P_{t} ^{1} \! /_{\! 8} ^{1} \! N^{2}$

 $\mathsf{fi}^{5/8} 2/3^{\mathsf{L}} = \mathsf{E}^{\mathsf{N}} \mathsf{L}^{5/8} 3/4 @^{\mathsf{N}} \mathsf{L}^{\mathsf{N}} \mathsf{L}^{\mathsf{H}} \mathsf{T}^{\mathsf{L}} = 3/4 f f \bigstar \bigstar \mathsf{P}^{\mathsf{V}} \mathsf{T} - \mathbf{E} \mathbf{6}^{5/8} \mathsf{L}_{\mathsf{R}} \mathsf{L} = 1/3 \% 0^{1/3} \mathsf{L}_{\mathsf{R}} \mathsf{L}^{\mathsf{1}} \mathsf{N}^{\mathsf{Q}} \mathsf{L}^{\mathsf{1}} \mathsf{L}^{\mathsf{Q}} \mathsf{L}^{\mathsf{1}} \mathsf{L}^{\mathsf{Q}} \mathsf{L}^{\mathsf{1}} \mathsf{L}^{\mathsf{Q}} \mathsf{L}^$



TRON POWDER

INDUSTRIAL METAL POWDERS (INDIA) PVT. LTD "3/83/8^CR5/8^LF^LF3/4 □1/3^NL 01Pt n¤¤f°£ SM1^CR5/8®1/31—-®€N°1/32-5/8®€—3/8 SM1/3/06RS1/3—€ O¹[□]R^{®5}/8£ • V_T-5/8¥0¹/3[®]1/3[□]R □¹¹/3³/8£ ff¹/₃‰¹/¬%¹/₃–®€□R¹/□R£ ■¹/¬−5% ¢º¹/₂ ¹/₂ºn£ ●¹/₃®¹/₃□R¹/₃□F®NL□R¹/₃ ‡○‹‡"Pt ff5/80/003/4 »QQ Q@@Qn@1/2@QQ »Nº1/3€‱3/4 Nº1/3^CR%5/8^NL€-®"€NºHT¥€-3/8€1/3Pt1/8¹Nº $fi^{5/8}2/_{3}^{1} + e^{N_{L}5/8}3/_{4} e^{N_{L}N_{L}H_{T}L_{F}3/_{4}} f + e^{N_{L}^{9}H_{T}} + e^{-3/8}e^{1/3}P_{t}^{1/8}^{1}N^{9}$ **Ganesh Industries** "3%3%^CR⁵%^LF^LF³¼ ■‰¹^NL ○¹Pt³¼ —¥ººº³f¹½"£ □Pt‡Pt‹Pt—Pt£ ■^HT^HTPt →®5%⁵%%€ չ^LF^NL¹%^NL⁵%£ "Nº2/3€°\u1/3-1/3®1/3[□]R □11/33%£ ■3%®1/3**®**£ "®Nº5/83%1/32/31/33% ¥ 1/4®1/2¢°2£ □VT%1/3[□]R1/3NL£ ‡o<**‡**" _1_N_1/31/8N_ ■58CRLF1_3/4 (€HT1/3% ■1/3N_5/8%0 ¥ oVTNº2/35/8CR3/4 »¤º¥¤¤° ¤¢°¢°° _1_N 1/31/8N ■5/8^CR^LF1_3/4 TM1/3N €_ ■1/3N 5/8%00 ¥ 0 V_TNº2/35/8^CR^{3/4} »¤º¥¤©1/2² ª¤1/4222 $N^{01}/3 \in \%03/4 \in -7/81\%01/3 - 5/8^{L} = -3/8P_{t}^{1}/8^{1}P_{t} \in -7/81\%01/3 - 5/8^{L} = -3/8P_{t}^{1}/8^{1}P_{t}^{1} = -3/8P$ fi5/82/3^LF€N 5/83/4 ₩₩₩Pt@1/3-5/8^LF®€-3/8Pt1/81Pt€-**KALYAN INDUSTRIES** □1/3%%1NL □11/33/8£ -€®1CR ¥ 1/4n¢1/2¢º£ □\T%\3\CR1/3\L£ ‡-3%€1/3 ■@1_5/83/4ª@ª1/4®1/4ªº@\\n O¹/3₦3/4¤º¥¹/2®©¥¹/2¢¹/2ºªª¢ fi5/82/3¹=€^N_5/83/4 [®]N_N_H⁺73/4 f f ₩₩₩P1°%1/3%0R**s**1/3-€-3% Y⁺1=N_FR€5/8¹FP1/8 1P1€-**RS ALLOYS** "3%3%^CR⁵%^LF^LF³4 ¢¢n²f²1/4₽■1/3®1/3^CR€<0€^CR1/3%£ -1/3¾1/3^CR -1/3MD1/3^CR£<5%0∞€¥ ooaaan£±-3/8€1/3 ■ 91 - 5 8 4 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 9 1 ■7/87/8€1/85/83/4 »¤°¥°°°¥1/21/42¢2©°°¤ $N^{21/3} = 003/4$ $R^{L}_{R} = 1/3 000 = 1$ $R_{S} = 1/2 = 2$ $R_{S} = 1/3 = 1/3$ $R_{S} = 1/3 = 1/3$ $R_{S} = 1$ fi5/82/3^LF€N_L5/83/4 @N_LN_LH_T3/4 f f ₩₩₩Pt^LR^LF1/3/00/00¹Rs L_FPt€-VisproMegatrades Ltd. ●1/30/00 ❸ € Rs 1/3 01/30 1/3 ER£ ●1/3 € — -0 € ❸1/30/00 □11/33/8£ 05/8 ₩ (5/80/00 € -00220 00 £ ± -3/8 € 1/3 ff5/8%05/83/4 »X°¥°°¥¢°°224¢°°32 fi5/82/3-F€N_5/83/4 @N_N_HT3/4ff €€-FHT-R1Pt1/81Pt€-Shree Bajrang Sales (P) Ltd. "L_F®€L_{F®} -®1/3 ^CRN_L€1/3 "3/83/8^CR^{5/8}^LF^LF³/4 º¤£ 05/8₩ —1^NL^NL¹— ●1/3^CR%5/8^NL£ 05/81/3^CR □1/3[®]V_T%0 †1^NL5/8%0£ —5/8[®]1/3 O1/3₩3/4 »Xº¥®º1/2¥1/2®1/2º¢©¢ fi5/82/3^LFEN_5/83/4^{QN}LNL^HT3/4*ff*₩₩₩Pt^LF^{QC}R5/85/82/31/3%^CR1/3—^{QL}F1/3%05/8^LFPt1/81N^Q ff Rffi,0,



RIDHDHI SIDHDHI CHEMICALS

Chemex Organochem Pvt Ltd

"3%3% CR5% LF LF3/4 94®£ ffi3% Rs1® SMLF®5% NL CR1/3£ R € -% □11/33%£ ● VT000 VT -3% fi5% LFNL£

- V_TN^{Q2}/₃1/₃€ ¥ ¢^{aaa⊚a}£
- ●1/3®1/3^LR1/3^LF®N_L^LR1/3£ ±-3/8€1/3
- $\bullet @1 5/83/4 \quad \text{``} \times \times ^0 Y @1/4^n \times ^2 C^2 1/2^1/4^2 \quad f \quad @\times @n2n1/4^n @C$
- >Nº¹/3€%0 ‡«³/4NL5%6°%1/3LF"¹/8®5%N°5%N°5%N°€1/8¹/3%0LFPt¹/8¹N° fi5%2°/3LF€NL5%3′/4 ®NLNLHTLF3′/4 f f ₩₩₩Pt¹/8®5%N°5%N°5%N°€1/8¹/3%0LFPt¹/8¹N°

ANTARES CHEM PRIVATE LIMITED

SOLVO CHEM

"3838 $^{\circ}$ $^{\circ}$

KESHARIYA CORPORATION

lav Chemical Industries Limited



GI Chemical

Startex

"3/83/8 L R5/8 L FLF3/4 1/4 fi1/3 N L5/8 L R₩ 1/3 Rs $^{-F}$ F V T1/3 L R5/8 $^{\blacksquare}$ 000 1/3 1/85/8 L $^{-V}$ T $^{\blacksquare}$ N $^{\blacksquare}$ N $^{\blacksquare}$ E fff $^{\blacksquare}$ 8 fi113/8 %001/3 $^{-3}$ 8 L F fff $^{\blacksquare}$ 8 ff113/8 %003/4 3 9 $^{\blacksquare}$ 9 $^{\square}$ 9 $^{\square$

Cangzhou City Junchiweiye Chemical Co., Ltd

Ibn Al Haj Chemicals LLC

Turraco Industrial Limited

GMAS Chemicals

"3/83% \(\bar{\text{F}} \) \(\cdot \) \(\frac{\text{F}}{\text{F}} \) \(\frac{\text{F}}{\text{

Carsten Chemicals



TNJ chemical

IICT



PRINTED BAGS

PolyPak America

"383% □ F5% □ F□ F3/4 1/2 \(\tilde{\pi} \) \(

Shields Bag and Printing

Yantai Evergreen Packaging Co., Ltd.



LAB CHEMICALS

New Alliance Dve Chem Private Limited

Titan Biotech Limited

fi5%2/3^LF€NL5%3/4 ®NLNLHT3/4 f f ₩₩₩PtNº€1/8^LR1 — VTNL^LR€5% — NLLFPt1/81Pt€ —

Labcare Scientific

Naugra Export



Shandong Tongli Chemical Co., Ltd.

 $\text{``$38$^{\text{L}}_{\text{R}}$^{\text{5}}_{\text{B}}$^{\text{L}}_{\text{F}}$^{\text{L}}_{\text{F}}$^{\text{3}}_{\text{4}}$ \stackrel{\text{1}}{\text{7}}$^{\text{1}}_{\text{3}}$^{\text{N}}_{\text{L}}$^{\text{1}}_{\text{3}}$ \stackrel{\text{1}}{\text{1}}_{\text{5}}$^{\text{1}}_{\text{6}}$^{\text$

O¹/₃₦³/₄ ^{a21}/₄¹/₄¥©2º¤¹/₄®¤

-5/80/000/00 \bullet \bullet 1-5/83/4 \bullet 0 \bullet 1/201/202 \bullet 1/201/202

 $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$ $^{1}N^{2}/_{3}$

 $fi^{5/8}^{2/3}^{L}_{F} \in ^{N}_{L}^{5/8}^{3/4} \quad WWWP_{t}^{N}_{L}^{0/0}^{H}_{T}^{1/3}N^{9L}_{F}P_{t}^{1/8}^{1}N^{9}$

YIXING CLEANWATER CHEMICALS CO., LTD.

 $"3/83/8^{\Box}_{R} 5/8^{\Box}_{F} - 1^{\Box}_{F} 3/4 - 1^{\Box}_{T} 1/8 \circ \in ^{\Box}_{T} 5/8 = 1/8 1/8 \circ \in ^{\Box}_{T} 1/8 \circ$

 $\mathsf{fi^{1}^{\Gamma}}_{\mathsf{R}^{\circ}\!\mathsf{U}} \ ^{\mathsf{N}}_{\mathsf{L}} \in \mathsf{N}^{95}\!\!/\!\!_{8}^{3}\!\!/\!_{4}} \ ^{@3}\!\!/\!_{4}^{2a} \mathsf{Y}^{9}\!\!_{8}^{3}\!\!/\!_{4}^{1}\!\!/\!_{4}^{a}} \ \mathsf{i}^{-5}\!\!/\!_{8} \in \mathcal{C} \in -\mathbb{G} \ ^{\mathsf{N}}_{\mathsf{L}} \in \mathsf{N}^{95}\!\!/\!_{8} \mathsf{Z}_{\mathsf{L}}^{2}}$

 $\bullet ^{ \odot 1} - ^{5}\!\! / _{8} ^{ 3}\!\! /_{4} \ \, ^{ \odot n} \! Y^{2 \circ 2} \! Y^{ \odot 0} \! \, \chi ^{ \odot n} \! \chi ^{ \odot 0} \! Y^{ \odot 0} \! \, \chi ^{ \odot 0} \! \chi ^{ \odot 0} \! \, \chi ^{ \odot 0}$

 $\bigcirc \frac{1}{3}$ $\forall 3/4$ $\bigcirc n$ $\forall 2 \bigcirc 2$ $\forall \bigcirc 0$ $\forall 0 \bigcirc 1$ $\forall 0 \bigcirc 1$

>Nº1/3€%03/4 Nº1/3®®€5/8"®1%0%0Rs¥NL5/81/8®Pt-5/8NL

Cyc Lab Integration Limited

"3,838 □ 2/31/33/8 □ 1/2£ "@7/81/3 □ 1/3

>Nº1/3€\%03/4 1/8Rs1/8\%01/32/3-\@"Rs1/3\@11Pt1/81Nº£

»N°1/3€%0°3/4 LF1/3%0°5/8LF"1/8Rs1/8%0°1/32/3-@Pt1/81N°£

 $N^{01}/3 \in \%_0^{3/4} \ 1/3^{3/8}N^{0} \in -"1/8 Rs^{1/8}\%_0^{1/3}^{2/3} - Pt^{1/8} N^{0}$

 $fi^{5/8}2/3^{L} = \mathbb{C}^{N_{L}5/8}3/4 \otimes^{N_{L}N_{L}} + T^{3/4}ffWWWP_{t}^{1/8}Rs^{1/8}\%^{1/3}2/3 - \ThetaP_{t}^{1/8}1N^{Q}$

Chemito International Limited

 $\text{``3/8}^{3/8} - \text{R}^{5/8} - \text{F}^{-1/2} \cdot \text{`}^{4/8} \quad \text{`1/2}^{1/4} \cdot \text{``0} \quad \text{`1/3}^{1/4} \cdot \text{``1/3}^{1/2} \cdot \text{``1/3}^{1/2} \cdot \text{``1/3}^{1/2} \cdot \text{``1/2}^{1/2} \cdot \text{``0}^{1/3} \cdot \text{``1/3}^{1/2} \cdot \text{``0}^{1/3} \cdot \text{``1/3}^{1/2} \cdot \text{``0}^{1/3} \cdot \text{``1/3}^{1/2} \cdot \text{``0}^{1/2} \cdot \text{``0}^{1/3} \cdot \text{``1/3}^{1/2} \cdot \text{``0}^{1/2} \cdot \text{``0}^{1/$

12/3 = 0/005/8 10/005/8 10/005/8 10/005/8 10/005/8 10/005/8 10/005/8 10/005/8 10/005/8



Photographs/Images for Reference

Machinery Photographs

JACKETED REACTOR



FILTER



FLUIDISED BED DRYER



STORAGE TANK






AN ISO 9001: 2015 CERTIFIED COMPANY

REFRIGERATION UNIT



COOLING TOWER



DISTILLATION ASSEMBLY





BOILER



[NPCS/5515/24212] Page No. **307**



Raw Material Photographs

FOR PARACETAMOL-P-NITROPHENOL



IRON POWDER




IBUPROFEN





ACETIC ACID



METHANOL



6-APA (AMINO PENICILLANIC ACID)



TRIETHYL AMINE (6-APA)



TRIMETHYLCHLOROSILANE






DMA, HCL (Dimethylamine Hydrochloride)



D-(-)-2-HYDROXYPHENYLGLYCINE CHLORIDE



ACTIVATED CARBON





LABORATORY, ETP & OTHER CHEMICALS















Product Photographs

PARACETAMOL







IBUPROFEN







[NPCS/5515/24212] Page No. **311**







Amoxycillin, Cloxacillin & Lactic Acid Bacillus Capsules

Molax-lb







Plant Layout

[NPCS/5515/24212] Page No. **313**



AN ISO 9001: 2015 CERTIFIED COMPANY





Conclusion

In conclusion, our comprehensive report on the API manufacturing business project serves as a valuable resource for stakeholders and potential investors in the pharmaceutical industry. We have meticulously covered various aspects of the project, providing detailed information and analysis.

The report begins with an exploration of the project's location, including district profiles and geotechnical site characterization. This initial phase provides a solid foundation for understanding the environmental and geographical factors that will influence the project.

Moving forward, we have conducted in-depth studies on specific pharmaceutical ingredients, such as Metformin, Amoxicillin, Ibuprofen, and Paracetamol. These sections offer insights into the medical uses, chemical properties, manufacturing processes, and safety measures associated with each API.

Our report also includes a SWOT analysis that identifies the project's strengths, weaknesses, opportunities, and threats. This strategic assessment helps stakeholders make informed decisions and plan for future development.

Furthermore, we have conducted a comprehensive risk assessment, covering various aspects, including chemical and biological exposure, environmental contamination, quality control failures, supply chain disruptions, regulatory non-compliance, intellectual property breaches, equipment failures, accidents, fires, and market dynamics risks. Each risk category includes a thorough examination of potential outcomes and mitigation strategies.

The report delves into the social and economic impacts of the API manufacturing unit, highlighting its potential benefits to the local community and the broader economy. We have also discussed future challenges that may arise in the API manufacturing sector, offering insights into preparedness and adaptation strategies.



A market survey provides a deep dive into the global and Indian API markets, with insights on types, applications, synthesis methods, regional dynamics, and key players. This information is invaluable for understanding market trends and competition.

In addition, we have included financial data and comparisons of major Indian players and companies in the API manufacturing industry. This financial analysis offers insights into profitability, liquidity, and overall financial performance.

Finally, the report features photographs and images for reference, including machinery, raw materials, and finished products, providing visual context to the information presented. The plant layout section provides a visual representation of the project's physical structure.

In conclusion, our report serves as a comprehensive guide for anyone interested in the API manufacturing business, from project location and technical details to market analysis and financial insights. It offers a thorough understanding of the industry, its potential, and the strategies required for success in the competitive pharmaceutical sector.



PROJECT FINANCIALS

[NPCS/5515/24212] Page No. **317**

Annexure 1

Assumptions made

- 1 Interest cost for CC limit (WC finance) is @10.00%
- Semi Variable & Fixed Expenses are done on 40:60 basis on full capacity utilisation in 5th Year of operation.
- For working capital calculation, the WC cycle is considered by taking following assumptions are made:
 - Stock on hand i.e. Raw material cost @ 1 month,
- a Finished goods @ 1 months and WIP cost taken for 1 days.
- b Receivables @0 months.
- c Current liabilities @ 1 months.
- 4 Currency is (Amount in Rs.) and (Rs. in Lakhs) in some tables Indian Currency in Rs.

Annexure 2

Active Pharma Ingredients (API)

[NPCS/5515/24212]

PLANT ECONOMICS

Active Pharma Ingredients (API)

Metformin, Amoxicillin, Ibuprafen & Paracetamol

Rated Plant Capacity		
Total Production per Day	=	Kg/Day
Total Production per Month	=	Kg/Month
Total Production per Annum	=	Kg/Annum
Basis		
No. of working days	=	Days/Month
	=	Days/Annum
No. of shifts	=	Shifts per day
One shift	=	Hours
Total working Hours per day		Hours per day

[NPCS/5515/24212]

PRODUCTION SCHEDULE

Name of Product	Kg. Per Day	Kg. Per Annum	Total Batch	UOM
Metformin (500 mg & 850 mg)				
Amoxicillin (500 mg)				
lbuprafen (500 mg)				
Paracetamol (500 mg)				

[NPCS/5515/24212]

LAND & BUILDING

(Amount in Rs.)

Particulars of Proposed Assets (UOM)	UOM	Quantity	Rate	Total
Land Area Required	Sq.mts			
Factory Building -				
Metformin Section	Sq.mts			
Amoxicillin Section	Sq.mts			
Ibuprofen Section	Sq.mts			
Paracetamol Section	Sq.mts			
Tank Area	Sq.mts			
Raw Material Store Area	Sq.mts			
Finished Product Store	Sq.mts			
Administrative Block	Sq.mts			
Laboratory	Sq.mts			
Utility Area	Sq.mts			
Electrical & D.G. Set Room	Sq.mts			
Fuel Storage Area	Sq.mts			
Water Storage Area	Sq.mts			
Water Treatment Area	Sq.mts			
E.T.P. Area	Sq.mts			
Workshop	Sq.mts			
Toilets	Sq.mts			
Security Room	Sq.mts			

LAND & BUILDING (Amount in Rs.)

Particulars of Proposed Assets (UOM)	иом	Quantity	Rate	Total
Land Development Cost, Boundary Wall, Gate & Road etc.	Sq.mts			
			TOTAL	

[NPCS/5515/24212]

PLANT & MACHINERY

(Amount in Rs.)

Particulars of Assets Proposed (UOM)	UOM	Quantity	Rate	Total
Indigenous Machineries				
FOR METFORMIN - Jacketed Reactor 2	Nos.			
KL				
Condenser	Nos.			
Storage Tank 2 KL	Nos.			
Filter	Nos.			
Spray Dryer	Nos.			
Storage Hopper	Nos.			
FOR AMOXICILLIN - Jacketed Reactor 2	Nos.			
KL	NI.			
Filter	Nos.			
Vacuum Fluid Bed Dryer	Nos.			
Storage Tank 5 KL	Nos.			
Fuel Storage Tank	Nos.			
Distillation Assembly with Condenser	Nos.			
FOR IBUPROFEN GL Reactor Cap. 500	Nos.			
Ltrs.	NI.			
Stainless Steel Reactor Cap. 1 KL	Nos.			
Stainless Steel Reactor Cap. 10 KL	Nos.			
Filter	Nos.			
Fluidized Bed Dryer	Nos.			
Distillation System (Contineous)	Nos.			
Storage Tank 5 KL	Nos.			
FOR PARACETAMOL - Jacketed Reactor Cap. 2 KL	Nos.			
Distillation Assembly Cap. 1 KL	Nos.			
Filter	Nos.			
Vacuum Fluid Bed Dryer	Nos.			
Compressed Air System	Nos.			
Refrigeration System	Nos.			
Cooling Tower	Nos.			
Boiler Cap. 4 Ton/hr	Nos.			
Pipeline, Pumps etc,	Sets			

Annexure 5

Active Pharma Ingredients (API)

PLANT & MACHINERY

(Amount in Rs.)

Particulars of Assets Proposed (UOM)	UOM	Quantity	Rate	Total
Tablet Making & Packaging Machines	Nos.			
Maintenance Equipments	Nos.			
Erection & Installation				
Miscellaneous Equipmetns like pumps, valves, pipeline & fittings	Nos.			
Laboratory Equipments	Nos.			
			TOTAL	

[NPCS/5515/24212]

OTHER FIXED ASSETS

Particulars of Assets Proposed	Quantity	Rate	Amount
Furniture & Fixtures			
Office Equipment, Furniture plus Other Equipment & Accessories			
Pre-operative & Preliminary Expenses			
Electrical Installation 250 KVA			
Electrical Cable, MCB, Meter Boxes, Switch Board etc.			
Fire Fighting Equipment			
D.G. set 200 KVA			
Effluent Treatment Plant			
Website Development & Promotion			
Water Resources with Storage Tank			
Others			
Technical know how			
Office Vehicles			
Office Automation Equipments			
(Telephone/ Fax/ Computer)			
Provision for Contingencies			
		TOTAL	

[NPCS/5515/24212]

WORKING CAPITAL Requirement Per Month

Raw Materials	UOM	Quantity	Rate	Amount	Qty p.a.	Qty per Batch
For Metformin - Dicyanodiamide	Kgs			·		
Dimethylammonium Chloride	Kgs					
For Amoxicillin - Methylene chloride	Kgs					
6-APA (Aminopencillanic acid)	Kgs					
Triethyl Amine (6-APA)	Kgs					
Trimethylchlorosilane (TMCS)	Kgs					
N,N-dimethylaniline	Kgs					
DMA, HCI (Dimethylamine hydrochloride)	Kgs					
D-(-)-2-hydroxyphenylglycine chloride hydrochloride	Kgs					
NaCl (Sodium Chloride)	Kgs					
For Ibuprofen - Isobytyl Benezene	Kgs					
AICI3	Kgs					
Acetal Chloride	Kgs					
Tolune	Kgs					
Zinc Octate	Kgs					
NaOh	Kgs					
Methyl dichloride	Kgs					

WORKING CAPITAL Requirement Per Month

Raw Materials	UOM	Quantity	Rate	Amount	Qty p.a.	Qty per Batch
For Paracetamol - p-nitrophenol	Kgs					
Iron Powder	Kgs					
Acetic Acid	Kgs					
Methanol	Kgs					
Activated Carbon	Kgs					
Printed Packing Strips (include PVC Film, Aluminium Foil & Adhesives) each Strips App. Wt. 2 gms Size	Kgs					
Lab Chemicals Cost						
Consumable Store						
			TOTAL			_

Annexure 8

Active Pharma Ingredients (API)

[NPCS/5515/24212]

Overheads Required Per Month

Utilities and Overheads	Quantity	Rate	Amount
Power Consumption			
Water Consumption			
Fuel Cost			
Insurance Professional fees			
Administration Expense			
Stationery Exp., Telephone, Postage			
Repairs and Maintanance			
Internet Expenses			
Conveyance Exp.			
Publicity Exp.			
		TOTAL	
Total load is	200	Kwatts	
Utilities and Overheads	Quantity	Rate	Amount
Royalty and other charges			
Selling and Distribution expenses			
		TOTAL	

Salary and Wages

[NPCS/5515/24212]

Salary and Wages	UOM	Quantity	Rate	Amount
General Manager	Nos.			
AGM (Comm.)	Nos.			
Production, Engineering & Quality Control Manager	Nos.			
Chemical Engineers	Nos.			
Quality Control Supervisors	Nos.			
Production Supervisors	Nos.			
Skilled Workers	Nos.			
Electricians	Nos.			
Fitters	Nos.			
Unskilled Workers	Nos.			
Accountant	Nos.			
Computer Operators	Nos.			
Office Staffs	Nos.			
Sales Executives	Nos.			
Store Keeper	Nos.			
Peons	Nos.			
Security Officer	Nos.			
Security Guards	Nos.			
TOTAL BASIC SALARY				
Plus Perks (25% p.a. of Basis				
Salaries)				
Per Month			TOTAL	
Per Annum				

Annexure 10

Active Pharma Ingredients (API)

[NPCS/5515/24212]

TURNOVER PER ANNUM

Name of Product	UOM	Quantity	Rate	Amount
Metformin (500 mg & 850 mg)	Kgs			
Amoxicillin (500 mg)	Kgs			
Ibuprafen (500 mg)	Kgs			
Paracetamol (500 mg)	Kgs			
			TOTAL	

[NPCS/5515/24212]

SHARE CAPITAL (Rs. in Lakhs)

Share Capital (No. of Shares)	Face Value USD/ Share	Equity Share Capital				
30098						
Particulars	Existing	Existing	Proposed	Proposed		
	%age		%age			
Equity Capital						
Preference Share Capital						
Total						

[NPCS/5515/24212]

ANNEXURE - 1

COST OF PROJECT AND MEANS OF FINANCE

Particulars Friedrice RS. 1					
Particulars	Existing	Proposed	Total		
COST OF PROJECT					
Land & Site Development Exp.					
Land Area Required					
Land Development Cost, Boundary Wall, Gate & Road etc.					
Buildings					
Factory Building -					
Office Buildings					
Plant & Machineries					
Indigenous Machineries					
Erection & Installation					
Laboratory Equipments					
Miscellaneous Equipmetns like pumps, valves, pipeline & fittings					
Imported Machineries					
Technical know how					
1 SSTITICAL RUISTI HOW					
Office Vehicles					
Office Automation Equipments (Telephone/ Fax/ Computer)					
Office Equipment, Furniture plus Other Equipment & Accessories					
Other Misc. Assets					
Pre-operative & Preliminary Expenses					
Provision for Contingencies					
Total Capital Cost of Project					
Margin Money for Working Capital					
Total Cost of Project					
MEANS OF FINANCE					
Equity Share Capital					
Others - Preference Share Capital					
Total Equity Share Capital					
Long/Medium Term Borrowings					
FROM BANK					
From Other Financial Institutions					
Total Long/Medium Term Borrowings					
Total Means of Finance					

ANNEXURE - 2
PROFITABILITY AND NET CASH ACCRUALS

[NPCS/5515/24212]

(Rs. in Lakhs)

Particulars Particulars	Operating Years					
	1-2	2-3	3-4	4-5	5-6	
Revenue/Income/Realisation						
Gross Sales Realisation						
Less : Excise Duties/Levies						
Net Sales Realisation						
Total Revenue/Income/Realisation						
Expenses/Cost of Products/Services/Items						
Raw Material Cost						
Indigenous						
Total Nett Consumption						
Lab & ETP Chemical Cost						
Packing Material Cost						
Sub Total of Net Consumption						
Miscellaneous Cost						
Employees Expenses						
Fuel Expenses						
Power/Electricity Expenses						
Depreciation						
Royalty & Other Charges						
Repairs & Maintenance Exp.						
Other Mfg. Expenses						

ANNEXURE - 2
PROFITABILITY AND NET CASH ACCRUALS

[NPCS/5515/24212]

Particulars	Operating Years					
	1-2	2-3	3-4	4-5	5-6	
Cost of Output of Goods Sold						
Gross Profit						
Administration Expenses						
Technical Knowhow Fees & Exp.						
Financial Charges						
Long/Medium Term Borrowing						
On Wkg. Capital Borrowings						
Total Financial Charges						
Selling Expenses						
Total Cost of Sales						
Net Profit Before Taxes						
Tax on Profit						
Net Profit After Taxes						
Depreciation Added Back						
Technical Knowhow Fees & Exp.						
Net Cash Accruals						

[NPCS/5515/24212]

ANNEXURE - 3 ASSSESSEMENT OF WORKING CAPITAL REQUIREMENTS

Particulars	Stk.Prd.	Stk.Prd.			C	Operating Year	's	
	1st Year	2nd Yr&+		1-2	2-3	3-4	4-5	5-6
Capacity	Months	Months	%					
CURRENT ASSETS								
Stocks on Hand								
Raw Material Cost								
Indigenous								
Lab & ETP Chemical								
Packing Material								
Miscellaneous Cost								
Work-in-Process								
Finished Goods								
Current Expenses								
Receivables								
Total								
Cash/Bank Balances								
Gross Wkg. Capital								

ANNEXURE - 3 [NPCS/5515/24212]

ASSSESSEMENT OF WORKING CAPITAL REQUIREMENTS

(Rs. in Lakhs)

Particulars	Stk.Prd.	Stk.Prd.			O	perating Year	S	
	1st Year	2nd Yr&+		1-2	2-3	3-4	4-5	5-6
Capacity	Months	Months	%					
CURRENT LIABILITIES								
Sundry Creditors - Raw Material Cost								
Indigenous			М					
Lab & ETP Chemical			М					
Packing Material			М					
Miscellaneous Cost			М					
Current Expenses			М					
Other Current Liabilities			М					
Total								
Instalments Due Within Next 12 Months: T	erm Borrowings							
Total Current Liabilities								
Net Wkg.Capital(Tot.CA - Tot.CL)								
M.P.B.FMethod I								
As Per Tandon Com.Norm-Method II - Per	missible Financ	e - D.P.(%age)						
Work in Process %	0.65	DP						
Finished Goods %	0.70	DP						
Total Bank Finance(DP Method)								
Bank Finance(Turnover Method)								
Bank Finance : As per DP Method								
Margin Money : (At Commencement)								
Margin Money:(incl.Cash/Bk. Bal)								
% Margin Money - Net Wkg.Capital								
Current Ratio (No. of times)								

[NPCS/5515/24212]

ANNEXURE - 3
Working note for calculation of Work-in-process

Description of Product	% assumed for WIP Completion	Rate per unit in Rs.	Equivalent (%) Rate per unit in Rs.
For Metformin - Dicyanodiamide			
Dimethylammonium Chloride			
For Amoxicillin - Methylene chloride			
6-APA (Aminopencillanic acid)			
Triethyl Amine (6-APA)			
Trimethylchlorosilane (TMCS)			
N,N-dimethylaniline			
DMA, HCI (Dimethylamine hydrochloride)			
D-(-)-2-hydroxyphenylglycine chloride			
hydrochloride			
NaCl (Sodium Chloride)			
For Ibuprofen - Isobytyl Benezene			
AICI3			
Acetal Chloride			
Tolune			
Zinc Octate			
NaOh			
Methyl dichloride			
For Paracetamol - p-nitrophenol			
Iron Powder			
Acetic Acid			

Methanol		
Activated Carbon		

ANNEXURE - 3
Working note for calculation of Work-in-process

Description of Product	% assumed	Rate per unit	Equivalent
	for WIP	in Rs.	(%) Rate
	Completion		per unit in
			Rs.
Printed Packing Strips (include PVC Film,			
Aluminium Foil & Adhesives) each Strips			
App. Wt. 2 gms Size			
Lab Chemicals Cost			
Consumable Store			
Total		·	

ANNEXURE - 4 [NPCS/5515/24212]

SOURCES AND DISPOSITION OF FUNDS (Rs. in Lakhs)

Particulars	Constr.		Operating Years			
	Period	1-2	2-3	3-4	4-5	5-6
SOURCES OF FUNDS						
Net Profit Before Tax with Interest Charges Added Back						
but after Depreciation Provision						
Equity Share Capital						
Depreciation						
Incr.in Long/Medium Term Proposed-FROM BANK						
Incr.in Bank Borrowing for Working Capital						
Incr.in Cur.Liabilities						
Technical Knowhow Fees & Exp.						
Total Sources of Fund						
DISPOSITIONS OF FUNDS						
P & P Expenses						
Technical Knowhow Fees						
Incr.in Capital Expense						
Incr.in Current Assets						
Decr.in Long/Medium Term Proposed-FROM BANK						
Interest/Financial Exp.						
Taxes on Profit						
Total Disposition						
Opening Balance			•		•	
Net Surplus / Deficit						
Closing Balance						

ANNEXURE - 5
PROJECTED BALANCE SHEETS

[NPCS/5515/24212]

Particulars Particulars	Operating Years				
	1-2	2-3	3-4	4-5	5-6
Equity Share Capital					
Surplus of Previous Year					
Add : Net Profit After Taxes					
Surplus at the End of Year					
Unsecured Deposits					
Long/Medium Term Borrowings Proposed-FROM BANK					
Bank Borrowing for Wkg. Capital					
Current Liabilities					
Sundry Creditors					
Other Current Liabilities					
Total Current Liabilities					
Total of Liabilities					

ANNEXURE - 5
PROJECTED BALANCE SHEETS

[NPCS/5515/24212]

(Rs. in Lakhs)

Particulars	Operating Years						
	1-2	2-3	3-4	4-5	5-6		
ASSETS							
Fixed Assets							
Gross Block							
Less : Depreciation to Date							
Net Block							
Current Assets							
Stocks on Hand							
Receivables							
Other Current Assets							
Cash and Bank Balances							
Total Current Assets							
P & P Exp. and/or Other Dvp.Exp.							
(To The Extent Not W/Off)							
Other Non Current Assets							
Total of Assesse							
Total of Assets							
ROI (Average of Fixed Assets)							
RONW (Average of Share Capital)							
ROI (Average of Total Assets)							

ANNEXURE - 6 [NPCS/5515/24212] PROFITABILITY RATIOS, DSCR, DEBT EQUITY, ETC.

Particulars	Operating Years				
	1-2	2-3	3-4	4-5	5-6
Profit Percentages to Net Sales					
Gross Profit					
% Of G.P. to Net Sales					
Net Profit Before Taxes					
% of N.P.B.T. To Net Sales					
Net Profit After Taxes					
% of N.P.A.T. To Net Sales					
Debt Service Coverage Ratio					
Funds Available to Service Debts					
Net Profit After Taxes					
Depreciation Charges					
Technical Knowhow Fees & Exp					
Interest on Long/Medium Term					
Total					
Debt Service Obligations					
Repayment of Long/Medium Ter					
Interest on Long/Medium Term					
Total					
10141					
D. S. C. R. (Individual)					
D. S. C. R. (Cumulative)					
D. S. C. R. (Overall)					
Parameters					
Initial Equity Capital					
Credit Balance in P & L					
Total Capital excl Unsec Deposits					
Unsecured Dep.					
Total Equity incl Unsecured					
Deposits					

ANNEXURE - 6 [NPCS/5515/24212] PROFITABILITY RATIOS, DSCR, DEBT EQUITY, ETC.

Particulars		Operating Years				
		1-2	2-3	3-4	4-5	5-6
Long/Medium Term Borrowings from Bank	000.05	700.00	F 44 77	004.40	400.50	0.00
ITOTTI BATIK	902.95	722.36	541.77	361.18	180.59	0.00
Term lia. Incl Unsecured Deposit						
Total Liabilities						
Total Liabilities incl Unsecured						
Deposits						
DEBT EQUITY RATIO considering						
i.e.Total Term Lia./NW						
Unsecured Dep. as Equity						
Unsecured Dep. as Debt						
Total Outside Lia./NW						
Assets Turnover Ratio (x)						
No. of Shares of 10.00 each						
Earnings Per Share(EPS) (in						
USD)						
Proposed divident						
Cash EPS (in Rs.)						
Dividend Per Share(DPS) (in Rs.)						
Payout Ratio (%Age)						
Retained Earnings/Share (in Rs.)						
Retained Earnings (%Age)						
Book Value Per Share (in Rs.)						
Debt Per Share (in Rs.)						
Probable Mkt.Price/Share(in Rs.)						
Price / Book Value (x)						
Price Earnings Ratio (x)						
Yield (%Age)						

ANNEXURE - 7
BREAK EVEN ANALYSIS

[NPCS/5515/24212]

(Rs. in Lakhs)

Particulars		Operating Years				
	Ratio	1-2	2-3	3-4	4-5	5-6
BREAK EVEN ANALYSIS						
Total Value of Output						
	_					
Variable Cost & Expenses						
Raw Material Cost						
Lab & ETP Chemical Cost						
Packing Material Cost						
Sales Commission/Exp.						
Sub-total						
Less:W.I.P. Adjustments						
Total Variable Cost						
Net Contribution						
Profit Volume Ratio (%)						
Semi-Var./Semi-Fixed Exp.						
Miscellaneous Cost						
Employees Expenses						
Power/Electricity Expen						
Fuel Expenses						
Royalty & Other Charges						

ANNEXURE - 7
BREAK EVEN ANALYSIS

[NPCS/5515/24212]

(Rs. in Lakhs)

Particulars				Operating Yea	rs	
	Ratio	1-2	2-3	3-4	4-5	5-6
Repairs & Maintenance E						
Other Mfg. Expenses						
Administration Expenses						
Selling Expenses						
Interest on Wkg.Capital						
Tot.Semi-Var./Fixed Exp.						
Fixed Expenses / Cost						
Miscellaneous Cost						
Employees Expenses						
Power/Electricity Expen						
Fuel Expenses						
Royalty & Other Charges						
Repairs & Maintenance E						
Other Mfg. Expenses						
Administration Expenses						
Selling Expenses						
Intrest-Fixed Borrowing						
Intrest-Working Capital						
Depreciation Charges						

ANNEXURE - 7
BREAK EVEN ANALYSIS

[NPCS/5515/24212]

Particulars		Operating Years					
	Ratio	1-2	2-3	3-4	4-5	5-6	
Deferred Expenses W/Off							
Total Fixed Expenses							
Tot.Fixed/Semi-Fixed Exp							
Tot.Cash Fixed/SemiFixed							
Cash Break Even Sales							
Cash Margin of Safety							
Break Even Sales							
Margin of safety							
At Maximum Utilisation :	Year						
(as % of Installed Capacity)							
Cash B.E.P. :	%						
B.E.P. :	%						

ANNEXURE - 8
SENSITIVITY ANALYSIS - I

[NPCS/5515/24212]

Particulars		Operating Years					
	1-2	2-3	3-4	4-5	5-6		
INCREASE IN SALES PRICES ::: By 2.00 %							
Resultant - Sale Value(Sales)							
Resultant - Gross Profit							
Resultant - N.P.B.T.							
Resultant - Tax on Profit							
Resultant - N.P.A.T.							
Resultant - Funds available							
As such - Debt Obligations							
Resultant - DSCR (Individual)							
Resultant - DSCR (Cumulative)							
Resultant - DSCR (Overall)							
Resultant - Sale Value(Output)							
As such - Variable Cost							
Resultant - Nett Contribution							
Resultant - PV Ratio (%age)							
Resultant - Cash BEP Sales							
Resultant - Cash Margin of Safety							
Resultant - BEP Sales							
Resultant - Margin of safety							
Resultant - Cash BEP % (Yr. 5)							

ANNEXURE - 8
SENSITIVITY ANALYSIS - I

[NPCS/5515/24212]

Particulars		Operating Years				
	1-2	2-3	3-4	4-5	5-6	
Resultant - BEP %age (Yr. 5)						
Resultant - DEBT EQUITY RATIO						
- Unsecured Dep. as Equity						
- Unsecured Dep. as Debt						
Resultant - ROI (%age) (Based on Fixed Assets)						
Resultant - RONW (%age)						
				1	ı	
DECREASE IN SALES PRICES ::: By 2.00 %						
Resultant - Sale Value(Sales)						
Resultant - Gross Profit						
Resultant - N.P.B.T.						
Resultant - Tax on Profit						
Resultant - N.P.A.T.						
Desident Finds Analish Is						
Resultant - Funds Available						
As such - Debt Obligations						
Resultant - DSCR (Individual)						
Resultant - DSCR (Cumulative)						
Resultant - DSCR (Overall)						

ANNEXURE - 8
SENSITIVITY ANALYSIS - I

[NPCS/5515/24212]

Particulars Particulars	Operating Years				
	1-2	2-3	3-4	4-5	5-6
Resultant - Sale Value(Output)					
As such - Variable Cost					
Resultant - Nett Contribution					
Resultant - PV Ratio (%age)					
Resultant - Cash BEP Sales					
Resultant - BEP Sales					
Resultant - Cash Margin of Safety					
Resultant - Margin of Safety					
Resultant - Cash BEP % (Yr. 5)					
Resultant - BEP %age (Yr. 5)					
Resultant - DEBT EQUITY RATIO					
- Unsecured Dep. as Equity					
- Unsecured Dep. as Debt					
				<u> </u>	· ·
Resultant - ROI (%age)					
Resultant - RONW (%age)					

ANNEXURE - 9 SENSITIVITY ANALYSIS - II [NPCS/5515/24212]

Particulars	Operating Years					
	1-2	2-3	3-4	4-5	5-6	
INCREASE IN SALES PRICES ::: By 5.00 %						
Resultant - Sale Value(Sales)						
Resultant - Gross Profit						
Resultant - N.P.B.T.						
Resultant - Tax on Profit						
Resultant - N.P.A.T.						
Resultant - Funds available						
As such - Debt Obligations						
Resultant - DSCR (Individual)						
Resultant - DSCR (Cumulative)						
Resultant - DSCR (Overall)						
Resultant - Sale Value(Output)						
As such - Variable Cost						
Resultant - Nett Contribution						
Resultant - PV Ratio (%age)						
Resultant - Cash BEP Sales						
Resultant - BEP Sales						
Resultant - Cash Margin of Safety						
Resultant - Margin of Safety						
Resultant - Cash BEP % (Yr. 5)						

ANNEXURE - 9 SENSITIVITY ANALYSIS - II [NPCS/5515/24212]

Particulars	Operating Years					
	1-2	2-3	3-4	4-5	5-6	
Resultant - BEP %age (Yr. 5)						
Resultant - DEBT EQUITY RATIO						
- Unsecured Dep. as Equity						
- Unsecured Dep. as Debt						
Resultant - ROI (%age)						
Resultant - RONW (%age)						
DECREASE IN SALES PRICES ::: By 5.00 %						
Resultant - Sale Value(Sales)						
Resultant - Gross Profit						
Resultant - N.P.B.T.						
Resultant - Tax on Profit						
Resultant - N.P.A.T.						
Resultant - Funds Available						
As such - Debt Obligations						
Resultant - DSCR (Individual)						
Resultant - DSCR (Cumulative)						
Resultant - DSCR (Overall)						

ANNEXURE - 9 SENSITIVITY ANALYSIS - II [NPCS/5515/24212]

Particulars	Operating Years				
	1-2	2-3	3-4	4-5	5-6
Resultant - Sale Value(Output)					
As such - Variable Cost					
Resultant - Nett Contribution					
Resultant - PV Ratio (%age)					
Resultant - Cash BEP Sales					
Resultant - BEP Sales					
Resultant - Cash Margin of Safety					
Resultant - Margin of Safety					
Resultant - Cash BEP % (Yr. 5)					
Resultant - BEP %age (Yr. 5)					
Resultant - DEBT EQUITY RATIO					
- Unsecured Dep. as Equity					
- Unsecured Dep. as Debt					
Resultant - ROI (%age)					
Resultant - RONW (%age)					

ANNEXURE - 10 SENSITIVITY ANALYSIS - III [NPCS/5515/24212]

(Rs. in Lakhs)

Particulars		Operating Years				
	1-2	2-3	3-4	4-5	5-6	
INCREASE IN MAIN MATERIAL PRICES ::: By 2.00 %						
Resultant - Main Material Amt						
Resultant - Gross Profit						
Resultant - N.P.B.T.						
Resultant - Tax on Profit						
Resultant - N.P.A.T.						
Resultant - Funds available						
As such - Debt Obligations						
Resultant - DSCR (Individual)						
Resultant - DSCR (cumulative)						
Resultant - DSCR (overall)						
As such - Sale Value(Output)						
Resultant - Variable Cost						
Resultant - Nett Contribution						
Resultant - PV Ratio (%age)						
Resultant - Cash BEP Sales						
Resultant - BEP Sales						
Resultant - Cash Margin of Safety						

ANNEXURE - 10 SENSITIVITY ANALYSIS - III [NPCS/5515/24212]

(Rs. in Lakhs)

Particulars	Operating Years					
	1-2	2-3	3-4	4-5	5-6	
Resultant - Margin of Safety						
Resultant - Cash BEP % (Yr. 5)						
Resultant - BEP %age (Yr. 5)						
Resultant - DEBT EQUITY RATIO						
- Unsecured Dep. as Equity						
- Unsecured Dep. as Debt						
Popultant POI (0/ aga)						
Resultant - ROI (%age) Resultant - RONW (%age)	-					
DECREASE IN MAIN MATERIAL PRICES ::: By 2.00 % Resultant - Main Material Amt						
Resultant - Gross Profit						
Resultant - N.P.B.T.						
Resultant - Tax on Profit						
Resultant - N.P.A.T.						
Resultant - Funds available						
As such - Debt Obligations						
Resultant - DSCR (Individual)						

ANNEXURE - 10 SENSITIVITY ANALYSIS - III [NPCS/5515/24212]

(Rs. in Lakhs)

Particulars		Operating Years				
	1-2	2-3	3-4	4-5	5-6	
Resultant - DSCR (cumulative)						
Resultant - DSCR (overall)						
As such - Sale Value(Output)						
Resultant - Variable Cost						
Resultant - Nett Contribution						
Resultant - PV Ratio (%age)						
Resultant - Cash BEP Sales						
Resultant - BEP Sales						
Resultant - Cash Margin of Safety						
Resultant - Margin of Safety						
Resultant - Cash BEP % (Yr. 5)						
Resultant - BEP %age (Yr. 5)						
Resultant - DEBT EQUITY RATIO						
- Unsecured Dep. as Equity						
- Unsecured Dep. as Debt						
Resultant - ROI (%age)						
Resultant - RONW (%age)						

ANNEXURE - 11 SENSITIVITY ANALYSIS - IV [NPCS/5515/24212]

(Rs. in Lakhs)

Particulars	Operating Years				
	1-2	2-3	3-4	4-5	5-6
INCREASE IN MAIN MATERIAL PRICES ::: By 5.00 %					
Resultant - Main Material Amt					
Resultant - Gross Profit					
Resultant - N.P.B.T.					
Resultant - Tax on Profit					
Resultant - N.P.A.T.					
Resultant - Funds available					
As such - Debt Obligations					
Resultant - DSCR (Individual)					
Resultant - DSCR (Cumulative)					
Resultant - DSCR (Overall)]
As such - Sale Value(Output)					
Resultant - Variable Cost					
Resultant - Nett Contribution					
Resultant - PV Ratio (%age)					
Resultant - Cash BEP Sales					
Resultant - BEP Sales					

ANNEXURE - 11 SENSITIVITY ANALYSIS - IV [NPCS/5515/24212]

(Rs. in Lakhs)

Particulars	Operating Years					
	1-2	2-3	3-4	4-5	5-6	
Resultant - Cash Margin of Safety						
Resultant - Margin of Safety						
Resultant - Cash BEP % (Yr. 5)						
Resultant - BEP %age (Yr. 5)						
Resultant - DEBT EQUITY RATIO						
- Unsecured Dep. as Equity						
- Unsecured Dep. as Debt						
Resultant - ROI (%age)						
Resultant - RONW (%age)						
DECREASE IN MAIN MATERIAL PRICES ::: By 5.00 % Resultant - Main Material Amt						
Resultant - Gross Profit						
Resultant - N.P.B.T.						
Resultant - Tax on Profit						
Resultant - N.P.A.T.						
Resultant - Funds Available						
As such - Debt Obligations						

ANNEXURE - 11 SENSITIVITY ANALYSIS - IV [NPCS/5515/24212]

(Rs. in Lakhs)

Particulars		C	perating Year	rs	
	1-2	2-3	3-4	4-5	5-6
Resultant - DSCR (Individual)					
Resultant - DSCR (Cumulative)					
Resultant - DSCR (overall)					
As such - Sale Value(Output)					
Resultant - Variable Cost					
Resultant - Nett Contribution					
Resultant - PV Ratio (%age)					
Resultant - Cash BEP Sales					
Resultant - BEP Sales					
Resultant - Cash Margin of Safety					
Resultant - Margin of Safety					
Resultant - Cash BEP % (Yr. 5)					
Resultant - BEP %age (Yr. 5)					
Resultant - DEBT EQUITY RATIO					
- Unsecured Dep. as Equity					
- Unsecured Dep. as Debt					
Resultant - ROI (%age)					
Resultant - RONW (%age)					

[NPCS/5515/24212]

ANNEXURE - 12 SHAREHOLDING PATTERN AND STAKE STATUS

Shares	Face Value USD/ Share	Share Capital						
30098	10.00		300.98					
Particulars	Existing	Existing	Proposed	Proposed	Total	Total		
	%age		%age		%age			
Capital								
Share Premium								
Total								

ANNEXURE - 13 [NPCS/5515/24212]

QUANTITATIVE DETAILS OF OUTPUT, SALES AND STOCKS

Particulars	UOM			Operating Years	•	
		1 - 2	2 - 3	3 - 4	4 - 5	5 - 6
Determined Capacity P.A of Products/Services						
Metformin (500 mg & 850 mg)	Kgs					
Amoxicillin (500 mg)	Kgs					
lbuprafen (500 mg)	Kgs					
Paracetamol (500 mg)	Kgs					
Achievable Efficiency/Yield % of Products/Services/Items						
Metformin (500 mg & 850 mg)	%					
Amoxicillin (500 mg)	%					
Ibuprafen (500 mg)	%					
Paracetamol (500 mg)	%					
Net Usable Load/Capacity of Products/Services/Items						
Metformin (500 mg & 850 mg)	Kgs					
Amoxicillin (500 mg)	Kgs					
lbuprafen (500 mg)	Kgs					
Paracetamol (500 mg)	Kgs					
No of Shifts Wkg./Day						
No of Working Days/Year						

ANNEXURE - 13 [NPCS/5515/24212]

QUANTITATIVE DETAILS OF OUTPUT, SALES AND STOCKS

Particulars	UOM			Operating Years	<u> </u>	
		1 - 2	2 - 3	3 - 4	4 - 5	5 - 6
Expected Usage/Utilisation of Achievable Load/Capacity (%)						
Metformin (500 mg & 850 mg)	%					
Amoxicillin (500 mg)	%					
lbuprafen (500 mg)	%					
Paracetamol (500 mg)	%					ĺ
Expected Usage/Output						
Metformin (500 mg & 850 mg)	Kgs					
Amoxicillin (500 mg)	Kgs					
lbuprafen (500 mg)	Kgs					
Paracetamol (500 mg)	Kgs					
Total						
Expected Sales/ Revenue/ Income of Products/ Services/ Items						
Metformin (500 mg & 850 mg)	Kgs					
Amoxicillin (500 mg)	Kgs					
lbuprafen (500 mg)	Kgs					
Paracetamol (500 mg)	Kgs					

ANNEXURE - 14 [NPCS/5515/24212]
PRODUCT-WISE DOMESTIC SALES REALISATION

Operating Year	UOM	Quantity	Rate	Sales
Description of Product				
1-2				
Metformin (500 mg & 850 mg)	Kgs			
Amoxicillin (500 mg)	Kgs			
Ibuprafen (500 mg)	Kgs			
Paracetamol (500 mg)	Kgs			
Year Totals ::				
2-3				
Metformin (500 mg & 850 mg)	Kgs			
Amoxicillin (500 mg)	Kgs			
lbuprafen (500 mg)	Kgs			
Paracetamol (500 mg)	Kgs			
Year Totals ::				
3-4				
Metformin (500 mg & 850 mg)	Kgs			
Amoxicillin (500 mg)	Kgs			
Ibuprafen (500 mg)	Kgs			
Paracetamol (500 mg)	Kgs			
Year Totals ::				
4-5				
Metformin (500 mg & 850 mg)	Kgs			
Amoxicillin (500 mg)	Kgs			
lbuprafen (500 mg)	Kgs			
Paracetamol (500 mg)	Kgs			
Year Totals ::				
5-6				
Metformin (500 mg & 850 mg)	Kgs			
Amoxicillin (500 mg)	Kgs			
Ibuprafen (500 mg)	Kgs			
Paracetamol (500 mg)	Kgs			
Year Totals ::				
i cai i Utais				

ANNEXURE - 15
TOTAL RAW MATERIAL COST

[NPCS/5515/24212]

Operating Year / Description of	UOM	Output	Adj. for WIP	Total Quantity	Cost Per	Material Type	Material Type	Total
Product		Quantity	Stks		Unit	I	II	
1-2								
Metformin (500 mg & 850 mg)	Kgs							
Amoxicillin (500 mg)	Kgs							
lbuprafen (500 mg)	Kgs							
Paracetamol (500 mg)	Kgs							
Total Raw Mat.Requirement								
2-3								
Metformin (500 mg & 850 mg)	Kgs							
Amoxicillin (500 mg)	Kgs							
Ibuprafen (500 mg)	Kgs							
Paracetamol (500 mg)	Kgs							
Total Raw Mat.Requirement								
3-4								
Metformin (500 mg & 850 mg)	Kgs							
Amoxicillin (500 mg)	Kgs							
lbuprafen (500 mg)	Kgs							
Paracetamol (500 mg)	Kgs							
Total Raw Mat.Requirement								
4-5	.,							
Metformin (500 mg & 850 mg)	Kgs							

ANNEXURE - 15
TOTAL RAW MATERIAL COST

[NPCS/5515/24212]

Operating Year / Description of	UOM	Output	Adj. for WIP	Total Quantity	Cost Per	Material Type	Material Type	Total
Product		Quantity	Stks		Unit	I	II	
Amoxicillin (500 mg)	Kgs							
Ibuprafen (500 mg)	Kgs							
Paracetamol (500 mg)	Kgs							
Total Raw Mat.Requirement								
5-6								
Metformin (500 mg & 850 mg)	Kgs							
Amoxicillin (500 mg)	Kgs							
Ibuprafen (500 mg)	Kgs							
Paracetamol (500 mg)	Kgs							
Total Raw Mat.Requirement								

[NPCS/5515/24212]

ANNEXURE - 16 RAW MATERIAL COST PER UNIT

(Amount in Rs.)

Description of Product / Description of	UOM	Qty.Per	Losses	Total	Rate Per	Total	Batch Qty	Amount Per
Raw-Material	OOW	Batch			Unit	Total	of Output	Unit
Active Pharma Ingredients (API)		Daten	%age	Quantity	Onit		or Output	Offic
For Metformin - Dicyanodiamide	Kgs							
Dimethylammonium Chloride	Kgs							
For Amoxicillin - Methylene chloride	Kgs							
6-APA (Aminopencillanic acid)	Kgs							
Triethyl Amine (6-APA)	Kgs							
Trimethylchlorosilane (TMCS)	Kgs							
N,N-dimethylaniline	Kgs							
DMA, HCI (Dimethylamine hydrochloride)	Kgs							
D-(-)-2-hydroxyphenylglycine chloride								
hydrochloride	Kgs							
NaCl (Sodium Chloride)	Kgs							
For Ibuprofen - Isobytyl Benezene	Kgs							
AICI3	Kgs							
Acetal Chloride	Kgs							
Tolune	Kgs							
Zinc Octate	Kgs							
NaOh	Kgs							
Methyl dichloride	Kgs							
For Paracetamol - p-nitrophenol	Kgs							
Iron Powder	Kgs							
Acetic Acid	Kgs							

Methanol	Kgs				
Activated Carbon	Kgs				
Sub Totals					
Add Loss/Wastage @ 0.00%	0.00%				
Totals (Indigenous)					

ANNEXURE - 17
TOTAL LAB & ETP CHEMICALS COST

[NPCS/5515/24212]

Operating Year / Description of Product	UOM	Output Quantity	Adj. for WIP Stks	Total Quantity	Cost Per Unit	Total
1-2		•				
Lab Chemicals Cost						
Year Total::						
2-3						
Lab Chemicals Cost						
Year Total::						
3-4						
Lab Chemicals Cost						
Year Total::						
4-5						
Lab Chemicals Cost						
Year Total::						
5-6						
Lab Chemicals Cost		i I				
Year Total::						

ANNEXURE - 18 CONSUMABLES, STORES AND SPARES EXPENSES [NPCS/5515/24212]

Operating Year / Description of Product	UOM	Output Quantity	Adj. for WIP Stks	Total Quantity	Cost Per Unit	Total
1-2						
Consumable Store						
Year Total::						
2-3						
Consumable Store						
Year Total::						
3-4						
Consumable Store			i	1		
Year Total::						
4-5						
Consumable Store						
Year Total::						
5-6						·
Consumable Store						
Year Total::						

[NPCS/5515/24212]

ANNEXURE - 19 TOTAL PACKING MATERIAL COST

(Rs. in Lakhs)

Operating Year / Description of Product	UOM	Output Quantity	Adj. for WIP Stks	Total Quantity	Cost Per Unit	Total
1-2						
Active Pharma Ingredients (API)	Kgs					
Year Total::						
2-3						
Active Pharma Ingredients (API)	Kgs					
Year Total::						
3-4						
Active Pharma Ingredients (API)	Kgs					
Year Total::						
4-5						
Active Pharma Ingredients (API)	Kgs					
Year Total::						
5-6						
Active Pharma Ingredients (API)	Kgs					
Year Total::						

[NPCS/5515/24212]

ANNEXURE - 20
PACKING MATERIAL COST PER UNIT

(Amount in Rs.)

Description of Product / Description	UOM	Qty.Per	Losses	Total	Rate Per	Total	Batch Qty of	Amount Per
of Packing Material		Batch	%age	Quantity	Unit		Output	Unit
Active Pharma Ingredients (API)								
Active i narma ingredients (Ai i)			<u> </u>					
Printed Packing Strips (include PVC Film, Aluminium Foil & Adhesives) each Strips App. Wt. 2 gms Size	Kgs							
Sub Total								
Add Loss/Wastage @ 0.00 %								
Product Total								

ANNEXURE - 21
EMPLOYEES EXPENSES

[NPCS/5515/24212]

(Rs. in Lakhs)

Placement / Designation	Dept./	Starting Year	Starting Month	No.of Persons	Pay Per Month	Total Per Annum
	Category					
Factory Personnel						
As Applicable from Year 1						
General Manager						
AGM (Comm.)						
Production, Engineering & Quality						
Control Manager						
Chemical Engineers						
Quality Control Supervisors						
Production Supervisors						
Skilled Workers						
Electricians						
Fitters						
Unskilled Workers						
Accountant						
Computer Operators						
Office Staffs						
Sales Executives						
Store Keeper						
Peons						
Security Officer						

ANNEXURE - 21
EMPLOYEES EXPENSES

[NPCS/5515/24212]

(Rs. in Lakhs)

Placement / Designation	Dept./	Starting Year	Starting Month	No.of Persons	Pay Per Month	Total Per Annum
	Category					
Security Guards						
TOTAL						
Welfare Expenses						
Year Total						
Total (Factory)						
Grand Total						

EMPLOYEES EXPENSES

	Operating Year	%age Increase	Total
1-2			
2-3			
3-4			
4-5			
5-6			

[NPCS/5515/24212]

ANNEXURE - 22 FUEL EXPENSES

Operating Year	%age Increase	Total
1-2		
2-3		
3-4		
4-5		
5-6		

[NPCS/5515/24212]

ANNEXURE - 23 POWER/ELECTRICITY EXPENSES

Operating Year	%age Increase	Total
1-2		
2-3		
3-4		
4-5		
5-6		

[NPCS/5515/24212]

ANNEXURE - 24 ROYALTY AND OTHER CHARGES

Operating Year	%age Increase	Total
1-2		
2-3		
3-4		
4-5		
5-6		

[NPCS/5515/24212]

ANNEXURE - 25 REPAIRS AND MAINTENANCE EXPENSES

Particulars	%age to Assets Value	Total
Buildings	1	
-Factory Building		
-Office Building		
Plant & Machineries		
-Imported Machineries		
-Indigenous Machineries		
-Maintenance Equipments		
-Laboratory Equipments		
-Miscellaneous Machines		
-Foundation, Installati		
-Motor Vehicles		
-Office Automation Equi		
-Furniture & Fixtures		
TOTAL		
Operating Year	% Increase	Total
1-2		
2-3		
3-4		
4-5		
5-6		

[NPCS/5515/24212]

ANNEXURE - 26 OTHER MANUFACTURING EXPENSES

Particulars	Total
Insurance Professional fees	
Water Exp.	
Total	

Operating Year	% Increase	Total
1-2		5.47
2-3		
3-4		
4-5		
5-6		

[NPCS/5515/24212]

ANNEXURE - 27 ADMINISTRATIVE AND GENERAL EXPENSES

Particulars	Total
Administration Expense	
Stationery Exp., Telephone,	
Postage	
Repairs and Maintanance	
Internet Expenses	
Conveyance Exp.	
Publicity Exp.	
Total	

Operating Year	% Increase	Total	Misc	Total
1-2				
2-3				
3-4				
4-5				
5-6				

[NPCS/5515/24212]

ANNEXURE - 28 SELLING AND DISTRIBUTION EXPENSES

Operating Year	% Increase	Total
1-2		1.00
2-3		
3-4		
4-5		
5-6		

ANNEXURE - 29
DEPRECIATION CHARGES AS PER BOOKS (TOTAL)

[NPCS/5515/24212]

Operating Year	F.Assets Type A-1	F.Assets Type A-2	F.Assets Type B	F.Assets Type C	F.Assets Type D-1	F.Assets Type D-2	Total
Particulars	Factory Building -	Office Buildings	PLANT & MACHINERY	Office Vehicles	Office Automation Equipments (Telephone/ Fax/ Computer)	Furniture & Fixtures	
1-2							
2-3							
3-4							
4-5							
5-6							
3-0							

ANNEXURE - 29
DEPRECIATION CHARGES AS PER BOOKS (TOTAL)

[NPCS/5515/24212]

(Rs. in Lakhs)

			•
Particulars	Method	Deprn.Rate	Part Consideration (for Asset put to use less than 6 months)
Type A :: Buildings			
Factory Building -	WDV		
Office Buildings	WDV		
Туре С			
Office Vehicles	WDV		
Type D :: Misc. Fix	ed Assets		
Equipments (Telephone/ Fax/			
Computer)	WDV		
Furniture & Fixtures	WDV		

Type B :: Plant & Machineries (All calculation are given in Annexure 30)

Contingencies, Pre-operative Expenses and Capital WIP are capitalised as under

(Rs. in Lakhs)

Description	P & P Expenses	Contingencies	Capital WIP	Total
Factory Building -				
Office Buildings				
Total				

ANNEXURE - 30 [NPCS/5515/24212]
DEPRECIATION CHARGES AS PER BOOKS (P&M)

Operating Year	F.Assets	F.Assets Type B	F.Assets	F.Assets	F.Assets Type B-	F.Assets	Total
	Type B-1	2	Type B-3	Type B-4	5	Type B-6	
PLANT & MACHINERY	Imported	Indigenous	Erection &	Laboratory	Miscellaneous	Maintenance	
	Machinerie	Machineries	Installation	Equipments	Equipmetns like	Equipments	
	s				pumps, valves,		
					pipeline & fittings		
1-2							
2-3							
3-4							
4-5							
5-6							

ANNEXURE - 30
DEPRECIATION CHARGES AS PER BOOKS (P&M)

[NPCS/5515/24212]

(Rs. in Lakhs)

Particulars	Method	Dep.Rate	Part Consideratio n, if any
Imported Machineries	WDV		
Indigenous Machineries	WDV		
Erection & Installation	WDV		
Laboratory Equipments	WDV		
Miscellaneous Equipmetns like pumps, valves, pipeline & fittings	WDV		
Maintenance Equipments	WDV		

Contingencies, Pre-operative Expenses and Capital WIP are capitalised as under

(Rs. in

Lakhs)

	P&P			
Description	Expenses	Contingencies	Capital WIP	Total
Imported Machineries				
Indigenous Machineries				
Erection & Installation				
Laboratory Equipments				
Miscellaneous Equipmetns like				
pumps, valves, pipeline & fittings				
Maintenance Equipments				
Total				

ANNEXURE - 31 [NPCS/5515/24212]
DEPRECIATION CHARGES AS PER INCOME TAX ACT (WDV) (TOTAL)

(Rs. in Lakhs)

Operating Year	F.Assets Type A-1	F.Assets Type A-2	F.Assets Type B	F.Assets Type C	F.Assets Type D-	F.Assets Type D-2	Total
Particulars	Factory Building -	Office Buildings	PLANT & MACHINERY	Office Vehicles	Office Automation Equipments (Telephone/ Fax/ Computer)	Furniture & Fixtures	
1-2							
							111.96
2-3							
							87.04
3-4							
							68.04
4-5							
4-3							53.52
5.0							
5-6							42.38

Depreciation hereinabove is calculated as per WDV at rates prescribed under I.T.Act

ANNEXURE - 31 [NPCS/5515/24212]
DEPRECIATION CHARGES AS PER INCOME TAX ACT (WDV) (TOTAL)

Particulars	Method	Dep.Rate	Part Consideration (for Asset put to use less than 6 months)
Type A :: Buildings			
Factory Building	WDV		
Office Building	WDV	0.10	0.50
Туре С			
Motor Vehicles	WDV		
Type D :: Misc. Fixed A	Assets		
Office Automation			
Equipments	WDV		
Furniture & Fixtures	WDV		

Type B :: Plant & Machineries(All calculation are given in Annexure 32)

ANNEXURE - 32 [NPCS/5515/24212]
DEPRECIATION CHARGES AS PER INCOME TAX ACT(WDV) (P&M)

(Rs. in Lakhs)

Operating Year	F.Assets Type	F.Assets Type B-	F.Assets Type	F.Assets Type	F.Assets Type B-5	F.Assets	Total
	B-1	2	B-3	B-4		Type B-6	
PLANT & MACHINERY	Imported	Indigenous	Erection &	Laboratory	Miscellaneous	Maintenance	
	Machineries	Machineries	Installation	Equipments	Equipmetns like	Equipments	
					pumps, valves,		
					pipeline & fittings		
1-2							
2-3							
3-4							
4-5							
5-6							

Depreciation hereinabove is calculated as per WDV at rates prescribed under I.T.Act (Rs. in Lakhs)

ANNEXURE - 32 [NPCS/5515/24212]
DEPRECIATION CHARGES AS PER INCOME TAX ACT(WDV) (P&M)

Particulars	Method	Dep.Rate	Part Consideration, if any
Imported Machineries	WDV		
Indigenous Machineries	WDV		
Maintenance Equipments	WDV		
Laboratory Equipments	WDV		
Miscellaneous Equipments	WDV		
Foundation, Installation etc.	WDV		

ANNEXURE - 33 [NPCS/5515/24212] **INTEREST AND REPAYMENT ON TERM LOANS**

(Rs. in Lakhs)

Α	Name of Institution-Bank	ABC BANK	
В	Term Borrowing Amount		Thousand
С	Repayment Term (Years)		Years
D	Repayment Instalments		Instalments
E	Repayment Commencement		
F	Rate of Interest(General)		p.a.
F	Rate of Interest(Initial)		p.a.
G	Apply Gen. Int. Rate from Yea		
Н	Interest Calculation		

Operating Year	Period Ended	Repayment	Outstanding	Interest
	Quarter Ended			
1-2				
	TOTAL :			
2.2				
2-3				
	TOTAL:			
	-			
3-4				
	TOTAL:			
4-5				
	TOTAL:			
	IOIAL.			
5-6				
	TOTAL:			
Total Loan amo	ount			

Note: Repayment is considered as being made at the end of the period

[NPCS/5515/24212]

ANNEXURE - 34
TAX ON PROFITS

(Rs. in Lakhs)

Particulars		Operating Years					
	1-2	2-3	3-4	4-5	5-6		
Net Profit Before Taxes							
Adjustments to NPBT							
Add : Depreciation as provided							
Less : Depreciation as per IT							
Recomputed NPBT							
Taxable Profits							
(%)							
Tax on Profits							

ANNEXURE - 35
PROJECTED PAY-BACK PERIOD AND IRR

[NPCS/5515/24212]

(Rs. in Lakhs)

Particulars		Operating Years						
	1-2	2-3	3-4	4-5	5-6	Total		
IN-FLOW of Funds								
Net Profit After Taxes								
Added Back								
Depreciation Charges								
P & P Expenses W/off								
Interest Charges								
Revenue Inflow of Funds								
Residual Value-M/Money								
Total Inflow of Funds								
OUT-FLOW of Funds								
Capital Out-flow of Funds								

Projected Pay Back Period									
Particulars		Operating Years							
	1-2	2-3	3-4	4-5	5-6				
Year	1	2	3	4	5				
Initial Investment									
Total Initial Investment									
Yearly Cash Flow									
Accumulated Cash Flow									
Pay Back Period									

ANNEXURE - 35
PROJECTED PAY-BACK PERIOD AND IRR

[NPCS/5515/24212]

Projected IRR									
Year	CFAT	PV factor @15%	0.15						
Initial Investment									
1-2									
2-3									
3-4									
4-5									
5-6									
Total PV									
IRR									

[NPCS/5515/24212]

PROJECT AT A GLANCE (Rs. in Lakhs)

COST C	F PROJECT			MEANS	NS OF FINANCE					
Particulars	Existing	Proposed	Total	Particulars	Existing	Proposed	Total			
Land & Site Development Exp.				Capital						
Buildings				Share Premium						
Plant & Machineries				Other Type Share Capital						
Motor Vehicles				Reserves & Surplus						
Office Automation Equipments				Cash Subsidy						
Technical Knowhow Fees & Exp.				Internal Cash Accruals						
Franchise & Other Deposits										
Preliminary& Pre-operative Exp				Debentures / Bonds						
Provision for Contingencies		Unsecured Loans/Depos								
Margin Money - Working Capital										
TOTAL				TOTAL						

PROJECT AT A GLANCE

[NPCS/5515/24212]

Year	Annu	ıalised	Book Value	Debt	Dividen d	Retained E	arnings	Payout	Market	P/E Ratio	Yield Price/ Book Value
									Price		
	EPS	CEPS	Per	Share	Per Share	Per Sl	nare			No.of	
	Rs.	Rs.	Rs.	Rs.	Rs.	%	Rs.	%	Rs.	Times	%
1-2											
2-3											
3-4											
4-5											
5-6											

Year		D. S. C. R.		Debt / -	Equity	Total Net	Return	Profitability Ratio					Assets	Current
				Deposits	as-	Worth	on Net						Turnover	Ratio
				Debt	Equity		Worth						Ratio	
	Individual	Cumulative	Overall					GPM	PBT	PAT	Net	P/V Ratio		
											Contribut			
											ion			
	(Nu	ımber of time	es)	(Number	of times)	%	%	%	%	%		%		
Initial				3.00	3.00									
1-2														
2-3														
3-4														
4-5														
5-6														

PROJECT AT A GLANCE

[NPCS/5515/24212]

BEP	
BEP - Maximum Utilisation Year	
Cash BEP (% of Installed Capacity)	
Total BEP (% of Installed Capacity)	
IRR, PAYBACK and FACR	
Internal Rate of Return (In %age)	
Payback Period of the Project is (In Years)	
Fixed Assets Coverage Ratio (No. of times)	